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Abstract 
Electrophysical agents (EPA) are a fundamental element of therapy practice and are vital for 
the treatment of a variety of conditions. Many of these agents employ some form of 
electromagnetic fields (EMF), in which radiofrequency (RF) is a major component. The 
therapeutic effects of RF are mainly linked to their effects on pain relief and potential effects 
on tissue repair. Although RF across various frequency ranges has been in use, reviews 
have shown that the frequency ranges currently used in therapy practice have narrowed to 
within 30 kHz–30,000 kHz (30 MHz). The most commonly used and hence the most 
commonly researched are shortwave therapies (SWT) that operate at 27.12 MHz, which is 
presently used predominantly in its pulsed form (PSWT). 
In addition to SWT, devices employing significantly lower RF ranges have also been used 
widely despite their lack of evidence. Capacitive Resistive Monopolar Radiofrequency 
(CRMRF) that operates at 448 kHz is one such RF. This programme of research was 
designed to investigate the physiological and clinical efficacy of CRMRF delivered using the 
‘Indiba Activ 902’ device. The project also evaluated the scope and evidence for RF-based 
EPAs in therapy, through a comprehensive review of literature. A total of 120 relevant 
clinical studies on either acute (30 studies) or chronic (90 studies) conditions were reviewed. 
Notable evidence was identified for chronic OA knee and acute postoperative pain and 
wound healing. Some evidence also exists for chronic low back pain and healing of chronic 
wounds. Only eight studies reported devices that employed RF outside the shortwave 
frequency band. 
In a randomised crossover laboratory study on asymptomatic adults, the effects of 
contrasting doses of CRMRF on skin temperature (SKT), skin blood flow (SBF), nerve 
conduction velocity (NCV), deep blood flow and the extensibility of tissues were examined 
against a placebo dose and a control condition with no treatment. The study further 
compared CRMRF results with that of PSWT. The results showed that high (moderately 
thermal) and low (sub/minimally thermal) doses of CRMRF significantly enhanced and 
sustained SKT (p<0.001), while only the high dose meaningfully increased SBF (p<0.001). 
High dose PSWT increased SKT marginally (p<0.001) but did not sustain it. Further, the high 
and low dose CRMRF significantly enhanced blood flow volume at depth (p=0.003), while 
PSWT failed to show any significant impact. None of the treatments significantly affected 
deep blood flow velocity, tissue extensibility or NCV. 
These results were reproduced on a cohort of patients affected by OA knee in a randomised 
controlled trial (RCT), and the effects appeared more pronounced in the patients than in the 
asymptomatic people. More importantly, the RCT showed that a four-week high dose 
CRMRF treatment (eight sessions) produced statistically and clinically significant gains in 
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pain and function associated with OA knee in the short to medium term (p<0.001), which 
was also significantly more pronounced than the gains produced by a placebo, or standard 
care (p=0.001for pain; p=0.031 for function). The findings of this study were considered 
promising. It is therefore suggested that CRMRF-based treatment can potentially be used as 
an adjunct to current therapeutic methods to enhance the clinical outcomes. However, 
further studies are needed to substantiate this, and the current results will provide credible 
baseline data for future research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
Acknowledgements 
My sincere thanks to the following people without whom this work would 
have fallen short... 
 
To Professor Tim Watson who has been inspirational and critical in the right measure, for 
being my perfect guide and best friend in this job for the last five years! 
To Mr Roy Smith (CEO, Indiba S. A.), Dr Sebastia Sendros, Mr Xavier Rami and other 
colleagues at Indiba S. A., Barcelona for all their support and continued funding throughout 
the project. 
To Dr Karen Beeton for her support on the provision of extended funding from the 
department. 
To Mr Jon Woollard for being extremely helpful on the laboratory matters throughout, and for 
being the most prolific participant in my experiments. 
To Mrs Diana Davis and other former and current colleagues at the University of 
Hertfordshire for their kind support and participation in the project. 
To Dr Anthony Herbland for his invaluable expertise and help with the ultrasound image 
analysis. 
To Dr Jane Simmonds for all her help, and for introducing me to this project in the first place. 
To all the colleagues at the Safari Therapy Unit, Hemel Hempstead Hospital for their help 
and support for the clinical trial. 
To all those patients at the Hemel Hempstead Hospital who kindly volunteered to participate 
in the clinical trial. 
…and finally 
To my parents who kept asking every other week that when was I going to finish this work! 
To my seven-year-old son Sidharth for appreciating that I was working on ‘something big’! 
To my wife Byju for all her patience and support (…and sometimes the lack of it)! 
 
Thank God. 
 
 
 
5 
List of contents 
Title page           1 
Abstract           2 
Acknowledgements          4 
List of contents          5 
Table of contents          6 
List of tables           14 
List of figures           16 
List of publications          21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
Table of Contents 
Table of Contents .................................................................................................................. 6 
1 Chapter 1 – Electromagnetism, radiofrequency and radiofrequency-based 
electrophysical agents: key concepts and project overview. ................................................ 23 
 Research context .................................................................................................. 23 
 Electromagnetic fields ........................................................................................... 23 
 Radiofrequency ..................................................................................................... 24 
 Radiofrequency and biological systems ................................................................ 25 
1.4.1 RF-tissue interaction ...................................................................................... 25 
1.4.2 Thermal versus nonthermal effects of RF ....................................................... 26 
1.4.3 RF tissue absorption ...................................................................................... 28 
1.4.4 Biological effects of RF .................................................................................. 28 
 Overview of the project ......................................................................................... 29 
1.5.1 Development and sequencing ........................................................................ 29 
1.5.2 RF-based treatment in therapy-related clinical practice .................................. 30 
1.5.3 Rationale ........................................................................................................ 31 
1.5.4 Key aims and research questions .................................................................. 31 
 Conclusions .......................................................................................................... 32 
2 Chapter 2 – Literature review on the biological effects of radiofrequency: methodology 
and main results. ................................................................................................................. 34 
 Introduction ........................................................................................................... 34 
 Methods ................................................................................................................ 35 
2.2.1 Search strategy and reference management ................................................. 35 
2.2.2 Narrative review ............................................................................................. 36 
2.2.3 Quality assessment of studies ........................................................................ 37 
 Main results........................................................................................................... 38 
 Radiofrequency-based treatment: the non-clinical literature .................................. 41 
2.4.1 Human studies in vivo on asymptomatic people ............................................. 41 
2.4.2 Animal studies, in vitro studies on cell and tissue models .............................. 42 
2.4.3 Experimental animal studies simulating acute clinical conditions.................... 43 
2.4.4 Experimental animal studies simulating chronic clinical conditions ................. 44 
 Conclusions .......................................................................................................... 44 
7 
3 Chapter 3 – Radiofrequency-based treatment in therapy-related clinical practice. ........ 45 
 Studies on acute conditions .................................................................................. 45 
3.1.1 Studies on pain and inflammation .................................................................. 49 
3.1.2 Studies on tissue healing ............................................................................... 53 
3.1.3 Studies on other applications ......................................................................... 54 
3.1.4 Conclusions ................................................................................................... 54 
 Studies on chronic conditions ................................................................................ 55 
3.2.1 Non-shortwave studies ................................................................................... 55 
3.2.2 Shortwave studies .......................................................................................... 59 
3.2.3 Conclusions ................................................................................................... 79 
 Section II summary ............................................................................................... 80 
4 Chapter 4 – Materials and methods, measurement principles and pilot experiments. ... 84 
 Introduction ........................................................................................................... 84 
 The RF treatment devices ..................................................................................... 84 
4.2.1 The CRMRF device........................................................................................ 84 
4.2.2 The PSWT device .......................................................................................... 86 
 Selection of physiological parameters to investigate ............................................. 87 
 Selection of a body area to treat ............................................................................ 87 
 Superficial physiological measurements ................................................................ 88 
4.5.1 Skin temperature ............................................................................................ 88 
4.5.2 Skin blood flow ............................................................................................... 89 
4.5.3 Nerve conduction velocity .............................................................................. 90 
4.5.4 The skin physiological measurement devices................................................. 91 
 Deep physiological measurements ........................................................................ 93 
4.6.1 Deep blood flow ............................................................................................. 93 
4.6.2 Tissue extensibility ......................................................................................... 94 
4.6.3 Ultrasound scanning devices ......................................................................... 94 
 Other outcome measures ...................................................................................... 95 
 Other devices used in the project .......................................................................... 95 
 Processing of physiological data ........................................................................... 95 
4.9.1 Processing of Biopac data.............................................................................. 95 
8 
4.9.2 Processing of ultrasound data ........................................................................ 96 
4.9.3 Processing of FlexComp Infiniti data .............................................................. 99 
 Methodological considerations and pilot experiments ............................................ 99 
4.10.1 The CRMRF device: familiarisation, operating principles and identifying the key 
issues (addressed aim 1)........................................................................................... 100 
4.10.2 Calibration of equipment (addressed aim 2) ................................................. 102 
4.10.3 Investigating signal interference (addressed aim 3) ..................................... 103 
4.10.4 Issues surrounding probe attachment and signal noise (addressed aims 4 & 5). 
……….... ................................................................................................................... 106 
4.10.5 Baselining of the data streams and electrode acclimatisation (addressed aims 
6 & 10). ……………………………………………………………………………………….109 
4.10.6 Sampling rate for the Biopac system (addressed aim 7) .............................. 109 
4.10.7 Validation of temperature readings using different measurement techniques 
(addressed aim 8)...................................................................................................... 109 
4.10.8 Electrode stability tests for NCV (addressed aim 9)...................................... 111 
4.10.9 Intra-rater reliability of ultrasound measurements (addressed aim 11) ......... 112 
 Conclusions ........................................................................................................ 114 
5 Chapter 5 – Basic considerations on CRMRF therapy: Skin thermal onset, thermal 
decay and thermal retention responses to the CAP and RES modes – a randomised 
crossover study ................................................................................................................. 115 
 Introduction ......................................................................................................... 115 
 Physiological effects of heat ................................................................................ 115 
 Key aims ............................................................................................................. 116 
 Materials and methods ........................................................................................ 116 
5.4.1 Apparatus .................................................................................................... 116 
5.4.2 Sample and groups ...................................................................................... 118 
5.4.3 Pretesting and pilot work .............................................................................. 118 
5.4.4 Experimental procedure ............................................................................... 119 
 Electrode temperature testing ............................................................................. 120 
 Data analysis ...................................................................................................... 121 
 Results ................................................................................................................ 121 
 Discussion .......................................................................................................... 133 
 Conclusions ........................................................................................................ 137 
9 
6 Chapter 6 – Skin and deep tissue physiological effects of CRMRF treatment: single-
blind randomised crossover study with a comparison to PSWT ......................................... 138 
 Introduction ......................................................................................................... 138 
 Aims .................................................................................................................... 138 
 Materials and methods ........................................................................................ 139 
6.3.1 Apparatus .................................................................................................... 139 
6.3.2 Sample and groups ...................................................................................... 139 
6.3.3 Experimental procedure ............................................................................... 141 
6.3.4 Data acquisition ........................................................................................... 141 
6.3.5 The CRMRF intervention ............................................................................. 144 
6.3.6 PSWT treatment .......................................................................................... 148 
6.3.7 Data analysis ............................................................................................... 148 
 Results ................................................................................................................ 149 
6.4.1 Skin temperature results .............................................................................. 151 
6.4.2 Skin blood flow results ................................................................................. 156 
6.4.3 Nerve Conduction Velocity results ................................................................ 161 
6.4.4 Blood flow volume ........................................................................................ 162 
6.4.5 Blood flow intensity ...................................................................................... 166 
6.4.6 Blood flow velocity ....................................................................................... 170 
6.4.7 Tissue extensibility ....................................................................................... 170 
6.4.8 Results from the control leg .......................................................................... 172 
6.4.9 Other results ................................................................................................ 173 
 Discussion .......................................................................................................... 174 
 Conclusions ........................................................................................................ 181 
7 Chapter 7 – Section III conclusions: key findings, limitations of the studies and 
implications for clinical practice and research .................................................................... 183 
 Key findings ........................................................................................................ 183 
 Methodological considerations and potential limitations of the studies ................ 184 
 Implications for practice and future research ....................................................... 186 
8 Chapter 8 – The effect of CRMRF on pain and function in patients with OA of the knee 
joint: a randomised controlled trial ..................................................................................... 188 
 Introduction to osteoarthritis ................................................................................ 188 
10 
8.1.1 Epidemiology ............................................................................................... 188 
8.1.2 Global costs ................................................................................................. 188 
8.1.3 Classification of OA ...................................................................................... 189 
8.1.4 Pathophysiology and symptoms of OA knee ................................................ 189 
8.1.5 Current best treatment for OA knee ............................................................. 190 
8.1.6 Physiotherapy interventions for OA knee ..................................................... 190 
 Rationale for the study ........................................................................................ 192 
 Key aims of the study .......................................................................................... 192 
 The study design ................................................................................................. 192 
 Materials and methods ........................................................................................ 193 
8.5.1 The CRMRF device...................................................................................... 193 
8.5.2 Outcome measures ...................................................................................... 194 
8.5.3 The study setting, Ethics approval, trial registration and key dates ............... 196 
8.5.4 The study population and sample recruitment .............................................. 197 
8.5.5 Sample size and power calculation .............................................................. 198 
8.5.6 The study groups ......................................................................................... 198 
8.5.7 Interventions ................................................................................................ 199 
8.5.8 Procedure .................................................................................................... 200 
8.5.9 Analysis of data ............................................................................................ 201 
 Results ................................................................................................................ 201 
8.6.1 Self-reported pain ........................................................................................ 204 
8.6.2 WOMAC osteoarthritis index ........................................................................ 207 
8.6.3 Walking ability .............................................................................................. 209 
8.6.4 Knee joint ROM ............................................................................................ 211 
8.6.5 Subgroup analyses and correlations ............................................................ 213 
8.6.6 Post-hoc power and sample size calculation ................................................ 215 
 Discussion .......................................................................................................... 216 
 Conclusions ........................................................................................................ 222 
9 Chapter 9 – Skin and deep physiological effects of CRMRF treatment in patients with 
OA of the knee joint: a single-blind randomised controlled trial .......................................... 223 
 Introduction ......................................................................................................... 223 
11 
 Materials and methods ........................................................................................ 223 
9.2.1 Changes to the experimental protocol .......................................................... 223 
9.2.2 Apparatus .................................................................................................... 224 
9.2.3 Sample and groups ...................................................................................... 224 
9.2.4 Experimental procedure ............................................................................... 224 
9.2.5 Data acquisition ........................................................................................... 226 
9.2.6 The CRMRF intervention ............................................................................. 227 
9.2.7 Analysis of data ............................................................................................ 227 
 Results ................................................................................................................ 227 
9.3.1 Skin temperature results .............................................................................. 227 
9.3.2 Skin blood flow results ................................................................................. 230 
9.3.3 Blood flow volume ........................................................................................ 233 
9.3.4 Blood flow intensity ...................................................................................... 235 
9.3.5 Blood flow velocity ....................................................................................... 237 
9.3.6 Core temperature, blood pressure and pulse rate ........................................ 239 
9.3.7 Comparison between the normative and patient data ................................... 239 
 Discussion .......................................................................................................... 239 
 Conclusions ........................................................................................................ 241 
10 Chapter 10 – General discussion and key messages ................................................. 242 
 Introduction ......................................................................................................... 242 
 Radiofrequency evidence base ........................................................................... 242 
10.2.1 Main findings ................................................................................................ 242 
10.2.2 Key messages ............................................................................................. 243 
 Experiments on physiological effects of RF ......................................................... 244 
10.3.1 Asymptomatic adults .................................................................................... 244 
10.3.2 Patients with OA knee .................................................................................. 247 
 The clinical outcomes from the OA knee study .................................................... 249 
10.4.1 Main findings ................................................................................................ 250 
10.4.2 Key messages ............................................................................................. 251 
 Concluding remarks ............................................................................................ 251 
12 
 Conflict of interest statement ............................................................................... 253 
11 References ................................................................................................................. 254 
12 Appendices ................................................................................................................ 304 
 Appendix 2.1: Key words and filter terms used in the literature searching ........... 304 
  Appendix 2.2: Cochrane risk of bias assessment tool ........................................ 306 
 Appendix 2.3: Downs and Black checklist for randomised and non-randomised 
studies ........................................................................................................................... 310 
 Appendix 4.1: Biopac system specifications ........................................................ 312 
 Appendix 4.2: MATLAB algorithm for colour Doppler image analysis in the 
laboratory study ............................................................................................................. 314 
 Appendix 4.3: MATLAB algorithm for power Doppler image analysis in the 
laboratory study ............................................................................................................. 316 
 Appendix 4.4: MATLAB algorithm for Elastography image analysis in the laboratory 
study…………….. .......................................................................................................... 318 
 Appendix 4.5: MATLAB algorithm for colour Doppler image analysis in the clinical 
study……… ................................................................................................................... 320 
 Appendix 4.6: MATLAB algorithm for power Doppler image analysis in the clinical 
study….. ........................................................................................................................ 321 
 Appendix 4.7: Biopac equipment calibration ........................................................ 322 
 Appendix 4.8: Ethics approval memo (Protocol number: HSK/PG/UH/00015) ..... 324 
 Appendix 4.9: Raw data from the thermometer validation study .......................... 325 
 Appendix 4.10: Informed consent for the intrarater reliability study for the ultrasound 
measurements............................................................................................................... 326 
 Appendix 4.11: Ethics approval for the intrarater reliability study for the ultrasound 
measurements (Protocol number: cHSK/PG/UH/00143) ............................................... 328 
 Appendix 4.12: Raw data from the intrarater reliability study for the ultrasound 
measurements............................................................................................................... 329 
 Appendix 5.1: Participant information sheet for the laboratory-based study ........ 330 
 Appendix 5.2: Informed consent for the laboratory-based study .......................... 333 
 Appendix 5.3: Ethics approval for the laboratory-based study (Protocol number: 
HSK/PG/UH/00015) ...................................................................................................... 335 
 Appendix 5.4: Randomisation chart for the order of attendance to the laboratory 
sessions ........................................................................................................................ 336 
 Appendix 5.5: Eligibility questionnaire and subjective information form for the 
participants .................................................................................................................... 337 
 Appendix 5.6: Image representative of the three heating points to be reported by 
the participants .............................................................................................................. 338 
 Appendix 5.7: Participant data collection form ..................................................... 339 
13 
  Appendix 6.1: Participant information sheet for the laboratory-based study ....... 342 
 Appendix 6.2: Ethics approval for the laboratory-based study (Protocol number: 
cHSK/PG/UH/00143) ..................................................................................................... 346 
  Appendix 6.3: Informed consent for the laboratory-based study ......................... 347 
 Appendix 6.4: Randomisation chart for the order of attendance to the laboratory 
study sessions ............................................................................................................... 349 
 Appendix 6.5: Eligibility questionnaire and subjective information form for the 
participants .................................................................................................................... 350 
 Appendix 6.6: Participant data collection form ..................................................... 351 
 Appendix 6.7: Randomisation chart for the order of attendance to the laboratory 
sessions in the pilot study determining CRMRF intervention ......................................... 355 
 Appendix 8.1: Visual analogue scale (VAS) for self-reported pain ....................... 356 
 Appendix 8.2: Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) ...................................................................................................................... 357 
 Appendix 8.3: NHS Health Research Authority (HRA) approval letter (REC 
reference: 15/NW/0529) ................................................................................................ 362 
 Appendix 8.4: Patient invitation letter to the potential participants in the OA knee 
trial………………………………………………………………………………………………. 366 
 Appendix 8.5: Participant information sheet in the OA knee trial ......................... 367 
 Appendix 8.6: Participant ‘form to return’ in the OA knee trial .............................. 372 
 Appendix 8.7: Patient randomisation chart for the OA knee clinical trial .............. 373 
 Appendix 8.8: Informed consent for the participants in the OA knee trial ............. 374 
 Appendix 9.1: Participant data collection form in the OA knee trial ...................... 376 
 
 
 
 
 
 
 
 
 
 
 
14 
List of tables 
Table 3.1: RF studies on acute therapy-related conditions…………………………………….46 
Table 3.2: Non-shortwave RF studies on chronic conditions…………………………………..58 
Table 3.3: Shortwave studies on OA knee……………………………………………………….63 
Table 3.4: Shortwave studies on pain and inflammation (except arthritis)……………………70 
Table 3.5: Shortwave studies on tissue healing………………………………………………....75 
Table 3.6: Shortwave studies on other applications…………………………………………….78 
Table 3.7: Key review findings from both acute and chronic subgroups of RF studies……..81 
Table 4.1: Level of agreement between the two sets of deep blood flow measurements…114 
Table 5.1: Demographic and the mean (SD) anthropometric data from 15 participants…..121 
Table 5.2: The mean (SD) time, energy and peak power reached at each of the three 
thermal stages for the 15 participants…………………………………………………………...122 
Table 5.3: The active electrode temperature at various times and intensity of application 
during localised CRMRF treatment……………………………………………………………...123 
Table 6.1: Demographic and the mean (SD) anthropometric data from the 15 participants 
who received CRMRF treatment…………………………………………………………………146 
Table 6.2: The mean (SD) treatment doses received by the participants of three 
experimental groups, and the mean (SD) room temperature and humidity..……………….147 
Table 6.3: Demographic and the mean (SD) anthropometric data from the 17 participants 
who received localised CRMRF treatment……………………………………………………...150 
Table 6.4: The mean (SD) treatment doses received by the participants in the five 
experimental groups, and the mean (SD) room temperature and humidity during the 
experimental sessions…………………………………………………………………………….150 
Table 6.5: Key results from the planned comparisons (contrasts) on the SKT responses 
across five experimental groups………………………………………………………………....152 
Table 6.6: Key results from the planned comparisons (contrasts) on the SBF responses 
across five experimental groups………………………………………………………………....157 
Table 6.7: Key results from the pairwise comparisons on blood flow volume responses 
across five experimental groups………………………………………………………………....163 
Table 6.8: Key results from the pairwise comparisons on the blood flow intensities across 
five experimental groups………………………………………………………………………….167 
15 
Table 6.9: The group mean (SD) data for core temperature, BP and PR…………………...174 
Table 6.10: Group mean (SD) data for room temperature and humidity…………………....174 
Table 8.1: Demographic and the mean (SD) anthropometric data………………………......202 
Table 8.2: Within-group pairwise comparisons for the pain scores………………..………...206 
Table 8.3: Between-group pairwise comparisons for the pain scores…………………..…...206 
Table 8.4: Within-group pairwise comparisons for the WOMAC global scores………..…...208 
Table 8.5: Between-group pairwise comparisons for the WOMAC global scores……...…..209 
Table 8.6: Within-group pairwise comparisons for the TUG scores………………...……….211 
Table 8.7: Within-group pairwise comparisons for the knee ROM……………………...…...213 
Table 8.8: Power and sample size for the main effects and interactions………………...…216 
Table 9.1: Within-group pairwise comparisons for SKT……………...……………………….229 
Table 9.2: Between-group pairwise comparisons for SKT……………………..……………..230 
Table 9.3: Within-group pairwise comparisons for SBF…………………………………..…..232 
Table 9.4: Between-group pairwise comparisons for SBF……………………………..……..232 
Table 9.5: Within-group pairwise comparisons for blood flow volumes…………………......234 
Table 9.6: Between-group pairwise comparisons for blood flow volumes……………….. ...234 
Table 9.7: Within-group pairwise comparisons for blood flow intensities……………..….....236 
Table 9.8: Between-group pairwise comparisons for blood flow intensities…………..…….236 
Table 9.9: Within-group pairwise comparisons for blood flow velocities……………..…......238 
Table 9.10: Between-group pairwise comparisons for blood flow velocities…………..…....238 
Table 9.11: Main interactions and pairwise comparisons between the normative and patient 
physiological data……………………………………………………………………………........239 
 
 
 
 
 
 
 
16 
List of figures 
Figure 1.1: A representation of the electromagnetic spectrum comparing wavelength and 
frequency…………………………………………………………………………………………….24 
Figure 1.2: Frequency distributions of RF as proposed by IEEE…………………….………..24 
Figure 1.3: EMF – tissue interaction………………………………………………………………25 
Figure 2.1: Schematic representation of the literature search process…………… …………36 
Figure 2.2: Stages of filtering from the ‘primary pool’ of articles…………………….…………39 
Figure 2.3: Types and numbers of articles in the primary pool………………………………...40 
Figure 2.4: Clinical application categories and types of studies…………………………….....41 
Figure 4.1: The ‘Indiba Activ 902’ device, electrodes and conductive cream………………...86 
Figure 4.2: The ‘Bosch Ultramed’ SWT device…………………………………...……………..86 
Figure 4.3: Representative image showing NCV measurement and device setup……….....90 
Figure 4.4: The ‘Biopac MP150’ system, modules, and PPG and SKT probes……………...92 
Figure 4.5: The ‘FlexComp Infiniti’ device, and PPG and SKT probes…………………….....92 
Figure 4.6: The ‘Thermofocus’ IR thermometer…………………………………………...........93 
Figure 4.7: The ‘Esaote’ ultrasound scanning devices and probe……………………………..94 
Figure 4.8: Raw and processed Biopac data………………………………………………….....96 
Figure 4.9: The ‘MATLAB’ analysis of the ultrasound machine colour scales………………..98 
Figure 4.10: Sample data report from the ‘BioGraph Infiniti’ software………………………...99 
Figure 4.11: EMG module calibration output data obtained using CBLCAL………………...103 
Figure 4.12: Effect of the distance from CRMRF device on the Biopac data streams……..105 
Figure 4.13: Biopac probe attachments used in the study…………………………………....106 
Figure 4.14: Sources of signal noise…………………………………………………………….108 
Figure 4.15: The mean (SD) temperatures obtained from Biopac SKT100C and 
Thermofocus IR thermometer in relation to pre-set thermode temperatures…………….....111 
Figure 4.16: ECG electrode brands compared based on response to external noise……..112 
Figure 5.1: Sample CRMRF machine output data……………………………………………..117 
Figure 5.2: Laboratory setup used for the experiment………………………………………...120 
17 
Figure 5.3a: CAP and RES mode mean skin thermal responses to localised CRMRF 
treatment……………………………………………………………………………………………124 
Figure 5.3b: CAP and RES mode individual skin thermal responses to localised CRMRF 
treatment (treated side)…………………………………………………………………………...125 
Figure 5.4a: CAP and RES mode mean skin thermal changes after localised CRMRF 
treatment (treated side)…………………………………………………………………………...126 
Figure 5.4b: CAP and RES mode individual skin thermal changes after localised CRMRF 
treatment (treated side)…………………………………………………………………………...127 
Figure 5.5a: CAP and RES mode mean skin thermal decay after localised CRMRF treatment 
(treated side)……………………………………………………………………………………….128 
Figure 5.5b: CAP and RES mode individual skin thermal decay after localised CRMRF 
treatment (treated side)…………………………………………………………………………...129 
Figure 5.6a: CAP and RES mode time-specific individual skin thermal responses to localised 
CRMRF treatment (treated side)…………………………………………………………………130 
Figure 5.6b: CAP and RES mode energy-specific individual skin thermal responses to 
localised CRMRF treatment (treated side)……………………………………………………...131 
Figure 5.6c: CAP and RES mode power (peak)-specific individual skin thermal responses to 
localised CRMRF treatment (treated side)……………………………………………………...132 
Figure 6.1: Schematic representation of the five study conditions (groups)………….……..140 
Figure 6.2: Images showing the Biopac electrode placement and sample data streams from 
the SKT, PPG and NCV modules………………………………………………………………..142 
Figure 6.3: Sample images showing Doppler Ultrasound and Elastography recordings before 
and after CRMRF treatment……………………………………………………………...……....143 
Figure 6.4: Mean (SD) SKT responses from three groups…………………………………....147 
Figure 6.5: Mean (SD) SBF responses from three groups…………………………………....147 
Figure 6.6: Data from CRMRF high, CRMRF low and PSWT high groups, showing the 
individual treatment doses delivered…………………………………………………………….150 
Figure 6.7a: The mean (SD) SKT responses showing the baseline, post treatment and 20-
minute follow-up data from all five groups………………………………………………………152 
Figure 6.7b: Percentage change of the mean SKT from the baseline to post treatment and 
from the baseline to the 20-minute follow-up for all five groups……………………………...153 
18 
Figure 6.7c: SKT data from the three active groups showing individual responses at the 
baseline……………………………………………………………………………………………..153 
Figure 6.7d: SKT data from the three active groups showing individual responses at post 
treatment……………………………………………………………………………………………154 
Figure 6.7e: SKT data from the three active groups showing individual responses at the 20-
minute follow-up……………………………………………………………………………….…..154 
Figure 6.7f: SKT data from the three active groups showing individual percentage changes 
from the baseline to post treatment………………………………………………………….…..155 
Figure 6.7g: SKT data from the three active groups showing individual percentage changes 
from the baseline to the 20-minute follow-up……………………………………………….…..155 
Figure 6.8a: The mean (SD) SBF responses showing the baseline, post treatment and 20-
minute follow-up data from all five groups………………………………………………….......157 
Figure 6.8b: Percentage change of the mean SBF from the baseline to post treatment and 
from the baseline to the 20-minute follow-up for all five groups………………………….…..158 
Figure 6.8c: SBF data from the three active groups showing individual responses at the 
baseline…………………………………………………………………………………..…….......158 
Figure 6.8d: SBF data from the three active groups showing individual responses at post 
treatment…………………………………………………………………………………………...159 
Figure 6.8e: SBF data from the three active groups showing individual responses at the 20-
minute follow-up……………………………………………………………………………………159 
Figure 6.8f: SBF data showing individual percentage changes from the baseline to post 
treatment……………………………………………………………………………………..…….160 
Figure 6.8g: SBF data showing individual percentage changes from the baseline to the 20-
minute follow-up…………………………………………………………………………….…......160 
Figure 6.9: The mean (SD) NCV responses showing the baseline, post treatment and 20-
minute follow-up data from all five groups………………………………………………………161 
Figure 6.10a: The mean (SD) deep blood flow volume responses showing the baseline and 
post treatment data from all five groups…………………………………………………….......163 
Figure 6.10b: Percentage change of the mean deep blood flow volume from the baseline to 
post treatment for all five groups…………………………………………………………….......164 
Figure 6.10c: Deep blood flow volume data from the three active groups showing individual 
responses at the baseline…………………………………………………………………..…....164 
19 
Figure 6.10d: Deep blood flow volume data from the three active groups showing individual 
responses at post treatment……………………………………………………………………...165 
Figure 6.10e: Deep blood flow volume data from the three active groups showing individual 
percentage changes from the baseline to post treatment………………………………….....165 
Figure 6.11a: The mean (SD) deep blood flow intensity responses showing the baseline and 
post treatment data from all five groups………………………………………………………...167 
Figure 6.11b: Percentage change of the mean deep blood flow intensity from baseline to 
post treatment for all five groups…………………………………………………………………168 
Figure 6.11c: Deep blood flow intensity data from the three active groups showing individual 
responses at the baseline………………………………………………………………………...168 
Figure 6.11d: Deep blood flow intensity data from the three active groups showing individual 
responses at post treatment……………………………………………………………………...169 
Figure 6.11e: Deep blood flow intensity data from the three active groups showing individual 
percentage changes from the baseline to post treatment………………………………….....169 
Figure 6.12: The mean (SD) deep blood flow velocity responses showing the baseline and 
post treatment data from all five groups………………………………………………………...170 
Figure 6.13a: The mean (SD) hardness volume and the mean (SD) hardness intensity of the 
tissues showing the baseline and post treatment data………………………………………..171 
Figure 6.13b: The mean (SD) intermediate tissue volume and the mean (SD) intermediate 
tissue intensity of the tissues showing the baseline and post treatment data………………171 
Figure 6.13c: The mean (SD) softness volume and the mean (SD) softness intensity of the 
tissues showing the baseline and post treatment data………………………………………..172 
Figure 6.14a: The mean (SD) SKT responses obtained from the control leg………….…...172 
Figure 6.14b: The mean (SD) SBF responses obtained from the control leg………….…...173 
Figure 6.14c: The mean (SD) NCV responses obtained from the control leg………….…..173 
Figure 8.1: The study design for the clinical trial………………………………………..……..193 
Figure 8.2: The flow of participants through the clinical trial…………………………...……..202 
Figure 8.3: The mean CRMRF doses of all eight sessions…………………………………...203 
Figure 8.4: The mean (SD) CRMRF doses delivered to the active group participants over the 
eight sessions……………………………………………………………………………………...203 
Figure 8.5: The mean (SD) pain scores………………………………………………...……....205 
Figure 8.6: Percentage change in the mean pain scores from the baseline…………...…...205 
20 
Figure 8.7: The mean (SD) WOMAC global scores……………………………………..…….207 
Figure 8.8: Percentage change in the mean WOMAC global scores from the baseline......208 
Figure 8.9: The mean (SD) TUG scores……………………………………………………......210 
Figure 8.10: Percentage change in the mean TUG scores from the baseline……………...210 
Figure 8.11: The mean (SD) knee ROM……………………………………………………......212 
Figure 8.12: Percentage change in the mean knee ROM from the baseline………….……212 
Figure 8.13: Pain scores – males versus females…………………………………………......214 
Figure 8.14: WOMAC global scores – males versus females……………………………......215 
Figure 9.1: The experimental timeline for the physiological study on patients…………......225 
Figure 9.2: The mean (SD) SKTs from the three groups…………………………………......228 
Figure 9.3: Percentage change in the mean SKTs from the baseline……………………….229 
Figure 9.4: The mean (SD) SBFs from the three groups………………………….……….....231 
Figure 9.5: Percentage change in the mean SBFs from the baseline……………………….231 
Figure 9.6: The mean (SD) blood flow volumes from the three groups…………………......233 
Figure 9.7: Percentage change in the mean blood flow volumes from the baseline……….234 
Figure 9.8: The mean (SD) blood flow intensities from the three groups……………………235 
Figure 9.9: Percentage change in the mean blood flow intensities from the baseline……..236 
Figure 9.10: The mean (SD) blood flow velocities from the three groups………………......237 
Figure 9.11: Percentage change in the mean blood flow velocities from the baseline…….238 
 
 
 
 
 
 
 
 
 
 
21 
List of publications 
1) Kumaran B, Watson T. Radiofrequency-based treatment in therapy-related clinical 
practice – a narrative review. Part I: acute conditions. Phys Ther Rev. 2015;20(4):241-
54. 
2) Kumaran B, Watson T. Radiofrequency-based treatment in therapy-related clinical 
practice – a narrative review. Part II: chronic conditions. Phys Ther Rev. 2016;20(5-
6):325-43. 
3) Kumaran B, Watson T. Thermal build-up, decay and retention responses to local 
therapeutic application of 448 kHz capacitive resistive monopolar radiofrequency: A 
prospective randomised crossover study in healthy adults. Int J Hyperthermia. 
2015;31(8):883-95. 
4) Kumaran B, Herbland A, Watson T. Continuous-mode 448 kHz capacitive resistive 
monopolar radiofrequency induces greater deep blood flow changes compared to pulsed 
mode shortwave: a crossover study in healthy adults. Eur J Physiother. 2017;19(3):137-
46. 
5) Kumaran B, Watson T. Skin physiological effects of 448 kHz Capacitive Resistive 
Monopolar Radiofrequency in healthy adults: A randomised crossover study and 
comparison with Pulsed Shortwave Therapy. Electromagn Biol Med. 2018; pp 1-12. 
6) Kumaran B, Watson T. Treatment using 448 kHz capacitive resistive monopolar 
radiofrequency improves pain and function in patients with osteoarthritis of the knee joint: 
A randomised controlled trial (in press). 
7) Kumaran B, Watson T. Capacitive resistive monopolar radiofrequency (CRMRF) therapy 
at 448 kHz: localized application significantly enhances and sustains skin physiological 
responses. Physiotherapy. 2015;101:e798. (Abstract presented at the WCPT Congress 
2015 in Singapore). 
8) Kumaran B., Herbland A., Watson T. Capacitive Resistive Monopolar Radiofrequency 
(CRMRF) therapy at 448 KHz: The effects on deep blood flow and elasticity of tissues. 
(Abstract presented at the CSP Physiotherapy UK 2015 Conference in Liverpool, UK). 
 
 
 
 
 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
SECTION I: INTRODUCTION AND OVERVIEW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
1 Chapter 1 – Electromagnetism, radiofrequency and 
radiofrequency-based electrophysical agents: key 
concepts and project overview. 
 Research context 
Capacitive Resistive Monopolar Radiofrequency (CRMRF) that operates at the base 
frequency of 448 kHz is a relatively newer type of electrophysical agent (EPA) used in 
therapy-related clinical practice. Although EPAs delivering CRMRF are commercially 
available, their evidence base for therapeutic use is largely anecdotal. This programme of 
research investigated the physiological effects of CRMRF on asymptomatic adults as well as 
their clinical effects on patients. Besides, the project also evaluated the scope and evidence 
for the use of all radiofrequency (RF)-based EPAs in therapy operating in the frequency 
range of 30 kHz – 30 MHz (RF-based EPAs outside of this range are seldom used) through 
a review of existing literature. 
The CRMRF and other similar, but more commonly used EPAs such as shortwave therapies 
(SWT) employ electromagnetic fields (EMF) within the RF frequency range for their 
operation. The first chapter of this thesis will explore the background and basic principles 
that relate to EMF, RF and RF-based EPAs. An overview of the project with its rationale, 
aims and the key research questions that were addressed will also be presented. 
 Electromagnetic fields 
Electromagnetic fields are omnipresent. Besides gravity and the weak and the strong 
nuclear forces, ‘electromagnetism’ is one of the four natural forces. They form an 
unavoidable part of life on earth. In layman terms, the electromagnetic waves/spectrum (EM 
waves/EM spectrum) (Figure 1.1) are a series of regular waves that travel at a constant 
velocity, the velocity of light (approximately 3 x 108 ms-1). The main characteristic that 
defines an EM wave is its frequency (or the corresponding wavelength). The wave 
parameters wavelength and frequency are interconnected and are inversely related. The 
frequency of the wave is directly proportional to the energy the wave carries. Throughout this 
thesis, the EM waves in question will be identified based on their frequencies. 
The EMF frequencies range from as low as 1 Hz of the Extremely Low Frequency (ELF) 
EMF to as high as 300 EHz (Exahertz, which is 1018 Hertz) of the Gamma rays. There are 
different ways of interaction of these EMFs with the living body depending on the wave 
frequencies. This concept will be further developed in the subsequent sections of this thesis. 
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Figure 1.1: A representation of the electromagnetic spectrum comparing wavelength and 
frequency 
 
 
 
 
 
 
 
 
 Radiofrequency 
Radiofrequency radiations constitute a significant part of the EM Spectrum. They are 
undetectable to the human senses, unlike some of the other EM waves such as the visible 
radiation. There is a lack of consensus among the researchers on the frequency ranges that 
constitute RF. Although many investigators define RF energy as being specifically limited to 
the frequency range of about 30 kHz – 300 MHz (both CRMRF and shortwaves fall within 
this range), the Institute of Electrical and Electronics Engineers Inc. (IEEE) proposes a 
broader frequency range of 3 kHz – 300 GHz to define RF (Figure 1.2).1,2 In addition to the 
usual range of 30 kHz – 300 MHz, IEEE proposes a more inclusive very low frequency (VLF: 
3 – 30 kHz), the ultra-high frequency (UHF: 300 MHz – 3 GHz), the super high frequency 
(SHF: 3 – 30 GHz) and the extremely high frequency (EHF: of 30 – 300 GHz) ranges.1 To 
put into context, the RF biological literatures that will be covered in this thesis were not 
collated based on the above frequency groupings. The emphasis placed on the literature 
within 30 kHz – 30 MHz was based on contemporary clinical practice. 
Figure 1.2: Frequency distributions of RF as proposed by IEEE 
 
 
 
 
Applications of RF are numerous. Their role is pivotal in communication, many industries, 
and in healthcare where they play a key role in various diagnostic, therapeutic and 
monitoring procedures in medicine. Whilst the RF literatures pertaining to these areas are 
Infrared (non-RF) EHF RF SHF RF UHF RF Normal range RF VLF RF ELF EMF (non-RF)
Frequency above 300 GHz 30 - 300 GHz 3 - 30 GHz 0.3 - 3 GHz 30 KHz - 300 MHz 3 - 30 KHz Frequencies below 3 KHz
Radiofrequency range
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substantial, they are beyond the primary focus of this thesis. The focus of this project will 
largely be limited to the non-invasive use of RF for treatment in therapy-related clinical 
practice. 
 Radiofrequency and biological systems 
To date, several thousand studies have examined the interactions between RF and 
biological systems, either advantageous or hazardous or both. Whether in vitro or in vivo; or 
whether in animals or in human beings, these studies have employed RF energy either in 
continuous or in pulsed modes. This section of the thesis will briefly discuss the interaction 
of RF with the biological systems, their underpinning mechanisms and effects. 
1.4.1 RF-tissue interaction 
The interaction between EMF (including RF) and biological systems is a process that occurs 
at three levels as illustrated in Figure 1.3 below. At first the external field couples with the 
field generated inside the body. Then this new induced field at the cellular or subcellular 
level couples with the target tissue, which then leads to a response from the target structure 
to the external field. 
Figure 1.3: EMF – tissue interaction (adapted from Foster 2000)3 
 
 
 
 
 
 
A biological response to an RF field must begin with the interaction of electric or magnetic 
field with an atom, molecule, or molecular system such as a cell membrane or neuron. This 
must be followed by a biochemical response leading to a functional alteration of the cell 
and/or organism (tissue response).3-7 
The ELF EMF (non-RF) primarily flows through the extracellular space in the tissues as the 
cell membranes offer high impedance with the charges getting accumulated against them, 
whereas at higher frequencies of 100 – 1000 kHz (0.1 – 1 MHz), the field flows through intra 
as well as extracellular spaces.3,4 Coupling the ELF field energy to the body (tissues) 
through air is difficult owing to the conductivity of body tissues. Hence in physical terms, if 
the body is considered a high-pass filter the cut off frequency for transmission is in the lower 
megahertz frequency range.3 Ultimately, the level of biological effect is determined by the 
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level of absorption of the EM energy into the tissues and the properties of the exposed 
tissues that enable it.8-11 The absorption can be quantified by a parameter known as the 
specific absorption rate (SAR). It is a numerical representation for the rate at which energy is 
absorbed by a known mass of tissue and varies by the frequency of the wave and the type 
of tissue.3,12,13 The SAR is calculated in watts per kilogram (Wkg-1). 
1.4.2 Thermal versus nonthermal effects of RF 
Many mechanisms, both ‘thermal’ and ‘nonthermal’ are proposed by which RF can interact 
with the biological systems regardless of whether they can produce any observable effects 
at practical exposure levels. However, the issue of 'nonthermal' effects is a matter of debate 
among the researchers, as to how much do they exist if they do, their possible health risks 
(for example harmful radiations from communication systems or health care systems), and 
the exposure conditions that might bring those effects.3,4,6,14-17 
While the term 'nonthermal' should ideally refer to the mechanism of RF interaction with the 
tissues rather than the low magnitude of temperature increase from the exposure, a potential 
source of ambiguity is caused by many authors associating ‘nonthermal’ with the latter 
meaning. In therapy and biophysics, this is further compounded with the use of terms such 
as ‘microthermal’ or ‘quasithermal’ to refer to substantially low levels of thermal changes in 
tissues. Besides, there is the issue of ‘imperceptible’ thermal changes that may often be 
termed as nonthermal. That is, there is a real thermal change much as very small, but the 
therapist and the patient (recipient) are unable to perceive it. 
Gross thermal effects might result from bulk temperature increase or from the rate of 
temperature increase even though the bulk temperature might be small. Non-thermal effects 
are thought to be evoked by SARs that do not cause a measurable rise in gross tissue 
temperature, and happen at cellular level, influencing the function of cell membranes and 
organelles.3,4,16,18 Several thermophysiological responses are induced by the conversion of 
RF energy into heat energy in tissues4,17,19,20 such as a rise in tissue temperature (both skin 
and deep), heat induced vasodilatation, increased blood flow (potentially both skin and deep 
blood flow), changes in the rates of biochemical reactions and changes in peripheral nerve 
conduction.1,21,22 As suggested, the extent of these responses will depend on several factors 
(relating to the wave and tissues) that determine the SAR such as the frequency of the 
wave, the thermal conductivity and thermal capacity of the tissues that absorb the energy, 
the rate of energy absorption, the rate of metabolism in the treated tissues and whether the 
circulating blood is able to dissipate the generated heat effectively.8-11 
Because of energy transfer into the tissues, all interactions between RF and biological 
systems are likely to increase tissue temperature. However, the nonthermal mechanisms are 
not believed to be directly associated with this temperature change. Other effects produced 
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by the RF fields in the tissues such as excitation of molecular vibrations, changes in protein 
conformation and changes to the behaviour of cell receptor proteins are proposed to be 
behind the nonthermal effects.21,23,24 Nonetheless, this is potentially a complex issue since it 
may be argued that an increase in molecular vibration and production of heat are 
synonymous and not mutually exclusive. 
At thermal doses, RF EMF evokes thermophysiological responses in the exposed tissues 
and the body as a whole.17,20,22 While the majority of the research conducted in this area is 
on laboratory animals (mainly rodents), studies on human exposure have also been 
reported.25-29 There are limitations to the extrapolation of the results obtained from animal 
models to human beings for most of the physiological systems. This is because the lab 
animals such as rodents are considered poor models for human beings owing to their limited 
physiological heat loss mechanisms. For example, while humans (wearing clothes) have a 
thermoneutral zone of 22–25 oC, rodents (mainly mice) have a higher thermoneutral zone of 
around 30 oC.30-32 Their inability to sweat through the hairy skin might make pigs a better 
alternative in some work. Whether the research itself was carried out on hair free skin is 
another issue to be considered. 
Some researchers argue that low-level nonthermal biological effects of RF do exist below a 
few megahertz and might be possible at frequencies as high as a few hundred megahertz 
(True nonthermal effects of RF might exist only below certain frequencies (<10 MHz) of the 
wave).6,7 Others argue that per se the frequencies of RF higher than 10 MHz may not induce 
any physiological effect at cellular level in the absence of heating.33 However, there is a lack 
of theoretical or experimental support for such effects between about 100 MHz and 150 GHz 
despite the extensive research in this area.4-7,26,34,35 Furthermore, thermal effects can occur 
even at very low levels of thermal change, as cell metabolism can be affected by even 
fractional changes in temperature. Since biological systems are constructs of molecules held 
together and affected by 'Coulomb' forces, it is reasonable to expect that RF might interact 
with them. However, to affect these systems with external fields, energy must be pumped in 
either causing both conformation and functional change or imposing fields large enough to 
affect the function of one or more of the various endogenous fields.5,20 
The endogenous fields that are linked to the biological processes can be disrupted or 
affected by the application of external fields on the same order of magnitude or greater, 
when applied with the proper direction, timing and frequency.36 The applied fields that 
augment these endogenous fields promote the biological activity and the applied fields that 
diminish them will have a suppressive effect. Experiments in plant cells showed that 
nonlinear behaviour at cell membranes does not occur above approximately 10 MHz in the 
absence of heating, which were later supported by theoretical analysis and recent 
experimental work in humans.33,37,38 RF fields at frequencies exceeding a few megahertz are 
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not rectified by the biological systems efficiently enough to affect endogenous fields, 
particularly by mechanisms involving electrical potential changes at the plasma 
membrane.5,6 It is well known that a single RF photon is not energetic enough to cause 
ionization. Hydrogen bonds, considered the weakest of chemical bonds, are on the order of 
1 – 5 kcal/mol, which would be equivalent in energy to a 10 THz (terahertz) photon. Much as 
RF cannot directly contribute to the breaking of chemical bonds, they are potentially capable 
of exciting molecules (cause them to vibrate). Such excitation and the associated heat 
mediated effects lead to changes in biochemical processes with demonstrable biological 
consequences.6,7 
1.4.3 RF tissue absorption 
During RF exposure, energy may be selectively deposited in specific tissue beds, their 
pattern varying with many physical factors of both the radiation and the target tissue. RF 
exposure may or may not produce a warm environment in the tissue depending on many 
parameters of the signal such as the frequency, intensity of application, duration of 
exposure, as well as the body locus and the exposed surface area. Higher RF frequencies 
(10 GHz or above) generally have a similar absorption profile as infrared (IR), getting 
absorbed in the most superficial layers of the skin. However, lower RF frequencies will be 
absorbed in complex patterns at other depths. In humans, a prediction of the ensuing 
thermal sensation is difficult because of the lack of thermoreceptors at depth. Irradiation of 
small skin areas by three or 10 GHz pulsed microwave (PMW) had to last at least five 
seconds for the minimal intensity to evoke a thermal sensation and the exact intensity 
depended on the area stimulated.3-5,14,21,39,40 Historically, pulsed wave (PW) radiation has 
been found more likely to produce certain biological effects than continuous wave (CW) 
radiation at the same average incident PD, with support from several studies.22,41 
1.4.4 Biological effects of RF 
There is extensive literature surrounding the effects of RF on biological systems. The 
literature relating to the health effects of RF can be classified as those studies that 
investigate the physiological / clinical responses due to intended exposure and those that 
investigate their adverse / undesirable effects, mainly due to occupational / unintended 
exposure to RF. The adverse health effects due to occupational or experimental exposure 
have been studied for several decades. They include numerous studies and their reviews on 
physiological systems such as the central nervous (CNS), cardiovascular (CVS), endocrine, 
reproductive and immunological systems; and specific conditions such as cancer and 
tumours.2,42,43 
A significant proportion of the experimental research on the biological effects of RF has been 
conducted on laboratory animals, with emphasis on rodents. A large proportion of 
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epidemiological studies published in recent years have addressed the potential health 
concerns from mobile phones. Although RF could cause various biological changes, the 
consensus is that either the epidemiological studies or the human exposure experiments 
does not suggest an actual health risk 1,21,44-46 from RF in general, or specifically from low 
frequency RF (<10 MHz).1,47 Furthermore, distinguishing the normal biological effects from 
adverse health effects is crucial, since many reported effects were within the normal 
physiological ranges. The relevance to health hazards is therefore uncertain.1,48 
The issue of the biological effects of RF formed the basis of this research project, which was 
investigated in multiple stages. As stated at the beginning of this chapter, the pertinent 
literature on all RF-based EPAs in therapy-related clinical practice and associated literature 
from experimental studies were reviewed. The physiological and clinical effects of RF at 448 
kHz were investigated in laboratory and hospital-based settings on asymptomatic adults and 
adult patients respectively. The rest of this chapter will provide a brief overview of the project 
and its development, its rationale, the research questions and overall aims.  
 Overview of the project 
1.5.1 Development and sequencing 
The funding for this study was provided by the external stakeholder (commercial 
organisation), who are a device manufacturer based in the EU (Indiba S. A., Barcelona, 
Spain). The manufacturer wished to conduct a study to investigate the clinical efficacy of 
CRMRF in a patient population. Upon discussions between Professor Tim Watson and 
Indiba S. A., it was concluded that the study should address wider issues including both 
physiological and clinical effects of CRMRF owing to its lack of evidence in the 
contemporary literature. At the time, it was also agreed that the study will be further 
developed and conducted as a PhD project. A draft outline of the main aims of the project 
and the potential phases of study were proposed by the principal supervisor (Professor Tim 
Watson) prior to the involvement of the research student (Binoy Radha Kumaran). These 
proposals were further developed by the student into a project containing three phases 
(phases I – III) in a logical order, to investigate the theoretical construct, existing evidence 
and the physiological and clinical effects of CRMRF-based therapy. 
In phase I, a general review of the relevant RF literature in relation to its biological effects 
and theoretical underpinning; and a detailed review of the relevant evidence base for the use 
of RF-based treatment in therapy-related clinical practice were planned. The findings from 
phase I were expected to inform the content and design of a phase II study, where a series 
of laboratory experiments were planned. A robust evaluation of the physiological effects of 
CRMRF in asymptomatic volunteers was expected to enable a fundamental consideration of 
the primary effects of this therapy. The phase II involved a step by step investigation of the 
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optimum dosage and delivery methods for CRMRF and the various skin and deep 
physiological effects to its multiple doses of delivery. Further, the findings from phase II was 
expected to help design a clinical study (as phase III) involving an appropriate patient group. 
CRMRF being an EPA designed to be used in the realm of therapy-related clinical practice, 
the researchers concluded that it was imperative to investigate the effects in a clinical 
population, regardless of the outcomes of the physiological studies in phase II. The aim was 
to conduct a robust randomised controlled trial (RCT) with sufficient statistical power; 
however, the researchers were aware that time and funding constraints could lead to the 
phase III being limited to a pilot or a feasibility study. In the end, with the help of extended 
time as well as extended funding, the project could achieve an adequately powered RCT in 
phase III. 
This research project started in February 2012. The phase I was completed by May 2013. 
The phase II was completed by December 2014. In phase III, the clinical trial endured 
substantial and unforeseen delays owing to several administrative hurdles. Eventually, it 
started in January 2016 and was completed by the end of October 2016. The content 
reported in this thesis is solely the work designed, carried out, analysed and written by the 
research student and the external stakeholder had no role in the process. 
1.5.2 RF-based treatment in therapy-related clinical practice 
RF-based EPAs have been used in physiotherapy since the early decades of last century.49-
54 Three types of RF modalities, which operated on three distinct frequency ranges in the RF 
spectrum, were mainly in use. Longwave diathermy (0.5 – 1.0 MHz) became obsolete in the 
1950s owing to its interference with the communication and broadcasting frequencies.55 
Shortwave therapy (SWT) (otherwise known as shortwave diathermy, or SWD) (27.12 MHz) 
and Microwave therapy (otherwise known as microwave diathermy, or MWD) (up to 2.45 
GHz) became more established. The literature on microwave therapy and longwave 
diathermy will not be considered in this thesis since the focus here is on EPAs that are still 
frequently used in therapy practice. Evidence suggests that microwave therapy is currently 
not commonly used in many countries.56-59 
Although historically SWT was used in several different frequencies, they were not the same 
in all countries. In 1947, three frequencies at the short end of the RF band (40.68 MHz, 
27.12 MHz and 13.56 MHz) were assigned by the Federal Communication Commission of 
the United States Government for the medical use of shortwave. This was done as an 
attempt to regulate the use of high frequency currents in different disciplines.60 The 
allocation of these frequencies relates to international regulation rather than their clinical 
efficacy. Of the three frequencies, 27.12 MHz is the most widely used in current clinical 
practice.18 
31 
There are two modes of SWT: continuous (CSWT) and pulsed (PSWT). The CSWT was the 
first to have become available, being widely used by clinicians since the early decades of 
20th century.49-54 However, the evidence suggests that CSWT has now become less popular 
and rarely used (especially in the western world).56,61 It may be argued that this drop in 
popularity is partly linked to a ‘fashionable shift’ since there is in fact an evidence base in 
favour of CSWT.18 On the other hand, PSWT, which was developed in the 1940s, is still in 
use among about 11% of outpatient clinics in the UK.56,61,62 
1.5.3 Rationale 
In addition to the above three modalities, RF-based devices operating at significantly lower 
frequency ranges (below 1 MHz) have also been used. However, despite a lack of robust 
research evidence such EPAs have become commercially available and used by therapists 
worldwide since many years. The CRMRF is one such relatively newer type of low frequency 
(448 kHz) RF used in the realm of physiotherapy and rehabilitation in many countries in 
Europe (e.g. Spain, Italy, Germany, France) and elsewhere (e.g. Singapore, Japan, Brazil). 
Consistent with the above statement the CRMRF evidence base for therapeutic use is 
largely anecdotal. This programme of research was designed to investigate the physiological 
effects of CRMRF on asymptomatic adults as well as their clinical effects on patients. 
Besides, the project also evaluated the scope and evidence for the use of all RF-based 
EPAs generally used in therapy practice, through a comprehensive review of existing 
literature. 
Throughout the various study elements of the project, CRMRF was delivered using the 
device named 'Indiba Activ 902', which is a commercially available kit manufactured by 
Indiba S. A., Barcelona, Spain. The project itself is funded by Indiba S. A.; however, the 
industry funders had no role in the designing and overall administration of the study, 
collection and analysis of data, or in the preparation of this thesis. 
The key aims, and research questions of this project are listed below. To address those 
aims three phases of research were undertaken: literature review, laboratory-based 
physiological study and hospital-based clinical study. These are covered in detail in the 
chapters that follow. 
1.5.4 Key aims and research questions 
1.5.4.1 Primary research questions 
1) How robust is the evidence base to support the use of RF-based treatment in 
therapy-related clinical practice? 
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2) What are the effects of 448 kHz CRMRF on the skin and deep physiological 
parameters in an asymptomatic population, and how do they compare with that of 
PSWT? 
3) Do the above-mentioned physiological effects vary between asymptomatic adults 
and patients? 
4) Does 448 kHz CRMRF therapy provide increased clinical benefits in patients with 
osteoarthritis of the knee joint when compared to the current exercise-based 
standard care or to a placebo? 
1.5.4.2 Overall aims of the programme of work 
1) Investigate the theoretical construct and the physiological and clinical effects of RF-
based EPAs in therapy-related clinical practice through a review of existing literature. 
2) Design a robust methodology and investigate the physiological effects of CRMRF on 
asymptomatic adults in a laboratory-based study and compare those effects to those 
obtained with existing similar RF-based EPAs such as PSWT. 
3) Based on the methodology evolved from the laboratory study, investigate the 
physiological and clinical effects and efficacy of CRMRF therapy in a randomly 
selected cohort of patients with knee osteoarthritis. 
4) Contribute to the body of existing evidence through dissemination of the above 
research findings and make recommendations for future research. 
 Conclusions 
Radiofrequency energy is omnipresent and is inseparable from our everyday lives. The 
biological effects of RF are proposed to be thermal, nonthermal, or both. While the thermal 
mechanisms of action are well established, the ‘so called’ nonthermal mechanisms are less 
clearly understood and are hence controversial. There is an extensive literature base that 
covers the biological effects of RF, although only part of it is specifically relevant to the 
purpose of this research project. Among the innumerable applications of RF, their use in 
therapy-related clinical practice forms the basis of this thesis. The current chapter provided 
an insight into the physics and theoretical underpinning of RF in general and the principles of 
RF-tissue interaction. The chapter has also laid down the rationale and key aims of this 
research project. The chapters in Section II will discuss the biological and clinical literature 
concerning RF in greater detail.  
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2 Chapter 2 – Literature review on the biological effects of 
radiofrequency: methodology and main results. 
 Introduction 
While the previous chapter provided a brief overview of RF as a whole, its physics and 
underpinning theory, the present chapter aimed to identify the literature directly relevant to 
the research questions addressed in this project. There is extensive literature on the 
biological effects of RF in the high frequency band (Microwaves: 300 MHz – 300 GHz). The 
smaller RF bands (10 – 100 MHz) that include the shortwaves and frequencies below 
shortwaves (30 kHz – 10 MHz) have also been studied, although to a lesser extent. These 
smaller frequency bands are mainly of use in present day therapy practice.1,19,63-107 
Radiofrequencies below the shortwave frequency band are the least researched of all.  
As stated in the previous chapter, three types of RF-based EPAs have mainly been used 
since their inception: Longwave diathermy, microwave diathermy, and pulsed / continuous 
SWT, of which PSWT is the most commonly used in contemporary practice. Besides PSWT, 
pulsed RF at 27.12 MHz is also employed by devices bearing other names such as pulsed 
electromagnetic energy (PEME), pulsed electromagnetic field (PEMF), pulsed high 
frequency electromagnetic energy (PHFE) or pulsed radiofrequency energy (PRFE). Such 
diverse nomenclature is a reason for confusion within the existing literature, not just because 
of the multiple names used for potentially similar devices, but also because some of these 
devices employ EMF outside of the shortwave frequency band108-120 while some use an RF 
frequency of 27.12 MHz.121-133 The devices that use 27.12 MHz as their operating frequency 
are fundamentally similar to PSWT. The dissimilar names appeared potentially because of 
some of the device manufacturers using different terms instead of the more generic PSWT. 
Throughout this thesis the term PSWT will be used collectively for devices that use a pulsed 
RF frequency within the shortwave frequency band to ensure consistency. 
The RF currently used in therapy-related clinical practice (based on literature published in 
English) is predominantly in the shortwave frequency band and largely limited to PSWT as a 
delivery mode.18,56,61,134-136 As stated in Chapter 1 RF-based devices operating at 
significantly lower frequency ranges (below 1 MHz) have also been reported and used in 
clinical practice despite a lack of robust evidence. The use of SWT for various specific 
clinical conditions have been well reviewed,49,61,135,137-139 although no one review covered all 
the therapy-related clinical literature in this frequency spectrum. Owing to the lack of clinical 
literature, no similar reviews are available for RF-based EPAs below the shortwave 
frequencies. This literature review aimed to: 
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1) Identify all relevant RF publications covering the frequency range of 30 kHz – 30 
MHz including clinical and non-clinical literature. 
2) Undertake a detailed narrative review of all relevant therapy-related RF clinical 
studies conducted on human patients. 
 Methods 
2.2.1 Search strategy and reference management 
Multiple sources, including the core subject specific electronic databases, printed 
publications, text books and other online resources were searched to identify peer-reviewed 
and published literature as well as the grey literature. Online bibliographic databases 
PubMed, Scopus, ISI Web of Science and CINAHL Plus were used for the electronic 
searches. Google Scholar was also used as an additional source and a source to identify the 
grey literature. Further hand searching of the reference lists of relevant publications and 
texts helped in revealing papers those were initially not identified through the electronic 
searches. EndNote X6 (Thomson Reuters) software package was used to manage the 
references. 
Publications from all the years to date (October 2016) were identified using key word (main 
search terms) searches. The results were then filtered using additional words/terms (primary 
filter). A ‘primary pool’ of articles dealing with the RF frequency range of 30 kHz – 30 MHz 
was then formed using a string of filter terms (secondary filter) and removing the duplicates 
using the EndNote filter. The full list of key words and filter words/terms used for searching 
the literature is given in Appendix 2.1. This pool contained all kinds of clinical, non-clinical, 
and review articles. The flowchart given in Figure 2.1 works through the process of literature 
searching. 
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Figure 2.1: Schematic representation of the literature search process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.2 Narrative review 
From the clinical studies in the primary pool, all studies that met the following criteria were 
selected for the narrative review. 
1) Published in English. 
2) Relating to any condition in therapy-related clinical practice. 
3) Conducted on human patients in vivo. 
4) Non-invasive and non-ablative methodology. 
An all-inclusive methodological approach was followed for this review. This was different to 
the methodology of a systematic review in that it did not exclude studies based on their 
study design or overall quality, which is usually the norm. Related and unrelated examples of 
several such all-inclusive reviews that adopted a similar methodology can be found in 
contemporary therapy literature.140-143 
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The included clinical studies were stratified as shortwave or non-shortwave (based on the 
frequency of RF employed), and as acute or chronic (based on the type and duration of 
clinical condition involved). Shortwave studies were those which employed devices 
generating RF waves of 10 – 30 MHz and non-shortwave studies were those which 
employed devices generating RF waves of 30 kHz – 10 MHz. Further stratifications were 
also done based on the study design (clinical trial, cohort study, case series) and the clinical 
category (pain and inflammation, tissue healing, others (all other less reported conditions, 
e.g. – acute pneumothorax)). 
An ‘acute’ condition was considered as a condition not older than 4 – 6 weeks and a 
‘chronic’ condition as a condition older than six weeks. Categorising studies in to distinct 
acute and chronic groups solely based on the duration of condition or the nature of the 
clinical category may not always be a valid method. This is because some of these 
conditions may overlap to a varied extent. However, there is no explicit definition given to the 
terms ‘acute’ and ‘chronic’ in the existing literature.144,145 Personal opinion or anecdotal 
evidence has tended to have played a major role in the durations used for such 
classification.146 
The methodology described above, which was used for categorising the included studies, 
was adopted in this review based on clinical practice. There are no specific guidelines 
available in this regard. Acute and chronic is potentially the commonest form of distinct 
categorisation employed in therapy practice since treatment goals, strategies, methods and 
outcomes could vary greatly between the two and it is important to approach them 
differently. Likewise, RF-based EPAs appeared to have been used mostly for conditions 
relating to either pain and inflammation or tissue healing (results of the review explained 
below). Hence, grouping the studies based on these categories was considered prudent and 
more relevant to clinical practice than any other potential forms of classifications. 
2.2.3 Quality assessment of studies 
The Cochrane risk of bias assessment tool147 (where appropriate) (Appendix 2.2) was used 
to screen the methodological quality of the studies, and the checklist proposed by Downs 
and Black148 for randomised and non-randomised studies (Appendix 2.3) was used to score 
them. The Downs and Black checklist contains 27 items concerning the quality of reporting, 
validity, bias and statistical power of the studies (maximum score of 32; higher the score 
better the quality of the study), and is a valid tool for assessing the methodological quality.149 
Modified versions of this checklist have also been used by some authors as a more 
appropriate tool, which was done by simplifying the ‘item 27’ (originally scored 0–5) that 
assesses statistical power.150,151 This is because the assessment of statistical power in the 
original version of the checklist is complex and is difficult to be applied to many studies. A 
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similar modified version was used in the current review. The item 27 was rated as either 
‘zero’ (insufficient power) or ‘one’ (sufficient power) for this review. The maximum possible 
score was hence 28. 
 Main results 
The ‘primary pool’ obtained after the broad literature search and the subsequent filtering to 
exclude the duplicates and irrelevant literature contained 604 articles within the 30 kHz – 30 
MHz frequency range. The flow chart that explains the stages of the filtering is given in 
Figure 2.2. Figure 2.3 provides the breakdown of the types and numbers of articles in the 
primary pool. The clear majority of these (567 articles, 94%) were shortwave studies and 
only 51 were non-shortwave studies. A few of them (14 articles) overlapped these nominal 
groupings. 
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Figure 2.2: Stages of filtering from the ‘primary pool’ of articles 
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Figure 2.3: Types and numbers of articles in the primary pool 
 
 
 
 
 
 
 
 
After the exclusions 120 clinical studies met the four criteria set for the narrative review. 
While 112 (93%) of these were shortwave studies, only eight were non-shortwave studies. 
Two potentially suitable studies employing shortwave were excluded as they had no proper 
abstracts and their full-texts were unavailable through the available resources.152,153 Overall 
89 studies related to pain and inflammation and 23 to conditions of tissue healing. A mixture 
of eight studies relating to less reported conditions (e.g. acute pneumothorax) was classed 
as ‘others’. Similarly, while 85 studies were multi-group trials, 30 were case studies and the 
remaining five of them were cohort studies (Figure 2.4). However, as identified, clearly there 
was potential overlap among the clinical application categories, such as between studies 
that considered tissue healing and that considered pain and inflammation. The allocation of 
papers to their groups was based on the primary outcome(s) as identified by their authors 
(e.g. pain, rate of healing). Only a third the studies (30 studies, 25%) investigated acute 
clinical conditions whereas the remaining 90 studies employed chronic clinical conditions. 
Except for five studies154-158 the full texts were available for all the studies included in the 
review. The abstracts of these five studies were available; hence the main results reported in 
those abstracts were drawn for this review. 
Figure 2.4: Clinical application categories and types of studies 
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The clinical studies will be reviewed in detail as acute and chronic categories in chapter 3. 
The rest of this chapter will briefly explore the RF-based studies outwith the clinical literature 
although a detailed review was not intended. 
 Radiofrequency-based treatment: the non-clinical literature 
This section will identify the relevant non-clinical RF literature outside of the 120 studies 
included in the narrative review. They include all the animal studies, healthy-human studies 
and the in vitro studies conducted on human or animal cell/tissue models. A limited number 
of experimental animal studies that simulated certain clinical conditions were also identified 
in both acute and chronic categories. Such studies will be discussed in more detail, so that 
comparisons with clinical studies can be drawn. 
2.4.1 Human studies in vivo on asymptomatic people 
The studies that investigated the physiological effects of RF on healthy people can be 
classified into various groups depending on the physiological parameters that were being 
investigated. Predominantly, the effects relating to thermophysiological responses such as 
tissue temperature,81,83,89,95,96,105,159-172 blood flow,19,79,86-88,90,92,173-184 or both temperature and 
blood flow77,80,85,104,185-187 were investigated. Many studies have also investigated connective 
tissue (e.g. muscle and tendon) responses to RF exposure,82,84,91,94,101,106,188-190 while some 
other studies investigated physiological responses such as the effects on peripheral 
nerves78,191,192 and immunological markers.193 None of the above in vivo studies employed 
RF below the shortwave frequency band. 
Many of the above studies employing RF devices that investigated the human 
thermophysiological responses such as temperature, blood flow and nerve conduction were 
comparable to the studies carried out in this project.77,80,85,86,187,192 Several of these studies 
that mostly employed RF at the shortwave frequency band investigated skin and/or deep 
thermal responses of humans to RF exposure.77,80,81,83,85,95,96,105,194 Among them many of the 
earlier published studies77,81,85,96 reported a significant rise and maintenance of both skin and 
intra-muscular temperatures. A more recent study that closely related to the methodology 
employed in this project was the study by Bricknell and Watson (1995).105 They employed 
incremental doses of PSWT on asymptomatic participants and reported their dose 
parameters that produced a ‘possible thermal perception’ (Mean ‘mean power (MP)’ of 6.58 
(±3.50) W) and a ‘definite thermal perception’ (Mean MP 10.88 (±3.32) W) on the skin. 
In another study, which was conducted at the University of Hertfordshire, Al-Mandeel and 
Watson80,192 reported significant rises in the skin temperature with high and low doses of 
PSWT (MP dose of 24 & 3 W respectively). Draper et al. (1999)83 investigated the 
temperature changes inside the gastrocnemius muscle in response to a 20-minute PSWT 
exposure (MP dose of 48 W). A mean (SD) temperature rise of 3.49 (±1.13) oC was reported 
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after the treatment and a decay of 1.78 (±0.69) oC was reported in the first 10 minutes post-
treatment. The methodology of this study was unrelated to that used in the current project as 
it was an invasive study (discussed in Section III). 
Likewise, among the studies that investigated the effects of PSWT on blood flow, some 
studies have proposed a significant rise in skin and/or muscle blood flow after treatment with 
PSWT19,176 while it has been disputed by others.90 Similar to the rise in tissue temperature as 
mentioned above, Al-Mandeel and Watson80,192 also reported a significant rise in blood flow 
in the skin during treatment with PSWT (MP dose of 24 W). However, this response dropped 
significantly once the PSWT exposure was stopped. Besides the studies on PSWT, further 
shortwave studies were reported employing CSWT, which suggested a high and/or 
sustained increase in temperature,81,96 blood flow,79,86 and both temperature and blood 
flow.77,85 Comparison of the effects of similar average doses of PSWT and CSWT on blood 
flow are also available.19 
Studies employing shortwave that investigated blood flow in deeper tissues and conducted 
on either healthy subjects19,77,91,195 or patients196-198 have also been reported similar to the 
current project. The current evidence available from the literature on the deep circulatory 
effect of PSWT is mixed.19,90 Morrisey (1966)90 reported that while irradiation of the calf 
muscles or abdomen using PSWT for 15 min at 40 W did not have any significant influence 
on the volume of blood flow in the leg, an 80 W exposure to the calf caused a significant 
increase in the blood flow. Similar increase in calf and foot blood flow after a 20-min 
abdominal exposure to PSWT at 65 W was reported by Silverman and Pendleton (1968),19 
while a 15 W abdominal exposure did not have any significant impact. These results 
demonstrated a dose response relationship. 
As evident from the main results of this review, overall a very low number of non-clinical 
studies employed RF below the shortwave frequency band. No in vivo human studies 
relating to this research project were found among them. 
2.4.2 Animal studies, in vitro studies on cell and tissue models 
Several RF studies conducted on either animals or in vitro tissue models have been reported 
over the past century. Unlike the healthy-human studies identified above, some studies that 
employed RF below the shortwave frequency band have also been identified in this 
category,98-100,102,199-205 all of which were in vitro studies unrelated to therapy practice. The 
animal studies belonging to the shortwave frequency band were related to a variety of 
experimental conditions such as the effects on bone and joint tissues,73,74,76,103,206-209 muscle 
and tendon,67,68,75,188,210 neural tissues,121,122,211,212 blood,70,213 tumours,165,214 histamine,215,216 
cardiorespiratory system,217 metabolism,218 wound healing,69 skin flaps219 and infection.93 
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Several in vitro studies conducted on human or animal tissue substrates employing RF 
within the shortwave frequency band were also identified.64,202,220-225 
2.4.3 Experimental animal studies simulating acute clinical conditions 
Six animal studies were identified in total, of which four studies investigated the effects of 
SWT on healing of acute experimental wounds. Two of these studies were based on the 
healing of skeletal muscle injuries67,68 and one study each was found on bone injury103 and 
skin wound.69 Of the remaining two studies, one study each investigated the resolution of 
experimental haematomas70 and arthritis73 with the application of PSWT. 
Hutchison (1951)103 conducted two experiments on adult dogs with bilateral tibial grafts and 
adult male rabbits with radial fracture. Conventional CSWT was used in both experiments at 
a ‘mild thermal’ dose (20 minutes twice daily). In both experiments, the authors concluded 
that CSWT ‘significantly delayed’ the healing of fractures and bone grafts compared to the 
untreated control group animals. These findings are contrary to the findings of the clinical 
study by Cameron (1964)226 (discussed in Chapter 3). Similarly, rabbits with skin cuts and 
guinea pigs with third degree skin burns were subjected to PSWT (38 W MP for 10 minutes 
once daily) by Constable and colleagues.69 Unlike the results from the clinical studies 
discussed in Chapter 3, PSWT did not improve wound healing in either of the animal groups. 
Calf muscle injury in rabbits, which was induced by injecting ‘xylocaine’ was treated by 
PSWT (dose parameters not fully reported) for 20 minutes twice daily for either eight or 16 
days in the study by Brown and Baker (1987).68 While the 8-day treatment failed to influence 
muscle healing, a trend towards enhanced healing was observed with a 16-day treatment 
programme. In another study on the effects of CSWT (five minutes daily for seven days at 
an intensity producing ‘bearable heat’) on induced biceps femoris muscle injury in adult 
dogs, Bansal and colleagues67 demonstrated early maturation of the collagen fibres at the 
healing site as well as regeneration of the injured muscle fibres. It is unclear how the authors 
could adjust the dose as ‘bearable heat’ in an animal model. Both the above studies were 
comparable to the clinical studies on postoperative wound healing discussed later in Chapter 
3, though the results were conflicting. 
Fenn (1969)70 reported the effects of PSWT (30 minutes twice daily for 9 days; dose 
parameters not fully reported) on experimental haematomas induced in the ears of 30 male 
rabbits. Fifteen actively treated animals demonstrated a significantly faster resolution of the 
haematoma compared to another group treated with a placebo. Similarly, Nadasdi (1960)73 
used PSWT (10 minutes for up to four times; dose parameters not fully reported) in rats with 
experimentally induced arthritis of the tibio-calcaneal joint. Significant inhibition of arthritis 
was obtained with PSWT when compared to the non-treated group. In another study, 
Silverman (1964)93 showed that either CSWT or PSWT was no different to a control or a 
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placebo condition in treating infected mice. Mice inoculated with pneumococcus bacterial 
colonies were irradiated for 15 minutes twice daily for three days or till the animals died. The 
treatment failed to improve the survival rate or time. No clinically relevant human studies 
were identified under any of these three conditions. 
2.4.4 Experimental animal studies simulating chronic clinical conditions 
Unlike for acute conditions, the researcher identified only one animal study74 that evaluated 
the effects of RF-based therapy that was directly relevant to chronic clinical conditions. 
Vanharanta (1982)74 investigated the effect of continuous shortwave therapy (CSWT) on the 
joint mobility and radiographic changes during the development of osteoarthritis (OA) of the 
knee joint. The authors developed an experimental model of OA knee by periodically 
immobilising the knee joints of rabbits. They were then treated with CSWT (55 sessions in 
11 weeks, 5 minutes per session) and compared with an identical group of non-treated 
rabbits in a control group. The groups did not show any significant difference between them 
post treatment, in terms of joint mobility or radiological changes. A lack of further animal 
studies relevant to chronic conditions made it difficult to draw a definite comparison with 
human studies. 
 Conclusions 
The methods adopted to identify the relevant RF literature within the frequency range of 30 
kHz – 30 MHz and the overall results of the literature search have been explained in this 
chapter. The results showed that 120 studies were conducted on patients using some form 
of RF therapy. Apart from the clinical studies, several experimental studies that were carried 
out on a non-clinical sample (tissue models, animals, asymptomatic subjects) were also 
identified. The next chapter in this section of the thesis will discuss in detail the RF clinical 
studies identified on acute and chronic conditions. 
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3 Chapter 3 – Radiofrequency-based treatment in therapy-
related clinical practice. 
 Studies on acute conditions 
As described in Chapter 2, out of the total of 120 relevant clinical studies that were identified 
for the narrative review, 30 studies were related to acute clinical conditions. Each of those 
studies will be considered in detail in the sections below. No studies employing a frequency 
below the shortwave range was identified among the acute conditions. All 30 studies used 
devices operating at 27.12 MHz. Conditions pertaining to pain and inflammation was 
reported by 22 studies.124-127,130,131,227-242 Tissue healing129,154,155,226,243-245 was reported by 
seven studies and one study reported other less reported conditions (acute 
pneumothorax).246 The main characteristics of all these studies along with their Downs and 
Black scores are reported in Table 3.1. 
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Table 3.1: RF studies on acute therapy-related conditions 
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3.1.1 Studies on pain and inflammation 
Studies on acute conditions relating to pain and inflammation were the largest group. 
Conditions included postoperative pain (nine studies),124,126,127,130,227,228,235,241,242 ankle injuries 
(six studies),125,229,231,234,236,239 fracture pain (two studies),238,240 hand injuries (one study),233 
acute low back pain (one study),232 whiplash injuries (one study)237 and pelvic trauma in 
women (one study).131 In addition, there was one case series on soft-tissue injuries in 
professional footballers.230 
3.1.1.1 Postoperative pain 
Significant reduction in postoperative pain, oedema and erythema was achieved using 
PSWT on patients who had undergone foot surgery (100 participants in two groups – active 
or placebo) in the study by Kaplan and Weinstock.227 PSWT applications were given for 10–
15 minutes twice daily to the operative site as well as to the epigastrium. However, only 
limited reporting (especially dosage and statistics) has been done by the authors when 
compared with current expected reporting standards, and it is unsure if the two study groups 
were statistically equal at baseline. Comparable results to this study were also achieved by 
Aronofsky,228 who used a similar dose of PSWT on patients who had undergone oral and 
dental surgical procedures (90 patients in three groups). Two treatment sessions (15 and 10 
minutes) were given pre-operatively and/or 10 minutes postoperatively to the surgical site of 
the participants in the active group(s). This was a methodologically poor-quality trial lacking 
objective outcome measures, without blinding or randomisation and lacking equivalence 
between groups at the baseline. 
Hutchinson and colleagues124 reported contrasting results from a similar group of dental 
surgery patients (82 participants in two groups – active and placebo), who failed to improve 
their symptoms after PSWT (10 minutes once daily) delivered over the dental surgical sites. 
It is unclear what dose of PSWT was delivered. Santiesteban and Grant235 agreed with 
Kaplan and Weinstock,227 as two 30-minute sessions of PSWT on the day of surgery 
significantly reduced NSAIDs intake and hospital stay among patients who underwent foot 
surgery (50 participants in two groups). It was interesting to note that favourable results were 
reported despite employing a substantially lower dose of PSWT and number of sessions. 
This was not a blinded trial and it was unclear if the two groups were equal at baseline. In 
another study, ‘non-thermal’ PSWT (15 minutes twice daily for two days) failed to improve 
patients who had undergone inguinal herniorrhaphy.127 However, it can be argued that an 
extremely low intensity of treatment (MP of 0.02 W, Table 3.1) with a short intervention 
period was equivalent to a placebo.80 
Four RCTs on small wearable type RF generators have been reported recently. Benefit from 
such therapy in terms of reduced postoperative pain and reduced consumption of pain 
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medication was shown by two small studies130,241 on patients who had undergone breast 
augmentation surgery. PSWT was delivered for 30 minutes 3–6 times per day for the first six 
postoperative days; and then two times per day until the follow-up visit on day seven In the 
first study by Heden and Pilla.130 PSWT was delivered continuously from postoperative day 
one till day seven in the second study by Rawe and colleagues.241 In another small study, 
Rohde and colleagues126 demonstrated a three-fold drop in the postoperative pain scores 
after being treated by a wearable PSWT device in 12 patients who underwent breast 
reduction surgery, compared to 12 placebo-treated patients. The study used a similar device 
and treatment regimen as Heden and Pilla.130 The authors also argued that an RF-induced 
modulation of the wound healing process resulted in a reduction in the interleukin 1-β levels 
of the wound exudate, which in turn indicated a faster wound resolution. These three studies 
were of good methodological quality although they were small. The results need to be 
interpreted with caution until larger studies have been reported. 
However, the above benefits were not reproduced when similar wearable device was used 
in a further study242 to treat patients who underwent bilateral upper blepharoplasty (57 active 
and 57 placebos). The participants did not report any difference between the active and 
placebo in terms of postoperative pain, oedema or ecchymosis in their eyes. However, 
compared to the placebo the physician-graded erythema was significantly lower in the 
actively treated eyes. The devices were worn for varying durations postoperatively (active for 
one eye and placebo for the other), for up to a week. Nonetheless, the participants in this 
trial also used other treatments such as cold patches where required, which were not 
controlled or accounted for in the final analysis. The use of PSWT devices varied greatly 
between participants, and the assessment periods may have differed between groups 
affecting the validity of data. Besides, it was unclear if the groups were equivalent at the 
baseline. 
Most of the studies in this category have claimed significant benefits from RF therapy. The 
RF intervention was started either pre-operatively or immediately postoperatively. The 
studies that reported RF therapy to be not beneficial have generally employed a lower dose 
and/or duration of treatment (Table 3.1). However, any potential range of ideal doses could 
not be identified because of the varied nature of dosage parameters used in the studies. The 
overall methodological quality was problematic for several studies, especially the earlier 
ones.124,127,227,228,235 Lack of sufficient statistical power and poor equivalence between the 
groups at baseline has weakened their overall impact. Also, the majority did not feature a 
true control group. The epigastric area (over the liver) was treated in some earlier studies, as 
preceding studies performed on healthy adults90,175 reported that it increased peripheral 
circulation. However, this trend disappeared in later years. 
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3.1.1.2 Acute ankle injuries 
Patients (20 active, 20 placebo) who sustained acute ankle inversion injuries experienced a 
reduction in pain and disability after receiving 60 minutes of PSWT for three consecutive 
days in an RCT by Wilson.229 These results were repeated in a further similar study that 
employed PSWT as well as CSWT, by the same author.125 Both studies had several 
methodological limitations. They were neither randomised nor adequately controlled or 
blinded, did not employ any follow-ups and the statistical reporting was poor. In contrast to 
their results, a much larger study published by Pasila and colleagues231 comprising 300 
patients with recent ankle and foot injuries failed to demonstrate any significant difference in 
pain and swelling secondary to PSWT. Two active groups receiving two types of PSWT, and 
one placebo group were employed. The mean PSWT dose was similar (38 W), but the 
treatment duration was much shorter (20 minutes daily for three days) in this study 
compared to that by Wilson.229 The methodological quality of the study remained equally 
poor and most of the methodological limitations listed above applied to this study as well. 
Similarly, no evidence in support of PSWT for acute ankle injuries (45 minutes each for three 
days) when compared to a placebo was revealed by Barker and colleagues.234 The study 
started with 73 participants, but experienced high drop-out at the follow-up, which were not 
accounted for in the data analysis. Dose parameters for PSWT were not fully reported and 
neither was there any evidence for the study groups being equal at baseline. 
PSWT (three 15-minute sessions) was not found to be beneficial by McGill,236 who studied 
patients (37 participants in two groups – active and placebo) with lateral ligament sprain of 
the ankle. However, the energy delivered was potentially too small to make a realistic 
impact, since only three short treatments were given. The latest study of this category 
published by Pennington and colleagues239 reported that fifty participants who had suffered 
grade I–II ankle sprain when treated with either PSWT or placebo for one session alone (30 
minutes medially and 30 minutes laterally to the ankle joint; 10 minutes to the epigastrium), 
the PSWT group demonstrated significant reduction in ankle oedema. This study provides 
little information regarding the benefit of PSWT treatment beyond one day. Also, it was 
unclear if the groups were equivalent at baseline. 
The evidence in this group was ambiguous and none of the studies was of acceptable 
methodological quality. Except in two studies where the RF intervention started with a delay 
of 3–4 days after the injury,231,239 the treatment commenced within 36 hours after the injury in 
all the other studies. Overall, the methodological shortcomings were several. The doses 
were varied (Table 3.1) where reported while many studies failed to report any dose-related 
information. A similar trend to that of the studies on postoperative pain was noted in this 
group as well, in that the studies that reported no benefit from RF therapy employed a lower 
dose and/or overall intervention duration. 
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3.1.1.3 Fracture pain 
Two RF studies were found in the fracture pain category. In the first study by Livesley and 
colleagues238 PSWT (30 minutes daily for 10 consecutive days) was not found to be 
beneficial in the management of fracture pain of the neck of humerus. Forty-eight patients 
(22 active, 26 placebos) were followed-up for up to six months. No significant differences, 
either for pain or for functional scores were noted at any stage. The study demonstrated 
good methodological quality but was not devoid of shortcomings. The dosage information 
was not fully reported; baseline equivalence of the outcome measure data was not 
established and potentially lacked adequate statistical power. 
In the second study, Buzzard and colleagues240 studied twenty patients with unilateral 
calcaneal fractures. Either PSWT (15 minutes twice daily for five days) or ice therapy 
(‘Cryocuff’ for 20 minutes, six times a day for five days) was applied. Both groups seemed to 
improve similarly and equally in the daily measurements of swelling and ankle ROM. This 
study only employed a very low mean dose of PSWT (Table 3.1), which may have been too 
low to be clinically effective. Moreover, it was neither randomised nor blinded, lacked 
sufficient statistical power and experienced high participant drop-out rates. 
3.1.1.4 Other acute conditions with pain 
Wright230 published a case report on the PSWT management of soft tissue injuries in 
professional footballers, where daily PSWT repeated for up to a week resulted in a rapid 
reduction in intra-muscular haematoma. This was not a randomised or controlled study and 
dose parameters for PSWT were not reported. Fifty-one female patients affected by acute 
low back pain were treated with either CSWT (20 minutes thrice weekly) or spinal 
manipulation, for up to six weeks in a clinical trial by Nwuga.232 This study did not make any 
objective assessment of pain or outcomes of functional quality of life (QoL). Spinal and 
pelvic range of movement (ROM) was the main outcome measured. Manipulation was 
shown to have a greater response compared to CSWT in terms of improving the same. Only 
female subjects were included in this study making it less generalizable and there were no 
follow-up assessments. 
Women who were recovering from pelvic trauma sustained during childbirth (414 
participants) when studied in four groups (PSWT, ultrasound, placebo-PSWT or placebo-
ultrasound) by Grant and colleagues,131 did not reveal any treatment being particularly 
beneficial. The PSWT treatment was given for 10 minutes daily for three days. This study 
was large, but lacked objective outcome measures, did not report dosage parameters and 
the intervention may have been too short. By contrast, in a large trial on 230 patients who 
had sustained hand injuries, Barclay and colleagues233 reported marked reduction in pain, 
swelling and disability in half the number of patients who were treated actively by PSWT (30 
minutes twice daily for up to seven days), as against a control group. The patients also used 
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pain medication, but it is unsure if they were controlled for. The study was not blinded, and it 
was unclear if the groups were equal at baseline. Similarly, 20 patients who had sustained 
acute whiplash injuries reported significant improvement in pain compared to a placebo 
when treated with PSWT (RF generating collar worn for eight hours daily for 12 weeks) in a 
well-designed study by Foley-Nolan and colleagues.237 This study was different from the rest 
of the studies in this group because it employed a low power wearable PSWT device more 
like the one used in the postoperative studies126,130,241,242 discussed earlier. The dose 
parameters were not reported fully. 
3.1.2 Studies on tissue healing 
Five studies out of the seven from this group were on healing of postoperative 
wounds.154,155,243-245 One study each reported bone healing226 and healing of lacerated lower 
limb wounds.129 All studies used devices delivering RF energy at a frequency of 27.12 MHz. 
3.1.2.1 Postoperative wound healing 
There were four clinical trials154,155,243,244 and one cohort study245 examining the effects of 
SWT on postoperative wound healing. Accelerated rate of bruise resolution in boys who 
underwent orchidopexy operation was achieved when PSWT was used (20 minutes locally 
to the operated site; 10 minutes to the epigastrium three times a day for four days) in a 
double-blinded RCT by Bentall and Eckstein.154 Full-text for this study was not available for a 
full review. Accelerated recovery was also achieved in patients who had undergone oral 
surgery, with daily exposure to PSWT (30 minutes locally and 20 minutes over the liver) by 
Rhodes244 in a study with over 500 participants. Although it had a large sample, the study 
was poor in methodological quality. It was not randomised or blinded, lacked objective 
outcome measures, there was no statistical analysis of the data and the intervention 
parameters were not reported adequately. 
In another study, Goldin and colleagues243 treated 29 skin grafted patients using PSWT in an 
RCT. There was significantly improved healing to their donor sites compared to 38 patients 
who received a placebo. One 30-minute treatment was given pre-medication to the donor 
site and then four times daily postoperatively, for seven days. The group sizes varied 
significantly, and it was unclear if they were equivalent at the baseline. Similar enhanced 
wound healing was shown in a pilot study of 21 cases of blepharoplasty when treated 
postoperatively with a wearable PSWT device (worn for 24 hours continuously 
postoperatively) by Nicolle and Bentall.245 However, this was not a controlled clinical trial, but 
only a case series report. Localised (15 minutes) and over the liver (30 minutes) treatment 
with PSWT increased blood plasma levels of fibronectin in postoperative patients, which 
correlated well with improvement in wound healing in the study by Arghiropol and 
colleagues.155 Full-text was not available for the latter study. 
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3.1.2.2 Other studies on tissue healing  
Favourable results with PSWT in bone and soft tissue injuries was reported in the study by 
Cameron.226 The large study had a total of 646 surgical and non-surgical orthopaedic 
patients benefitting from PSWT (20 minutes over the liver and 20 minutes over the wound, 
twice daily for four days). The study however lacked in most methodological areas including 
the design, outcome measures and statistics, and hence the results could not be accepted 
on face value. By contrast to the above results, Lower limb injuries (pre-tibial lacerations) 
when treated with PSWT (10 minutes three times a week) in addition to standard wound 
dressing did not result in accelerated wound healing in the study by Muirhead and 
colleagues (RCT on 129 participants in two groups).129 Overall, the reporting in this study 
was inadequate, including dosage parameters. 
3.1.3 Studies on other applications 
Only one study was identified in this category. Twenty-two patients with pneumothoraxes of 
less than 30% volume were studied in a blinded RCT by Ma and colleagues.246 A daily dose 
of 25 minutes of CSWT (at an intensity causing ‘just perceptible warmth’) was given to one 
of the groups. Another group (control group) was kept under observation with only bed rest. 
Significantly faster lung re-expansion was achieved in the CSWT group compared to the bed 
rest group (3–12.5 days and 8–17 days respectively). Although this pilot trial was published 
several years ago, more studies on this condition have not been reported. 
3.1.4 Conclusions 
The evidence for RF-based therapy within the referred frequency range in acute clinical 
conditions is mixed. As the review did not employ a cut-off (Downs and Black) score for the 
methodological quality, all the identified studies were included. However, the conclusions 
drawn here were influenced primarily by the results from well-designed studies besides the 
overall evidence from all the studies. 
No studies were reported below the shortwave RF range. Within the SWT, the majority were 
carried out using PSWT (93%), with CSWT only featuring in three studies. One study 
employed both devices. Significant benefits of PSWT treatment on postoperative pain was 
reported by the bulk of the studies in that group. The same cannot be stated about acute 
ankle injuries as the studies have shown mixed results. As identified, dose-dependency 
issues were apparent in both these groups. Only a limited number of studies were identified 
on the effects of RF-based therapy for other acute conditions giving rise to pain. 
As identified, the ‘postoperative pain’ and ‘postoperative wound healing’ groups potentially 
overlapped. The allocation of studies was performed based on the main outcome as 
identified by their author. Based on these results there is reasonable volume and quality of 
evidence to support the use of PSWT for postoperative pain and postoperative wound 
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healing. Where reported the dosage ranges were varied. Hence based on the reported 
studies an ideal PSWT treatment recipe for either the postoperative pain or wound healing 
condition cannot be recommended. Evidence for any other acute conditions is sparse and 
conflicting. 
 Studies on chronic conditions 
As stated in Chapter 2, there were 90 studies that investigated the effects of RF-based 
therapy on chronic clinical conditions. They are considered in detail in the following sections. 
The key features of the studies, including dose parameters (where reported) and the Downs 
and Black scores are given as tables in the respective sections. 
3.2.1 Non-shortwave studies 
There were eight studies that employed RF at frequencies between 30 kHz – 10 MHz to 
treat chronic therapy-related clinical conditions. Among these five studies were clinical 
trials,247-251 one was a cohort study194 and the other two were case studies.252,253 All eight 
non-shortwave studies investigated the effects of RF on pain and inflammation. OA of the 
knee joint,194,249-251 shoulder pain,253 temporo-mandibular joint (TMJ) pain and dysfunction,247 
tendinopathy248 and chronic pain conditions252 were the study areas. A frequency range of 
250 kHz – 500 kHz was used in all studies, except Takahashi and colleagues194 and Nelson 
and colleagues251 where 6,000 kHz – 8,000 kHz (6–8 MHz) was the frequency used. 
Three studies on OA knee were RCTs. Nelson and colleagues251 reported that 15 
participants when treated with an active 6.8 MHz PEMF device (80 (±9) sessions in 42 days, 
15 minutes per session) presented a three-fold significant improvement in the pain scores 
compared to 19 placebo-treated participants. There were no follow-ups, and pain was the 
only outcome measured. The benefits of this treatment beyond the immediate post treatment 
phase and its effects on the functional QoL are therefore unknown. The study also failed to 
fully report the RF dose parameters. 
Taverner and colleagues250 used 480 kHz transcutaneous pulsed radiofrequency (TPRF) 
therapy against a placebo on patients awaiting total knee replacement (TKR) (52 
participants in two groups: active and placebo). Significant reduction in the pain scores at 
one and four weeks post treatment was reported by the active group participants compared 
to the placebo group. Only one session of RF treatment that lasted 10 minutes was 
delivered in this study. Dosage parameters were not fully reported. While the patients also 
took pain medications, they were not accounted for in the data analysis. Pain was the only 
outcome measured; hence its effect on functional QoL is unknown similar to the above 
study. Besides, it was unclear if the groups were equal at baseline. 
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Very similar results were obtained by Alcidi and colleagues249 who tested a similar type of 
500 kHz RF as above (five sessions in five days, 20 minutes per session) against TENS (50 
Hz, 0.5-millisecond square waves for 20 minutes per session for five days) in patients with 
OA knee (40 participants in two groups of 20 each). The authors claimed that the RF therapy 
yielded a greater and longer lasting reduction in pain than the TENS. However, although a 
20-minute treatment may suffice for RF, it may be deemed too short for TENS.254 Moreover, 
TENS is shown to induce more effective pain relief during treatment as opposed to post-
treatment.255 The study did not undertake a between-group statistical comparison at any 
time point (baseline, post treatment or one-month post treatment) to be able to claim that 
one treatment was better than the other. 
Twelve patients presenting with OA knee were treated using an 8 MHz RF applicator (three 
sessions in three weeks, 20 minutes per session) by Takahashi and colleagues194 in a pilot 
study. Hyperthermia was induced inside the knee joints and significant pain relief was 
obtained. The authors used an invasive metallic thermocouple that remained in situ for the 
duration of treatment to record the temperature inside the joint. Therefore, a direct heating of 
the thermocouple by the RF could not be ruled out. It was unclear whether the researchers 
had attempted to mediate this effect. This was not a controlled clinical trial; hence the results 
needed to be interpreted with caution. The authors measured pain and function (WOMAC), 
but the WOMAC results were left unreported. 
Balogh252 presented a case series of TPRF therapy, which was applied to four patients, 
three of whom had suffered lumbar intervertebral disc injuries and one patient with multiple 
injuries secondary to a road traffic accident. Conventional TENS electrodes and a 500 kHz 
RF generator (10 minutes at 1–5 weekly intervals) were used. Three out of four patients 
experienced improved pain and function. However, the patient treatment protocols were 
variable depending on their condition. In another similar study, Taverner and colleagues253 
used RF at 480 kHz (single session of TPRF therapy for up to 12 minutes) to treat shoulder 
pain. No further details about the condition were reported. A cohort of 13 patients (15 
shoulder joints) were studied, two-thirds of which reported pain relief over three months. The 
dose parameters used were not reported in either study. Both studies being small case 
series did not provide much insight into the usefulness of such therapy. 
Reduction in TMJ pain and improvement in mandibular range of movement (ROM) was 
reported by Al-Badawi and colleagues247 in a double-blinded RCT (40 participants in two 
groups of 20 each). The participants received either 250 kHz pulsed RF (PRF) or a placebo 
(six sessions in two weeks, 90 seconds per session). The immediate relief of pain and 
mandibular ROM obtained by 448 kHz CRMRF therapy were significantly better than the 
placebo, but the groups were not equivalent at the baseline. Dose parameters were not fully 
reported either. 
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Costantino and colleagues248 reported that 448 kHz CRMRF was not significantly better than 
cryoultrasound therapy or laser CO2 therapy when used to treat 45 athletes affected by 
Achilles, patellar or elbow extensor tendinopathy (3 equal groups, each receiving 12 
sessions of one of the three EPAs). CRMRF was delivered for 30 minutes, laser for 15 
minutes and cryoultrasound for 20 minutes. Intervention duration and dosage parameters 
were incompletely reported. This study had several significant methodological issues. 
Despite being a multi-group study, it was not randomised, controlled or blinded. There were 
no follow-up assessments. At the baseline, it was unclear if the group outcomes were 
equivalent. 
It is obvious from the literature discussed so far, that only a very small number of clinical 
studies have been published in the non-shortwave RF category. The indication from the 
studies available is that RF below 10 MHz might deliver appreciable therapeutic benefits. 
However, there is no clear indication from the previously reported experimental studies as to 
how RF frequencies below the shortwave band may induce biological effects that may lead 
to clinical benefits. Moreover, the results of the clinical studies themselves must be weighed 
against their volume and overall methodological quality, several of which were seriously 
lacking as described above. Substantially more quality research is warranted in this area 
given the non-existence of quality evidence in the form of well-designed RCTs. The base 
frequencies used were different in virtually every study, hence no comparison was possible. 
As of now it is unclear which RF frequency in this category is most appropriate for therapy 
should they prove to be genuinely beneficial. Key points from the non-shortwave studies are 
summarised in Table 3.2. 
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Table 3.2: Non-shortwave RF studies on chronic conditions 
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3.2.2 Shortwave studies 
Eighty-two clinical studies related to chronic therapy-related clinical conditions were 
identified within the shortwave frequency range of 10 – 30 MHz. The base shortwave 
frequency of 27.12 MHz either in continuous (CSWT) or in pulsed (PSWT) form was used in 
all the studies. Fifty-nine studies were related to conditions on pain and inflammation, 16 
studies to tissue healing and the remaining seven studies to other less reported conditions 
such as joint stiffness. 
3.2.2.1 Studies on pain and inflammation 
Nearly half of the 59 studies (28 studies) reported the effects of SWT on arthritis, mainly OA 
of the knee joint.55,256-282 Except one cohort experimental study,257 all were multi-group 
clinical trials. Eight clinical trials156,283-289 and a cohort study290 were on chronic low back pain 
(LBP). One clinical trial291 and five case studies292-296 involved various gynaecological 
conditions giving rise to pelvic pain. 
In addition, Chronic neck disorders (three clinical trials),132,297,298 carpal tunnel syndrome (two 
clinical trials),158,299 plantar fasciitis (one clinical trial133 and one case study300), chronic 
shoulder problems (one clinical trial301 and one case study302),  one clinical trial each on TMJ 
pain,303 trigger point pain304 and myofascial pain305 and one case study each on Herpes 
Zoster pain,306 heel neuroma,307 avascular necrosis of the femoral head,308 and multiple 
cases of pain53 were also identified. 
Arthritis 
Studies on arthritis formed the single largest group. They have been published as early as 
the 1950’s. A varied group of 62 patients affected by either rheumatoid arthritis (RA of hands 
or knees) or OA knee were studied by Hamilton and colleagues.256 They reported improved 
outcomes of walking and stair climbing among the participants who were treated with CSWT 
(12 sessions in 4 weeks, 20 minutes per session). CSWT exposure (single session for 20 
minutes) was shown to improve circulation to the knee joints of people affected by RA if the 
condition was quiescent, but counterproductive if RA was active in an experimental study by 
Harris.257 CSWT (18 sessions in 6 weeks, 20 minutes per session) gained better long-term 
improvement over placebo tablets and placebo injections among patients with OA knee (38 
participants in three groups) in the study by Wright.258 Till the early 1990’s, several more 
studies were published where neither CSWT nor PSWT were found to be significantly better 
than other treatments for OA.55,259-265 The majority of those studies were based on CSWT. 
Results were mixed, but generally favoured the use of CSWT for OA knee. However, all 
these early studies were affected by significant methodological limitations such as improper 
randomisation, lack of appropriate statistical analysis, lack of validated outcome measures 
and inequivalent groups at baseline. The reporting remained poor in almost all studies. 
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More recently, Klaber Moffett and colleagues266 found no significant benefit with PSWT (nine 
PSWT sessions in three weeks, 15 minutes per session) for self-reported pain and QoL 
measures of 92 participants affected by hip and knee OA in a well-designed RCT. However, 
the study may not have attained sufficient statistical power. Two more very similar clinical 
trials,268,269 that employed four different PSWT doses (six and nine sessions respectively in 
two weeks, 20 minutes per session) reported that there were no significant benefits from 
PSWT. Of this the study by Callaghan and colleagues268 was very small and statistically 
underpowered. Also, it was unclear if the study groups were equivalent at the baseline. The 
second study by Laufer and colleagues269 also had similar limitations despite being a larger 
trial. Their method was non-randomised, and the possibility of a type II error was confirmed 
by their post-hoc analysis. 
PSWT (10 sessions in two weeks, 15 minutes per session) was combined with ultrasound 
therapy and progressive resistance exercises in the study by Tuzun and colleagues 40 
participants in two groups).267 Pain and function was improved by both low and high doses. 
However, it cannot be ascertained from this study whether the benefits were due to the 
addition of PSWT since both groups improved equally. It may be assumed that either both 
doses of PSWT were equally beneficial or else they had no impact at all. In another study, 
Jan and colleagues270 demonstrated lower pain and knee joint synovial thickness in CSWT-
treated group (30 sessions in 8 weeks, 20 minutes per session) compared to a control group 
irrespective of their NSAID intake. The study had a modest sample (36 participants in three 
groups) but did not use a randomised design. Moreover, the groups were not equal at the 
baseline in terms of pain levels, and the use of pain medication was not monitored or 
controlled for. 
Later studies compared the effects of SWT to spa, ultrasound, ice or exercise therapies,271-
273,277 none of which suggested added benefit from either CSWT271-273 or from PSWT.277 
Similar methodological issues that were noticed in the previously discussed trials were 
present in these studies too, as only the RCT conducted by Rattanachaiyanont and 
Kuptniratsaikul277 employed a well-designed methodology. However, even they included only 
female participants. Another contentious issue with this study was that the mean PSWT 
power dosage used (3.2 W) was potentially too low to be of benefit in a chronic condition 
such as OA knee. 
Recently, Cetin and colleagues274 reported that CSWT (24 sessions in 8 weeks, 15 minutes 
per session) reduces pain and improves function among women with OA knee (100 patients 
in 5 groups) when used with hot packs and isokinetic exercises. Confounding factors such 
as medication intake was not controlled for. Also, there was 15% drop-out of participants, 
which was not considered in the data analysis. Akyol and colleagues278 contradicted the 
above findings in another similar study (40 patients in 2 groups) with CSWT (12 sessions in 
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four weeks, 20 minutes per session) and isokinetic exercises. Both studies only applied to 
women of menopausal age group. 
Among the recent PSWT studies, Ovanessian and colleagues276 reported that PSWT 
delivered at a mean power (MP) of 14.5 W (9 sessions in 3 weeks, either 19 minutes or 38 
minutes per session) produced significantly better outcomes compared to a control group. 
The study suggested that increasing the treatment duration did not commensurately 
increase the rate of improvement of symptoms. This was a small pilot study with 36 
participants in three groups and no follow-ups. Agreeing to Ovanessian and colleagues, 
Fukuda and colleagues published two well-designed RCTs275,279 on the effects of PSWT on 
pain and function in women affected by OA knee. PSWT at a MP of 14.5 W (9 sessions in 3 
weeks, either 19 or 38 minutes per session) were tested. Both studies suggested that PSWT 
improved the clinical outcomes regardless of the treatment durations they used.  
Atamaz and colleagues280 reported another well-designed multi-centre RCT (203 patients in 
6 groups) recently in which TENS, interferential therapy, PSWT and their three placebo 
versions were employed alongside exercises and advice in all six groups (15 sessions in 
three weeks, 20 minutes per session). All groups including the placebos improved their pain 
scores significantly and the only difference between the groups was that there was reduced 
paracetamol intake in the active groups at the end of the intervention, with no difference 
between the active groups. Longer term results are not known, as there were no follow-up 
assessments. Like the Rattanachaiyanont and Kuptniratsaikul277 study, the mean active 
PSWT power dose in this study was only 3.2 W, which was potentially too low to be 
effective. 
Most recently, Boyaci and colleagues282 compared CSWT (10 sessions in two weeks, 20 
minutes per session) with ultrasound and ketoprofen phonophoresis in OA knee (101 female 
participants in three groups). Self-reported pain and function improved in all three groups 
significantly, but the group results were not significantly different from each other. In a 
second smaller pilot study (24 participants in two groups of 12 each) by Teslim and 
colleagues,281 both CSWT and PSWT (eight sessions in four weeks, 20 minutes per session 
in both groups) improved the knee ROM and pain, but the CSWT results were significantly 
better than PSWT. Follow-up assessments were absent in both studies and neither did they 
report the dose parameters. The absence of a control group was a further limitation of both 
studies. 
While many of the more recently published studies have supported the use of SWT (mainly 
PSWT) for treating OA knee, the earlier studies mostly gave conflicting results and were also 
affected by methodological issues. Reporting of the full dosage parameters has been an 
issue with many studies. Where reported the treatment power and overall duration of 
intervention varied greatly, but the rationale for such a selection was not reported. The 
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number of intervention weeks varied from single to several weeks in most studies (average 
of 3–6 weeks). No CSWT studies have reported their actual doses employed. Overall, based 
on the outcomes of the more recent studies that supported the application of PSWT for OA 
knee, there is moderate evidence to support the use of PSWT in OA knee. The intervention 
parameters reported in those studies suggest that a mean dose at or above 14.5 W, 8–12 
sessions over 4–6 weeks, and 15–20 minutes per session may be considered as an 
effective intervention. Additional information on the RF-based management of OA knee can 
be obtained from systematic reviews that are already published.137,139,309,310 These reviews 
also include some of the studies covered in this thesis. Key points from all the shortwave 
studies on OA knee are summarised in Table 3.3. 
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Table 3.3: Shortwave studies on OA knee 
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Low back pain 
Two large multi-group trials by Gibson and colleagues285 (12 CSWT sessions in four weeks, 
session duration not reported) and Sweetman and colleagues287 (six CSWT sessions in two 
weeks, 20 minutes per session) reported that CSWT was not particularly beneficial over the 
comparator treatments (exercises, traction, osteopathy or placebo-CSWT). In the first study, 
the use of medication was not controlled, and the authors failed to report the intervention 
parameters. In the second, the intervention only lasted two weeks. Both studies did not 
demonstrate sufficient equivalence between the groups at baseline. 
Conversely, the effects of both pulsed and continuous SWT were significant in relation to 
pain relief in two other small clinical trials by Davies and colleagues284 (CSWT dose 
parameters not reported) and Wagstaff and colleagues288 (six PSWT sessions in three 
weeks, 15 minutes per session). The outcome was unaffected by adding an exercise regime 
to the intervention or using different shortwave pulse patterns. Both studies did not 
demonstrate sufficient equivalence between the groups at baseline. The intervention 
parameters were not reported in the first study. The study by Wagstaff and colleagues288 had 
several additional methodological issues. The authors did not control for medication intake. 
All three treatment groups employed SWT and exercises; hence it was difficult to determine 
the effect of SWT alone. 
Both CSWT and PSWT (10 sessions of 20 minutes each) were reported to effectively reduce 
LBP although the effects of PSWT were greater in the study by Kerem and Yigiter.286 They 
studied 60 participants in three groups (CSWT and two different doses of PSWT). This was 
not a randomised or blinded study. Like the Wagstaff and colleagues288 study, all three 
treatment groups employed SWT and exercises; hence it was difficult to determine the effect 
of SWT alone. Similarly, CSWT (18 sessions in 6 weeks, 15 minutes per session) 
significantly improved chronic LBP in three studies published by Shakoor and 
colleagues.156,283,290 It was further supported by Kim and colleagues,289 who reported in their 
study on 11 patients with LBP that CSWT (single session of treatment, duration not 
reported) significantly complement manual therapy (nerve mobilisation) when compared to 
manual therapy alone. 
The number of SWT studies on LBP was much smaller compared to that for OA knee. 
CSWT was the favoured method of treatment in most studies. Similar methodological 
shortcomings as in the OA knee studies were apparent in this group as described above. 
Likewise, no commonalities could be drawn on dosing or any dose-related information owing 
to the lack of information supplied and the inconsistency where such information was 
supplied. The average duration of intervention was 3–5 weeks in most studies (ranged 
between single sessions to six weeks), based on the studies that have reported beneficial 
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effects of SWT. Except for two, all studies reported the intervention to be beneficial for the 
management of LBP; hence there exists some evidence in favour despite all the 
methodological shortcomings within the literature. 
Pelvic pain 
The effect of SWT on pelvic conditions were studied as early as 1938, when Waters296 
published positive responses to CSWT (up to 36 sessions delivered) from 120 patients in 
their case study. Subsequently, 50 cases of pelvic sepsis treated by CSWT (12–16 sessions 
in 4–6 weeks, 30 minutes per session) to obtain intra-vaginal hyperthermia was reported by 
Burgess293 as case studies. Cases of chronic inflammation due to pelvic sepsis benefitted 
from the RF treatment. Later studies included gynaecology patient studies by Punnonen and 
colleagues295 (10–15 PSWT sessions on alternate days) and case studies on pelvic 
inflammatory disease (PID) by Balogun and Okonofua292 (9 CSWT sessions in 3–4 weeks, 
25–60 minutes per session) and Lamina and Hanif294 (15 CSWT sessions in 30 days, 30 
minutes per session). All the above studies were supportive of the use of RF to treat pelvic 
pain in women. Only one of the six studies in this category was an RCT.291 Lamina and 
colleagues studied 32 participants (in three groups) with pelvic inflammatory disease. CSWT 
(15 sessions in 30 days, 20 minutes per session) showed greater benefit over analgesics 
and a control condition in reducing pain. However, the groups were not shown to be 
equivalent at the baseline. 
Neck pain 
Three well-designed RCTs were identified, examining the effects of PSWT on chronic neck 
pain, although two studies were based on the same data.297,298 PSWT therapy gave better 
outcomes of pain and neck ROM compared to a placebo in the study by Foley-Nolan and 
colleagues.132 PSWT generating soft cervical collar was worn for eight hours daily for six 
weeks. This was a small study (20 participants in two groups) without any long follow-up 
assessments. The RF device used in this study was similar to those wearable devices used 
on the acute postoperative patients described in the previous chapter. Although the MP dose 
of such devices is extremely low, a significant amount of energy will still be delivered since it 
is worn for several hours during the day. 
In a more recent and larger RCT 350 patients (three groups – manual therapy, PSWT and 
control (advice and exercise)) were studied over 32 weeks (8 PSWT sessions in 6 weeks, 
15–20 minutes per session) by Dziedzic and colleagues.297 The treatment dosage was not 
fixed for the whole sample. The finding was that the addition of PSWT to ‘advice and 
exercise’ did not provide a greater outcome than the other two. However, this study involved 
55 different therapists to deliver the intervention, potentially raising reliability concerns. Lewis 
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and colleagues298 later evaluated the economic outcomes of the above study and concluded 
that PSWT was unlikely to be the most cost-effective intervention among the three. 
Other conditions with pain and inflammation 
Brook and colleagues133 demonstrated a significant reduction of morning pain in 70 patients 
affected by plantar fasciitis (42 active, 28 placebos) after using a wearable type low power 
PSWT device during the night (did not specify the duration) for seven days. The study did 
not recruit the anticipated number of participants (70 instead of the expected 140). Michel300 
supported this in their case study with six patients. Their intervention duration was 
significantly longer with the wearable device (over 200 sessions in 13 – 15 weeks, 30 
minutes twice daily) although dose parameters were not reported. 
Chronic shoulder pain is another clinical area where studies have been identified. PSWT (10 
minutes to the shoulder and 10 minutes to the liver) gave ‘impressive clinical results’ (in 
author’s own words) according to Ginsberg302 in his multiple case study (94 patients affected 
by shoulder bursitis with calcification). The study completely lacked any objective reporting; 
hence no inference could be made regarding the efficacy of PSWT. In another clinical 
trial,301 CSWT (10 sessions in 2 weeks, 20 minutes per session) produced significant 
improvement among 40 cases of shoulder adhesive capsulitis. However, the effects were 
less pronounced when compared to manual therapy (Cyriax approach). Shortwave dose 
parameters were not reported and the duration of intervention at two weeks may potentially 
have been too short for a chronic condition such as the adhesive capsulitis. 
Mild and moderate carpal tunnel syndromes (CTS) were reported to improve with both 
CSWT and PSWT (15 sessions in 3 weeks, 20 minutes per session) (CSWT was reported to 
be more effective) in two recently published studies.158,299 Pain, hand function and the 
electrophysiological measurements improved significantly in the active groups when 
compared to the placebo groups. The dosage parameters were not reported in either study. 
The full-text was unavailable for one of the studies.158 
Among other less reported conditions, Gray and colleagues303 compared CSWT, PSWT, 
laser and ultrasound (12 sessions in 4 weeks; CSWT 10 minutes per session, PSWT 20 
minutes per session) in a clinical trial on 176 patients with TMJ pain. All groups reported 
similar and significant improvement. TMJ-related myofascial pain was also shown to improve 
markedly by CSWT in another trial305 (120 patients in three groups – drug therapy, CSWT 
and ultrasound; 14 sessions of CSWT in 2 weeks, 20 minutes per session), although the 
effects were less pronounced compared to ultrasound. Both studies had significant 
methodological flaws including a lack of standardised objective outcome measures and poor 
reporting. 
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A single treatment of CSWT (20 minutes) was found to have a greater effect than a similar 
single treatment with moist heat for reducing tenderness from trigger points in another small 
study.304 This single-session experimental study does not provide much information about 
the potential prolonged effect of CSWT on this condition. Case studies where SWT was 
found to be effective in the management of pain arising from other conditions included 
studies on Herpes Zoster306 (daily CSWT sessions of 20 minutes each), heel neuroma307 (6–
12 PSWT sessions in 3–4 weeks, 10–15 minutes per session), and avascular necrosis of the 
femoral head308 (PSWT for varying durations). As above, these reports do not provide much 
information to the reader. 
Key points from the all SWT studies on pain and inflammation (except arthritis) are 
summarised in Table 3.4. The effects of SWT on various chronic conditions giving rise to 
pain and inflammation were reviewed in this section. Except for OA knee and LBP, sufficient 
numbers of studies have not been reported. As already stated, there is moderate evidence 
to support the use of PSWT in OA knee and some evidence exists for the use of CSWT for 
LBP. The evidence for other conditions is sparse and conflicting. 
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Table 3.4: Shortwave studies on pain and inflammation (except arthritis) 
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3.2.2.2 Studies on tissue healing 
The majority among the 16 studies (14 studies (88%)) identified in this category examined 
the effect of shortwave on chronic wounds or chronic ulcers.123,128,311-322 The remaining two 
studies examined bone healing.157,323 Radiofrequency at 27.12 MHz in the pulsed mode 
(PSWT) was used in all studies. Nine were case studies128,315-322 and one cohort study.311 
Four clinical trials were also reported.123,312-314 
Itoh and colleagues311 reported faster healing when PSWT (30 minutes twice daily) was 
used in addition to conventional wound dressing to treat a group of 22 patients with pressure 
ulcers. On average, stage II ulcers unhealed after 3–12 weeks of conventional dressing 
alone healed in 2.33 weeks with PSWT and stage III ulcers unhealed after 8–168 weeks 
healed in 8.85 weeks. This was not a controlled study and neither did it undertake any 
statistical analysis. 
Comorosan and colleagues312 in their clinical trial treated elderly patients with pressure 
ulcers (30 participants in three groups) with PSWT (30 minutes twice daily locally, 20 
minutes once daily to the liver) and reported that the PSWT group improved faster (Stage II 
ulcers healed in 3.28 weeks and Stage III ulcers healed in 4.87 weeks on average) 
compared to the poor or no improvement in placebo and control groups. This trial had 
numerous methodological limitations including absence of valid outcome measures and 
absence of statistical analysis. 
Improved methods were employed by Salzberg and colleagues313 and Kloth and 
colleagues314 in their studies although the sample was small in the latter. In the first study 
the healing of stage II and stage III pressure ulcers in spinal cord injured patients were 
significantly accelerated by a 12-week PSWT treatment programme (intervention 
parameters not reported).313 Significantly higher healing rate was obtained with four weeks 
of PSWT (20 sessions, 30 minutes per session) when compared to a placebo in the second 
study.314 In another well-designed study, Seaborne and colleagues123 conducted a well-
controlled double-blinded RCT on 20 non-ambulatory male patients in a small clinical trial. 
The participants were treated for four weeks with four different PSWT pulse and field 
protocols (the study had four groups, each acting as its own control) (20 sessions, 20 
minutes per session). While all groups improved significantly, there were no significant 
differences between the groups, which implied that there was no dose-response relationship 
in this case. All three studies were potentially statistically underpowered and there were 
issues with poor baseline equivalence between their study groups. 
Among the other studies, accelerated bone repair (as against standard treatment) with 
externally applied PSWT in 16 cases of non-union of fractures (case study) and in 45 
patients with post-traumatic algoneurodystrophies were reported by Sharp323 and 
Comorosan and colleagues (full-text not available).157 Diabetic foot ulcers,128,315,319 chronic 
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pressure ulcers,316,322 chronic lower extremity wounds,317,320 and venous/microvascular stasis 
ulcers318,321 were the conditions reported in the case studies. The case studies are not being 
explained here in detail. Their key details and outcome are given in Table 3.5. 
Well-designed and adequately controlled studies on tissue healing were low in number. 
While there is a pressing need for further quality research, the existing studies suggested 
the potential benefits of PSWT in wound healing. Similar methodological limitations and 
dosing and reporting issues as discussed previously alongside the other groups of studies 
were also relevant to this segment. Key points from all the SWT studies on tissue healing 
are summarised in Table 3.5. 
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Table 3.5: Shortwave studies on tissue healing 
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3.2.2.3 Studies on other applications 
It is evident from the results and discussions so far that most of the research surrounding the 
use of RF in therapy-related clinical practice is centred on conditions of pain and 
inflammation and tissue healing. A small number of studies investigated other unrelated 
conditions, for example post-traumatic/post-surgical stiffness and ROM,196,197,324-326 and 
vascular disorders.327,328 
Potential therapeutic benefit of PSWT on ‘intermittent claudication’ were reported by 
Hedenius and colleagues in 1966.327 Eighteen patients treated with PSWT (372 individual 
sessions in 62 weeks, 20 minutes per session) had their skin temperature and walking 
tolerance significantly improved compared those who did not receive PSWT. This was also 
supported by Santoro and colleagues328 in their study (10 participants) on patients affected 
by peripheral vascular disease (PVD), when treated by CSWT (20 sessions in 4 weeks, 30 
minutes per session). While the first one was a non-randomised multi-group study, the 
second study only featured one group with no comparator treatments. 
Clinical effectiveness of PSWT for improving ankle joint ROM197 (8–13 sessions in 5 weeks, 
20 minutes per session), elbow joint ROM196,324 (4–9 sessions in 2–3 weeks, 20 minutes per 
session) and necrotising fasciitis326 (12–15 sessions in 6 weeks, 20 minutes per session to 
each body segment treated); and CSWT (daily sessions for 2 weeks, 20 minutes per 
session) for post-operative ROM in the knee joint325 were demonstrated by Draper and 
colleagues in their case studies. They combined RF treatment with manual therapy and/or 
joint mobilisations to obtain the best results. PSWT was applied safely over areas with metal 
implants. The authors suggested that proper technique and caution will enable such safe 
delivery of a thermal modality.324 Treatments at 38–48 W of RF energy were used in all 
studies with the intervention period lasting for 2–6 weeks. The above studies only provided 
limited information as they were not clinical trials. Full multi-group clinical trials with 
appropriate methodology need to be carried out before any conclusions can be drawn. Key 
points from all the SWT studies included in this category are summarised in Table 3.6. 
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Table 3.6: Shortwave studies on other applications 
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3.2.3 Conclusions 
The evidence for RF-based therapy within the referred frequency range in chronic clinical 
conditions is mixed, and some of the general conclusions that were drawn within the acute 
category are relevant to the chronic section as well. As the review did not employ a cut-off 
(Downs and Black) score for the methodological quality, all the identified literature was 
included. However, the conclusions drawn here are influenced primarily by the results from 
well-designed studies besides the overall evidence from the respective cohort (like the acute 
studies). A clear association could not be found between the quality scores obtained by the 
studies and their reported clinical outcome. Even though some studies that scored highly (> 
20) on the Downs and Black scale supported the use of RF, some others have disagreed. 
Similar trend was noted among the studies that scored low (< 20) on the scale. 
Most of the identified studies were in the shortwave frequency range. Within the SWT, the 
majority were carried out using PSWT. Although several of the earlier studies gave 
conflicting reports about SWT management of OA, a majority of well-designed recent studies 
have supported its use in the treatment of OA; mainly in its pulsed form (PSWT). Hence, it is 
concluded that overall there is moderate evidence to support the use of PSWT for OA knee. 
Based on the available evidence, for OA knee, a mean PSWT dose at or above 14.5 W, 8–
12 sessions over 4–6 weeks, and 15–20 minutes per session may be considered as an 
effective intervention. Some evidence is also available favouring the use of CSWT to treat 
chronic LBP. However, recommendations on CSWT dosage for the treatment of LBP cannot 
be given based on the available evidence, as the dosage parameters were not adequately 
reported. Only a limited number of studies were identified on the effects of RF-based therapy 
for other chronic conditions giving rise to pain. 
Some evidence, although weak, also exists for the use of PSWT to promote the healing of 
chronic wounds. Most of the studies identified in this category were case studies. Well-
designed and adequately controlled studies on tissue healing were low in number. While 
there is a pressing need for further quality research, the existing studies suggested the 
potential benefits of PSWT in wound healing. Like LBP, dosage recommendations cannot be 
made owing to the lack of reporting and the considerable variations in durations of 
intervention among the studies. 
It is evident from the review that most of the research surrounding the use of RF in therapy-
related clinical practice was centred on conditions of pain and inflammation and tissue 
healing. A small number of studies investigated other conditions such as tissue extensibility 
and ROM. Like most of the studies on tissue healing, all the identified studies in this area 
were case studies. They recommended that PSWT may be useful for improving ROM in 
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conditions like post-traumatic stiffness. Proper clinical trials are yet to be carried out in this 
area; hence no recommendations can be made. 
Only a very small number of clinical studies have been published in the non-shortwave RF 
category. The indication from the studies available is that RF below 10 MHz might deliver 
appreciable therapeutic benefits. However, there is no clear indication from the experimental 
studies as to what may be their underpinning mechanism of action. It is anticipated that at 
frequencies less than 1 MHz such EPAs may be able to induce both thermal and nonthermal 
mechanisms of action in the tissues. Substantially more quality research is warranted in this 
area given the non-existence of quality evidence in the form of well-designed RCTs. The 
base frequencies used were different in virtually every study, hence no comparison was 
achievable. 
The overall quality of the studies should be considered while interpreting the evidence 
reported here. Reporting has been poor overall, although the trend seemed to improve in the 
newer studies (reporting of dose-related information continued to be a problem). Lack of 
robustness in the methodology (e.g. grouping issues and several other issues mentioned in 
the discussion) also followed a similar trend as reporting. In this review recommendations 
have been made where possible depending on the level of information available. However, 
dosage parameters for the RF used and their criteria for selection have been either unclear 
or left unreported, making recommendations problematic. The same is true for the statistical 
information given in the reports. Where participant drop-outs were high, they were not 
accounted for in the final analysis in most studies (no intention-to-treat analysis) as would be 
expected from a more recent publication. 
 Section II summary 
Radiofrequency is a multifaceted entity in the wider clinical world. The literature pertaining to 
the clinical applications of RF is extensive. Since most of that literature was outwith the 
primary remit of this project, only those studies that were directly relevant to therapy-related 
clinical practice were included here. RF-based EPAs have long been used in therapy 
practice. Over the years, the RF frequency ranges employed in such EPAs have narrowed 
owing to various reasons identified in the previous sections. Recent research suggested that 
in contemporary practice the use of RF-based EPAs is largely limited to the frequency range 
of 30 kHz – 30 MHz. The literature pertaining to this frequency band is much smaller 
compared to the wider clinical literature relating to RF as stated above. Only 120 clinical 
studies (published in English) concerning the use of RF-based treatment in therapy-related 
clinical practice were identified from a comprehensive literature search within the above 
frequency range. Several studies that were relevant to this research project but conducted 
on non-clinical samples/populations such as laboratory animals, tissue models (in vitro 
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studies) or asymptomatic humans (healthy-subject studies) have also been discussed 
briefly. 
All 120 clinical studies have been reviewed in detail in chapter 3. The studies belonged to 
either a smaller ‘acute conditions’ (30 studies; 25%) subgroup or a larger ‘chronic conditions’ 
(90 studies; 75%) subgroup. Both groups contained studies that employed various 
methodological approaches ranging from case studies to multi-group clinical trials. They also 
contained similar application categories – mainly the studies on pain and inflammation and 
the studies on tissue healing. A comparison and contrast of the main results of the reviews 
from both the acute and chronic subgroups are given in Table 3.7. 
Table 3.7: Key review findings from the acute and chronic subgroups of RF studies 
 
 
 
 
 
 
 
 
 
Together, for the acute and chronic conditions, notable evidence only exists for chronic OA 
knee, acute postoperative pain and acute postoperative wound healing. Some evidence also 
exists for chronic LBP and healing of chronic wounds. None of the other clinical areas where 
studies were identified has sufficient evidence to support the use of RF-based therapy. The 
clinical areas of research, methodological shortcomings of the studies, and issues with 
reporting remained common for both acute and chronic subgroups. In both categories, a 
clear association could not be found between the quality scores (Downs and Black) obtained 
by the studies and their reported clinical outcome. Several studies considered here were 
affected by significant methodological issues as identified in the relevant sections, which 
appeared to be common to both acute and chronic categories. 
RF-based EPAs have been used in therapy practice for almost a century. Yet, research in 
this area continues to be minimal, warranting substantially more work. The non-shortwave 
RF band is particularly less well investigated since only eight out of the 120 studies in this 
review employed RF frequencies other than the commonly employed frequency of 27.12 
MHz. It was non-existent in the acute category with zero studies identified. This is clearly 
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surprising since EPAs employing RF frequencies below shortwave are already in clinical use 
in many countries for decades. This observation is also true for non-clinical studies 
investigating the theory underpinning the potential modes and mechanisms of RF action in 
tissues. 
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4 Chapter 4 – Materials and methods, measurement 
principles and pilot experiments. 
 Introduction 
The previous two sections provided a detailed account on the fundamental principles of RF-
tissue interaction and the literature on the effects of RF-based therapy. It also outlined the 
rationale, aims and objectives of this research project. It is clear from the existing literature 
that there is a lack of research to show how specific RF frequencies below the shortwave 
frequency band interact with the human body, while there are reasonably good levels of 
such research available on the higher frequencies (shortwaves and microwaves, 
microwaves not covered here). It is reasonable to state (based on the literature that was 
published in English) that EPAs based on RFs below shortwave have become commercially 
available and embedded into clinical practice without extensive underpinning evidence. 
Besides the lack of clinical studies, no in vivo human or animal studies were identified 
investigating the physiological effects of 448 kHz CRMRF, which is the frequency of RF 
being investigated in this project. This is true also for all other RF frequencies below 
shortwaves. 
The purpose of this chapter is primarily to outline all physiological measurement techniques 
that were relevant to the work carried out in this research project, explain the principles of 
measurement and report all pilot experiments that were carried out. To avoid repetition in the 
following chapters, reference will be made to the contents of this chapter where relevant 
while describing the methodology. The chapter will also describe the procedures adopted to 
process the resultant data. It will explain the measures relating to superficial, deep and 
systemic physiological responses. All measures adopted in this project were non-invasive 
and those that reflect the changes to body’s thermoregulatory/thermophysiological system 
when subjected to exogenous EMF. Numerous researchers have used such or similar 
measures in related RF research.77-81,85,87,95,96,105,175,178-180,187,191,329 Numerous pilot studies 
were conducted as part of this project to ascertain the reliability of the involved methods 
(equipment and techniques) in comparison with other similar methods, where multiple 
methods were available for use; and to ascertain the intra-rater reliability where the 
techniques were complex. 
 The RF treatment devices 
4.2.1 The CRMRF device 
The CRMRF treatment was administered using ‘Indiba Activ 902’ device (Indiba S. A., 
Barcelona, Spain) (Figure 4.1). It was a brand-new factory calibrated machine pretested to 
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ensure reliability and accuracy of output. The peak power of the device is 200 W (or 450 
Volt-Ampere (VA)). It delivers RF energy in two modes: Capacitive (CAP) and Resistive 
(RES), which are delivered using different types of electrodes. RF is generated at 448 kHz in 
a continuous wave form in either mode. The intensity of the energy delivery is given as 
percentage output. The theory underpinning the CAP mode function is similar to the 
capacitive method of SWT. Likewise, the RES mode is similar to the inductive method of 
SWT. These methods of SWT are well-documented.18 The mechanism of RF-tissue 
interaction is already covered in detail in the previous sections. 
The two main differences between the CRMRF and SWT are: 
1) The operating frequency – SWT is delivered mainly at 27.12 MHz while CRMRF is 
delivered at 448 kHz. 
2) In CRMRF the energy is applied via a contact method using a coupling medium unlike in 
SWT where the transmission is over an air gap. 
The CAP electrode is coated with a polyamide material that acts as a dielectric medium. 
This medium insulates its metallic body from the skin surface, thereby forming a capacitor 
with the treated tissues. The RES electrode is uncoated. Energy delivery to the body is 
enabled using a conductive cream (coupling medium) (Figure 4.1), since the frequency of 
the RF is not high enough to be able to conduct through air. The device offers different sizes 
of round metallic treatment electrodes for both modes of treatment (Figure 4.1). The size is 
chosen according to the size of the body area being treated. The return electrode is metallic 
and is either flat or cylindrically shaped. The machine can be operated from a close distance 
using a remote control that has start/stop and intensity up/down functions. In the research 
environment, a monitoring device can be attached to the machine to transfer the operating 
data wirelessly using computer-based monitoring software. 
The device used in this project was modified by the manufacturer to meet the requirements 
of blinded and randomised laboratory testing, and the appropriate monitoring of the energy 
delivery. However, the fundamental functions and the working of the device remained 
identical to a commercially available device except for the following modifications. 
1) An additional setting allowing the therapist to choose treatment programmes from 0 – 99, 
half of which were active treatment programmes and half placebo. 
2) The CAP mode display would normally show the energy delivery units in Volt-Ampere; 
however, the current device displayed this information in Watts to enable identical 
energy monitoring for both CAP and RES modes. 
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Figure 4.1: The ‘Indiba Activ 902’ device, electrodes and conductive cream 
 
 
 
 
 
 
 
 
Electrodes measuring of 65 mm in diameter were used as treatment electrodes and a 
flexible rectangular metallic electrode measuring 200 x 260 mm was used as return 
electrode throughout the current project. A conductive cream that was supplied by the 
device manufacturer was used as a coupling medium between the electrode and the skin. 
The machine displays the RF intensity and the energy output while the treatment is being 
delivered, which is also mapped by the computer-based monitoring software. 
More details are discussed in the pilot study section of this chapter. 
4.2.2 The PSWT device 
PSWT was delivered using ‘Bosch Ultramed’ machine (Robert Bosch GmbH, Germany) 
(Figure 4.2) that operates at the base shortwave frequency of 27.12 MHz. The Bosch 
Ultramed is a therapeutic apparatus that can deliver shortwave in both continuous and 
pulsed modes. In the pulsed mode, the device can deliver pulses that are fixed at 400 µs in 
duration (pulse duration; PD), repeating at a rate (pulse repetition rate; PRR) of 15–200 Hz 
enabling the operator to vary the output. The peak power (PP) can be varied from 100 to 
1000 Watts (W). The desired mean power (MP) output can be obtained by manipulating the 
various pulse parameters. The device was fully tested and calibrated prior to the 
commencement of the study. 
Figure 4.2: The Bosch Ultramed SWT device 
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 Selection of physiological parameters to investigate 
The RF physiological studies published so far (including animal studies) have focussed 
predominantly on the thermophysiological effects such as changes to tissue temperature, 
blood flow, nerve conduction and tissue extensibility. These studies were mainly conducted 
either using pulsed or using continuous SWT devices. Since similar research is non-existent 
among the lower frequency non-shortwave RF (including the 448 kHz CRMRF), a series of 
laboratory-based studies were designed to investigate the effect of CRMRF on the 
physiological parameters in an asymptomatic sample. The chapters that follow in this section 
will address the various physiological responses of CRMRF under different experimental 
conditions and doses. A comparison of the effects of CRMRF with those obtained with a 
comparable dose of PSWT will also be undertaken later in the section (chapter 6). 
 Selection of a body area to treat 
The literature shows various body segments being exposed to RF-based treatment and to 
the measurement of physiological responses. They included the lower limb80,81,83,89,90,95,105 in 
many studies and the upper limb77-79,85 in some other studies. The studies often followed key 
anatomical landmarks (such as a specific joint or a muscle group), which can be related 
directly to clinical conditions. In other words, if the use of an RF-based EPA is shown to be 
feasible on a body segment and if the effects are present in terms of physiological 
parameters such as blood flow or nerve conduction, then its clinical application pertaining to 
a condition specific to that body segment potentially becomes more feasible. 
One of the main aims of this project was to investigate the clinical effect of CRMRF in a 
relevant musculoskeletal condition. The choice of a condition must be based on its 
prevalence, impact of the condition on patients’ health-related QoL, its resistance to existing 
conservative treatment methods (recalcitrance), potential response to RF-based treatment 
and the feasibility of a clinical evaluation in terms of availability of participants for the study. 
The literature review has shown that OA of the knee joint is the single largest clinical area 
investigated by the existing RF studies and showed some of the best available evidence. 
The condition is still regarded as one of the most pressing chronic public health issues 
affecting the functional QoL of people.330-334 Hence, OA of the knee was regarded as the 
most appropriate condition to be investigated for the clinical effects of CRMRF treatment and 
be compared to existing forms of RF treatment such as PSWT. Hence, in the laboratory-
based physiological investigation the knee region was chosen as the body area to be treated 
and assessments to be undertaken. 
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 Superficial physiological measurements 
Skin temperature (SKT), Skin blood flow (SBF) and nerve conduction velocity (NCV) were 
the localised superficial outcome measurements obtained. They are explained in detail 
below alongside the various measurement systems used to obtain them. 
4.5.1 Skin temperature 
The SKT is an important physiological parameter that can reflect on the presence of disease 
and injury. It can also characterise the body’s interaction with the environment and plays a 
fundamental role in thermoregulation. Hence monitoring of SKT is important for both clinical 
and non-clinical settings.335-337 Since RF is used in therapy predominantly for its thermal 
effects, it is prudent to use SKT as a key outcome. SKT should be distinguished from core 
temperature, which in simple terms is the temperature of the inside of the body. While the 
normal SKT varies depending on the body area, metabolic level and the environment, the 
core temperature reflects the temperature in the hypothalamus and undergoes rhythmical 
variations through the day; however, under normal circumstances the core temperature is 
maintained within a narrow band of 36 – 38 oC.336,338-342 Although core temperature will be 
monitored in this study (mentioned later), the main focus is on the local SKT changes in 
response to localised therapeutic application of non-invasive RF. 
There is extensive literature on various methods of SKT measurements. Broadly, there are 
contact (conductive) and contactless (non-conductive) methods of skin temperature 
measurement. There are a wide variety of these devices available. Three of the most 
popular types of devices employed in research and clinical practice are thermocouples, 
thermistors and telemetry sensors (e.g. iButtons).343-345 Wireless sensors are also available, 
which have been validated against thermocouples and thermistors.337,346 
The contactless devices are normally the quick response IR surface thermometers that are 
used by many researchers,347-352 or IR thermography.353-359 Similar to the contact conductive 
devices, the IR thermometers provide a ‘spot’ measurement, which is the average 
temperature of the small surface area where it is measuring.336 Some IR thermometers 
require skin contact to enable measurement, but the majority of them do not. Usually there is 
a manufacturer instruction as to how far from the skin the device can be held (e.g. 50 mm) 
while a reading is taken. There are devices that allow a greater distance and hence a 
greater measurement area; however, this often will affect the accuracy.360 
Instant response thermistors are usually employed for real-time temperature monitoring, 
enabling up to thousands of readings to be taken every second via computer-based 
monitoring software (e.g. Biopac system (Figure 4.4)). They are highly temperature sensitive 
and accurate within the human physiological range.336,344 Although there is a disadvantage in 
being a wired device and that they are much more expensive (the encoders), thermistors are 
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a valid and reliable method of skin temperature measurement used in both clinical practice 
and research.80,192,350,352,361,362 
4.5.2 Skin blood flow 
The measure of SBF can be a good indicator of perfusion in the superficial tissue structures. 
It responds to both internal and external factors such as rest, physical activity, hormones, 
heat, cold and a range of chemical and mechanical stimuli. The physiology of SBF and the 
effects of heat and cold on SBF are well documented.8,254,341,342,363-368 Besides SKT, the 
changes in SBF can be used as an important outcome measure to understand the 
physiological effects of RF since tissue effects of RF are thought to be predominantly 
thermal and the changes in SBF being predominantly a thermophysiological response.1,21,22 
It has been used extensively as an outcome measure in previous research with RF in the 
shortwave frequency range.77,80,85,86,192 
Over the years, numerous studies on the methods (invasive or non-invasive)369-389 and their 
innovations and refinements382,390-403 have been reported in order to achieve accurate 
measurement of SBF. Describing all those techniques in detail is beyond the scope of this 
thesis. Two of the most popular and robust non-invasive measurement techniques that are 
widely used in clinical research are Photoplethysmography (PPG)369,379,389,390,392,404-413 and 
Laser Doppler Flowmetry (LDF).371,374,383,400,414-418 Both are valid and reliable techniques to 
make spot measurements of SBF and several comparative studies between the two are also 
available,375,406,409,419-421 the consensus of which is that both techniques can be used 
effectively for SBF monitoring. Both LDF and PPG were available for use in this research 
project. However, the LDF probe sustained mechanical damage and could not be repaired 
or replaced in time for use. PPG was hence used as the measure of SBF in all the studies of 
this project (Figure 4.4). 
LDF measures the microcirculatory blood flow using either a fibre optic probe (laser Doppler 
perfusion monitoring, LDPM) or an imaging system (laser Doppler perfusion imaging, LDPI). 
The technique infers the blood perfusion rate by analysing the Doppler frequency shift from 
the scattered monochromatic laser light reflected by the moving RBCs.374,414,416,422 PPG, 
which was first described by Hertzman386,423,424 in 1937, detects the changes in blood volume 
in the microvascular bed of tissues. It utilises a light emitting diode (LED) to emit light into 
the tissues. While this light gets absorbed and scattered in the tissues, a small amount of 
this scattered light is received by a photodetector plate placed adjacent to the LED source. 
Variations in this photodetector signal relates to the changes in blood flow.379,382,389,404,405,411 
Besides being used in research, PPG has widespread clinical applications providing 
valuable information about the circulatory system. The technology is utilised in several 
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commercially available systems such as pulse oximeters, vascular diagnostics and certain 
BP monitoring devices.369,411 
4.5.3 Nerve conduction velocity 
Unlike SKT and SBF, RF of any frequency is not known to influence NCV greatly. Literature 
in this area has been limited, with only few studies that showed mixed results.78,191,192 
However, as stated the existing literature is solely based on SWT with no information 
available on any potential effects of CRMRF on nerve conduction. In fact, the literature is 
completely lacking for any RF frequencies below the shortwave frequency band. 
In simple terms, NCV is the speed with which an electrical impulse (action potential) travels 
along a nerve fibre either orthodromically or antidromically in a sensory, motor or mixed 
nerve. In clinical practice, it is used as a diagnostic measure of the pathophysiology of a 
nerve. During the test, the nerve is stimulated at one point using mild short electrical 
impulses that are applied to the skin using an attached surface electrode patch (stimulating 
electrode). The nerve response to this impulse is recorded at a suitable distance along the 
same nerve using another attached surface electrode patch (recording electrode). The NCV 
is then calculated from the distance between the stimulating and recording electrodes and 
the time taken by the impulse to reach the recording electrode (Figure 4.3).425-430 
Figure 4.3: Representative image showing NCV measurement and device setup 
 
 
 
 
 
 
 
 
 
The velocity of conduction varies from nerve to nerve and from person to person. In general, 
the larger the diameter of the nerve fibre and higher the degree of myelination (myelin 
sheath forms an ‘insulation’ around the nerve fibre), the faster the nerve conduction is. A 
normally functioning nerve with undamaged fibre and intact myelination will transmit the 
impulses more effectively than an injured nerve.431-434 This is like a large and properly 
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insulated electrical cable being able to transmit a strong electric signal consistently than a 
thin wire with no proper insulation. 
Several devices exist that can measure NCV; however, they all consist of similar 
components. There will be a stimulator to deliver the impulse, a recording unit to capture the 
nerve response and an amplifier to magnify the recorded signal. This system is connected 
through stimulating and recording electrodes along with their lead wires. A ground electrode 
is also used to reduce stimulation artefacts, noise and interferences. The amplifier utilises 
high or low pass filters to keep unnecessary signals (noise) out. NCV can also be recorded 
using needle electrodes; however, in the current project only non-invasive methodologies 
were employed hence standard square ECG twin electrodes were used. A separate pilot 
study was undertaken (explained later in this chapter) to identify the most suitable ECG 
electrode for this purpose by testing many commercially available brands. 
4.5.4 The skin physiological measurement devices 
4.5.4.1 The Biopac system 
Biopac MP150 (Biopac Systems, CA) (Figure 4.4) physiological measurement system was 
used in the main study (study described in chapter 6) to record all three outcome measures 
described above (SKT, SBF and NCV). The existing Biopac MP100 that was successfully 
used in an earlier PhD project192 and whose findings have also been published,80 was 
upgraded to MP150 for the current project incorporating the latest modules, transducers and 
the latest version of the computer-based software. Biopac systems are used world over in 
contemporary research, in similar or unrelated subject areas.435-442 It is an acquisition system 
that can collect, analyse, store and retrieve data. There are 16 input/output channels and a 
maximum sampling rate of up to 200 K samples/second. The technical specifications of the 
unit are further detailed in Appendix 4.1. 
The local SKT was recorded using the SKT100C amplifier module and the TSD202A 
thermistor transducer. SBF was recorded using the PPG100C photoplethysmogram (PPG) 
amplifier module and the TSD200 PPG transducer. Nerve conduction velocity was 
measured using the STM100C stimulator (STM) and EMG100C electromyography (EMG) 
amplifier modules used in combination. The cited accuracy of the MP150 system was 
±0.003% of full scale range. 
The TSD202A (together with the SKT100C module) used to record SKT employs a fast 
response thermistor with a response time of 0.6 seconds. It is appropriate for measuring skin 
temperature in small areas, and for use in locations where temperature varies rapidly. The 
TSD200 PPG transducer (together with the PPG100C module) consists of a matched 
infrared emitter and photo diode, which transmits the changes in blood density (caused by 
blood pressure changes), at specific body locations. When the TSD200 is attached to the 
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skin, the infrared light is modulated by blood pulsing through the underlying tissues. The 
modulated, reflected light results in small changes in the resistance of the photo resistor, 
which yields a proportional change in the voltage output. The peak measurement recorded 
by the device indicates the point of maximal blood density at the respective location. The 
blood flow values are obtained in arbitrary units rather than absolute values. 
Figure 4.4: The Biopac MP150 system, modules, and PPG (top right) and SKT (bottom right) 
probes 
 
 
 
 
 
 
 
4.5.4.2 The FlexComp Infiniti system 
The FlexComp Infiniti (SA7550) (Thought Technology Ltd., Montreal, Canada) (Figure 4.5) is 
a 10-channel multi-modality device (encoder) for real-time computerized psychophysiology, 
biofeedback and data acquisition. It is a portable unit that can render a wide range of 
objective physiological measures in clinical practice and research. In this project, the device 
was used to obtain SKT and SBF from the participants of the clinical trial (final stage). The 
device has been used in research in other subject areas443-445 
Figure 4.5: The FlexComp Infiniti device, and PPG and SKT probes 
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To study the relative change in SBF, a Heart Rate/Blood Volume Pulse (HR/BVP) Sensor 
(P/N: SA9308M), which is the same as a PPG sensor was used. Default sampling settings 
with a minimum of 256 samples per second was employed. The SKT was recorded using 
the Skin Temperature Sensor (P/N: SA9310M). It can perform real-time temperature 
measurement between 10 oC – 45 oC. This thermistor converts changes in temperature to 
changes in an electrical signal, which is mapped by the encoder and the software. The 
underpinning principles of both these probes are similar to that of the Biopac probes. 
4.5.4.3 Hand-held IR surface thermometer 
A hand-held contactless IR skin surface thermometer (Thermofocus 01500A3) (Tecnimed 
Srl, Varese, Italy) (Figure 4.6) was used for skin surface temperature measurement where 
the Biopac system was not used (Chapter 5). It had a measurement accuracy of ±0.3 oC 
between 20.0–42.5 oC, with an improved accuracy of ±0.2 oC between 36.0–39.0 oC. This 
was an inexpensive device suitable for use in both clinical and research settings. 
Figure 4.6: The Thermofocus IR thermometer 
 
 
 
 
 
 Deep physiological measurements 
Deep blood flow and tissue extensibility were the measures obtained from deeper tissues. 
They both are explained in detail below along with the ultrasound devices that were used to 
measure them. 
4.6.1 Deep blood flow 
Blood flow to the deeper tissues (two centimetres or more from the skin) was monitored 
using Doppler ultrasound measurements that provided information on the velocity, volume 
and intensity of blood flow. Even though the function of blood flow has been a subject of 
science since centuries, quantitative methods to study deep blood flow in man have not 
been available until the beginning of last century. Addition of advanced instruments such as 
Doppler ultrasound to the battery of measurement tools enabled objective recording of the 
blood flow in larger blood vessels inside the body without interfering with the process of 
circulation.446 The power Doppler imaging is relatively new when compared to colour 
Doppler and displays blood flow with significantly improved sensitivity than the conventional 
colour Doppler imaging.447 The colour Doppler is most effectively used when examining 
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whole vessel flow and power Doppler for tissue perfusion or microcirculation. Further 
technological advancements in ultrasound imaging in the past few decades have made the 
technique more accurate, without the need of being invasive or needing to administer 
intravascular contrast agents. 
4.6.2 Tissue extensibility 
The indices of tissue extensibility (measurements of ‘hard’, ‘intermediate’ and ‘soft’ tissues) 
were obtained using Sonoelastography. Sonoelastography provides an estimation of tissue 
elasticity (extensibility) by analysing the degree of distortion in tissues secondary to the 
application of an external force. This dynamic technique employs ultrasound and is 
comparatively new. In this technique, the relative extensibility of the tissues is displayed as a 
colour overlap on the standard grey (B-Mode) image.448,449 Although used mainly for the 
imaging of tumours, it is proposed to be a promising tool in determining the elastic properties 
of human tendons and skeletal muscles.448 
4.6.3 Ultrasound scanning devices 
An ‘Esaote MyLab70 XVG’ (Esaote S.p.A, Genoa, Italy) (Figure 4.7) ultrasound scanner was 
used alongside a linear array probe ‘LA523’ that supports a frequency range of 4–13 MHz 
(Esaote S.p.A, Genoa, Italy) to collect the deep blood flow and Elastography data in the 
main laboratory study (Chapter 6). Since this device was not portable, another portable 
device ‘Esaote MyLab 25’ (Esaote S.p.A, Genoa, Italy) was used in the clinical trial phase 
(Chapter 9) to ensure safe and easy transportation from and to the trial site. The LA523 
probe was compatible with both scanning devices. 
Figure 4.7: The Esaote ultrasound scanning devices and probe 
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 Other outcome measures 
Core temperature, blood pressure and pulse rate were the other outcomes monitored 
alongside the main outcome measures described in the above sections. There is no 
evidence in the existing literature to suggest that localised application of any frequency of 
RF will impact on systemic parameters such as core temperature, blood pressure or pulse 
rate. There is also no indication that the application of CRMRF to local tissues may induce 
any changes to the same. However, monitoring these systemic physiological parameters 
would enable a better understanding of the extent of effects of the local therapeutic 
application of CRMRF. 
An infra-red (IR) tympanic thermometer (Braun ThermoScan IRT 4520, Braun GmbH, 
Kronberg, Germany) was used for core temperature measurement. It had a measurement 
accuracy of ±0.2 oC between 35.5–42.0 oC and ±0.3 oC outside of this range. Blood pressure 
(BP) and pulse rate (PR) were monitored using a digital upper arm BP monitor (Omron M2, 
Omron Healthcare Europe B.V., Hoofddorp, Netherlands). 
 Other devices used in the project 
During the experiments three other devices in addition to the outcome measure devices 
were used to collect the anthropometric data, room temperature and humidity and to assist 
with the method of treatment delivery (Chapter 5). A body composition monitor (Omron 
BF508, Omron Healthcare Europe B.V., Hoofddorp, Netherlands) was used to obtain the 
weight, body fat percentage, visceral fat and the body mass index (BMI) measurements of 
the participants. The room temperature and humidity were monitored using an electronic 
thermohygrometer (RS 212-124, RS Components Pte Ltd., Singapore). An electronic 
metronome (Seiko Corporation, Japan) and a computer-based timer were used to aid the 
experimental procedure described in chapter 5. 
 Processing of physiological data 
This section will explain how the raw physiological data obtained from the Biopac, FlexComp 
Infiniti and ultrasound devices were processed to obtain the corresponding numerical data to 
be analysed statistically. 
4.9.1 Processing of Biopac data 
The Biopac data provides actual values for SKT and NCV, but for SBF the PPG module 
reports the data in Volts from which the relative change in SBF can be inferred. For both 
SKT and PPG, 60 seconds worth recordings were processed to obtain each of the three 
measurements (pre-treatment, post treatment and follow-up). The Biopac ‘AcqKnowledge’ 
software allowed the processing and required calculations to be made on each data stream. 
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Before obtaining the measurement values the data streams were subjected to the ‘Comb 
Band Stop’ and ‘Low Pass’ digital filters to exclude the unwanted signal noise. For SKT the 
mean value over the selected 60 seconds was taken. For PPG, the area under the curve 
was obtained by first reversing the negative cycles and then using the ‘integral’ function of 
the software. For NCV after applying the above digital filters the area of one action potential 
was magnified and the area between two peak responses (external stimulus and 
subsequently the nerve response) was marked. This denoted the time lag (∆T) between the 
peaks of the stimulus and the nerve response, which is essentially the nerve conduction 
time. The distance between the stimulating and recording electrodes is already known. From 
this time and distance, NCV can be calculated. Figure 4.8 shows the raw and processed 
data streams of SKT, PPG and NCV obtained during an experimental session from one of 
the participants. 
Figure 4.8: Raw (left) and processed (right) Biopac data. SKT & PPG (top), NCV (bottom) 
 
 
 
 
 
 
 
  
 
 
 
4.9.2 Processing of ultrasound data 
The ultrasound images were computationally analysed using MATLAB (MathWorks, 
Massachusetts) to process the colour image data into numerical data. The MATLAB 
algorithms were written by Dr Anthony Herbland (Educational Technologist & Senior 
Lecturer, School of Health and Social Work, University of Hertfordshire) after the idea was 
discussed and conceived among the researcher (BK), the supervisor (TW) and Dr Herbland. 
For every image frame the MATLAB algorithms generated two types of data: the total 
number of coloured pixels (pixel count) in the ‘region of interest’ (ROI) indicating the volume 
information, and the total colour intensity value based on the intensity value for all the colour 
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pixels in the ROI. The intensity value in turn was calculated based on the linear property of 
the green colour component in the colour and power Doppler scales. The green colour 
decimal value range varied linearly from 0 to 232 for the colour Doppler scale and from 0 to 
241for the power Doppler scale. 
In all results, the pixel count was expressed as ‘kilo pixels’ (total number of pixels divided by 
1000) and the ‘colour intensity index’ as the mean colour index per pixel by dividing the total 
colour score of a frame by the total number of pixels in that frame. For colour Doppler, the 
‘colour intensity index’ scores (total green colour intensity divided by pixel count as 
described above) indicated the relative velocity of the flow of blood. For power Doppler, both 
‘pixel count’ and ‘colour intensity index’ were taken in to account separately. The total 
number of pixels (pixel count) represented the overall ‘blood flow volume’ and the colour 
intensity index (calculated as in colour Doppler) represented ‘blood flow intensity’. Higher the 
count and/or index, higher were the flow of blood. 
The degree of tissue compliance (level of ‘hard/soft’ ness) in Sonoelastography was 
analysed differently to the Doppler data in that all three colour components red, blue and 
green were analysed as described above, for the hard, intermediate and soft tissue types 
respectively. 
The MATLAB analysis of the machine colour scales for the colour and power Doppler and 
Elastography is further illustrated in (Figure 4.9). The algorithms used for the processing of 
the ultrasound images obtained from the MyLab 70 device (laboratory study) are given in 
Appendices 4.2, 4.3 & 4.4. Appendices 4.5 & 4.6 show the algorithms used for analysing the 
ultrasound images obtained using the MyLab 25 portable device (clinical study). 
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Figure 4.9: The MATLAB analysis of the ultrasound machine colour scales 
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4.9.3 Processing of FlexComp Infiniti data 
The FlexComp Infiniti measurement unit was used as the portable alternative to Biopac to 
measure SBF and SKT in real-time on the participants of the clinical trial. The device works 
with the BioGraph Infiniti software system that was used to obtain the session reports from 
each of the recording made using the FlexComp Infiniti hardware. Like Biopac the SKT was 
given in degree Celsius as actual values whereas the PPG report was shown as the 
amplitude mean (relative value) of the blood volume pulse (BVP). The software showed 
session means (mean of 120 seconds of data) by default. Figure 4.10 shows an example of 
a session report obtained from one of the participants in the clinical trial. 
Figure 4.10: Sample data report from the BioGraph Infiniti software 
 
 
 
 
 
 
 
 
 
 
 
 
  Methodological considerations and pilot experiments 
This section will discuss a series of methodological aspects relating to the conduct of the 
study through all primary pilot laboratory experiments performed as part of this project, some 
of which were simple desktop experiments while others were studies involving human 
participants (asymptomatic volunteers). 
The aims of the pilot studies were: 
1) To establish key issues regarding the CRMRF treatment device. 
2) To calibrate the equipment where necessary. 
3) To study the potential signal interference between devices. 
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4) To identify and address issues with probe attachment. 
5) To identify and address the sources of signal noise. 
6) To analyse signal baselining time. 
7) To determine Biopac sampling rate. 
8) To establish the agreement between various SKT measurement devices. 
9) To identify suitable NCV electrodes for signal stability. 
10) To study the effect of CRMRF on NCV electrodes attached to the skin. 
11) To establish the test retest reliability of ultrasound measurement techniques. 
4.10.1 The CRMRF device: familiarisation, operating principles and identifying 
the key issues (addressed aim 1) 
Extensive practice sessions and testing of the CRMRF device was undertaken to fully 
understand the operating principles and identify the key issues. 
4.10.1.1 Machine parameters 
Among the various machine parameters, the output intensity settings on the device were 
dissimilar on either mode of treatment. While the RES mode allowed more incremental 
dosages reaching up to 100%, the CAP mode allowed only a smaller number of dosage 
selections until 100% power was reached. In addition, the increments were not linear in 
either mode. From the study point of view this meant that a direct dosage comparison 
between the two modes will be problematic. The treatment electrodes were available in a 
variety of sizes for either mode. Considering the size of the treatment area (knee), 65 mm 
treatment electrodes were considered the most appropriate to ensure uniform field 
distribution. Since the treatment was set to be delivered to the participant while he/she was 
positioned in supine, the ideal position for the return plate electrode was under the calf 
muscle. Like SWT (in the capacitor field method) the distance between the active and return 
electrodes had to be adequate to ensure a uniform field density in the tissues, by preventing 
field accumulation closer to the junction between the electrodes. 
4.10.1.2 The coupling medium 
A manufacturer supplied conductive cream was used for energy delivery. It was found that 
this cream was sensitive to heat when the treatment was delivered, commensurate with the 
level of dose. As the cream temperature increased, its viscosity reduced resulting in the 
cream flowing out of the skin. To compensate, it was decided that sufficient quantity of 
cream should be added at the starting point of treatment itself to prevent drying. After testing 
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it was decided that 20 ml of cream was sufficient for either mode. The return plate electrode 
was also decided to be coated with 20 ml of cream to ensure consistency. 
4.10.1.3 Provision for blinding 
As stated before, the device supplied for this research study was modified by the 
manufacturer to add the provision for blinding. An additional item was integrated into the set-
up menu that allowed the selection of any treatment programme from 0 – 99. At random, half 
of these settings represented active treatment with normal energy delivery and the other half 
represented a placebo with zero energy delivery. After testing these settings, it was clear to 
the researcher that despite the provisions for blinding, the therapist will not be able to be 
blinded since skin heating and cream issues discussed above will be present. Hence, it was 
decided to only use the settings ‘zero’ (represented active) and ‘one’ (represented placebo) 
for the study. However, the participant who is unaware of the potential sensations that might 
arise from the RF delivery would remain blinded to what level of doses he/she may be 
receiving. Also, it was decided that at the end of each randomised study involving active and 
placebo versions a concealment checking would be undertaken to find out the extent of 
blinding achieved. This can be achieved by asking the participant if they could recollect and 
identify the sessions they received. 
4.10.1.4 Treatment duration and sequence  
The manufacturer had recommended to use CAP mode first for five minutes followed by 
RES modes for 10 minutes in sequence and to end the treatment session with a second 
five-minute CAP application. Thus, a total 20 minutes per treatment session was 
recommended by the manufacturer. However, this recommendation was not based on 
evidence-based reasoning. Moreover, sessions lasting 15 minutes (5 min CAP + 10 min 
RES) were sufficient commensurate with current practice in the UK. Hence, a CAP-RES 
sequence was employed instead of a CAP-RES-CAP sequence. 
4.10.1.5 Issues with application techniques 
The treatment had to be delivered with the electrode exerting mild to moderate pressure on 
the skin and by moving constantly in uniform circles to avoid undue accumulation of energy 
and adverse heat build-up. The ideal speed was identified to be one cycle per second. It was 
decided that a metronome should be used in the lab study to ensure consistency of this 
technique. The researcher had to at the same time prevent the loss of coupling medium by 
not letting it flow out of the zone (cream issue discussed above). As the treatment doses 
were incrementally raised the recipients felt heat sensation on the skin, which increased 
commensurately with the dose. It was hence decided that the recipient had to be tested and 
cleared for any lack of skin thermal perception prior to receiving treatment. 
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4.10.2 Calibration of equipment (addressed aim 2) 
The CRMRF treatment device was new and factory calibrated. No periodic user calibration 
was recommended by the manufacturer. The PSWT device was certified as serviced and 
calibrated for accuracy of output prior to its use in the study by a licenced engineer who 
visited the site. Out of the main outcome measure devices, the Thermofocus hand-held 
thermometer was factory pre-set to run its own periodic self-calibration while in idle mode. 
The FlexComp Infiniti portable unit was newly supplied and did not require user calibration. 
The Biopac MP150 main unit and key modules used in this study were new and factory 
calibrated. Repeat user calibration was not recommended per se; however, the 
manufacturer suggested that accuracy of output may be tested by assessing the noise levels 
and ensuring that the baseline signal has no voltage drift. Calibration/accuracy testing of the 
Biopac modules is explained below. The accuracy testing of the modules was done on a 
weekly basis while the data was being collected. 
4.10.2.1 Calibrating the SKT biopotential amplifiers 
The fast response TSD202A thermistor transducer can be calibrated while setting the 
channel up for measurement. The user was only required to choose between Degree 
Celsius (oC) and Degree Fahrenheit (oF) in the channel setup. Once the desired 
measurement unit, gain level, sampling rate and channel number were chosen no further 
modifications were required. All temperature measurements in this study were done in the 
absolute (oC) readings. The physical controls on the amplifier module can be used to change 
the gains and filters where required. The module has the available gain settings of 0.5, 1, 2 
and 5 oF/V. The gain setting used in this study was 5 oF/V and the module auto scaled the 
measurement settings accordingly. 
4.10.2.2 Calibrating the PPG biopotential amplifiers 
The PPG100C photoplethysmogram (PPG) amplifier module and the TSD200 PPG 
transducer do not require user calibration according to the manufacturer. When turned on 
without connecting the transducer, the amplifier module shows the baseline signal 
constituting only the noise in Volts. When testing for accuracy, if the scaling of this signal 
shows either a positive or a negative drift from zero Volts, it can be brought back to zero by 
manipulating the zero-adjustment screw at the top front of the module. The PPG modules 
used in this study were new and unused; hence they were not displaying any voltage drift 
from zero. The module has gain settings of 10, 20, 50 and 100. A gain level of 100 was used 
in the study by default. 
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4.10.2.3 Calibrating the EMG biopotential amplifiers 
The EMG100C is factory set and does not require user calibration according to the 
manufacturer. However, to confirm the accuracy of the device, they recommended using the 
CBLCAL, which is a special output cable that can diminish the recorded signal into a known 
stimulus and re-route it into the amplifier, to be amplified by the selected gain setting. The 
accuracy of the EMG was tested at all the gain settings on the module (500, 1000, 2000 and 
5000). The gain setting of 5000 was used in this study for all NCV measurements. The step 
by step procedure, as detailed in the Biopac hardware guide (Appendix 4.7) was followed for 
calibrating the module at the required gain levels (Figure 4.11). 
Figure 4.11: EMG module calibration output data obtained using CBLCAL (Left – before 
calibration; Right – after calibration at gains 5000, 2000, 1000 & 500 (left to right)) 
 
 
 
 
 
 
 
4.10.2.4 Calibration of the stimulator 
The STM100C is a single-channel stimulator amplifier that is designed for use in stimulus 
response and testing and in biofeedback procedures. The device is factory calibrated and 
any user calibration is not advised by the manufacturer. 
4.10.3 Investigating signal interference (addressed aim 3) 
The administration of RF energy involves electric (E) and magnetic (M) field emission, which 
could potentially extend several meters beyond the perimeter of the device,18,450-452 and 
could potentially affect the functioning of other electronic devices around it. Hence, 
establishing the safe working distance between the RF device and the data acquisition 
system and a safe working environment for the participants is imperative. Pilot experiments 
were conducted on one participant to explore the effect of both CAP and RES modes of 
CRMRF on the Biopac data streams while they were both functional. The study was 
approved by the Health and Human Sciences Ethics Committee with Delegated Authority 
(HHSECDA) of the University of Hertfordshire (Protocol number: HSK/PG/UH/00015) 
(Appendix 4.8). Similar work, extensively investigating the effect of PSWT fields on Biopac 
data streams has been previously undertaken within the same research group192 and were 
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hence not duplicated in this project. Unlike in the previous PSWT study,192 in this study the 
Biopac unit was not recording data while RF was being delivered. The measurements were 
obtained only before and after treatment. So, ensuring the purity of data streams by avoiding 
RF interference was not the primary concern. However, the safety of the measurement 
probes and avoidance of skin irritation at the site of probe attachment on the participant 
needed to be ensured in the presence of RF fields, by identifying the optimum distance 
between devices.  
4.10.3.1 Effect of the distance between CRMRF device and Biopac unit 
To determine the safe yet practicable positions of the treatment and measurement units in 
relation to each other the SKT, PPG and EMG electrodes were attached to the lower medial 
thigh of the participant and the Biopac was set to run at the default setting. Signals were 
recorded at three distances (2 m, 1.5 m & 1 m) between the two units, while both the CAP 
and RES modes of the CRMRF device were turned on. At 1 m, considerable noise was 
observed in the data stream when the CAP/RES modes were turned on. At 1.5 m, the noise 
in the signal was very minimal, whereas there was no noise when the devices operated from 
a distance of 2 m (Figure 4.12). However, 2 m distance between the devices was not 
deemed practicable for the experiment due to the cables being stretched. Therefore, a 
distance of over 1.5 m was chosen for this study. 
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Figure 4.12: Effect of the distance from CRMRF device on the Biopac data streams. Top left – Units switched on when one metre apart. Top 
right – Units switched on and off when one metre apart. Bottom left – Units switched on when one and half metres apart. Bottom right – Units 
switched on when two metres apart. 
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4.10.4 Issues surrounding probe attachment and signal noise (addressed aims 
4 & 5) 
Before attaching the probes, the skin was prepared by cleaning the area with two types of 
wipes; firstly with ‘Clinell© Universal Sanitising Wipes’ and secondly with ‘Clinell© Alcoholic 
2% Chlorhexidine Wipes’. This process cleaned the skin off any dirt and greasy material 
thus enabling better conductivity. It was decided not to shave the hair off as it would cause 
considerable skin irritation. However, it was challenging to properly attach the probes on 
male participants who had hairy legs. Probes were positioned at the medial aspect of the 
lower one fourth of the right thigh (Figure 4.13). 
Figure 4.13: Biopac probe attachments used in the study 
 
 
 
 
 
 
 
 
 
The SKT and PPG probes were attached without touching each other, to the middle of the 
upper half of the square that was boundary marked using Micropore© tape. The points of 
attachment were identified using a tape measure from the inner end of the square and were 
clearly marked using pen markers to ensure repeatability during re-attachment. The NCV 
electrodes were placed proximally and distally to the marked square region where the RF 
was delivered. With the average size of the square expected to be around 11 cm based on 
assumption, the inner distance between the NCV electrodes would be around 15 cm. Hence 
the distance from the middle of one set of twin electrodes (stimulating electrodes) to the 
other (recording electrodes) was 22 cm. It was decided based on this observation that 22 cm 
will be taken as the NCV measurement length for all participants for all sessions. After 
treatment with CRMRF it initially took three minutes for the process of clearing the skin and 
re-attaching the probes. With practice, the researcher could do this in two minutes. A two-
minute delay was considered reasonable and was taken as standard across the study. 
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The SKT probes did not have any attachment leads on them. Hence, either an adhesive 
tape or a Velcro© strap needed to be used to attach them firmly to the skin. Given the probes 
were small; the much larger straps were not identified as appropriate. The probes changed 
position and orientation when attached using Velcro© straps, unless they were tied very tight 
to the skin. Making the attachment too tight would make the participant uncomfortable and 
affect the blood flow data. Micropore© tape measuring 13 mm in width was found to be the 
most suitable method for attaching the SKT probe, with zero movement of the probe in 
relation to the skin. On the contrary, the PPG probes were too big to be attached with the 
Micropore© tape. Moreover, the PPG data stream was noisy with no firm skin contact when 
attached with Micropore© tape. Securing the probe around the leg solely using a Velcro© 
strap resolved these issues. The NCV electrodes were self-adhesive and did not require 
additional securing once attached to the skin. 
The potential effects of external sources of noise on the data stream were investigated using 
simulated conditions that were likely to occur during the experiment. They included 
movements (participant’s body, probe or cable), pressure on the probes/electrode and 
cables touching each other. Electromagnetic interference from mobile phone or other smart 
devices was avoided by default, by turning all such devices off during the experiment. 
However, conditions like movement and cables crossing each other may be unavoidable 
during an experiment. Once the researcher could successfully identify and distinguish the 
noise from real physiological change, the data can be processed accurately. 
To investigate the noise, the probes and electrodes were attached to a participant as it 
would be the case in the real experiment. The modules were set to run while the above 
mentioned potentially noise generating conditions were applied. The variations happening to 
the signal in response were observed (Figure 4.14). While all data streams were susceptible 
to noise, PPG produced the largest artefacts. In addition, even slight limb movements, 
including any muscle contractions significantly affected the PPG data stream by introducing 
large spikes of noise. Although these were easily distinguishable from real data and could be 
excluded during the analysis, the important point identified from the pilot was that the 
participant must be resting still, fully relaxed by trying to avoid any voluntary muscle 
contraction. 
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Figure 4.14: Sources of signal noise. Top left – Cable movement. Top right – Participant limb movement. Bottom left – Pressure on the probe. 
Bottom right – Cables crossing each other 
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4.10.5 Baselining of the data streams and electrode acclimatisation (addressed 
aims 6 & 10) 
The stabilisation times for the different Biopac data streams (except NCV) were assessed by 
running a simple experiment. The device was setup to run in capture mode one hour before 
the start, which was taken as standard for all experimental sessions. The probes were 
attached to the skin of the participant and then the data capture was restarted. Prior to 
attachment the probes remained at room temperature. The data streams were observed to 
assess the time taken for them to stabilise (reach the baseline level). The PPG signal was 
quick to stabilise, within seconds. Although the manufacturers had claimed that the SKT 
probes were fast-response thermistors, it took approximately two minutes for them to 
stabilise and reach the participant’s baseline SKT level. It was decided that this two-minute 
period should be accounted for when SKT is recorded in the main studies. 
After testing, it was decided that the NCV electrodes need not be removed from the skin, if 
their connecting leads are detached. The participant reported skin irritation from under the 
electrodes while delivering RF treatment if the leads were left connected. However, once the 
leads were detached, the skin irritation disappeared. Hence, the NCV electrodes remained 
on the skin and did not need any acclimatisation time. The intensity of the STM stimulus 
applied was chosen at a level that did not cause any discomfort to the participant, but at the 
same time strong enough to elicit an adequate nerve response. There was no evidence from 
the pilot study of any difference in NCV between a weaker stimulus and a stronger stimulus. 
4.10.6 Sampling rate for the Biopac system (addressed aim 7) 
The sampling rate for the Biopac system was chosen to be 200 Hz although the system was 
capable of recording at significantly higher rates. Considerable work was carried out in the 
previous project by Al-Mandeel (2004)192 comparing the sample rates 200 Hz and 500 Hz. 
Pilot experiments were carried out using PPG, the results of which showed no difference 
between the signals obtained using 200 Hz and 500 Hz. 
4.10.7 Validation of temperature readings using different measurement 
techniques (addressed aim 8) 
To establish the reliability and repeatability of the temperature measurements obtained in 
this study, a desktop experiment was conducted using two measurement devices and a 
temperature source (heated thermode from TSA II Neurosensory Analyser). The 
neurosensory analyser is a device used for quantitative sensory testing by inducing 
mechanical stimuli such as heat. The thermode can generate and sustain pre-set 
temperatures with good accuracy. 
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4.10.7.1 Methods 
Using the TAS II thermode as a source of constant temperature (stable within 0.1 oC), a 
comparative study was conducted between the readings of Thermofocus hand-held IR 
thermometer and the Biopac SKT100C module and TSD202A thermistor transducer. The 
thermode was set at five different temperatures that were arbitrarily chosen – 26, 29, 32, 35 
and 38 oC. It was anticipated that these temperatures would fairly reflect the range of SKTs 
that were likely to be obtained from the study. 
The Biopac thermistor was attached to the thermode surface using Micropore© tape after 
applying sufficient quantity of an inert conductive material (supplied by the TSA II 
manufacturer) around the probe. The inert material ensured that the surface area between 
the thermode and the probe was large enough to maintain good contact. Without this 
material, the point of contact is small, given that the probe is round and the thermode 
surface flat. The probe was attached towards the corner of the surface of the thermode so 
that there was adequate space left on the surface for measurement using the hand-held 
thermometer. The room temperature at the time of the experiment was 24 oC and the 
humidity 34%. 
The experiment started at the lowest temperature level of 26 oC. The thermode temperature 
reached the set level within seconds, as displayed on the TAS II software. The Biopac was 
set to run continuously for 20 minutes at each temperature, but the Thermofocus was used 
once every two minutes for a total of 20 minutes, giving 10 readings at each temperature 
level. When analysing, the corresponding two-minute data points were retrieved from the 
Biopac data stream. A reliability analysis was then performed on the data using SPSS 
(Version 20, IBM SPSS Statistics) to obtain the Intraclass Correlation Coefficient (ICC) 
(3,1).453 
4.10.7.2 Results and conclusion 
The raw temperature data is shown in (Appendix 4.9). The mean (SD) temperature values 
obtained from the 10 readings in relation to the thermode are plotted in Figure 4.15. The 
projected reliability between the temperature readings (ICC (3,1)) was 0.989, with 95% CI 
(0.965, 0.995). The result indicated that there is perfect agreement between the 
measures,454 meaning either of the two devices (Thermofocus or Biopac) could be reliably 
used for spot SKT measurement within the tested range. It appears from the results that at 
higher temperatures there was no agreement between the thermode temperature and the 
two thermometers. It is possible that the thermode temperature might not have reached the 
set levels due to a calibration issue with that device although the researcher was unable to 
confirm this. 
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Figure 4.15: The mean (SD) temperatures obtained from Biopac SKT100C and 
Thermofocus IR thermometer in relation to pre-set thermode temperatures 
 
 
 
 
 
 
 
 
 
 
4.10.8 Electrode stability tests for NCV (addressed aim 9) 
A simple desktop experiment was carried out to identify the best electrodes for use in the 
NCV measurement. The electrodes, when attached face-to-face and connected to the EMG 
module, a zero Volts reading should be obtained if both the module and electrodes are 
working properly. The EMG module had already been tested for accuracy (discussed earlier 
in the chapter). Some electrodes might have a permanent offset from zero depending on 
their quality and conductive property of the electrodes. For this study five commercially 
available medical recording electrodes were obtained through local purchase. The details of 
the brands are not being identified. 
4.10.8.1 Methods 
The Biopac unit with the EMG module were set up to run for one hour prior to this study, as 
standard. Two electrodes each were taken from every brand. Each pair was stuck face-to-
face ensuring correct approximation of the gel and metallic conductors. The data acquisition 
was paused momentarily. The two EMG leads were then connected to either side of the 
electrodes. The acquisition was then re-started to observe the following. 
1) Time taken for stabilisation of the data stream. 
2) Time taken for zeroing of the data stream. 
3) The signal response to direct pressure applied on the electrodes. 
4) The signal response while the cables were moved. 
5) Noise during the CAP and RES modes of CRMRF. 
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To assess the above, a total of 45 minutes’ worth data was recorded from each electrode 
pair exposing them through the above conditions in order. The room temperature at the time 
of the experiment was 24 oC and the humidity was 34%. 
4.10.8.2 Results and conclusion 
The individual response to each pair of electrodes is not being reported here. No statistical 
analysis of any parameters was performed. The quality of the data streams was assessed 
by visual examination. Figure 4.16 shows a comparison between the tested electrodes. After 
assessing all five brands of electrodes, it was concluded that 3M™ Red Dot™ was the most 
stable and least noisy electrode brand. 3M™ Red Dot™ was hence used for NCV 
measurement in all studies. 
Figure 4.16: ECG electrode brands compared based on response to external noise. 3M™ 
Red Dot™ is given at the top. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.10.9 Intra-rater reliability of ultrasound measurements (addressed aim 11) 
Ultrasound imaging is a specific skill that requires considerable training and practice. The 
researcher received essential training from a subject expert in musculoskeletal 
ultrasonography (Mr John Leddy) and received further help and guidance from colleagues at 
the University of Hertfordshire who were qualified in ultrasonography. Several hours of self-
practice was also undertaken to gain sufficient confidence in the imaging technique. 
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Subsequently, the test retest reliability of the researcher for both the Doppler and 
Elastography measurements was investigated.  
4.10.9.1 Methods 
The reliability study was conducted in the same research lab prior to the commencement of 
the main laboratory study (Chapter 6). The same Ultrasound scanner and probe that was 
used in the main lab study were used. Similar scanning procedure that would be employed 
in the main physiological study was employed. 
Twelve asymptomatic adult volunteers from among the members of the University of 
Hertfordshire took part in the study. Each participant attended the physiotherapy research 
laboratory once, in a session that lasted about one hour. An informed consent was signed 
prior to the study (Appendix 4.10). Anthropometric data was collected prior to the 
assessment using the body composition monitor described earlier in this chapter. The study 
was approved by the Health and Human Sciences Ethics Committee with Delegated 
Authority (HHSECDA) of the University of Hertfordshire (Protocol number: 
cHSK/PG/UH/00143) (Appendix 4.11). 
4.10.9.2 Procedure 
On the day of the study the participants were asked to attend the sessions by avoiding food, 
beverages and strenuous exercises within one hour before the start. This was to ensure that 
their physiological condition remained stable during the sessions.80,455,456 The participants 
positioned themselves in supine fully supported with pillows on the couch, as would be the 
case in the main study. Medial aspect of the lower one fourth of the right thigh was marked 
with tape in a square shape. Twenty-minute acclimatisation time was allowed in the lying 
position prior to the start, during which the participants rested. 
For each participant, two measurements were performed with an interval of 30 minutes in 
between. This interval was chosen based on the approximate anticipated interval between 
the pre-and post ultrasound measurements in the main study. Blood flow was identified by 
manoeuvring the ultrasound probe over the lower anteromedial aspect of the quadriceps 
femoris muscle. Once the most prominent pulsatile (arterial) flow was identified, skin 
markings were used to establish the accuracy of probe placement and ensure repeatability. 
For Sonoelastography measurements, a fixed position was adopted for all participants with 
minimal probe manoeuvring. The probe was placed parallel to the longitudinal axis of thigh, 
perpendicular to the skin in the middle lower part of the marked area. Minimal probe 
pressure and liberal amount of conductive gel were used to avoid any undue compression of 
the tissues. For all participants, the machine settings remained the same for both pre-
treatment and post treatment measurements. Recordings were performed in the following 
order. 
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1st  Colour Doppler for velocity of flow 
2nd  Power Doppler for volume and intensity of flow 
3rd  Elastography for the compliance of tissues 
Up to five seconds of data clips were recorded with colour Doppler, power Doppler and 
Sonoelastography during each of the two measurements.  
4.10.9.3 Statistical analysis 
The ultrasound image data was processed to numerical data by using MATLAB analysis as 
described earlier. The agreement between the two sets of numerical data was tested by 
performing a reliability analysis using SPSS (Version 20, IBM SPSS Statistics) to obtain the 
Intraclass Correlation Coefficient (ICC) (3,1).453 
4.10.9.4 Results and conclusion 
The full data set obtained from the 12 participants is given in Appendix 4.12. The ICC values 
are given in Table 4.1. The results indicate substantial to perfect levels of agreement 
between the two measured scores,454 and hence intrarater reliability has been established. 
Table 4.1: Level of agreement between the two sets of deep blood flow measurements 
 
 
 
 
 
 
 
 
  Conclusions 
This chapter addressed the measurement principles, methodological aspects and key issues 
relating to the laboratory-based investigation of the physiological effects of CRMRF therapy. 
The pilot experiments helped to identify the appropriate methods and confirmed the 
robustness of the involved techniques. The next two chapters will describe the two studies 
undertaken on asymptomatic participants to investigate the physiological effects of CRMRF 
therapy. 
 
Lower Upper
Blood flow velocity 0.611 0.087 0.870 0.013
Blood flow volume 0.987 0.955 0.996 < 0.001
Blood flow intensity 0.818 0.483 0.944 < 0.001
Hardness volume 0.985 0.950 0.996 < 0.001
Hardness intensity 0.974 0.913 0.993 < 0.001
Intermediate volume 0.957 0.858 0.987 < 0.001
Intermediate intensity 0.960 0.866 0.988 < 0.001
Softmess volume 0.998 0.993 0.999 < 0.001
Softness intensity 0.996 0.987 0.999 < 0.001
Confidence interval
Parameter
ICC value for 
single measures
p  value
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5 Chapter 5 – Basic considerations on CRMRF therapy: 
Skin thermal onset, thermal decay and thermal retention 
responses to the CAP and RES modes – a randomised 
crossover study 
 Introduction  
The key to gauging the optimum therapeutic efficacy of a thermal modality such as CRMRF 
is to have a clear understanding of its levels of thermal activity in tissues. For RF-based 
EPAs it is important to understand their thermal profile in tissues, since induced 
hyperthermia is believed to be their main tissue response. The CRMRF has two modes of 
applications: CAP and RES, both of which are proposed to have dissimilar methods of 
action, and hence dissimilar thermal profiles. In clinical practice, the CAP and RES modes 
are used in combination to induce tissue hyperthermia, but without an up-to-date 
understanding of the optimum therapeutic design to enable an evidence-based treatment 
delivery. Clinicians often employ their own preferred methods of treatment based on 
experience or ‘best guess’ or on anecdotal evidence provided by the device manufacturers. 
In this study, the thermal responses to either modes of CRMRF therapy were investigated in 
a controlled laboratory-based experiment to enable a better understanding of their thermal 
effects. 
 Physiological effects of heat 
The main physiological effect of CRMRF is believed to be tissue hyperthermia. It is hence 
important to briefly discuss the physiological benefits of the application of heat treatment 
from a physiotherapy perspective. There is a rich amount of literature on the physiological 
effects of heat on living tissues. Heat can affect the superficial and deep tissues, both at 
cellular and at systemic levels. Most cellular activity can be accelerated and/or increased by 
a modest rise in temperature (mild hyperthermia), and the local blood flow in the tissues can 
be enhanced by heat-induced vasodilatation.254,341,457,458 Depending on the level of 
temperature rise heat can also change the properties of connective tissues. It can increase 
the extensibility of tendon and ligaments, and to some extent reduce the tone and spasm of 
muscles.195,254,341,457,459,460 
Heat therapy is often used in clinical practice as a mode of relieving pain and inflammation 
and thereby enhancing tissue healing.8,18,457 Changes arising in tissues from an increase in 
the blood flow, oxygen uptake and chemical reaction rates are believed to be the 
physiological mechanisms underpinning the effects of heat on pain and tissue repair.8,461 An 
increase in tissue temperature by about 1 oC will help to therapeutically relieve mild 
116 
inflammation whereas an increase of 2–3 oC will lead to a reduction in pain and muscle 
spasm. A higher increase in the range of 3–4 oC can alter tissue extensibility.457,462 A 
temperature rise to this extent can only be termed ‘mild hyperthermia’, which is notably 
different to tissue hyperthermia induced by techniques such as RF ablation/coagulation used 
in the treatment of pain463-465 or in the treatment of cancer.466-468 
 Key aims 
The main aims of this study were: 
1) To identify the point of onset of heating, the point of optimum heating, and the point of 
onset of heat discomfort with the application of either mode of CRMRF therapy. 
2) To record the baseline skin temperature, to record the immediate post treatment skin 
temperature and to periodically record the subsequent post treatment decline in skin 
temperature (thermal decay process) at the treated area. 
These aims would enable the researcher to identify and establish the 'thermal banding' of 
the energy delivered by CRMRF therapy, the time taken to attain each of those three time 
points and the corresponding ‘CRMRF power dose’. It was anticipated that such information 
would enable a comparison between the effects of CAP and RES mode effects and 
ultimately provide a better understanding about the differences between a low dose 
(minimally thermal dose) application and a high dose (moderately thermal dose) application 
of CRMRF energy. 
 Materials and methods 
5.4.1 Apparatus 
5.4.1.1 CRMRF treatment device 
The CRMRF treatment was administered with an ‘Indiba Activ 902’ device (Indiba S. A., 
Barcelona, Spain), which has been described in chapter 4. The machine displays the RF 
intensity and the energy output while the treatment is being delivered, which is also mapped 
by computer-based monitoring software (Figure 5.1). 
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Figure 5.1: Sample CRMRF machine output data (exported using the monitoring software) 
 
 
 
 
 
 
 
 
 
 
 
5.4.1.2 Skin temperature measurement 
A hand-held contactless infra-red (IR) skin surface thermometer (Thermofocus 01500A3) 
was used for skin surface temperature measurement (chapter 4). Although the main 
segment of the lab study (chapter 6) used the Biopac system for SKT measurement, it was 
unavailable for the current experiment. The Biopac kit was being upgraded and the new SKT 
modules and thermistors were being awaited. Besides, since concomitant SBF 
measurement (using Biopac PPG) was not present in this study, real-time SKT 
measurement was deemed not necessary. Numerous studies have suggested that hand-
held thermometers (contact or contactless) are a valid, reliable and convenient method of 
recording the skin temperature.347-352 It has been suggested that the IR thermometer has an 
equal or greater level of responsiveness and reliability when compared to traditional 
thermistors.350,352 Studies have also used these devices on different segments of the body 
such as hand,348,351 knee,347 ankle349,352 and multiple sites.350 
5.4.1.3 Other devices 
An infra-red tympanic thermometer (Braun ThermoScan IRT 4520) was used for core 
temperature measurement. Anthropometric measures were taken using a body composition 
monitor (Omron BF508). An electronic metronome (Seiko) and a computer-based timer were 
used to aid the experimental procedure. The room temperature and humidity were monitored 
using an electronic thermohygrometer (RS 212-124). 
118 
5.4.2 Sample and groups 
A cohort of 15 asymptomatic (self-reported) adults were randomly selected from among the 
staff and students (around 27,000) of the University of Hertfordshire. Recruitment emails 
were sent out university-wide along with the participant information sheet (Appendix 5.1). 
Screening for inclusion was performed consecutively, with the first 15 eligible volunteers 
being recruited (eligibility criteria explained below). An informed consent (Appendix 5.2) was 
signed by all participants prior to the study. The study was approved by the Health and 
Human Sciences Ethics Committee with Delegated Authority (HHSECDA) of the University 
of Hertfordshire (Protocol number: HSK/PG/UH/00015) (Appendix 5.3). 
There were two experimental groups: CAP and RES. All participants attended two study 
sessions each, one session representing each group in a random order. Thus all 15 
participants represented both study groups (crossover design). The order of attendance to 
the sessions was randomised by concealment and blinded from the participant. A computer-
generated randomisation chart (IBM SPSS Statistics, Version 20) was used for this purpose 
(Appendix 5.4). 
5.4.3 Pretesting and pilot work 
Extensive pilot work in the form of pretesting was carried out prior to the commencement of 
the study to establish the following. Potential confounding factors, measurement issues and 
apparatus testing have already been explained in the previous chapter. 
1) To ascertain the time taken to stabilise the baseline SKT. 
2) To design and test an appropriate workable experimental protocol specific to the study. 
It was established in pretesting that a minimum of 48 hours is needed between the sessions 
to ensure that no residual effects from the first session were present at the time of the 
second. This is also evidenced in the literature with other RF research.80,458 It was also 
identified that similar times (± one hour) of the day has to be chosen for either session for 
each participant in order to minimise core temperature variations as also suggested in the 
literature.80,341 It required a minimum of 20 minutes for the baseline SKT in the measurement 
area to stabilise. A minimum of 90 minutes was required to complete one session of the 
experiment. It was clear from the pilot experiments that after RF application was stopped 
once the participant reported the onset of heat discomfort, the skin temperature may not 
return to baseline levels within 45 minutes in all participants. However, it was not practically 
feasible to continue the experiment beyond the 90-minute mark to continue the monitoring of 
temperature decay owing to time constraints on the part of the participants. Anterior aspect 
of the lower end of thigh just above the patella was identified as the appropriate site for 
treatment delivery and the measurement of skin temperature. 
119 
5.4.4 Experimental procedure 
Participants were asked to attend the sessions by avoiding food, beverages and strenuous 
exercises within one hour before the start. This was to ensure that their physiological 
condition remained stable during the sessions.80,455,456 An eligibility questionnaire was used 
to screen the participants (Appendix 5.5). This questionnaire included questions relating to 
any recent injury or illness and accepted contraindications to RF therapy (pregnancy, 
malignancy, metal or electronic implants in the body). 
Subsequently, using test tubes filled with water at approximately three different temperatures 
(±0.5 oC): 45 oC (warm), 35 oC (neutral) and 25 oC (cold), the participants’ ‘skin thermal 
sensitivity’ was tested. It was important to ensure that all participants had the full ability to 
distinguish between hot and cold to remain safe by avoiding excessive heating and potential 
burn injuries during the treatment. It was decided that any potential participant who failed to 
make this distinction will be excluded from the study. Once this screening was completed, 
demographic and anthropometric data were collected. 
The participants positioned themselves in supine on a treatment plinth and were fully 
supported with pillows. The length of thigh was measured from the anterior superior iliac 
spine (ASIS) to the base of the patella. The leg was measured from the head of fibula to the 
lateral malleolus. The area covering the lower one-fourth of the anterior aspect of right thigh 
was marked with tapes as a square (established in the pilot). Skin temperature was recorded 
from the middle of the square area on the treated leg as well as the corresponding area of 
the untreated leg. This was repeated every two minutes until stabilised. The stabilised 
temperature was considered the baseline temperature. The untreated left leg was 
considered as a control. The core (tympanic) temperature was also monitored at the same 
time. 
The return electrode was positioned one-fourth way down the length of the leg under the calf 
muscle belly. The CRMRF treatment was applied within the marked square area using the 
active electrode and 20 ml of conductive cream. The return plate also had 20 ml of cream 
smeared over it. For either mode of treatment, the intensity of delivery started at the 
minimum permitted level on the device and was raised by one level every 30 seconds (30 s 
timer was set running on the computer). Treatment was given in circular movements, one 
per second. This process was guided by the electronic metronome. 
During treatment, the participants reported clearly and promptly at three time points: Firstly, 
at the onset of heating of the skin (thermal onset), secondly, when the heat builds up to a 
moderate (yet comfortable) level (definite thermal sensation), and thirdly, at the point when 
the heat starts to cause discomfort (onset of thermal discomfort). The three time points and 
the corresponding CRMRF intensity were noted. The treatment was promptly stopped once 
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the ‘onset of thermal discomfort’ was reached. At the beginning of the treatment session, 
these time points were explained to the participants showing a picture of an imaginary heat 
map (Appendix 5.6).  
Once the treatment stopped, the skin was wiped clean of all remaining cream. After clearing 
the skin, the temperature measurement was repeated from both sides (post treatment (peak) 
temperature) from the same spot used for the baseline measurement. The core temperature 
was also recorded now. Repeated measurements of the skin temperature were done every 
30 seconds from the treated leg and every five minutes from the control leg. This was 
continued for 45 minutes or till the skin temperature on the treated leg returned to baseline. 
Core temperature, room temperature and humidity measurements were only repeated at the 
end of the experiment. All data were entered a participant data collection form (Appendix 
5.7). The lab experimental setup is shown in Figure 5.2. 
Figure 5.2: Laboratory setup used for the experiment 
 
 
 
 
 
 
 
 
 
 
 Electrode temperature testing 
After the main study, a second brief desktop experiment was conducted to map the 
temperature of the treatment electrodes at various stages in response to set treatment 
intensities of the CRMRF energy. For this experiment three incremental intensity levels 
(arbitrary) along with a fourth intensity level (mean peak power reached during each mode of 
the main experiment) were chosen (Table 5.3 (given in the results section)). This experiment 
was conducted on one of the participants from the main study. This participant had received 
a peak power dose (the dose at the point of thermal discomfort) higher than the group mean 
dose that was used in this desktop experiment, during both CAP and RES sessions, hence 
there was no risk of an excessive level of CRMRF being delivered. The treatment procedure 
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was similar to the main experiment except that the participant did not have to report the 
three time points. Instead, when the required pre-set intensity levels were reached the 
treatment delivery was paused to measure the electrode temperature. 
 Data analysis 
Data processing was done using Microsoft Office Excel (Version 2010, Microsoft 
Corporation). The statistical analysis of the processed data was performed with IBM SPSS 
Statistics (Version 20) for Windows. The group data were compared using either a two-way 
(intervention and time) repeated measures analysis of variance (ANOVA) model at three 
time points (baseline, post treatment and 45-minute follow-up) or using Friedman’s two-way 
ANOVA by ranks, depending on the distribution of data (Shapiro-Wilk). The statistical 
significance was set at p≤0.05 (0.8P, 95%CI). 
 Results 
Both modes of the CRMRF treatment were well tolerated, with no accounts of any 
undesirable incidents that might have resulted directly or indirectly from the treatment, 
including potential concerns due to overheating or any other delayed tissue reactions. All 15 
participants completed both their treatment sessions and assessments as anticipated. The 
participants’ demographic and the mean (SD) anthropometric data are reported in Table 5.1. 
Table 5.1: Demographic and the mean (SD) anthropometric data from 15 participants 
 
 
 
 
 
 
SD – standard deviation; kg – kilogram; m – metre; BMI – body mass index 
The mean (SD) as well as individual skin thermal responses obtained from all 15 participants 
in both CAP and RES modes of CRMRF therapy are shown in Figures 5.3 (a–b), 5.4 (a–b) 
and 5.5 (a–b). The baseline, post treatment and 45-minute follow-up mean (SD) skin 
temperatures obtained for the CAP mode were 30.9 (±1.1) oC, 34.3 (±1.6) oC and 31.5 (±1.4) 
oC respectively, and for the RES mode were 31.1 (±1.0) oC, 35.0 (±1.2) oC and 33.2 (±1.4) 
oC respectively. 
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The mean (SD) time needed, energy delivered, and the peak power reached to attain each 
thermal stage are shown in Table 5.2. The individual data for the mean (SD) values reported 
in Table 5.2 are shown in Figures 5.6 (a–c). 
The baseline skin temperatures of both groups were identical, with no significant differences 
between the two. Overall, the thermal response patterns produced by the CAP and RES 
modes differed significantly (F (1, 14) = 16.639, p = 0.001). However, the peak skin 
temperatures obtained from both modes were not significantly different. The (group) mean 
increase in temperature (∆T) from baseline to peak was 11.1% in CAP mode, and 12.7% in 
RES mode. 
Table 5.2: The mean (SD) time, energy and peak power reached at each of the three 
thermal stages for the 15 participants 
 
 
 
 
 
 
 
 
SD – standard deviation; J – joules; W – watts; s – seconds 
A significant retention of the gained temperature (at the 45-minute follow-up), when 
compared to their respective baseline, was noted in both CAP and RES modes (CAP: F (1, 
14) = 8.690, p = 0.011; RES: F (1, 14) = 70.321, p < 0.001). Nonetheless, the rate of this 
temperature retention was significantly higher for the RES mode compared to the CAP mode 
(53.6% and 17.5% respectively) (F (1, 14) = 36.173, p < 0.001). 
The actual power of the obtained ANOVA results reported above was confirmed to be 1.0 in 
a post-hoc power analysis using G*Power (Version 3.1). The results of the second desktop 
experiment that mapped the temperature changes in the two CAP and RES electrodes used 
for the main study in response to varying treatment doses are reported in Table 5.3. 
The untreated control side temperature and the core (tympanic) temperature did not show 
any meaningful variation at any time point in either group. The mean (SD) room temperature 
was 24.0 (±0.8) oC for the CAP mode and 23.9 (±1.2) oC for the RES mode. Both these 
values were within the thermoneutral zone of humans. 
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Table 5.3: The active electrode temperature at various times and intensity of application 
during localised CRMRF treatment 
 
 
 
 
 
 
 
 
 
PP – peak power; VA – volt-ampere; W – watts; oC – degree Celsius; XX – not measured 
due to thermal discomfort to the participant. 
# denotes the mean peak power obtained from 15 participants during the CAP and 
RES modes of the main experiment. 
* Moderate heating reported by the participant. 
** High heating reported by the participant. 
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Figure 5.3a: CAP and RES mode mean skin thermal responses to localised CRMRF treatment. The data shown (baseline, post treatment and 
45-minute follow-up) are from 15 participants. 
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Figure 5.3b: CAP and RES mode individual skin thermal responses to localised CRMRF treatment (treated side). The data shown (baseline, 
post treatment and 45-minute follow-up) are from 15 participants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28
29
30
31
32
33
34
35
36
37
38
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Te
m
p
er
at
u
re
 in
 D
eg
re
e
 C
el
ci
u
s
Participants
CAP Mode
Post
treatment
45-minute
follow-up
Baseline
28
29
30
31
32
33
34
35
36
37
38
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Te
m
p
er
at
u
re
 in
 D
eg
re
e
 C
el
ci
u
s
Participants
RES Mode
Post
treatment
45-minute
follow-up
Baseline
126 
 
Figure 5.4a: CAP and RES mode mean skin thermal changes after localised CRMRF treatment (treated side). The data shown (thermal build-
up, thermal decay and thermal retention) are the changes in relation to the baseline from 15 participants. 
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Figure 5.4b: CAP and RES mode individual skin thermal changes after localised CRMRF treatment (treated side). The data shown (thermal 
build-up, thermal decay and thermal retention) are the changes in relation to the baseline from 15 participants. 
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Figure 5.5a: CAP and RES mode mean skin thermal decay after localised CRMRF treatment (treated side). The data are from 15 participants, 
showing the decay process from post treatment to 45-minute follow-up. 
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Figure 5.5b: CAP and RES mode individual skin thermal decay after localised CRMRF treatment (treated side). The data are from 15 
participants, showing the decay process from post treatment to 45-minute follow-up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28
29
30
31
32
33
34
35
36
37
38
0 5 10 15 20 25 30 35 40 45 50 55 60
Te
m
p
er
at
u
re
 in
 D
eg
re
e
 C
el
ci
u
s
Time in minutes
CAP Mode
28
29
30
31
32
33
34
35
36
37
38
0 5 10 15 20 25 30 35 40 45 50 55 60
Te
m
p
er
at
u
re
 in
 D
eg
re
e
 C
el
ci
u
s
Time in minutes
RES Mode
130 
 
Figure 5.6a: CAP and RES mode time-specific individual skin thermal responses to localised CRMRF treatment (treated side). The data shown 
(thermal onset, definite thermal and thermal discomfort) are from 15 participants. 
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Figure 5.6b: CAP and RES mode energy-specific individual skin thermal responses to localised CRMRF treatment (treated side). The data 
shown (thermal onset, definite thermal and thermal discomfort) are from 15 participants. 
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Figure 5.6c: CAP and RES mode power (peak)-specific individual skin thermal responses to localised CRMRF treatment (treated side). The 
data shown (thermal onset, definite thermal and thermal discomfort) are from 15 participants. 
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 Discussion 
The type of energy delivered by the EPA and its depth of penetration are the two main 
external factors that decide the extent of physiological effects induced by the heating 
modalities (EPAs).101 Exposure to pulsed RF is likely to induce certain biological effects that 
are more likely to occur than when exposed to continuous RF at the same average incident 
pulse density (and vice versa). Similarly, whilst the IR energy (non-RF) is low penetrative 
and gets absorbed in the most superficial layers of skin causing superficial heating, RF 
frequency bands are more complexly absorbed at other depths,22 potentially leading to 
deeper thermophysiological effects. Any potential deep heating effects of either CAP or RES 
were not measured in this study. However, other researchers have reported that RF-based 
EPAs may be used to achieve deep heating and are more effective in inducing physiological 
effects such as increasing tissue extensibility, compared to superficial heating.195,469 
The CAP and RES modes of CRMRF therapy differ significantly in the patterns of skin 
heating they produce, as shown by the results of this study (when intermittently measured 
using a hand-held skin thermometer). In relation to the three thermal stages (onset, definite 
heating and heat discomfort), the CAP mode reached these stages considerably faster. 
However, the gained temperature decayed faster leading to a smaller overall retention in the 
CAP mode when compared to that of the RES mode. It needs to be considered that there 
was a lack of linearity between the intensity settings of the two modes, which renders any 
objective comparison problematic. The lack of linearity would also have had a telling 
influence on the peak power achieved at each time point. The greater the temperature 
increase due to heating, the greater was the drop during the follow-up phase for either 
mode, as suggested by the individual data (Figure 5.4b). 
As stated, the mean (SD) peak skin temperature reached was 34.3 (±1.6) oC for the CAP 
mode and 35.0 (±1.2) oC for the RES mode (Figure 5.3a). The highest temperature recorded 
for a participant was 37.4 oC in the CAP mode and 37.0 oC in the RES mode (Figure 5.3b). 
These two values are at the level of the normal core temperature. Hence, the rise in skin 
temperature achieved are solely in relation to the baseline skin temperatures recorded at the 
treatment site and can only be termed ‘mild hyperthermia’ at best. Per se, it is only when the 
temperature is raised to supra-physiological levels, that it can be termed hyperthermia (that 
is, to around 40–45 oC, or even higher for thermal ablation). The cytotoxic effects of heat and 
cell death are prominent over a temperature range of 40–55 oC, with a ‘break point’ at 
around 43 oC as in vitro cell studies have shown.470-473 
Quantification of a thermal dose given during a heat treatment can be represented as 
cumulative or equivalent thermal dose.474 The cumulative or total equivalent thermal dose is 
expressed as Cumulative Equivalent Minutes (CEM) in relation to the arbitrarily chosen 
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temperature of 43 oC (CEM 43). This was proposed by Sapareto and Dewey.475 A ‘time–
temperature’ history can be converted to a single number by using this method. This single 
number represents a ‘thermal isoeffect dose’, which is an equivalent number of minutes of 
heating at 43 °C. If the temperature remained constant, the following formula can be used 
for this calculation:  
CEM 43 oC = tR(43-T) 
‘CEM 43 °C’ is the cumulative number of equivalent minutes at 43 °C, ‘t’ is the time 
(duration) of treatment, ‘R’ is a constant related to the temperature dependence of the rate of 
cell death (R (T< 43 °C) = 0.25, R (T>43 °C) = 0.5) and ‘T’ is the temperature during ‘t’. 
For a complex time-temperature history, the CEM 43 °C is calculated for each small time 
interval (t) where the temperature (T) has remained relatively constant and summated over 
the entire period using the formula: 
CEM 43 oC = ∑tR(43-Tavg) 
In this formula ‘Tavg’ is the average temperature for each time interval (t). The resulting CEM 
43 °C value represents the effect of the entire history of heat exposure. 
In the dosimetry of cancer thermotherapy and of magnetic resonance (MR) systems,474 
estimates of ‘thermal isoeffect dose’ are routinely used. This estimation can also be done for 
CRMRF therapy as it has been used to induce hyperthermia for cancer98-100,102 and to 
produce other cellular effects.203 
In the current study, only the baseline and peak temperatures were recorded, which means 
the temperature variations in the tissues during the treatment delivery is unknown. If it is 
assumed that the peak temperature attained was maintained for the total duration of 
treatment for each participant, the mean (SD) CEM 43 °C thermal dose for the sample was 
0.0004 (±0.0008) minutes for the CAP mode and 0.0005 (±0.0008) minutes for the RES 
mode. However, this estimation is only relevant to the skin area from which the temperature 
measurements were attained. For the deeper tissues, the thermal dose might have been 
completely different, so no such estimation can be done using the current data. 
In a normal treatment session where a set treatment dose may be delivered from the 
beginning, the CRMRF powers required to achieve the three time points could be different to 
that obtained in this study. The peak powers reported in Table 5.2 and Figure 5.6c only 
denote the peak powers that may be achieved if the intensity is incrementally raised every 
30 seconds starting at the minimum dose. The mean (SD) of mean powers (MP) (the ‘mean 
overall power’ provided for each participant for the duration of the treatment) delivered to 
reach the thermal onset, definite thermal and thermal discomfort stages were 3.89 (±0.99), 
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6.05 (±1.36) and 11.70 (±1.67) Watts respectively for the CAP mode and 10.61 (±3.78), 
17.87 (±5.36) and 28.74 (±4.74) Watts respectively for the RES mode. 
Temperature recordings were not made at the thermal onset and definite thermal stages, as 
this would have affected the continuity of treatment. Also, this could have delayed the 
attainment of the following thermal stage due to a ‘thermal washout’. Despite the non-
linearity of their intensity settings, the peak skin temperatures attained were not significantly 
different between the two modes. However, while the CAP mode (mean) temperature 
declined sharply in the immediate post treatment phase, the RES mode (mean) temperature 
increased in the first few minutes after the treatment stopped. This post treatment behaviour 
is unlikely to have been influenced by the intensity settings. 
Heat retention in RES mode at the end of the 45-minute follow-up was more than 60% 
(Mean (SD) of 60.3 (±34.5)%) as against 15% (Mean (SD) of 15.5 (±20.1)%) in the CAP 
mode (Figure 5.4a). Neither the core temperature nor the untreated control leg showed any 
significant change at any time point for either condition. The core temperature was not 
expected to change since a local application of RF energy may not influence the core 
temperature.22 The result from the control leg was contrary to the ‘crosstalk’ effect 
(undesirable effect generated in the neighbouring untreated area) that was reported from 
PSWT research.80 This indicates that potentially, there may be only lower levels of 
‘scattering’ of the waves from CRMRF therapy compared to SWT. 
The CAP mode CRMRF may be relatively superficial in its penetration of the tissues. The 
faster heating and faster thermal decay shown to be associated with it the may be indicative 
of the same. Comparable to the ‘capacitive method’ of application in SWT, there may be a 
higher proportion of ‘electric’ (E) than ‘magnetic’ (H) field causing a capacitive (faradic) effect 
in the tissues.18,462 There is a higher concentration of field in the superficial tissues, hence 
proportionally more faradic energy is absorbed in the superficial tissues (such as the skin 
and fat layers) than in the deeper tissues (underlying tissues such as muscles).476  
The RES mode CRMRF may be compared to the ‘inductive method’ in SWT in a similar 
manner as they both generate an effect that is predominantly due to an H field.18,462 A higher 
penetration of energy in the RES mode is suggested by the higher retention of heat and the 
fact that there was no sharp fall in the post-treatment temperature. The energy absorption 
for inductive treatment is greater in deeper tissues such as blood and muscles. This is due 
to their lower resistance and higher electrolyte content. In tissues such as skin and 
subcutaneous fat that have higher resistance, the absorption of inductive energy is less and 
therefore heat up less compared to the deeper tissues.18 
The conductivity of the tissues and the strength of the field have a proportionate influence on 
the amount of heat generated.462 The size of treatment electrodes will also influence the 
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penetration of RF energy; with the larger electrodes having more penetrative ability than the 
smaller electrodes.18 SWT and CRMRF are fundamentally different from each other when 
the frequency and other characteristics of their RF waves are considered. Therefore, the 
physical principles underpinning the shortwave-tissue interactions may not apply to CRMRF. 
Compared to SWT, there is little published research on the physical principles of CRMRF-
tissue interaction. 
Data reported in Table 5.3 shows that the temperature of the electrodes at any point (as in 
the main experiment) was not notably higher than the peak skin temperature reached. The 
peak electrode temperature in RES mode stayed consistently below that of the skin. The 
electrode temperature in CAP mode increased marginally when the intensity of exposure 
was sustained for longer periods. These suggest that the rise in skin temperature was due to 
RF-tissue interaction, and not due to contact heating from a hot electrode. 
The participants felt superficial heating in the CAP mode, with the heating reported mainly 
on the skin of the treated area. They did not report much heat sensation through the knee 
joint or into the calf. However, they generally reported deeper and more homogenous 
heating with the RES mode, with the knee joint and calf both giving sensation of heat. 
Nevertheless, caution should be exercised when interpreting these claims about perception 
of heat at depth. Cutaneous receptors are primarily responsible for localised thermal 
perception and it is somewhat controversial as to whether thermal perception at depth is in 
fact nociception.341 The evidence on the existence of subjective perception of temperature 
from deeper tissues such as muscle is scant. 
Thermal perception at depth might exist, but when tissue temperature is approximately 
between 25–41 oC that mechanism may be at a subconscious level. Beyond this level of 
temperature, nociception is arguably more potent than thermal perception. It is also debated 
that, in humans nociceptors and other pressure and mechanosensitive receptors in the 
muscle might also function as peripheral sensors for subjective temperature sensation.341,342 
The sensation of heat in the tissues depends on thermal change and the rate of thermal 
change (the pattern of thermal energy delivery).22,254,341 Deep heating may have occurred 
from the CRMRF therapy; however, given the above reasons it is proposed that a variation 
in the rate and distribution of temperature change (resulting from the CAP and RES modes) 
in the more superficial tissues such as the skin and superficial fascia, where there is a 
presence of thermoreceptors may have led to the participants reporting the different heating 
sensations from these two treatments. 
Variability in the anthropometric factors of participants may explain any potential variability in 
the thermal response data between individual participants. The correlation between the 
anthropometric factors and the thermal responses were statistically analysed. The body fat 
percentage showed a moderate negative correlation (significant at p<0.05 level) with the 
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CAP thermal onset and discomfort points. The same was noted for the RES mode thermal 
discomfort. A moderate negative correlation (significant at p<0.05 level) also existed 
between the room temperature and the RES mode thermal onset and definite thermal 
points. No other meaningful correlations were noted to draw any conclusions. 
Several RF (predominantly the shortwave frequencies) studies investigating their skin and/or 
deep thermal responses on humans have been identified,77,80,81,83,85,95,96,105,194 in which a 
significant rise and maintenance of both skin and intra-muscular temperatures were reported 
by many of the earlier published studies.77,81,85,96 As stated previously, all those studies have 
been either shortwave frequencies or above, making the current study the first of its kind. 
Unlike this one only a limited number of those studies have mapped skin temperature for as 
long as 45 minutes after treatment. 
Earlier, Bricknell and Watson105 employed incremental dosing of PSWT in their study and 
reported their dose parameters that produced a ‘possible thermal perception’ (Mean ‘mean 
power (MP)’ of 6.58 (±3.50) W) and a ‘definite thermal perception’ (Mean MP 10.88 (±3.32) 
W) on the skin. From baseline to the definite thermal stage, a mean temperature elevation of 
2.10 oC was reported. A significant rise in the skin temperature with high (MP 24 W) and low 
(MP 3 W) doses of PSWT was also reported in another study by Al-Mandeel and Watson.80 
Temperature changes inside the gastrocnemius muscle in response to a 20-minute 
treatment with PSWT (MP 48 W) was investigated (invasive study) by Draper et al.83 A mean 
(SD) temperature rise of 3.49 (±1.13) oC was reported after the treatment and a decay of 
1.78 (±0.69) oC was reported in the first 10 minutes post-treatment. Takahashi et al.194 
reported a 5 oC rise in temperature inside the knee joint with a 20-minute pulsed RF (8 MHz, 
200 W) treatment (invasive, non-shortwave study) on patients affected by osteoarthritis of 
the knee. The temperature decay was not monitored by the authors. 
 Conclusions 
This study confirmed that skin temperature can both be increased and sustained significantly 
by both CAP and the RES modes of CRMRF therapy, although the RES mode thermal 
retention is significantly greater than that of the CAP mode. The doses were delivered 
incrementally, and the average time, energy and power required in achieving thermal onset, 
definite thermal and thermal discomfort sensations were identified for both modes. There 
was a significant difference between the thermal response patterns produced by the CAP 
and RES modes; however, the lack of linearity in their intensity settings renders a direct 
comparison problematic. 
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6 Chapter 6 – Skin and deep tissue physiological effects 
of CRMRF treatment: single-blind randomised 
crossover study with a comparison to PSWT 
 Introduction 
The first chapter of this section (Chapter 4) considered all the measurement principles and 
physiological outcome measures, described the CRMRF device and conducted various pilot 
experiments leading to the main laboratory studies. The second chapter (Chapter 5) 
explored the CAP and RES components of CRMRF therapy in more detail and studied their 
effects on the skin thermal responses (build-up, decay and retention) when applied as 
separate treatment components. 
Skin physiological outcome measures such as SKT, SBF and NCV, and deep physiological 
outcome measures such as Doppler ultrasound and ultrasound Elastography have been 
explained in detail in chapter 4. For temperature measurement, good agreement was found 
between the hand-held thermometer and the Biopac SKT100C thermistor module. In deep 
blood flow and tissue extensibility measurements, good intrarater test retest reliability was 
established for Doppler ultrasound and ultrasound Elastography. Testing of various 
commercially available self-adhesive surface (ECG) electrodes were also undertaken to 
determine the best choice of electrodes for NCV measurements using the Biopac system. 
The present chapter will explain in detail the main segment of the laboratory study, which 
compared multiple doses of CRMRF therapy and high dose PSWT on an array of 
physiological parameters including both skin and deep measurements mentioned above. 
More details on the rationale for the selection of body area to treat and the rationale for the 
selection of physiological outcomes have been discussed in chapter 4. Prior to the 
commencement of the main experiment, a pilot study was conducted on 15 volunteers to 
determine the interventional design and experimental protocol. This will be explained in 
detail in the relevant section below.  
 Aims 
The main aims of this study were: 
1) To compare the effects of multiple doses of CRMRF therapy on SKT, skin and deep 
blood flow, NCV and extensibility of tissues on a group of asymptomatic adults in a 
randomised crossover study. 
2) To compare the above effects with those obtained from a high dose PSWT treatment in 
the same group of people. 
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3) Make recommendations for future research and clinical practice where possible. 
 Materials and methods 
6.3.1 Apparatus 
6.3.1.1 CRMRF device 
The ‘Indiba Activ’ CRMRF machine has been described in chapter 4. 
6.3.1.2 PSWT device 
The ‘Bosch Ultramed’ machine has been described in chapter 4. 
6.3.1.3 Skin data acquisition system 
The Biopac MP150 physiological measurement system that was used to record the skin 
temperature (SKT), skin blood flow (SBF) and nerve conduction velocity (NCV) from the 
studied knee joint area has been described in chapter 4. 
6.3.1.4 Doppler ultrasound and Elastography 
Blood flow to the deeper tissues (two centimetres or more from the skin) and the indices of 
tissue extensibility were monitored by Doppler ultrasound and ultrasound Elastography using 
‘Esaote MyLab70 XVG’ ultrasound scanner and a linear array probe ‘LA523’ that has been 
described in chapter 4. 
6.3.1.5 Other devices 
An infra-red (IR) tympanic thermometer (Braun ThermoScan IRT 4520) was used for core 
temperature measurement. Blood pressure (BP) and pulse rate (PR) were monitored using a 
digital upper arm BP monitor (Omron M2). A body composition monitor (Omron BF508) was 
used to obtain the anthropometric data. The room temperature and humidity were monitored 
using an electronic thermohygrometer (RS 212-124). 
6.3.2 Sample and groups 
A randomly selected cohort of 18 asymptomatic (self-reported) adults from among the 
27,000 staff and Students of the University of Hertfordshire participated in the study. The 
recruitment was done through emails sent out university-wide along with the participant 
information sheet (Appendix 6.1). The respondents were screened for inclusion 
consecutively, and the first 18 eligible respondents were recruited (eligibility criteria 
explained below). Later, one participant withdrew from the study because of unrelated illness 
(respiratory infection) restricting the total number to 17. An a priori sample size calculation 
was unable to be performed as no baseline data was available. Hence an interim analysis of 
the data was decided to be undertaken after the first 15 participants completed the study, to 
determine the power and required sample size. 
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The study was approved by the Health and Human Sciences Ethics Committee with 
Delegated Authority (HHSECDA) of the University of Hertfordshire (Protocol number: 
cHSK/PG/UH/00143) (Appendix 6.2). The participants signed an informed consent on their 
first visit, prior to the commencement of the study (Appendix 6.3). All 17 participants 
attended four sessions, each representing one of the four experimental conditions listed 
below (Figure 6.1). The order of attendance to these conditions (otherwise experimental 
groups) was randomised by concealment using a computer-generated randomisation chart 
(IBM SPSS Statistics, Version 20) (Appendix 6.4), and blinded from the participants. 
6.3.2.1 Experimental conditions 
1) CRMRF high dose (with evident thermal perception) 
2) CRMRF low dose (sub/minimal thermal perception) 
3) CRMRF placebo dose (device turned off after thermal onset) 
4) Control condition with no RF intervention 
In addition to the above four conditions, fifteen participants who were available and willing to 
appear for a fifth session attended the ‘PSWT high dose condition’. Attendance to the PSWT 
session was neither randomised nor blinded; however, the participants were only informed 
that it was ‘a type of RF-based treatment’. Like the previous study (Chapter 5), based on 
pilot experiments and existing literature a minimum gap of 48 hours was allowed between 
the sessions so that no residual effects from the preceding session were present at the 
following session.80,458 Similar times (±1 hour) of the day were chosen for all the sessions for 
each participant to avoid unwanted impacts from any core temperature variations.80,341 
Figure 6.1: Schematic representation of the five study conditions (groups). Groups 1–4 were 
represented by all 17 participants. Group 5 was represented by 15 participants only. 
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6.3.3 Experimental procedure 
Like the previous experiment (Chapter 5), on the days of the study the participants were 
asked to attend the sessions by avoiding food, beverages and strenuous exercises within 
one hour before the start. This was to ensure that their physiological condition remained 
stable during the sessions.80,455,456 The experimental procedure was undertaken as per the 
designed and pretested experimental protocol. The participants were screened using an 
eligibility questionnaire including questions relating to any recent injury or illness and 
accepted contraindications to RF therapy (pregnancy, malignancy, metal or electronic 
implants in the body) (Appendix 6.5). Subsequently, their ‘skin thermal sensitivity’ and the 
ability to distinguish between warm and cold was tested using test tubes filled with water at 
approximately three different temperatures (±0.5 oC): 45 oC (warm), 35 oC (neutral) and 25 
oC (cold). After this screening, demographic and anthropometric data were collected. 
To start the experiment the participants positioned themselves in supine on a treatment 
plinth and were fully supported using pillows. Skin over the medial aspect of both thighs was 
prepared and a square area covering the lower one-fourth of the medial aspect of the right 
and left thighs were marked with tape to deliver the treatment and obtain the physiological 
measurements. For all participants, the right leg was chosen as the active (treated) side, 
while the untreated left leg served as control. Skin temperature was recorded from the 
middle of the square area on the treated leg as well as the corresponding area of the 
untreated leg. This was repeated every two minutes until stabilised. The stabilised 
temperature was considered the baseline temperature. The core (tympanic) temperature 
was also monitored at the same time. All data, except those from the Biopac and Doppler 
were entered manually into a participant data collection form (Appendix 6.6). 
6.3.4 Data acquisition 
6.3.4.1 Skin physiological measurements 
All skin physiological measurements on both sides were performed pre-treatment, 
immediately post treatment and 20-minute post treatment for all conditions. The PPG and 
SKT probes and the NCV electrodes from the Biopac data acquisition system were attached 
to the predetermined marked areas on both legs. The probes were positioned within the 
treatment zone and attached using Micropore™ (3M™) tape. For NCV, self-adhesive 
monitoring electrodes (3M™ Red Dot™) were used and placed with 22 cm between the 
stimulating and measuring electrodes, close to the outer border of the treatment zone 
(established during pilot). During each assessment, the outcome measurements were 
performed in the following order. 
1st  NCV on the treated side 
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2nd  NCV on the untreated side 
3rd  SKT and SBF performed together for both sides 
The NCVs were performed separately since it was identified in the pilot that they were 
interfering with each other. Performing unilaterally also minimised the skin discomfort for the 
participants. All the probes and connecting leads on the treated leg, except the NCV 
electrodes were removed from the skin prior to the RF treatment and reattached for post 
treatment measurements. This was done to avoid potential signal interference, probe 
damage and tissue irritation, as explained in chapter 4 (pilot experiments). The NCV 
electrodes were left in place since they were situated outside the treated area, and to 
minimise the discomfort caused to the skin while removing them. No signal interference or 
unwanted heating was noted from these electrodes once the leads were detached. All the 
attachments on the control leg remained in place throughout the experiment since they did 
not cause any interference or skin irritation (established during pilot). Reliability of probe and 
electrode placements was established by extensive pilot works. The sampling rate for 
Biopac was chosen to be 200 samples/second based on previous evidence.192 
The Biopac system was set up to run one hour before the start of the experiment to ensure 
proper baselining of the data streams. Both SKT and PPG data were collected for 10 
minutes pre-treatment, and once restarted post treatment, they were kept running through to 
the 20-minute follow-up phase. The NCV was recorded for a fixed 30 seconds at each 
assessment. The core (tympanic) temperature, BP and PR were also concurrently monitored 
at the three time points. The probe and electrode attachments and sample Biopac data 
streams are shown in Figure 6.2. 
Figure 6.2: Images showing the Biopac electrode placement and sample data streams from 
the SKT, PPG (top) and NCV (bottom) modules 
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6.3.4.2 Deep physiological measurements 
The deep blood flow and Sonoelastography measurements were performed pre-and post-
intervention only, and only from the treated side unlike the skin measurements. For each 
participant, blood flow was identified by manoeuvring the ultrasound probe over the lower 
anteromedial aspect of the quadriceps femoris muscle. Once the most prominent pulsatile 
(arterial) flow was identified, skin markings were used to establish the accuracy of probe 
placement and ensure repeatability. Prior to this study, the intra-rater reliability for both 
Doppler and Sonoelastography measurements was established in a separate pilot study that 
involved 12 healthy adult participants (explained in chapter 4, pilot experiments). 
For Sonoelastography measurements, a fixed position was adopted for all participants. The 
probe was placed parallel to the longitudinal axis of thigh, perpendicular to the skin in the 
middle lower part of the marked area. Minimal probe pressure and liberal amount of 
conductive gel were used to avoid any undue compression of the tissues. For all 
participants, the machine settings remained the same for both pre-treatment and post 
treatment measurements. Recordings were performed from the treated side in the following 
order. 
1st  Colour Doppler for velocity of flow 
2nd  Power Doppler for volume and intensity of flow 
3rd  Elastography for the softness and hardness of tissues 
Up to five seconds of blood flow data clips were recorded with colour Doppler, power 
Doppler and Sonoelastography during each measurement, which was then broken down into 
image frames for analysis. Sample ultrasound images obtained from one participant before 
and after treatment are shown in Figure 6.3. 
Figure 6.3: Sample images showing Doppler Ultrasound and Elastography recordings before 
(left side) and after (right side) CRMRF treatment. The images shown are: Colour Doppler 
(top left), Power Doppler (bottom left), and Elastography (right side) showing the hard (red), 
intermediate (blue) and soft (green) tissue types. 
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6.3.5 The CRMRF intervention 
6.3.5.1 Pilot study to determine the intervention 
The design of the CRMRF intervention was determined using a pilot randomised crossover 
study on a similar cohort of asymptomatic volunteers, prior to the commencement of the 
main study being described in this chapter. The methods adopted for this pilot study were 
identical to the main study except that the pilot study employed only three groups with a 
maximum of 15 participants in each group; and that it only employed SKT and SBF as 
outcome measures, with measurements obtained only from the treated leg without follow-up. 
6.3.5.2 Pilot study rationale, aims and methodology 
There are no evidence-based recommendations currently available with regards to the 
optimum intervention design for CRMRF therapy beyond the recommendations from the 
manufacturer derived from user experience and product development. Besides the lack of 
understanding on the time and sequencing of the CAP and RES modes, there is a lack of 
awareness on the optimum treatment delivery methods too. For example, with regards to the 
application, the manufacturer actively encourages the use of manual therapy techniques 
(such as soft tissue mobilisations or massage) to be simultaneously delivered with CRMRF. 
This is achieved by holding the treatment electrode in one hand and the manual techniques 
delivered using the other hand. However, such suggestions are not based on published 
evidence and are backed only by ‘in-house research’ by the manufacturer and anecdotal 
evidence from the users of this device. 
Nonetheless, it can be argued that employing manual therapy techniques such as massage 
or other soft tissue treatment techniques combined with a thermal modality employing RF 
may generate a cumulative physiological response in the tissues by increasing fluid 
drainage, improving thermal distribution and improving tissue compliance although the 
quality of current evidence is lacking.84,91,326,459 In general, the physiological effects of various 
manual therapy techniques such as massage, joint mobilisation and manipulation are well 
documented through reviews of literature477-480 and in relevant text books.481,482 There is 
considerable evidence in the literature suggesting that massage and soft tissue mobilisation 
can influence tissue temperature superficially483-485 and possibly at depth,455 and can improve 
peripheral blood flow.486-488 If the addition of similar manual therapy techniques (massage) to 
the CRMRF application has a significant additional effect on the tissue physiological 
responses, then its inclusion would need to be incorporated into the experimental protocol. 
If, however the addition of the manual therapy component, as advocated by the 
manufacturer, made no significant difference to the physiological response, then it could be 
reasonably omitted from further experimentation, thereby reducing it as a potential 
confounding factor. 
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Hence, the key aim of this pilot study was to determine whether CRMRF delivered in 
conjunction with manual therapy in the form of soft tissue mobilisation (massage) has a 
greater physiological effect compared to a same thermal dose of CRMRF delivered without 
the manual therapy component. To address this aim 15 volunteers attended two study 
groups (groups 1 & 2 stated below) in a random order using a computer-generated 
randomisation chart (IBM SPSS Statistics, Version 20) (Appendix 6.7) in a crossover study. 
Nine of the participants also attended a third session (non-random control session) receiving 
similar treatment, but with the CRMRF device output turned off. 
The three study groups and the number of participants attending those groups are as below. 
Group 1 – CRMRF high (15 participants) 
Group 2 – CRMRF high + manual therapy (15 participants) 
Group 3 – CRMRF zero output + manual therapy (9 participants) 
The CRMRF treatment was delivered for 15 minutes (5 minutes CAP followed by 10 minutes 
RES) within the marked area of the right lower limb, using 20 ml of conductive cream for 
each mode. The active electrode produced firm circles on the skin, at a rate of approximately 
one per second. The return plate electrode was smeared with 20 ml of conductive cream 
and placed under the calf muscle belly, one-fourth way down the distance from the fibular 
head to the lateral malleolus of the treated leg. 
Predetermined treatment doses were not delivered for either of the two CRMRF groups, but 
rather the dosage was adjusted based on the concurrent feedback given by the participants, 
as would be the case in a real clinical situation. The intensity of application was gradually 
increased, by one level at a time (standardised as once every five seconds until the intensity 
reached 25% output and once every 30 seconds thereafter, based on pilot) using the remote 
controller till the participants reported moderate yet comfortable heating. This moderate level 
of heating was then maintained throughout the session by adjusting the intensity if required. 
In the treatment group where manual therapy was also delivered, circular kneading massage 
was applied alongside the electrode movements using the web of fingers of the free hand. 
There is no evidence available as to which manual therapy technique works best alongside 
CRMRF. The current technique was adopted based on pilot work, where it was found to best 
suit the proposed methodological protocol. 
SKT and SBF measurements were obtained using the Biopac system before and 
immediately after treatment employing the same methodology described above. All data was 
processed and analysed using Microsoft Office Excel Version 2010 (Microsoft Corporation, 
USA) and IBM SPSS Statistics Version 20 (IBM Corporation, USA). Two separate data 
analyses, first with the two active CRMRF groups (two-group analysis) and secondly with all 
three groups including the manual therapy-only group (three-group analysis) were carried 
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out. While the first analysis had 15 participants per group, the second analysis was based on 
nine participants. To ascertain whether there were any statistically significant differences 
between the treatment conditions, the group data were compared using either a two-way 
(intervention and time) repeated measures analysis of variance (ANOVA) model at three 
time points (baseline, post treatment and 20-minute follow-up) or using Friedman’s two-way 
ANOVA by ranks, depending on the distribution of data (Shapiro-Wilk). The statistical 
significance was set at p ≤ 0.05 (0.8 P, 95% CI). 
6.3.5.3 Pilot study results 
All 15 participants completed the two RF sessions of CRMRF therapy and/or manual 
therapy, and the assessments as anticipated. Nine participants attended a third session and 
underwent its assessments. All treatment types were well tolerated and there were no 
reports of any adverse events that might be a consequence of the intervention, including any 
issues due to potential overheating. 
The demographic and the mean (SD) anthropometric data from the participants are reported 
in Table 6.1. There were no differences between any of the three conditions in either 
characteristic since this was a crossover (repeated measures) study. The mean (SD) RF 
dose received by the participants is given in Table 6.2, along with the mean (SD) room 
temperature and humidity at the time of the experiment. Figure 6.4 shows the mean (SD) 
SKT results recorded at the two time points from all three groups. Figure 6.5 shows the 
mean (SD) SBF results recorded at the two time points from all three groups. 
Table 6.1: Demographic and the mean (SD) anthropometric data from the 15 participants 
who received CRMRF treatment 
 
 
 
 
 
kg – kilogram; m – metre; BMI – body mass index 
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Table 6.2: The mean (SD) treatment doses received by the participants of three 
experimental groups, and the mean (SD) room temperature and humidity 
 
 
 
 
 
CRMRF – Capacitive Resistive Monopolar Radiofrequency; RF – radiofrequency; MT – 
manual therapy 
In the two-way ANOVA no significant main effects, interactions or changes between groups 
were noted for any of the intervention groups for any time point in either SBF analysis. In the 
SKT analysis, no significant main effects, interactions or changes between groups were 
noted for any of the intervention groups for any time point in the two-group analysis. In the 
three-group SKT analysis, the third group (manual therapy only group) differed significantly 
from both the other groups (p < 0.001; Bonferroni). Significant within group changes were 
noted in both the RF groups for both SKT and SBF (p < 0.001), but not in the third group. 
Figure 6.4: Mean (SD) SKT responses from three groups 
 
 
 
 
 
 
 
Figure 6.5: Mean (SD) SBF responses from three groups 
 
 
 
 
 
 
148 
6.3.5.4 Pilot study conclusions 
The aim of this pilot study was to determine if delivering CRMRF in combination with manual 
therapy had a greater physiological effect than CRMRF delivered on its own. The results 
obtained here suggest that there is no greater effect generated by the addition of manual 
therapy for the employed experimental protocol. Besides, the group means suggests that 
CRMRF delivered on its own may induce a more pronounced physiological response. The 
manual therapy component was hence excluded from the intervention delivered in the main 
study. 
6.3.5.5 CRMRF treatment in the main study 
The treatment was delivered for 15 minutes in all conditions (5 min CAP followed by 10 min 
RES). For the CRMRF high dose condition, the intensity of application was gradually 
increased till the participants reported moderate, yet comfortable heating as explained in the 
above section. This moderate level of heating was then maintained throughout the session 
by adjusting the intensity if required. For the CRMRF low dose condition, the intensity was 
gradually increased till the participants reported a feeling of heat, using the same method as 
above. It was then reduced marginally to avoid the heating sensation, and this sub-thermal 
level was maintained throughout the session. For CRMRF placebo, the intensity was 
gradually increased till the participants felt heat as in for the low dose, but the device output 
was then turned off for the rest of the session. The control condition did not involve any 
intervention, hence the participants only rested on the treatment plinth for 15 minutes. 
6.3.6 PSWT treatment 
The nearest available PSWT dose to the mean CRMRF high dose (42.37 W) used in the 
study was 47 W (PD–400 µs, PRR–200 Hz, PP–600 W). Hence, a MP dose of 47 W was 
delivered to all 15 participants who attended the PSWT session, for the duration of 15 
minutes. The treatments were applied using a drum (monode) applicator electrode placed 
1.5 cm from the skin over the marked area. 
6.3.7 Data analysis 
6.3.7.1 Processing of Biopac data and the ultrasound images 
This has been explained in detail in chapter 4. 
6.3.7.2 Statistical analysis of data 
All data including the Biopac data and the ultrasound image data (after MATLAB analysis) 
were processed using Microsoft Office Excel Version 2010 (Microsoft Corporation) and 
statistically analysed using IBM SPSS Statistics Version 20 (IBM Corporation). It was 
decided to perform two separate data analyses, first with the three CRMRF and the control 
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groups (four-group analysis) and secondly with all five groups including the PSWT high 
group (five-group analysis). While the first analysis had 17 participants per group, the 
second analysis was based on 15 participants. To ascertain whether there were any 
statistically significant differences between the treatment conditions, the Biopac group data 
were compared using either a two-way (intervention and time) repeated measures analysis 
of variance (ANOVA) model at three time points (baseline, post treatment and 20-minute 
follow-up) or using Friedman’s two-way ANOVA by ranks, depending on the distribution of 
data (Shapiro-Wilk). The ultrasound data was subjected to the same analysis, but at two 
time points (baseline and post treatment). The statistical significance was set at p ≤ 0.05 (0.8 
P, 95% CI). 
 Results 
All 17 participants completed three sessions of CRMRF therapy and the control condition, 
and the accompanying assessments as anticipated. Among them, 15 participants attended 
the fifth session (PSWT) and underwent the assessments. Both types of RF were well 
tolerated and there were no reports of any adverse events that might be a consequence of 
the intervention, including any issues due to potential overheating. 
The demographic and the mean (SD) anthropometric data from the participants are reported 
in Table 6.3. There were no differences between any of the five conditions in either 
characteristic since this was a crossover (repeated measures) study (the conditions will be 
referred to as ‘groups’ from here on for convenience, although they were not independent 
groups). 
The mean (SD) RF dose received by the participants is given in Table 6.4, along with the 
mean (SD) room temperature and humidity at the time of the experiment. As identified, the 
CRMRF placebo group received a negligible average dose of treatment, while the PSWT 
high group received a fixed dose of 47 W. To illustrate the level of variation that was 
observed in the doses of CRMRF high and low groups, the individual data from the three 
actively treated groups are plotted in Figure 6.6. 
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Figure 6.6: Data from CRMRF high, CRMRF low and PSWT high groups, showing the 
individual treatment doses delivered. Participants 9 & 10 did not attend the PSWT session. 
 
 
 
 
 
 
 
 
Table 6.3: Demographic and the mean (SD) anthropometric data from the 17 participants 
who received localised CRMRF treatment 
 
 
 
 
 
 
Table 6.4: The mean (SD) treatment doses received by the participants in the five 
experimental groups, and the mean (SD) room temperature and humidity during the 
experimental sessions 
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The results of each physiological parameter obtained from the treated leg are reported 
below. 
6.4.1 Skin temperature results 
Figures 6.7 (a–b) shows the mean (SD) SKTs recorded at three time points and the 
percentage changes of mean. Figures 6.7 (c–g) shows the individual SKT responses at the 
three time points and the individual percentage changes in SKT (from baseline to post 
treatment and from baseline to the 20-minute follow-up) within the three actively treated 
groups (CRMRF high, CRMRF low and PSWT high). 
For SKT of the treated side, a 4*3 (intervention, time) repeated measures ANOVA revealed 
a significant main effect for the intervention (the applied dose between CRMRF high, 
CRMRF low, CRMRF placebo and control groups) [F (3, 48) = 29.545, p < 0.001, observed 
power = 1.00]; for the time (pre, post and follow-up) [F (2, 32) = 8.458, p = 0.001, observed 
power = 0.95]; and a significant interaction between the intervention and time [F (2.997, 
47.952) = 62.261, p < 0.001, observed power = 1.00]. Therefore, the applied dose made a 
significant difference to the observed SKT changes and there was a significant overall 
difference between the pre, post and follow-up data. There was no significant difference 
between the baseline SKTs of the four groups. 
In the five-group analysis (15 participants; repeated measures ANOVA), similar results were 
obtained for all the above comparisons in terms of significance values (all p < 0.001). 
However, the baseline SKT of the PSWT high group was significantly lower compared to the 
other four groups [F (4, 56) = 10.341, p < 0.001]. 
Within the CRMRF high group there was a significant rise in SKT from baseline to post 
treatment [F (1, 16) = 129.695, p < 0.001, r = 0.943, observed power = 1.00] and a 
significant retention of this gained temperature at the 20-minute follow-up when compared to 
the baseline [F (1, 16) = 96.567, p < 0.001, r = 0.926, observed power = 1.00]. A similar 
significant response, although less strong was noted from baseline to post [F (1, 16) = 5.404, 
p = 0.034, r = 0.502, observed power = 0.589] and from baseline to the 20-minute follow-up 
[F (1, 16) = 5.901, p = 0.027, r = 0.519, observed power = 0.626] also in the CRMRF low 
group. No meaningful changes were noted in the temperature recordings of either placebo 
or control groups. In the PSWT high group although a significant rise in SKT was noted from 
baseline to post treatment [F (1, 14) = 146.312, p < 0.001, r = 0.955, observed power = 
1.000], there was no significant retention of this gained temperature at the follow-up. 
The key results of planned comparisons (contrasts) between all five groups are reported in 
Table 6.5. Effect sizes (r) and the results of a post-hoc power analysis using G*Power 
(Version 3.1) are also reported (where the interaction was significant). As it can be noted, 
both the high and low dose CRMRF groups differed significantly from both the placebo and 
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control groups, but the high dose group response was significantly stronger than that of the 
low dose group. There was no meaningful difference between the placebo and control 
groups apart from the fact that placebo group temperature decreased, potentially due to the 
application of the cold conductive cream. The overall SKT responses within the PSWT high 
group was less strong compared to the CRMRF high and low groups, but stronger (except 
for follow-up) than that in the placebo and control groups. 
Table 6.5: Key results from the planned comparisons (contrasts) on the SKT responses 
across five experimental groups. Comparisons involving PSWT high group are based on 15 
participants, and all others are based on 17 participants. 
 
 
 
 
 
 
 
 
 
 
Figure 6.7a: The mean (SD) SKT responses showing the baseline, post treatment and 20-
minute follow-up data from all five groups. 
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Figure 6.7b: Percentage change of the mean SKT from the baseline to post treatment and 
from the baseline to the 20-minute follow-up for all five groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7c: SKT data from the three active groups showing individual responses at the 
baseline 
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Figure 6.7d: SKT data from the three active groups showing individual responses at post 
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7e: SKT data from the three active groups showing individual responses at the 20-
minute follow-up 
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Figure 6.7f: SKT data from the three active groups showing individual percentage changes 
from the baseline to post treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7g: SKT data from the three active groups showing individual percentage changes 
from the baseline to the 20-minute follow-up 
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6.4.2 Skin blood flow results 
Figures 6.8 (a–b) shows the mean (SD) SBFs recorded at three time points and the 
percentage changes of the mean. Figures 6.8 (c–g) shows individual SBF responses at the 
three time points and the individual percentage changes (from baseline to post treatment 
and from baseline to the 20-minute follow-up) within the three actively treated groups. 
Analysis of the SBF data was performed using Friedman’s two-way ANOVA by ranks, since 
several data sets broke the assumptions of normality (Shapiro-Wilk). In the four-group 
analysis (excluding the PSWT high group), a significant main effect for the interventions was 
found at the post treatment stage [2 (3) = 27.494, p < 0.001] and at the 20-minute follow-up 
[2 (3) = 31.047, p < 0.001]. Therefore, the applied dose made a significant difference to the 
observed SBF changes. There was no significant difference between the baseline SBFs of 
the four groups. 
In the five-group analysis (15 participants per group; Friedman’s two-way ANOVA), similar 
results were obtained for both the above comparisons in terms of significance values (all p < 
0.001). There was no significant difference in SBF between the five groups at baseline. 
As the participants rested on the plinth over the course of the experiment, it was noted that 
the SBF went up marginally and somewhat plateaued after the first 20–30 minutes (based 
on the control group data) even after the initial stabilisation period (20 minutes). Within the 
CRMRF high group there was a substantial and highly significant rise in SBF from baseline 
to post treatment (Friedman, p < 0.001, r = −0.780, 1.000 P), with almost all that gain being 
retained at the 20-minute follow-up (Friedman, p = 0.001, r = −0.632, 0.970 P). A significant 
change, although less strong (like the SKT response), from baseline to post (Friedman, p = 
0.006, r = −0.529, 0.904 P) and a significant retention at the 20-minute follow-up (Friedman, 
p = 0.001, r = −0.618, 0.964 P) was noted also in the CRMRF low group. No such 
meaningful changes were noted in the SBF recordings of either CRMRF placebo or PSWT 
high groups. 
The key results of pairwise comparisons (Friedman) between all five groups are reported in 
Table 6.6. Effect sizes (r) and the results of a post-hoc power analysis using G*Power 
(Version 3.1) are also reported (where the interaction was significant). Only the CRMRF high 
group differed significantly from the responses of other groups. Although the CRMRF low 
group showed a significant within group change (as detailed above), it appears that this 
change was not significantly higher than the random changes noted in the control group and 
is hence unlikely to be clinically meaningful. 
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Table 6.6: Key results from the planned comparisons (contrasts) on the SBF responses 
across five experimental groups. Comparisons involving PSWT high group are based on 15 
participants, and all others are based on 17 participants. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8a: The mean (SD) SBF responses showing the baseline, post treatment and 20-
minute follow-up data from all five groups 
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Figure 6.8b: Percentage change of the mean SBF from the baseline to post treatment and 
from the baseline to the 20-minute follow-up for all five groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8c: SBF data from the three active groups showing individual responses at the 
baseline 
 
 
 
 
 
 
 
 
 
 
 
 
128.39
113.45
40.28 45.04
4.35
11.52
19.81 19.1015.66
28.83
-25
0
25
50
75
100
125
150
Baseline to Baseline to
Post treatment Follow-up
Pe
rc
en
ta
ge
RF High
RF Low
RF Placebo
Control
PSWT High
1
2
3
4
5
6
7
8
9
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
A
rb
it
ra
ry
 u
n
it
s
Participants
CRMRF High
CRMRF Low
PSWT High
159 
Figure 6.8d: SBF data from the three active groups showing individual responses at post 
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8e: SBF data from the three active groups showing individual responses at the 20-
minute follow-up 
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Figure 6.8f: SBF data showing individual percentage changes from the baseline to post 
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8g: SBF data showing individual percentage changes from the baseline to the 20-
minute follow-up 
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6.4.3 Nerve Conduction Velocity results 
For NCV of the treated side, the four-group analysis was performed using a Friedman’s two-
way ANOVA by ranks, since several data sets broke the assumptions of normality (Shapiro-
Wilk), while the five-group analysis was performed using 4*3 (intervention, time) repeated 
measures ANOVA. No significant main effects, interactions or changes within groups were 
noted for any of the intervention groups for any time point in either analysis. Figure 6.9 
shows the mean (SD) NCVs recorded at the three time points for all five groups. 
A post-hoc power analysis using G*Power (Version 3.1) was undertaken for the SKT and 
SBF main effects using the data (four groups only) obtained from 14 participants (not 15 
participants as originally planned, since one participant had withdrawn after attending two 
sessions). The analysis showed that sufficient power had been achieved (SBF 0.99; SKT 
1.00). Hence the recruitment was stopped. Three more participants who had already started 
went on to complete the study, taking the total sample to 17 participants. The final analysis 
revealed that the overall power obtained for both the four-group (17 participants) and the 
five-group (15 participants) analyses were ‘1.00’ for SBF as well as SKT. 
Figure 6.9: The mean (SD) NCV responses showing the baseline, post treatment and 20-
minute follow-up data from all five groups 
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6.4.4 Blood flow volume 
Figures 6.10 (a–b) shows and compares the mean (SD) blood flow volumes recorded at the 
two time points and the percentage changes of the mean, for all five groups. Figures 6.10 
(c–e) shows and compares the individual blood flow volume responses at the two time 
points and the individual percentage changes (from baseline to post treatment) of the three 
active intervention groups (CRMRF high, CRMRF low and PSWT high). All data are 
represented in arbitrary units. 
Analysis of the blood flow volume data was performed using Friedman’s two-way ANOVA by 
ranks, since several data sets broke the assumptions of normality (Shapiro-Wilk). In the four-
group analysis (excluding the PSWT group), a significant main effect for the interventions 
was found at the post treatment stage [2 (3) = 13.659, p = 0.003]. Therefore, the applied 
dose made a significant difference to the observed changes in blood flow volume. At the 
baseline, the groups did not differ significantly, except for the control and placebo groups, 
which showed a significant difference between them (Friedman, p = 0.009). 
In the five-group analysis (15 participants; Friedman’s two-way ANOVA) that also included 
the PSWT group, similar result was obtained for the between-group comparison at the post 
treatment stage [2 (4) = 20.000, p < 0.001]. There was no significant difference between 
any of the five groups at the baseline. 
Within the CRMRF high group there was a substantial and highly significant rise in the flow 
volume from baseline to post treatment (Wilcoxon, p = 0.001, r = 0.60, 0.95 P). A significant 
increase, although less strong was also noted in the CRMRF low group (Wilcoxon, p = 
0.006, r = 0.47, 0.84 P). No such meaningful changes were noted in the blood flow volume 
recordings of the other three groups. 
The key results of pairwise comparisons (Friedman) between all five groups are reported in 
Table 6.7. Effect sizes and the results of a post-hoc power analysis using G*Power (Version 
3.1) are also reported (where the interaction was significant). The CRMRF high group 
differed significantly from the responses of all the other groups except the CRMRF low 
group.  The CRMRF low group only differed significantly from The PSWT group. 
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Table 6.7: Key results from the pairwise comparisons on blood flow volume responses 
across five experimental groups. Comparisons involving PSWT group are based on 15 
participants, while all others are based on 17 participants. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10a: The mean (SD) deep blood flow volume responses showing the baseline and 
post treatment data from all five groups 
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Figure 6.10b: Percentage change of the mean deep blood flow volume from the baseline to 
post treatment for all five groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10c: Deep blood flow volume data from the three active groups showing individual 
responses at the baseline 
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Figure 6.10d: Deep blood flow volume data from the three active groups showing individual 
responses at post treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10e: Deep blood flow volume data from the three active groups showing individual 
percentage changes from the baseline to post treatment 
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6.4.5 Blood flow intensity 
Figures 6.11 (a–b) shows and compares the mean (SD) blood flow intensities recorded at 
the two time points and the percentage changes of mean, for all five groups. Figures 6.11 
(c–e) shows and compares the individual blood flow intensity responses at the two time 
points and the individual percentage changes (from baseline to post treatment) of the three 
active groups (CRMRF high, CRMRF low and PSWT high). All data are represented in 
arbitrary units. 
Analysis of the blood flow intensity data was performed using Friedman’s two-way ANOVA 
by ranks, since several data sets broke the assumptions of normality (Shapiro-Wilk). In the 
four-group analysis (excluding the PSWT group), a significant main effect for the 
interventions was found at the post treatment stage [2 (3) = 14.788, p = 0.002]. Therefore, 
the applied dose made a significant difference to the observed changes in blood flow 
intensity. There was no significant difference between the baseline scores of the four 
groups. 
In the five-group analysis (15 participants; Friedman’s two-way ANOVA) that also included 
the PSWT group, similar result was obtained for the between-group comparison at the post 
treatment stage [2 (4) = 18.240, p = 0.001]. There was no significant difference between 
any of the five groups at the baseline. 
Within the CRMRF high group there was a substantial and highly significant rise in flow 
intensity from baseline to post treatment (Wilcoxon, p = 0.001, r = 0.55, 0.92 P). No such 
meaningful changes were noted in the blood flow intensity recordings of the other four 
groups. 
The key results of pairwise comparisons (Friedman) between all five groups are reported in 
Table 6.8. Effect sizes and the results of a post-hoc power analysis using G*Power (Version 
3.1) are also reported (where the interaction was significant). The CRMRF high group 
differed significantly from the responses of the control and PSWT groups. Although the 
CRMRF low group also showed a significant difference with the control group, this is not a 
meaningful change as there was no significant within group change in the CRMRF low 
group. 
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Table 6.8: Key results from the pairwise comparisons on the blood flow intensities across 
five experimental groups. Comparisons involving PSWT group are based on 15 participants, 
while all others are based on 17 participants. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11a: The mean (SD) deep blood flow intensity responses showing the baseline and 
post treatment data from all five groups 
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Figure 6.11b: Percentage change of the mean deep blood flow intensity from baseline to 
post treatment for all five groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11c: Deep blood flow intensity data from the three active groups showing individual 
responses at the baseline 
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Figure 6.11d: Deep blood flow intensity data from the three active groups showing individual 
responses at post treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11e: Deep blood flow intensity data from the three active groups showing individual 
percentage changes from the baseline to post treatment 
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6.4.6 Blood flow velocity 
For the blood flow velocity of the treated side, the four-group analysis was performed using 
Friedman’s two-way ANOVA by ranks since several data sets broke the assumptions of 
normality (Shapiro-Wilk), while the five-group analysis was performed using a 4*2 
(intervention, time) repeated measures ANOVA model. No significant main effects, 
interactions or changes within groups were noted for any of the intervention groups for any 
time point in either analysis. Figure 6.12 shows and compares the mean (SD) blood flow 
velocities (measured in arbitrary units) recorded at the two time points for all five groups. 
Figure 6.12: The mean (SD) deep blood flow velocity responses showing the baseline and 
post treatment data from all five groups 
 
 
 
 
 
 
 
 
 
 
 
 
6.4.7 Tissue extensibility 
In total, six parameters pertaining to the volume (pixel count in kilo pixels) and intensity 
(colour intensity index) of the ‘hard’, ‘intermediate’ and ‘soft’ tissue types were compared in 
both four and five group analyses using either a 4*2 (intervention, time) repeated measures 
ANOVA model or by using Friedman’s two-way ANOVA by ranks model depending on the 
distribution of data (Shapiro-Wilk). No significant main effects, interactions or changes within 
groups were noted for any of the intervention groups for any time point in either the four-
group or the five-group analysis. Figures 6.13 (a–c) shows and compares the mean (SD) 
group data (measured in arbitrary units) recorded at the two time points for all five groups. 
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Figure 6.13a: The mean (SD) hardness volume and the mean (SD) hardness intensity 
measures of the tissues showing the baseline and post treatment data 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13b: The mean (SD) intermediate tissue volume and the mean (SD) intermediate 
tissue intensity measures of the tissues showing the baseline and post treatment data 
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Figure 6.13c: The mean (SD) softness volume and the mean (SD) softness intensity 
measures of the tissues showing the baseline and post treatment data 
 
 
 
 
 
 
 
 
 
 
 
 
6.4.8 Results from the control leg 
There were no meaningful changes in the skin physiological results of any of the above 
parameters from the untreated control leg for any of the five groups. The group mean data 
are reported in figures 6.14 (a–c). 
Figure 6.14a: The mean (SD) SKT responses obtained from the control leg 
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Figure 6.14b: The mean (SD) SBF responses obtained from the control leg 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.14c: The mean (SD) NCV responses obtained from the control leg 
 
 
 
 
 
 
 
 
 
 
 
6.4.9 Other results 
No statistically significant or meaningful variations were noted in the core temperature, pulse 
rate or blood pressure of any of the participants during any of the sessions (Table 6.9). The 
mean (SD) room temperatures varied between 24.3 (±0.56) oC and 25.53 (±1.11) oC in the 
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whole study. All room temperatures were within the thermoneutral zone of humans. The 
mean (SD) humidity varied between 32.70 (±4.37) % and 41.79 (±6.50)% (Table 6.10). 
Table 6.9: The group mean (SD) data for core temperature, BP and PR 
 
 
 
 
 
 
 
Table 6.10: The group mean (SD) data for room temperature and humidity 
 
 
 
 
 
 Discussion 
The latter half of the past century saw a surge in research activity on the effects of RF-based 
therapy (within the frequency band of 30 kHz–30 MHz), mainly the continuous and pulsed 
SWTs. Numerous studies have looked at the RF effects in humans as well as in animal 
models. At the same time, there is a dearth of evidence to support either the physiological or 
the clinical effects of RF below shortwave frequencies, as explained in the literature review 
section. In contrast, numerous studies were identified on the shortwave frequencies. 
Following up on the earlier study on the thermal build-up, decay and retention responses to 
the application of CRMRF (Chapter 5), the current study investigated the thermal, vascular, 
nerve conduction and tissue compliance responses. It studied both superficial tissue (skin) 
responses, the vascular responses from tissues up to a depth of 5 cm, and changes in 
compliance of tissues up to about 2 cm depth from the skin in response to the application of 
multiple doses of CRMRF therapy. In addition, a high dose application of PSWT was also 
employed to enable a comparison between the two types of RF treatments. 
As mentioned, skin measures relating to blood flow, temperature and nerve conduction 
closely reflect changes to the body’s thermoregulatory system.1,21,22 Although many similar 
Core 
temperature 
(
o
C)
Cystolic BP 
(mmHg)
Diastolic BP 
(mmHg)
PR (per sec)
RF High 36.9 (0.12) 114 (11.27) 67 (7.98) 59 (10.34)
RF Low 36.9 (0.17) 115 (10.83) 67 (7.40) 61 (11.33)
RF Placebo 36.8 (0.26) 112 (11.04) 65 (5.25) 58 (10.14)
Control 36.9 (0.25) 113 (11.40) 65 (5.79) 59 (10.74)
PSWT High 36.8 (0.23) 118 (12.00) 70 (5.47) 59 (10.46)
RF High RF Low RF Placebo Control PSWT High
Room 
temperature (
o
C)
25.1 (1.14) 25.5 (1.11) 25.4 (1.06) 25.2 (1.04) 24.3 (0.56)
Humidity (%) 41 (6.38) 41 (7.40) 40 (6.24) 42 (6.50) 33 (4.37)
175 
physiological studies involving shortwaves have been reported over several 
decades,77,80,85,86,187,192 this is the first such study carried out in vivo employing RF below the 
shortwave frequency band. Similarly, measures relating to deep blood flow and tissue 
compliance closely reflect the body’s response to RF energy delivered to deeper tissues, 
with the RF potentially inducing a hyperthermic effect at depth.83,194 Although similar studies 
involving shortwave conducted on either healthy subjects19,77,91,195 or patients196-198 have 
been reported before, this is the first study that employed RF below the shortwave frequency 
band and that investigated either deep blood flow or tissue compliance. 
In contemporary literature, there is an ongoing discourse about the thermal versus non-
thermal effects of RF. In this study, the authors did not aim to study the thermal – non-
thermal distinction of CRMRF per se, but rather, a thermal – sub/minimally thermal 
difference was investigated. It is challenging to deliver a completely non-thermal dose of RF 
unless substantially low intensities are selected. This is especially the case with continuous 
mode RFs due to the prospect of heat accumulation (discussed below). Moreover, many of 
the physiological/clinical benefits of heating such as reduction of pain and inflammation or 
increasing tissue extensibility occur when temperatures are raised by 2–4 oC.457,462 Although 
cell metabolism can be affected by changes in temperature that are as small as a fraction of 
a degree,6 investigating such effects at the cellular level was beyond the scope of this study. 
Traditionally in therapies where RF is used in continuous mode (e.g. CSWT) at relatively 
higher intensities, a fixed treatment dose is seldom used. Instead, the dosage is adjusted 
based on the perceived heat reported by the recipient. This is because in continuous mode 
exposure there is no sufficient ‘washout period’ to enable the person’s circulatory system to 
drain the accumulated heat away from the area. This is often not the case for pulsed mode 
therapies (e.g. PSWT), where the ‘off cycle’ enables the body’s circulatory system to 
dissipate most of the generated heat, thus minimising heat accumulation.18 For this reason, 
it is problematic to compare a continuous mode application such as CRMRF with a pulsed 
mode application such as PSWT. Nonetheless, comparison of these two EPAs was done on 
the basis that PSWT is the most relevant comparator to CRMRF in contemporary therapy 
environment. The clinical use of CSWT has decreased significantly in the western world over 
the recent decades.56,61 
In agreement with clinical practice, fixed RF doses were not delivered in this study except for 
PSWT. Data reported in Figure 6.6 shows considerable variation in the amount of energy 
received by individual participants among the high and low dose groups of CRMRF therapy. 
They reflect the differences in thermal perception and thermal tolerance among the 
participants. Although the participants often reported perceived heat from the CRMRF low 
dose, the treatment protocol allowed the delivery to be controlled so that the heat perception 
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was not globally apparent (‘sub thermal’ or otherwise ‘minimally thermal’ in a clinical 
context). 
Contrary to CRMRF, the PSWT high group received a fixed dose of 47 W (highest MP 
allowed by the ‘Ultramed’ device for a ‘monode’ applicator) throughout the treatment. 
Although the plan was to reduce the dose if the participants reported undesirable heating, it 
turned out that the level of heating was only ‘mild’ at best. One of the potential drawbacks 
with conventional PSWT devices used in therapy is that there is no attached monitoring 
system, which can record the actual amount of RF energy delivered to the recipient. Without 
the need for a special conducting medium, shortwave units are known to emit stray 
radiations in the air.18,452 Hence, some of the energy will be lost through scattering, making it 
difficult to focus the delivery in the area treated.450,451 
Scattering also makes it challenging to estimate the specific absorption rate (SAR) of 
radiofrequency energy in the recipient for either intervention. It is challenging also to 
calculate the SAR for the treated area per se since the accurate mass of the area exposed 
to treatment cannot be determined. If it is assumed that there was zero scattering and that 
whole of the applied energy was absorbed by the target tissues, the mean (SD) whole body 
SAR can be estimated to be 0.60 (0.09) W/kg for CRMRF high group, 0.27 (0.07) W/kg for 
CRMRF low group, 0.04 (0.02) W/kg for CRMRF placebo group and 0.67 (0.10) W/kg for 
PSWT group. However, although the mean estimated SAR was lower in the CRMRF high 
group compared to the PSWT high group, its actual SAR is likely to have been higher than 
PSWT owing to lower scattering. 
In therapy-related clinical practice, it is widely accepted that a thermal (high) dose of RF is 
not advisable for acute clinical conditions.18 In other words, a substantial rise in tissue 
temperature is not desirable when there is an acute inflammatory response. For example, in 
an acute injury where swelling and/or haematoma are present, application of heat may 
exacerbate the symptoms by causing vasodilatation and thus increasing the interstitial fluid 
volume.8 Literature suggests that a mild rise in tissue temperature of about 1 oC will help to 
relieve mild inflammation, but an increase of 2–4 oC is required to decrease pain and 
increase tissue extensibility.457,462 
The greater physiological responses obtained from the CRMRF high dose group would 
make it potentially suitable for treating conditions giving rise to chronic pain and 
inflammation and in conditions where enhancement in tissue temperature and blood flow are 
a treatment aim, but unsuitable for application in an acute condition, where neither is 
recommended. The CRMRF low dose increased the local SKT marginally (yet significantly), 
but not the local SBF when compared to the placebo or control groups. Although there has 
been a significant rise in SBF within the low dose group, this is unlikely to have been 
clinically relevant as a similar change was also noted in the control group. This makes the 
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low dose application potentially suitable for treatment in acute conditions. Similar effects 
were also noted with the PSWT dose used in this study, where a mild increase in SKT was 
obtained without impacting on the SBF significantly. The modest response in SKT obtained 
from the PSWT high group and/or its lack of sustenance over the follow-up are consistent 
with the results of several past studies.80,90,95,105 
Unlike for temperature rise, there are no recommendations in the literature as to what level 
of rise in blood flow (superficial or deep) will produce clinical benefits. The change in local 
blood flow secondary to RF application is a thermophysiological response, which is 
influenced commensurately by the level of rise in the local temperature and its depth of 
penetration.8 The differences in deep blood flow responses secondary to exposure by 
various EPAs are mainly down to the differences in their ability to penetrate tissues. For 
example, the low penetrative infrared radiation has been shown to increase cutaneous 
circulation183 whereas RF-based EPAs are more penetrative and can influence blood flow at 
various depths.80,195 It appears from the results of this study though, that a mild increase in 
SKT of around 1 oC had no significant or sustained impact on the corresponding blood flow. 
However, since the measurements were taken only after the end of treatment, it is not 
known if the blood flow response was greater during the intervention. 
Abnormalities in blood flow have an overarching relationship to pathological states and their 
treatment; hence an accurate measurement of blood flow without interfering with the process 
itself is imperative. A relative change in the local blood flow can characterise a variety of 
physiological states, either normal or pathological. For example, an increase in local blood 
flow may be noticed when there is tissue inflammation.447 When localised RF treatment is 
given, monitoring of the blood flow can help in determining how much heating will occur in 
the skin as well as in the deeper tissues. Hence, it enables a protective mechanism ensuring 
that the heating is modulated and there is no undue hyperthermia in the tissues.365 
The blood flow response to tissue heating at depth is more complex than it is to skin heating. 
Potentially there are multiple mechanisms for the increased human muscle blood flow in 
response to prolonged external local heating. Heat can cause direct vasodilatation and a 
reduction in the resistance of arterial walls.8,341 The response at depth involves a balance 
between the direct vasodilatory effect of heat as well as the increased blood flow resulting 
from the increased muscle metabolic activity on one hand, and the vasoconstrictive effect 
and reduced blood flow induced by thermoregulation on the other hand.8 
Both active vasoconstriction and vasodilatation can alter heat transfer and blood flow. When 
there is large alteration in blood flow (such as while exercising) there is also a large effect on 
heat transfer across the tissues. Anthropometric factors such as the level of subcutaneous 
fat also play a crucial role.10,11 In chapter 5 the body fat percentage was shown to have a 
significant negative correlation to the amount of energy that could be absorbed. Additionally, 
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various bodily factors (internal factors) such as the efficiency of circulating blood in 
dissipating the generated heat, the anatomical characteristics of the area treated (size and 
shape of tissue), the thermal conductivity and thermal capacity of tissues absorbing the 
energy (impedance), the rate of energy absorption and the rate of metabolism in the treated 
tissues also determine the thermophysiological response.8,462 
The size and geometry of treatment electrodes,18 the thermal properties and conductivity of 
the coupling medium (in the case of CRMRF) and the strength of the electromagnetic field 
are the external factors that could influence the RF-tissue interaction. Large circular 
electrodes measuring 65 mm in diameter that were deemed appropriate for the size of the 
area treated were used as the active electrodes in this study. While the external factors 
discussed above remained constant for all five groups, the randomised crossover (repeated 
measures) design that was employed in this study helped to mitigate the internal factors. 
This study shows that a high (thermal) dose of CRMRF can significantly increase the volume 
and intensity of blood flow in deeper tissues. Although less significant, even a low (minimally 
thermal) dose of CRMRF can induce increased blood volume at depth, but not the intensity 
of flow. Either dose of CRMRF failed to significantly increase the velocity of deep blood flow, 
although there was a 13% increase in velocity in the high dose group. In contrast to CRMRF, 
the high dose PSWT exposure failed to induce any such effects on the volume, intensity or 
velocity of blood flow in the deeper tissues. Since similar studies that employed RF at 
frequencies lower than shortwave have not been undertaken in the past, any comparison 
from the existing literature was unable to be drawn.  
Mixed reports about the deep circulatory effect of PSWT are available from the literature.19,90 
Morrissey (1966)90 reported that while irradiation of the calf muscles or abdomen using 
PSWT for 15 min at 40 W did not have any significant influence on the volume of blood flow 
in the leg, an 80 W exposure to the calf caused a significant increase in the blood flow. 
Similar increase in calf and foot blood flow after a 20-min abdominal exposure to PSWT at 
65 W was reported by Silverman and Pendleton (1968), while a 15 W abdominal exposure 
did not have any significant impact. Other studies on deep circulatory effects of shortwave 
were conducted on CSWT.77,79,88 Comparison between the effects of similar average doses 
of PSWT and CSWT on deep blood flow is also available.19 The above results from PSWT 
studies indicate that when compared to CRMRF, a substantially higher dose of PSWT is 
required to increase blood flow volume at depth. 
Previous research with shortwave has proposed that a tissue temperature rise more than 40 
oC may be necessary to increase muscle blood flow.96 Since deep tissue temperature was 
not monitored in this study, any such correlations cannot be drawn for the presented results. 
However, the tissue temperature in the current study is unlikely to have risen to levels above 
40 oC. Even then a rise in both the volume and intensity of deep blood flow were noted with 
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the high dose CRMRF, while even the low dose CRMRF increased the volume of flow. 
Furthermore, the Doppler measurements were only able to be performed about six minutes 
after the end of the intervention (discussed below), which meant that any deep blood flow 
responses during and immediately after the treatment were not accounted for. Hence, it is 
proposed that unlike SWT, the CRMRF can increase and sustain the blood flow at depth at 
substantially lower tissue temperatures. It may also be proposed that the mechanism 
underpinning the blood flow response at depth secondary to the application of a low 
frequency RF such as the CRMRF is not purely thermophysiological, but rather the non-
thermal mechanisms may also be involved. 
Early work has shown that heat changes the behaviour of collagenous tissue making it more 
viscoelastic,75,188 and reduces the spasm in muscles.457 However, for a notable effect, the 
tissue temperature will need to be raised at least to the level of 40 oC.8 Although not 
monitored, the deep tissue temperature achieved in this study is unlikely to have reached 
such high levels (as discussed above for blood flow), and hence failed to demonstrate any 
changes in tissue compliance when measured using Sonoelastography. However, like the 
Doppler measurements, Sonoelastography measurements were only able to be done 
several minutes (eight minutes on average) after the end of treatment (discussed below), 
thus any effect during or immediately after the intervention should clearly have been missed. 
Also, the participants were asymptomatic adults who had normal muscle tone, so it is 
unclear if any further reduction in muscle tone could have been achieved. 
As expected the CRMRF high intervention more than doubled the SBF and sustained it 
significantly over the follow-up phase. Like the SKT results discussed above, the PSWT 
intervention failed to have any significant impact on the SBF. While this agrees with the 
suggestions by some earlier studies,90 they are contrary to some others that had proposed a 
significant rise in skin and/or muscle blood flow after treatment with PSWT.19,176 More 
recently, Al-Mandeel and Watson reported a significant rise in SBF during treatment with 
PSWT (MP of 24 W). However, the response dropped significantly once the treatment 
ended.80 Other shortwave studies that suggested a much higher and/or sustained increase 
in temperature;81,96 blood flow;79,86 and both temperature and blood flow77,85 were performed 
using CSWT. Comparison of the effects of similar average doses of PSWT and CSWT on 
blood flow are also available.19 
There are not many examples available from the literature to show the influence of low 
frequency RF on nerve conduction in humans, apart from a handful of studies done using 
shortwave, which showed mixed results.78,191,192 No such data on nerve conduction exists for 
RF below shortwaves. The present study failed to obtain any impact on NCV with either 
CRMRF or PSWT, although it was anticipated that NCV might change in response to 
changes in tissue temperature.80,192 
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The Biopac MP150 physiological measurement system and the associated modules used in 
this study are widely employed in research and has been used previously by the same 
research group in similar studies involving shortwave.80,192 The PPG technique to measure 
SBF has been in use since decades.404,411 Surface thermistors are a valid and reliable mode 
of recording local SKT,350,352 and the Biopac TSD202A thermistor transducer enables real-
time SKT monitoring. The system can collect up to 2,000 samples per second. 
Once the RF treatment ended, the post-treatment measurements of SKT and SBF were 
started only after three minutes on average. About two minutes (established in the pilot) 
were required to clear the skin and re-attach the measurement probes before the recording 
could be re-started. Once ready, the NCV was recorded first, which lasted 30 seconds for 
each limb. Then SKT and SBF monitoring were started and continued till the 20-minute 
follow-up. Although the measurements during the PSWT session could have been started 
sooner as no skin preparation was required, similar time frame as in the CRMRF was 
followed to ensure protocol consistency. 
It is possible that the study failed to capture the peak responses, which might have occurred 
during the immediate post-treatment phase (within the first two minutes). Similarly, 
responses during the intervention phase was also not mapped, unlike in some of the 
previous PSWT studies where SBF80 and temperature83 (invasive study) were monitored 
during the intervention. The follow-up measurements were not continued beyond 20 minutes 
owing to time constraints. 
It is unsurprising that the core temperature did not change for any of the conditions, since a 
local application of RF energy is not expected to influence the core temperature.22 Similar 
responses were also expected for pulse rate and blood pressure, both of which did not 
change significantly.77,80 Also, no significant changes were noted in any of the physiological 
parameters of the control leg for any of the treatment groups. This suggests that there was 
no lasting ‘crosstalk’ effect (undesirable effect generated in the neighbouring untreated 
area), possibly due to the low scattering of RF waves from the CRMRF device. It was not 
possible to determine if there was any crosstalk effect during the intervention phase since no 
recordings were performed at the time. 
By contrast, SKT of the untreated leg was shown to have risen considerably after PSWT 
intervention in the previous study by Al-Mandeel and Watson.80 However, it should be noted 
that there was a three-minute delay in the post-treatment SKT measurements in this study 
and it is unclear how much delay (if any) was encountered in their study. In addition, it 
should be noted that unlike CRMRF, which is delivered using a contact method, PSWT is 
delivered using a non-contact method potentially causing more scattering of the RF energy 
through air. 
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As explained in the methods section, CRMRF was delivered for 15 minutes using the CAP 
mode first (5 minutes) followed by the RES mode (10 minutes). This sequence and the 
durations of application were based on recommendations by the manufacturer (Indiba S. A., 
Spain) rather than on optimum evidence. However, the combined delivery time of 15 
minutes was appropriate for a clinical session used in contemporary therapy practice. 
Among the two high dose groups in this study the participants described a ‘uniform and deep 
feel’ of heating in the CRMRF high intervention, while the feeling of heating was ‘mild’ at 
best for the PSWT high group. However, the reported feeling of deep heating should be 
interpreted with caution because localised thermal perception is based primarily on 
cutaneous receptors341 and there remains some controversy as to whether thermal 
perception at depth is thermal perception per se or nociception.  In the PSWT high group 
when asked to rate their perception of heat on a scale of one to four, where one was ‘no 
heat’ and four ‘high heat’, the majority (11 participants out of 15) rated the effect as mild 
heating. Four participants reported that there was no perceptible heat. This is commensurate 
with the mild to moderate rise in the mean post-treatment SKT noted in the PSWT high 
group. These findings agree with some of the previous PSWT studies,80,105 but at the same 
time it is interesting to note that those studies had only employed a lower MP dose of PSWT. 
At the end of the fourth session the participants were unblinded of their treatment sequence. 
Prior to this, the participants were asked if they can identify the treatment sessions 
themselves. About two-thirds identified RF high and control sessions correctly whereas only 
about a third of the participants could distinguish between RF low and RF placebo sessions. 
While it is unsurprising that the majority could identify the high dose and control conditions 
given the nature of intervention, RF low and placebo protocols were closely matched making 
the blinding reasonably effective. 
 Conclusions 
The results of this study suggest that a high (thermal) dose as well as low (sub/minimally 
thermal) dose of CRMRF can significantly enhance and sustain local SKT, while only the 
high dose has a meaningful impact on SBF. An equivalent high dose of PSWT increased the 
SKT marginally (yet significantly) but did not sustain it over the follow-up phase. PSWT also 
failed to show any meaningful effect on the SBF. The results also suggest that the high and 
low dose treatments of CRMRF can significantly enhance blood flow volume at depth, while 
only the high dose can significantly enhance both volume and intensity of flow. An equivalent 
high dose of PSWT failed to show any impact on either of the above parameters. 
None of the treatment groups had a statistically significant impact on the velocity of deep 
blood flow, although the high dose RF increased the velocity marginally. The hardness and 
softness of tissues, NCV, PR and BP were also not influenced by a local therapeutic 
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application of either type of RF therapy. The untreated contralateral leg did not show any 
meaningful change in its physiological responses. 
The above findings are based on a baseline, post treatment (2–3 minutes post treatment for 
skin; 6–8 minutes post treatment for deep) and a 20-minute post treatment follow-up 
assessment of skin response using surface probes/electrodes and ultrasound Doppler and 
Elastography. Skin or deep responses during the intervention phase were not measured in 
this study. 
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7 Chapter 7 – Section III conclusions: key findings, 
limitations of the studies and implications for clinical 
practice and research 
In summary, the laboratory study phase of this project investigated an array of physiological 
responses to cutaneous application of 448 kHz CRMRF in asymptomatic adults. Such 
research had previously been conducted on RF at or above shortwave frequencies; 
however, this is the first of its kind on RF below the shortwave frequency range. In addition 
to the two main studies (described in chapters 5 & 6), a considerable number of pilot 
experiments were also undertaken leading up to the main research work. Together, the 
results provide significant insight into the basic principles and some of the physiological 
effects of CRMRF therapy, which has remained unexplored thus far. Some of the key 
findings, the potential limitations incurred and the implications and recommendations for 
future research are summarised in the sections below. 
 Key findings 
The initial study (Chapter 5) on the thermal response patterns of the two components of 
CRMRF therapy showed that CAP and RES modes instigate significantly different skin 
thermal response patterns. The deep thermal effects were not tested but extrapolating from 
the skin thermal decay patterns observed from either mode, the CAP mode is believed to 
have effects predominantly superficially and the RES mode deeper into the tissues. The 
study confirmed that skin temperature can both be raised and sustained significantly by both 
CAP and the RES modes of CRMRF therapy, although the RES mode thermal retention was 
significantly more pronounced and longer than that of the CAP mode. Additional data 
obtained during the above study also showed that at high intensities tissue heating in either 
mode of treatment was not caused by contact heating from a hot electrode, but rather due to 
RF-tissue interaction. In fact, the electrode temperatures were consistently lower than the 
skin temperatures obtained (especially so for the RES mode). 
In the second study (Chapter 6), which was a larger experiment, the effects of multiple 
doses of CRMRF and a high dose PSWT were compared in a randomised crossover trial. 
The high dose CRMRF was shown to significantly increase and sustain SKT and SBF and 
significantly increase blood flow volume and intensity at depth (no data was collected on the 
retention of increased deep blood flow beyond the post treatment measurement). The low 
dose CRMRF showed similar response on the SKT results, but only increased the blood flow 
volume at depth (no rise in SBF). The high dose PSWT did increase the SKT significantly 
but failed to sustain that effect. PSWT also did not have any effect on the other physiological 
parameters. Tissue extensibility, blood flow velocity, NCV and the other systemic 
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parameters such as core temperature, BP and PR did not respond significantly to any of the 
RF treatments. 
 Methodological considerations and potential limitations of the 
studies 
The reported effects from the current project and other studies in the past were based on the 
convention that the participants maintained their treatment position throughout the 
experiment (mostly lying or sitting). ‘Supine lying’ was the position adopted for all the studies 
in this project. Clinically, supine is the most likely position that would be adopted when 
treating the knee. Also, it will minimise the effects of gravity on the body systems and relax 
the individual’s musculoskeletal system. Moreover, it would have been challenging to 
maintain another position for similar sustained periods since the experiments lasted for more 
than an hour. A change in position will trigger a change in the physiological processes. 
Nonetheless, it is challenging to predict the effect of a change in position upon the observed 
physiological effects in an experiment. It will be interesting to see how the results of this 
experiment might change if the positions of the participants are altered. A recently published 
study demonstrated the changes in skin temperature and potentially the blood flow in the 
lower limbs in response to different sitting positions.487 They concluded that the knee and hip 
positions adopted while sitting have a significant impact on the blood flow and temperature 
in the lower limbs. 
The results obtained in this experiment are likely to have been influenced by external factors 
such as the size (large; 65 mm in diameter) and geometry (circular) of the treatment 
electrodes used, the thermal and conductive properties of the cream, and other individual-
specific internal factors such as anatomy of the area treated, tissue resistance and the 
anthropometric factors (e.g. – body fat percentage, BMI). The influence of such individual 
internal factors on the comparative group results would have been mitigated by the 
randomised crossover study design and blinded allocation of the treatment order. However, 
in the main study (Chapter 6) the PSWT session was neither randomised nor blinded, and 
was always the fifth session for all participants, which was one of the potential limitations of 
this study. 
The magnitude of the generated EMF and the field/current density are influenced by the size 
of electrode.18 The electrode size used here was deemed appropriate for the size of the area 
treated. Potentially, this has helped the homogeneity of field distribution. The large 
electrodes would have ensured that the field density would not have been disproportionately 
high under the treatment electrode, but rather, distributed more evenly through the tissues 
(based on energy dissipation models). The current density and field distribution were not 
aimed to be analysed in the present study as it is a separate research area. There is no data 
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currently available on CRMRF based on different electrode sizes or varying CAP/RES mode 
treatment combinations. The combination of modes used in this project (5 min CAP + 10 min 
RES) was largely based on manufacturer recommendations, which in turn was based on 
their in-house research together with user/therapist feedback. 
This study did not investigate the temperature changes at depth; however, there is 
reasonable evidence from the given results that considerable generation and hence 
absorption of heat may have occurred in the deeper tissues due to CRMRF exposure. Non-
invasive methods that are appropriate for temperature measurement at depth were not 
available in this project. Invasive temperature measurements, like those reported in some of 
the previous studies, have several potential issues. Where the measurement device 
(thermocouples or thermistors) was left attached while the RF was delivered (e.g. as in the 
study by Takahashi et al.194), there is a significant possibility that the electromagnetic field 
might have directly heated the device. This could lead to false temperature readings. In 
addition, the invasive procedure itself can cause a tissue inflammatory response potentially 
affecting the local physiological activity (e.g. change in blood flow). Techniques such as 
magnetic resonance (MR thermometry) and ultrasound (US thermometry) are available for 
non-invasive temperature measurement at depth. These are gaining ground and are 
employed in areas like cancer thermotherapy.490,491 However, such techniques were beyond 
the scope of this study. 
One of the common limitations of laboratory studies is that often the participants may be 
young adults who are more physically fit than the average population, limiting the 
generalizability of the results. In all the studies conducted in this project, the participants 
were reasonably physically fit and active; however, their age ranges were intentionally kept 
wide, and their activity levels were considerably varied, making the sample more 
representative of the general population. Besides, the studies were carried out at 
‘thermoneutral’ room temperature conditions for humans. Although the above factors make 
the presented results more generalizable, it is problematic to extrapolate these results to a 
patient population because their physiological responses could be different to that of an 
asymptomatic population. 
There was no blinding on the part of the therapist who delivered the interventions and 
undertook the measurements making this study only single-blind at best. The post treatment 
assessments were only able to be started at least two minutes after the end of treatment due 
to the need for skin preparation. No measurements could be performed during the 
intervention phase. Also, in the second study follow-up assessments were not carried out 
beyond 20 minutes. Together, these factors somewhat limited the extent to which the 
physiological responses were understood. However, for the active CRMRF groups there has 
not been any sharp decline in the responses over the follow-up phase. Hence, extrapolating 
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from the findings of both studies (Chapters 5 & 6), it is reasonable to expect that the effects 
would have been sustained significantly for more than 20 minutes. From a clinical 
perspective, this knowledge is valuable as it provides a reasonable (so-called) ‘therapy 
window’ to the treating clinician (assuming similar effects could be reproduced in clinical 
populations as well). 
 Implications for practice and future research 
The physiological responses obtained in healthy participants with CRMRF therapy may be 
indicative of its potential clinical effectiveness. The more pronounced physiological 
responses obtained from the CRMRF high dose group would make it potentially suitable for 
treating conditions giving rise to chronic pain and inflammation where enhancement in tissue 
temperature and blood flow is a treatment aim, but unsuitable for application in an acute 
condition where a significant rise in either parameter is undesirable. The modest effects of 
CRMRF low dose on SKT and blood flow would make it potentially suitable for treating acute 
conditions. 
The above suggestions assume that the physiological changes demonstrated in 
asymptomatic participants can be reproduced similarly in the patient populations as well 
(potentially leading to clinical benefits), but per se the given results cannot be extrapolated to 
a patient population who could respond differently to the same intervention. As discussed 
earlier, there is also the possibility that all physiological parameters might have undergone 
prominent changes during the treatment phase, which will have implications on its choice for 
clinical applications. 
The study did not aim to provide recommendations on CRMRF dosing based on perceived 
heat or physiological responses; however, they may provide guidance to clinicians for 
clinical decision making when they may decide to use such therapy. It also provides useful 
baseline data for further research in the low frequency ranges of RF therapy that has 
remained largely unexplored. Further studies that explore additional physiological responses 
by addressing the limitations of this study (as detailed previously) and clinical studies that 
involve patient groups are therefore necessary. Forthcoming physiological studies should be 
fully randomised and double-blinded. Longer follow-up periods are also desirable. To find 
out the full extent of physiological responses future studies should explore the means of 
monitoring them while the CRMRF intervention is being delivered, minimise the time delay 
between the end of intervention and the beginning of post treatment measurements, and 
incorporate temperature measurement at depth into the protocol. 
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8 Chapter 8 – The effect of CRMRF on pain and function in 
patients with OA of the knee joint: a randomised 
controlled trial 
 Introduction to osteoarthritis 
8.1.1 Epidemiology 
Osteoarthritis (OA) is the most common among the various forms of arthritis and a leading 
condition affecting function and QoL among middle-aged and older adults.334,492-494 Overall, it 
is one of the commonest diagnoses made in the older people consulting their general 
practitioner.494 Although OA can affect any synovial joint in the body, the condition is more 
common among the larger joints, the hip and knee being the most prominent.334,493 Out of 
the two, OA of the knee495-498 is more prevalent than OA of the hip.499-502 Data suggest that in 
the community as many as 40% of adults who are aged over 65 years (which is a significant 
proportion of that population) may be affected by either of these conditions. Hence, in most 
populations of people over 65 years of age OA is the most common cause for long-term 
disability.334,503,504 People of all ethnic groups in all geographic locations are affected by OA 
and women tend to be more prone when compared to men.505-507 
8.1.2 Global costs 
There is a strong positive correlation between advancing age and the incidence of OA, 
which also means more and more people aged over 40 years are now affected by this 
condition given the rise in the numbers of older people due to increasing life expectancy.508 
This in turn has significant economic implications commensurate with the growing 
prevalence of OA and the profound effects it has on the QoL of people. Although OA is 
currently a major worldwide cause for economic loss due to its direct as well as indirect 
costs, there is a lack of global estimates regarding its overall economic burden.334,509 
Chen et al. (2012)509 reported in their review on the global economic impact of OA that there 
is only limited evidence available from the eastern countries of the world regarding the 
economic cost of OA. Besides, they further reported that although studies have been 
conducted about the costs in the west, clarity was lacking making the results inconclusive. It 
is alleged that cost-related studies frequently fail to separate the cost of OA from under the 
rubric of ‘musculoskeletal conditions’, leading to many gaps in the OA economic data.333 
Nonetheless, in the USA alone, it has been estimated that over 10 million QoL years are lost 
annually due to knee OA.510 
189 
8.1.3 Classification of OA 
The most common type of OA is primary or idiopathic OA. In this type, there is no known 
cause for joint degeneration.511,512 Another type of OA called the secondary OA, which is 
less common, develops from joint degeneration due to causes such as injuries to the joint or 
other pathologies that have an impact on the joint. These pathologies can be developmental, 
hereditary, inflammatory, metabolic or neurological disorders, or even a combination of such 
factors.511,512 While primary OA seldom occurs in people younger than 40 years, secondary 
OA may occur in younger or older adults.513-515 Patients with idiopathic OA may also present 
themselves with a predisposing cause such as a genetic predisposition or biomechanical 
stress to the joint accelerating the degenerative process.334 
8.1.4 Pathophysiology and symptoms of OA knee 
OA-related knee pain is the commonest cause for physical disability in older adults.494 The 
disease and its symptoms start from the degeneration of the synovial joint, either tibio-
femoral or patello-femoral, or both and affect the periarticular tissues. It is an active process 
involving progressive degeneration of the articular cartilage, which is accompanied by its 
attempted repair, sclerosis and thickening of the subchondral bone and possibly the 
formation of osteophytes and subchondral bone cysts.512,516 The clinical syndrome is 
presented with chronic knee pain and inflammation, tenderness, restriction of movement, 
stiffness of the joint, effusion and weakness. The pain can be during activity, during rest or at 
night, and is often described as a poorly localised deep aching discomfort, the level of which 
may increase with an increase in physical activity and a drop in atmospheric temperature. As 
the condition progresses, the functional ability and hence the QoL diminish and the 
individual may develop physical deformities leading to psychological and social 
isolation.334,492,494 
Reflecting on accepted clinical practice, the guidelines published by the American College of 
Rheumatology classified OA as a clinical syndrome in older adults who are presented with 
knee pain, morning stiffness and crepitus,517-519 although such classification may not be 
devoid of shortcomings.520 Radiographs of the knee joint have traditionally been the corner 
stone for diagnosis of OA knee; however, the history and clinical assessment of the 
symptoms also play a crucial role. This is because; up to a third of older adults may show 
radiographic evidence of joint degeneration, half of whom are not presented with the pain 
and associated symptoms of OA.495,498,521,522 Conversely, half of such people who are 
presented with the pain and other symptoms of OA fail to show definite arthritic evidence in 
their radiograph.497 Hence clinical decision making may depend on radiograph, history and 
symptoms. 
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8.1.5 Current best treatment for OA knee 
Since there is no cure for OA available, current management plans are aimed at reducing 
the symptoms, improving function and enhancing QoL.331,523-527 Where possible, slowing 
down the progression of the joint degeneration is also important in order to avoid or delay 
expensive invasive procedures such as total knee replacement (TKR).330 Conservative 
treatment for OA (all non-surgical treatment methods) has several pathways: medical 
management, intra-articular injections, physical medicine and rehabilitation and promoting 
self-management by educating the patient about the condition.524 With the rapidly growing 
evidence-base for OA management, updated clinical practice guidelines have been 
published by many societies recently.525-527 The predominant theme across all these 
guidelines is the emphasis placed on the non-drug non-surgical management options. There 
is an increasing urge to focus on patient-driven self-management rather than clinician-
centred passive interventions,330 although rehabilitation is recommended widely and is even 
considered the core treatment of OA knee in key guidelines.525-528 
8.1.6 Physiotherapy interventions for OA knee 
Physiotherapy for OA knee combines the broad base of non-drug, non-surgical treatment 
options. It mainly includes patient education on self-help, activity modification, biomechanical 
correction where needed (e.g. using orthotics), exercise therapy in various forms (land-
based or aquatic), manual therapy, electrophysical agents and acupuncture. Exercise is 
recommended as a key treatment for OA knee by all clinical guidelines.331,525-527,529-531 This 
recommendation is justified by the fact that a recent updated Cochrane review529 on 44 
RCTs concluded that there is high quality evidence to suggest that a land-based exercise 
programme is significantly beneficial for OA knee when compared to no exercise, with the 
beneficial effects such as reduction in pain sustained up to six months after the end of formal 
treatment. 
Exercise may involve both regular physical activity by the patients themselves (activities 
involving skeletal muscle activity that requires energy expenditure)525,527,532,533 and exercise 
therapy using prescribed therapeutic exercises usually delivered by a physical therapist 
(planned and structured physical activity).534,535 In OA knee, exercise intervention of either 
type is aimed at improving the joint ROM, muscle strength, soft tissue compliance, 
proprioception and aerobic performance. Nonetheless, although exercise-based 
rehabilitation is a key part of OA knee management there is no consensus on the optimal 
content of an exercise-programme.528,535 Rather, in current practice the exercise intervention 
is tailored to fulfil the specific needs of the individual besides accommodating their limitations 
and comorbidities. Without tailoring the exercises to the clinical presentation, the clinical 
effects may attenuate and not reach the optimum benefit level.330,526 
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Although exercise therapy is at the forefront of conservative OA knee management, there is 
no evidence to suggest that exercise alone is adequate to improve the condition in the long 
term. Adherence to and benefits from exercise may diminish over time especially given the 
relatively modest effect sizes for pain (0.39 – 0.49) and function (0.31 – 0.52) proposed by 
several studies.529,536-539 Based on this, there is a need to improve the overall treatment 
effects by facilitating the sustenance of treatment effects. The physical therapists may 
combine exercise intervention with manual therapy (MT) techniques aimed at alleviating the 
symptoms and restoring function.537,540 Although some authors have reported the benefits of 
MT for OA knee,541-544 the available evidence was not deemed strong enough to warrant 
recommendation in clinical guidelines. 
Another area being advocated in the management of OA knee is the use of physical agents 
(including electrophysical agents). The NICE guidelines for the care and management of OA 
in adults states that the use of thermotherapy (therapeutic heat) should be considered along 
with the other treatments.545 Half of all non-pharmacological interventions suggested by 
‘European League against Rheumatism (EULAR)’ as potential treatments for the 
management of OA knee are electrophysical agents.546 These agents are: acupuncture 
(including electroacupuncture), low level laser therapy (LLLT), transcutaneous electrical 
nerve stimulation (TENS, including interferential therapy (IFT)), ultrasound (US) and pulsed 
electromagnetic fields (PEMF, including shortwave therapy (SWT)).547 In a review Bjordal 
and colleagues547 questioned the lack of recommendation given to physical agents by 
EULAR for OA knee management despite them demonstrating the same level of evidence 
as certain analgesics such as paracetamol, opioids and coxibs. The review went on to 
conclude that LLLT, TENS and PEMF exhibited statistically significant effects over placebo 
within 1 – 4 weeks, while the evidence for acupuncture was mixed. The outcome on TENS, 
which had the most number of studies in their review, was also supported by other 
reviews.548 
In agreement with the above report, the effect of SWT on OA knee was demonstrated by the 
comprehensive review of literature undertaken in this project, which has also been 
supported by other researchers in the past.137 Twenty-six SWT studies on OA55,256,258-264,266-
282 and four studies on OA using RF devices operating at frequencies below the shortwave 
frequency range194,249-251 were identified. Overall, it was concluded that there is moderate 
evidence to support the use of PSWT in OA knee. Based on this evidence and the available 
data for OA knee, it was recommended that a mean PSWT power dose at or above 14.5 W, 
8–12 sessions over 4–6 weeks, and 15–20 minutes per session may be necessary for the 
treatment to be beneficial. With only four studies identified, currently there is no substantive 
evidence available to support the use of RF below the shortwave frequency band for the 
management of OA knee. 
192 
 Rationale for the study 
A lack of research emphasis has been particularly evident on the non-shortwave RF band, 
where only a small number of studies were identified in the literature review. This warrant 
emphasis in this area especially since EPAs delivering non-shortwave RF are already in 
clinical use and that the studies published so far have reported encouraging results. Purely 
based on the reported results of the studies identified, such low frequency RF may be 
beneficial in delivering useful therapeutic effects. However, the paucity of controlled trials 
and the poor methodological quality of available studies suggest that more studies need to 
be conducted in this area before such therapy can be considered. 
It should be noted that the studies conducted on asymptomatic adults strongly indicated a 
significantly more pronounced physiological response from CRMRF as against PSWT. It is 
anticipated that such physiological response may lead to more pronounced clinical benefits. 
Since OA knee is a pressing health issue that warrants conservative management and since 
RF interventions such as PSWT has proven to be effective in its management, it is prudent 
to investigate the potential clinical benefits of 448 kHz CRMRF in a similar population of 
patients affected by chronic OA of the knee joint(s).  
 Key aims of the study 
The main aims of this study were to investigate: 
1) Whether 448 kHz CRMRF treatment can reduce symptoms and significantly improve 
function in patients affected by chronic OA of the knee joint(s). 
2) Whether any such potential clinical benefit is significantly better than a placebo treatment 
or the current standard treatment for OA that is based on exercise and advice. 
 The study design 
A placebo-controlled RCT was employed to address the above aims of the study. The three-
group study lasted four months (one-month intervention period and three months’ follow-up) 
and involved an experimental group, control group and a placebo group. Participants in each 
group were assessed using clinical outcome measures at four time points stated below, to 
examine the effects of the intervention: 
1) Before the start of the intervention (pre-treatment) 
2) After the intervention ended (post treatment) 
3) One month after the intervention ended (one-month follow-up) 
4) Three months after the intervention ended (three-month follow-up) 
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The RCT design is considered the best research design for primary clinical studies 
investigating the efficacy of interventions.549,550 An RCT with experimental, control and 
placebo groups enable the researcher to statistically weigh the effect of the experimental 
intervention in question against a ‘control' condition where any changes would have 
happened not by the influence of the experimental intervention; and against a ‘placebo 
intervention' to assess the potential for the so-called ‘placebo effect’.549,550 It is generally 
accepted that certain types of treatments can induce placebo effect on the patients (for 
example, placebo medications) for up to 40%.551-553 
The basic study design is illustrated in Figure 8.1. The groups, outcome measures and 
interventions are explained in detail in the following sections. 
Figure 8.1: The study design for the clinical trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Materials and methods 
8.5.1 The CRMRF device 
The CRMRF treatment device and its operating principles have been described in detail in 
chapter 4. As explained, it had active and placebo settings. 
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8.5.2 Outcome measures 
Four clinical outcome measures, which were valid and reliable and widely used in clinical 
practice and OA research, were used to assess the response obtained towards CRMRF 
treatment over the course of the study. They are explained below. 
8.5.2.1 Self-reported pain 
Average pain experienced by the participants over the preceding 24 hours was rated using a 
self-administered visual analogue scale (VAS) (Appendix 8.1). At every assessment, the 
level of pain was self-reported by the participants as ‘pain over the last 24 hours’ on a 10 cm 
VAS. On this scale, the pain is rated from 0 – 10, where a score of ‘0’ meant no pain at all 
and ‘10’ meant the worst imaginable pain. While administering, the participants were asked 
to mark on the scale what they believed their pain level was. The distance to this mark on 
the scale was measured from zero using a ruler. The obtained value, which was between ‘0’ 
and ‘10’ (inclusive), was taken as the pain score for that assessment. It was assumed that 
the participants were blinded to their previous score. 
Subjective assessment of pain using VAS is a quick and easy to administer measuring tool 
that can reflect real change in patients’ pain symptoms, and which is commonly used in 
clinical research.554,555 VAS is proven to be valid, reliable and responsive for a variety of 
clinical conditions including musculoskeletal disorders.554-564 A reduction in pain by a score of 
around 1.9 – 2.0 out of 10 (19 – 20%) is generally accepted as a minimum clinically 
important difference (MCID) for VAS.565-567 
8.5.2.2 WOMAC osteoarthritis index 
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) (Appendix 8.2) 
was used for the assessment of functional ability of the participants throughout the study.568-
570 The WOMAC is a questionnaire that assesses the levels of pain, stiffness and physical 
function in patients with OA of the hip/knee. The index consists of 24 items based on 
symptoms and physical function, divided into three subscales as given below: 
1) Five items on pain 
2) Two items on stiffness 
3) Seventeen items on the level of physical function 
The items can be scored by marking on a 10 cm VAS or on a five-point Likert scale (both 
forms are equally valid) with the answers ranging from ‘none’ to ‘extreme’ where the patients 
indicate their level of problem by marking in the appropriate box.569 The five-point Likert type 
questionnaire was used in this study as the researcher had previous experience with this 
form of WOMAC. Once the questionnaire is completed, the assessor scores each item from 
0 – 4 depending on the responses given (severity of the problem), as follows: 
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1) Score 0 for ‘none’. 
2) Score 1 for ‘mild’. 
3) Score 2 for ‘moderate’. 
4) Score 3 for ‘severe’. 
5) Score 4 for ‘extreme’. 
Hence, the three subscales of pain, stiffness and physical function can score a maximum of 
20, 8 and 68 respectively.571 The higher the score, the higher is the severity of the problem 
and vice versa. The WOMAC global score can be calculated by totalling the scores of the 
three individual subscales. Hence, the maximum WOMAC global score that can be achieved 
by a participant at any assessment is 96. A 16% reduction from the baseline WOMAC global 
score can be considered as its MCID.572 
The questionnaire is among the most widely used outcome measures in OA research with 
proven psychometric properties,570,571,573-580 and is officially available in over 65 language 
formats in addition to English.581 WOMAC has also been validated for telephonic582 and 
computerized/electronic administration.583,584 In this study all participants administered the 
questionnaire ‘in person’ during their visits to the clinic. 
8.5.2.3 Walking ability 
The walking ability of the participants was assessed using the Timed Up and Go (TUG) 
test.585 The test measures the time (in seconds) taken by the person to rise from sitting from 
a standard arm chair, walk three metres in a straight line, turn around, walk back to the chair 
and sit down again. The participants were given standard instructions on how to perform the 
task at their ‘normal speed’ when the assessor asks them to ‘start’. They could use their 
walking aid if they needed it. The researcher assessed the walking time in seconds using a 
timer while the participants performed the task. They wore their regular footwear during the 
assessment. 
The performance on TUG is linked to multiple factors such as balance, strength and agility. It 
is also linked to age, cognitive ability and the type of footwear used.586-589 TUG is widely 
used in clinical and research settings to get valuable information on the risk of falls among 
the elderly and frail, and to assess the functional decline among different clinical populations 
such as fractures, OA knee/hip, COPD, cancer and various neurological conditions affecting 
gait and balance such as stroke.590-594 Although originally developed for the assessment of 
elderly population, it is also used widely in the arthritic population and has proven 
psychometric properties.585,595-601 The MCID of TUG test has been reported to be 3.4 
seconds.602 
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8.5.2.4 Knee joint range of movement 
The knee joint active ROM was measured by the assessor using a universal goniometer with 
the participant in supine, supported by pillows. The measurement was always performed at 
the lateral aspect of the treated knee joint, since the participant was always to be positioned 
with the treated side facing the assessor. The participant was asked to bend/straighten their 
knee to the best they can, within the level of pain. The assessor measured the knee 
flexion/extension using the greater trochanter, lateral condyle of the femur, head of the fibula 
and lateral malleolus as bony landmarks.603,604 
For the analysis, ROM was regarded as the flexion and extension movement ranges 
combined, by adding the two values together. Where the knee was not extending fully to 180 
degrees, a negative value was assigned to the extension ROM depending on the level of lag 
from 180 degrees. Where the extension was beyond 180 degrees owing to joint 
hypermobility or deformity from OA knee the extension ROM was a positive value. The 
flexion ROM was always a positive value. The extension ROM had positive and negative 
values. Combining the flexion and extension scores eliminated all negative scores. 
Reduction in the knee ROM is one out of the numerous factors proposed to be contributing 
to the reduced level of physical function among people affected by OA knee.605-608 Reduced 
knee ROM is also one of the clinical signs used in the diagnosis of OA knee.609,610 Hence it is 
prudent to assess the ROM as an outcome measure in OA research since any improvement 
in ROM is directly indicative of an improvement in the symptoms. Universal goniometry is 
widely used in research and clinical practice to obtain instant measure of joint ROM since 
several decades, and is established to be a valid and reliable tool for manual 
administration.604,611-615 
8.5.3 The study setting, Ethics approval, trial registration and key dates 
This study was carried out at the outpatient physiotherapy wing of the Safari Therapy Unit in 
the Hemel Hempstead General Hospital, Hemel Hempstead, Hertfordshire. The centre 
operates under the ‘Hertfordshire Community NHS Trust’. The ethics approval for the study 
was granted on 25 June 2015 by the ‘NRES Committee North West - Greater Manchester 
South’ under the Research Ethics Service of the NHS Health Research Authority (HRA) 
(REC reference: 15/NW/0529; Protocol number: HSK/PG/NHS/00312; IRAS project ID: 
173691) (Appendix 8.3). Participant recruitment was started in December 2015. The first 
participant visit was on 04 January 2016. The last participant was recruited at the end of 
June 2016. The study was formally completed on 28 October 2016 with the final set of 
assessments completed. The study was registered with the ISRCTN registry (Registration 
number: ISRCTN10995065) and with the National Institute of Health Research (NIHR) 
Clinical Research Network (CRN) (Portfolio) (study ID: 20264). 
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8.5.4 The study population and sample recruitment 
The study population was formed by the communities under the care of Safari Therapy Unit, 
Hemel Hempstead General Hospital, Hemel Hempstead under the Hertfordshire Community 
NHS Trust. Patients who were on the waiting list for physiotherapy treatment after being 
diagnosed with OA knee and referred by their general practitioners (GP) or the concerned 
specialist consultants, were invited in writing seeking their willingness to take part in the 
study if they met the following criteria (inclusion criteria): 
1) Clinical and/or radiological diagnosis of OA knee, meeting the American College of 
Rheumatology clinical criteria for OA knee.517 
2) OA symptoms present since a minimum of six months. 
3) Over 18 years of age. 
The patients were sent an invitation package containing an invitation letter (Appendix 8.4) a 
participant information sheet (Appendix 8.5), a return form (Appendix 8.6) to indicate 
whether they wish to be considered for the study and postage paid return envelope. Where 
the patients were willing to be considered for inclusion, they were contacted by the 
researcher by phone to collect further details about their condition. Subsequently, they were 
recruited if they did not meet any of the below criteria (exclusion criteria): 
1) RF-based treatment contraindicated for any of the following reasons: 
a) Pregnancy 
b) Active cancer/malignancy 
c) Active tuberculosis 
d) Metal implant in the affected knee 
e) Pacemaker or another sensitive electronic implant present 
2) Significant comorbidities such as neurological impairment precluding them from study 
participation 
3) Any active skin lesions/conditions around the affected knee joint 
4) Known hypersensitivity to heat 
5) Any recent invasive procedures to the affected knee within the last three months 
6) Any invasive procedures planned during the potential study period 
7) Inability to attend the hospital for intervention/assessments 
8) Inability to provide written consent 
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8.5.5 Sample size and power calculation 
No baseline data was available concerning the use of CRMRF therapy on patients affected 
by OA knee. Based on a Minimal Clinically Important Difference (MCID) of 16 – 20% 
reduction on the WOMAC global score (Effect size of 0.5),572,616,617 a total of 42 participants 
(in three groups) was required to demonstrate a statistically and clinically significant 
difference with 95% confidence and 80% power (G*Power 3.1). Allowing for a maximum 
drop-out of 20%, it was anticipated that 17 participants per group would be needed to 
achieve a sufficiently powered study. Hence, the estimated overall sample required was 51. 
8.5.6 The study groups 
After screening, those patients who satisfactorily passed the inclusion/exclusion criteria were 
recruited into the study. The patients were randomly allocated to one of the three study 
groups at the time of recruitment. The randomisation was performed with concealed 
envelopes, which were prepared a priori using a computer-generated randomisation chart 
(Appendix 8.7) (IBM SPSS Statistics, Version 20), and blinded from the participants. The 
three study groups were as given below (Figure 8.1). 
1) ACTIVE GROUP – Received CRMRF therapy + Current standard treatment for OA 
knee. Received eight sessions of treatment in four weeks. 
2) PLACEBO GROUP – Received placebo CRMRF therapy + Current standard treatment 
for OA knee. Received eight sessions of treatment in four weeks. 
3) CONTROL GROUP – Received current standard treatment for OA knee only. Received 
three sessions of treatment in four weeks, commensurate with normal departmental 
practice. 
In this study, whichever group the participant was randomly allocated to, the ‘current 
standard treatment’ they would have received even if they were not a participant in this study 
was continued to be delivered uninterrupted. This was important from an ethical standpoint 
because no patient was disadvantaged because of their participation in the study. On the 
other hand, those participants who were randomised into the active or placebo groups 
received additional CRMRF or placebo CRMRF treatment sessions. Since the active and 
control groups received dissimilar number of treatment sessions, it raises the issue of non-
equivalence between the groups. However, if the number of sessions for the control group 
was increased to match that of the active group it would not have reflected standard clinical 
practice. Similarly, the active group number of sessions could not be reduced to match that 
of the control group because that would have meant too few CRMRF sessions delivered. 
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8.5.7 Interventions 
8.5.7.1 The CRMRF intervention 
A high dose of CRMRF that generated a ‘moderate’ skin thermal sensation employing the 
same method and principle used for delivering the ‘CRMRF high’ intervention in the 
physiological study (Chapter 4) was used for the active group of this study. The intensity of 
delivery was therefore not fixed but adjusted according to patient feedback on their 
perception of moderate heating. Fifteen minutes of treatment (5 minutes CAP + 10 minutes 
RES) was delivered twice a week for four consecutive weeks providing a total of eight 
sessions. The treatment was delivered to the knee joint area covering the lower aspect of 
the quadriceps femoris muscle, around the patella and the medial and lateral joint lines. 
However, emphasis was given to the areas of the joint reported by the patients as more 
symptomatic. The return plate electrode was placed under the calf one-fourth way down the 
distance between the fibular head and the lateral malleolus (like the laboratory study), which 
was the standardised position adopted. 
8.5.7.2 The CRMRF placebo intervention 
The device mode was set to the placebo setting (treatment option ‘1’) on the dial prior to the 
start of the treatment. The treatment was delivered using the exact techniques as in the 
active group except that no verbal feedback was sought from the participants since there 
was no energy delivery. The intensity was raised as for the real treatment, until the output 
display was at around similar levels to those of real treatments delivered to the active group. 
From the participant perspective, the treatment procedures and machine appearance were 
identical in active and placebo interventions. 
8.5.7.3 Current standard treatment 
By default, all patients in all three groups received the current standard care offered to the 
patients undergoing physiotherapy treatment for OA knee in the UK. This included advice 
and education regarding OA knee and exercises (home/gym-based exercise programme). 
Both components were tailored to suit individual participants. All participants in all three 
groups were given this intervention on their first visit. Subsequently, they were reviewed and 
re-emphasised at the fourth visit for the participants in the CRMRF and placebo groups, and 
at the second visit for the control group (the control group participants only received three 
sessions in four weeks). 
The exercise programme included open and closed chain knee ROM exercises, open and 
closed chain knee strengthening exercises, and mild-to moderate gym-based tasks such as 
exercising on a static bike. The advices included restricting the activities that place 
excessive load and shear forces on the affected knee joint. This included cutting down on 
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walking briskly on hard/uneven surfaces, cutting down on kneeling, crouching and stair 
climbing where possible. The patients were also urged to use footwear that provides proper 
support to the limb while walking. The standard treatment protocol was designed based on 
departmental practice and current best evidence. 
8.5.8 Procedure 
On the first day of the study, an informed consent (Appendix 8.8) was signed by both parties 
(researcher and participant) before the start of the proceedings. Subsequently, the 
participant’s ‘skin thermal sensitivity’ and the ability to distinguish between warm and cold 
temperatures was tested using test tubes filled with water at approximately three different 
temperatures (±0.5 oC): 45 oC (warm), 35 oC (neutral) and 25 oC (cold). After screening, a 
brief clinical assessment including the history of the condition, duration, and the past and 
present treatment history was carried out and recorded. A brief description about the 
assessment and treatment procedure was provided depending on their group allocation. 
Then, the clinical assessment data was collected in the following order: 
1) Demographic and anthropometric data 
2) TUG test at the designated area outside the treatment room 
3) VAS and WOMAC 
4) Knee ROM 
To start the treatment session the participants in the active/placebo groups positioned 
themselves in supine on a treatment plinth, fully supported with pillows. The CRMRF 
intervention was delivered using the methods explained earlier. After the treatment, the 
standard care package with exercises and advice was delivered. Participants of the control 
group only received the standard care package as mentioned. A standardised application of 
treatment relevant to the allocated group was ensured for all participants. At the end of the 
first session, subsequent treatment sessions were booked. The control group participants 
were asked to attend two more sessions two weeks apart and all others were asked to 
attend twice weekly for the next four weeks ensuring a uniform gap between the sessions 
during the week (two days gap between sessions was ensured). 
If any RF treatment sessions were missed due to an unforeseen reason, the intervention 
durations were extended till all planned sessions were completed. However, if more than two 
RF sessions were missed (> 25% of the total number of sessions) the intervention was 
considered invalid. If any control group participant missed their second session, they were 
contacted by phone to discuss any concerns and to reinforce the message about exercises 
and self-care. At sessions 2 – 7, the active/placebo participants attended the clinic to receive 
their 15-minute RF intervention only. At session 8, participants in all three groups underwent 
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the clinical assessments 2 – 4 mentioned above before being treated. The assessment was 
done before treatment to avoid the immediate impact of the intervention on the participants’ 
performance. For example, the pain from the exercise (if any) can influence all the above 
assessments. 
At the end of eight sessions, two follow-up visits were booked (first one after one month and 
the second after three months from the 8th session). All participants were advised to continue 
with the home exercises and self-care programme at least until the second follow-up. At the 
follow-up sessions, the clinical assessments 2 – 4 mentioned above were repeated. 
8.5.9 Analysis of data 
All data was processed and analysed using Microsoft Office Excel Version 2010 (Microsoft 
Corporation, USA) and IBM SPSS Statistics Version 20 (IBM Corporation, USA). To 
ascertain whether there were any statistically significant differences within the treatment 
groups or between the groups, the group data were compared on an intention to treat (ITT) 
basis using a mixed model analysis of variance (ANOVA) at four within-group time points 
(baseline, post treatment, one-moth follow-up and three months follow-up) and three 
between-group conditions (active, placebo and control). Where the data demonstrated 
deviation from normality, and/or inequality of variances, data transformation was performed 
using the square root function before conducting the ANOVA. Additionally, correlational 
analyses were performed involving the percentage changes in outcomes, dosage 
parameters (mean CRMRF dose and SAR in the active group) and the demographic and 
anthropometric data using either Pearson correlation or Spearman’s rho depending on the 
distribution of data. The statistical significance was set at p ≤ 0.05 (0.8 P, 95% CI). 
 Results 
The flow of participants through the study is shown in Figure 8.2. Two participants from the 
control group and one participant from the placebo group withdrew from the study during the 
intervention phase (due to losing interest in one case and a lack of progress/deterioration of 
symptoms due to unrelated reasons in two cases). There were no withdrawals from the 
active group. Hence a total of 42 participants (93%) completed the interventions and all the 
assessments. All types of interventions and assessments were tolerated well and there were 
no reports of any adverse events that might be a consequence of the intervention, including 
any issues due to potential CRMRF-induced overheating. 
The demographic and the mean (SD) anthropometric data from all 45 participants are 
reported in Table 8.1. There were no significant differences between any of the three groups 
in any characteristic. 
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Figure 8.2: The flow of participants through the clinical trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8.1: Demographic and the mean (SD) anthropometric data 
 
 
 
 
 
Fixed treatment doses were not delivered to the active group (like the laboratory study, 
chapter 6). The overall mean (SD) CAP and RES doses received by the participants in the 
Mean (SD) age 
(years)
Males Females
Mean (SD) 
duration (years)
Height (m) Weight (kg) Body fat (%) BMI
Study Group
CRMRF High 63.33 (9.93) 6 9
CRMRF Placebo 62.60 (10.38) 6 9 4.30 (3.85)
Control 59.67 (6.21) 6 9 5.97 (5.73) 95.51 (16.08) 42.18 (8.53)
Demographic data Mean (SD) anthropometric data
31.33  (3.77)
30.53 (5.64)
34.22 (5.66)1.67 (0.07)
87.79 (16.71) 39.15 (7.55)
1.63 (0.09) 81.77 (16.77) 38.01 (12.58)
1.67 (0.10)5.57 (4.14)
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active group over the eight sessions were 17.29 (1.37) W and 60.56 (6.00) W respectively. 
The overall mean (SD) total dose (CAP + RES) over the eight sessions was 46.13 (4.26) W. 
Figure 8.3 shows the individual mean doses (CAP, RES, total) over the eight sessions for 15 
participants. Figure 8.4 shows the mean (SD) total doses from sessions 1 – 8. The mean 
doses delivered over the eight sessions did not vary significantly. As explained before, the 
differences in the treatment dose among participants were due to the doses being adjusted 
based on the participants’ thermal perception and verbal feedback. 
Figure 8.3: The mean CRMRF doses of all eight sessions 
 
 
 
 
 
 
 
 
 
 
Figure 8.4: The mean (SD) CRMRF doses delivered to the active group participants over the 
eight sessions 
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The results of all four clinical outcome measures based on the four time points are given 
below. The post treatment results are based on the effects of seven treatment sessions 
instead of eight (except the control group) since the post treatment outcomes were obtained 
prior to delivering the last treatment session. This was done to avoid the immediate impact 
of treatment influencing the outcomes, especially TUG and knee ROM. 
8.6.1 Self-reported pain 
The group wise mean (SD) 24-hour pain rated by the participants at each assessment point 
is plotted in Figure 8.5. Figure 8.6 shows the percentage changes of mean from the 
baseline. The statistical analysis (4*3 mixed methods ANOVA (time, group)) revealed a 
significant main effect for the time (within-group change) (F (2.086, 87.602) = 15.918, p < 
0.001) and a significant interaction between the group and time (F (4.172) = 5.172, p = 
0.001). Therefore, the type of intervention made a significant difference to the reported pain 
scores and there was a significant overall difference between the pre, post and the one-
month and three-month follow-up scores. There was no significant difference between the 
baseline pain scores of the three groups. Whilst the change in the mean VAS score of the 
active group reached accepted MCID levels when compared between the baseline and all 
the other time points, MCID was not attained for placebo and control groups. 
Results of the pairwise comparisons (adjustment for multiple comparison: Bonferroni), their 
significance values and their effect sizes (where the interaction was significant) are reported 
in Tables 8.2 & 8.3. All significant effects and interactions have been highlighted. For the 
between-group pairwise comparisons it is evident that the active group differed significantly 
from both placebo and control groups at post treatment (time point two) while there was no 
difference between the placebo and control groups. However, at the one-month follow-up 
(time point three) the significant difference was limited to between active and control groups. 
Further, no groups differed from each other at the three-month follow-up (time point four). 
Within the active group, there was a highly significant reduction in the pain scores from 
baseline to post treatment, which was sustained significantly over the follow-up phase. No 
such meaningful changes where noted within the other two groups, except between the 
baseline and one-month follow-up in the placebo group. 
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Figure 8.5: The mean (SD) pain scores 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.6: Percentage change in the mean pain scores from the baseline 
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Table 8.2: Within-group pairwise comparisons for the pain scores 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8.3: Between-group pairwise comparisons for the pain scores 
 
 
 
 
 
 
 
 
 
 
 
RFP .126 .106 .730
CTR .242 .106 .084
RFH -.126 .106 .730
CTR .116 .106 .842
RFH -.242 .106 .084
RFP -.116 .106 .842
RFP -.790
* .200 .001 1.29
CTR -.817
* .200 .001 1.49
RFH .790
* .200 .001
CTR -.028 .200 1.000
RFH .817
* .200 .001
RFP .028 .200 1.000
RFP -.502 .232 .108
CTR -.676
* .232 .017 1.10
RFH .502 .232 .108
CTR -.174 .232 1.000
RFH .676
* .232 .017
RFP .174 .232 1.000
RFP -.204 .305 1.000
CTR -.217 .305 1.000
RFH .204 .305 1.000
CTR -.013 .305 1.000
RFH .217 .305 1.000
RFP .013 .305 1.000
4 RFH
RFP
CTR
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Bonferroni.
3 RFH
RFP
CTR
Mean 
Difference Time Group
2 RFH
RFP
CTR
Std. Error Sig.
b
Effect size 
(Hedges's g)
1 RFH
RFP
CTR
2 1.168
* .129 .000 2.46
3 1.068
* .159 .000 1.92
4 .762
* .208 .004 1.41
1 -1.168
* .129 .000
3 -.100 .080 1.000
4 -.407 .181 .180
1 -1.068
* .159 .000
2 .100 .080 1.000
4 -.307 .173 .503
1 -.762
* .208 .004
2 .407 .181 .180
3 .307 .173 .503
2 .253 .129 .339
3 .440
* .159 .049 0.79
4 .432 .208 .266
1 -.253 .129 .339
3 .188 .080 .147
4 .180 .181 1.000
1 -.440
* .159 .049
2 -.188 .080 .147
4 -.008 .173 1.000
1 -.432 .208 .266
2 -.180 .181 1.000
3 .008 .173 1.000
2 .109 .129 1.000
3 .150 .159 1.000
4 .303 .208 .923
1 -.109 .129 1.000
3 .042 .080 1.000
4 .194 .181 1.000
1 -.150 .159 1.000
2 -.042 .080 1.000
4 .152 .173 1.000
1 -.303 .208 .923
2 -.194 .181 1.000
3 -.152 .173 1.000
2
3
4
b. Adjustment for multiple comparisons: Bonferroni.
Effect size 
(Hedges's g)Group Time
RFP 1
2
3
4
CTR 1
2
3
4
RFH 1
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
Std. Error Sig.
b
Mean 
Difference 
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8.6.2 WOMAC osteoarthritis index 
The group wise mean (SD) WOMAC global scores obtained from the questionnaires at each 
assessment point are plotted in Figure 8.7. Figure 8.8 shows the percentage changes of 
mean from the baseline. The statistical analysis (4*3 mixed methods ANOVA (time, group)) 
of the WOMAC global scores revealed a significant main effect for the time (within-group 
change) (F (2.168, 91.075) = 18.206, p < 0.001) and a significant interaction between the 
group and time (F (4.337) = 2.712, p = 0.031). Therefore, the type of intervention made a 
significant difference to the reported scores and there was a significant overall difference 
between pre, post, one-month follow-up and three-month follow-up WOMAC global scores. 
There was no significant difference between the baseline scores of the three groups. The 
changes in the WOMAC global scores reached the MCID levels for all three time points in 
both active and placebo groups, although the difference was almost two-fold in the active 
group. In the control group, the MCID level was attained only by the one-month follow-up, 
which was also sustained at the three-month follow-up. 
Results of the pairwise comparisons (adjustment for multiple comparison: Bonferroni), their 
significance values and their effect sizes (where the interaction was significant) are reported 
in Tables 8.4 & 8.5. All significant effects and interactions have been highlighted. In the 
between-group pairwise comparisons the only significant difference was found between the 
active group and control group at post treatment (time point two). No other groups differed 
significantly from each other at any other time point. Within the active and placebo groups, 
there was a significant reduction in the WOMAC global scores from baseline to post 
treatment, which was sustained significantly over the follow-up phase. Nonetheless, the 
improvement in the outcome was much more pronounced in the active group compared to 
the placebo. No such meaningful changes where noted within the control group. 
Figure 8.7: The mean (SD) WOMAC global scores 
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Figure 8.8: Percentage change in the mean WOMAC global scores from the baseline 
 
 
 
 
 
 
 
 
 
 
 
Table 8.4: Within-group pairwise comparisons for the WOMAC global scores 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 1.940
* .297 .000 1.53
3 2.163
* .343 .000 1.72
4 1.670
* .455 .004 1.16
1 -1.940
* .297 .000
3 .222 .203 1.000
4 -.270 .428 1.000
1 -2.163
* .343 .000
2 -.222 .203 1.000
4 -.492 .414 1.000
1 -1.670
* .455 .004
2 .270 .428 1.000
3 .492 .414 1.000
2 .977
* .297 .012 0.79
3 1.093
* .343 .016 0.74
4 1.412
* .455 .021 0.84
1 -.977
* .297 .012
3 .116 .203 1.000
4 .434 .428 1.000
1 -1.093
* .343 .016
2 -.116 .203 1.000
4 .318 .414 1.000
1 -1.412
* .455 .021
2 -.434 .428 1.000
3 -.318 .414 1.000
2 .094 .297 1.000
3 .711 .343 .265
4 1.056 .455 .151
1 -.094 .297 1.000
3 .617
* .203 .025
4 .962 .428 .180
1 -.711 .343 .265
2 -.617
* .203 .025
4 .345 .414 1.000
1 -1.056 .455 .151
2 -.962 .428 .180
3 -.345 .414 1.000
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Bonferroni.
Mean 
Difference Std. Error Sig.
b
RFH 1
2
3
4
RFP
4
CTR 1
2
3
4
1
2
3
Group Time
Effect size 
(Hedges's g)
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Table 8.5: Between-group pairwise comparisons for the WOMAC global scores 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.6.3 Walking ability 
The group wise mean (SD) TUG scores obtained at each assessment point are plotted in 
Figure 8.9. Figure 8.10 shows the percentage changes of mean from the baseline. The 
statistical analysis (4*3 mixed methods ANOVA (time, group)) of the TUG scores revealed a 
significant main effect for the time (within-group change) (F (2.022, 84.917) = 15.199, p < 
0.001); however, there was no significant interaction between the group and time. Therefore, 
the type of intervention did not make a significant difference to the reported TUG scores, but 
there was a significant overall difference between pre, post, one-month follow-up and three-
month follow-up TUG scores for all groups. There was no significant difference between the 
baseline scores of the three groups. All three group results failed to reach the MCID levels. 
Results of within-group pairwise comparisons (adjustment for multiple comparison: 
Bonferroni), their significance values and their effect sizes (where the interaction was 
significant) are reported in Table 8.6. All significant effects and interactions have been 
highlighted. All three groups demonstrated a significant improvement in walking time from 
baseline to post treatment and from baseline to one-month follow-up; however, there was no 
significant difference between the baseline and the three-month follow-up. 
 
RFP -.038 .369 1.000
CTR .558 .369 .414
RFH .038 .369 1.000
CTR .596 .369 .341
RFH -.558 .369 .414
RFP -.596 .369 .341
RFP -1.001 .510 .169
CTR -1.288
* .510 .046 0.94
RFH 1.001 .510 .169
CTR -.287 .510 1.000
RFH 1.288
* .510 .046
RFP .287 .510 1.000
RFP -1.107 .572 .178
CTR -.893 .572 .377
RFH 1.107 .572 .178
CTR .214 .572 1.000
RFH .893 .572 .377
RFP -.214 .572 1.000
RFP -.297 .733 1.000
CTR -.056 .733 1.000
RFH .297 .733 1.000
CTR .241 .733 1.000
RFH .056 .733 1.000
RFP -.241 .733 1.000
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Bonferroni.
3 RFH
RFP
CTR
4 RFH
RFP
CTR
1 RFH
RFP
CTR
2 RFH
RFP
CTR
Mean 
Difference 
Effect size 
(Hedges's g)Time Group Std. Error Sig.
b
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Figure 8.9: The mean (SD) TUG scores 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.10: Percentage change in the mean TUG scores from the baseline 
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Table 8.6: Within-group pairwise comparisons for the TUG scores 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.6.4 Knee joint ROM 
The group wise mean (SD) knee ROM obtained at each assessment point are plotted in 
Figure 8.11. Figure 8.12 shows the percentage changes of mean from the baseline. The 
statistical analysis (4*3 mixed methods ANOVA (time, group)) of the knee ROM revealed a 
significant main effect for the time (within-group change) (F (3, 126) = 9.070, p < 0.001) and 
a significant interaction between the group and time (F (6) = 2.553, p = 0.023). Therefore, 
the type of intervention made a significant difference to the observed knee ROM and there 
was a significant overall difference between the pre, post, one-month follow-up and three-
month follow-up knee ROM. There was no significant difference between the baseline 
values of the three groups. 
Although there was a significant main effect for the interaction between time and group, the 
pairwise comparisons did not reveal any significant interactions between any of the groups 
2 .166
* .043 .002 0.72
3 .230
* .050 .000 1.09
4 .139 .067 .274
1 -.166
* .043 .002
3 .064 .030 .213
4 -.027 .064 1.000
1 -.230
* .050 .000
2 -.064 .030 .213
4 -.091 .050 .448
1 -.139 .067 .274
2 .027 .064 1.000
3 .091 .050 .448
2 .145
* .043 .009 0.41
3 .156
* .050 .020 0.39
4 .150 .067 .188
1 -.145
* .043 .009
3 .011 .030 1.000
4 .005 .064 1.000
1 -.156
* .050 .020
2 -.011 .030 1.000
4 -.006 .050 1.000
1 -.150 .067 .188
2 -.005 .064 1.000
3 .006 .050 1.000
2 .136
* .043 .017 0.33
3 .176
* .050 .006 0.45
4 .158 .067 .143
1 -.136
* .043 .017
3 .040 .030 1.000
4 .023 .064 1.000
1 -.176
* .050 .006
2 -.040 .030 1.000
4 -.018 .050 1.000
1 -.158 .067 .143
2 -.023 .064 1.000
3 .018 .050 1.000
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Bonferroni.
CTR 1
2
3
4
RFP 1
2
3
4
RFH 1
2
3
4
Mean 
Difference Std. Error Sig.
b
Effect size 
(Hedges's g)Group Time
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for any of the time points and are hence not reported here. Results of the within-group 
pairwise comparisons (adjustment for multiple comparison: Bonferroni), their significance 
values and their effect sizes (where the interaction was significant) are reported in Table 8.7. 
All significant effects and interactions have been highlighted. Within the active group, there 
was a highly significant improvement in the observed knee ROM values from baseline to 
post treatment, which was sustained significantly over the one-month follow-up phase. No 
such meaningful changes were noted at any time point within the other two groups. 
Figure 8.11: The mean (SD) knee ROM 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.12: Percentage change in the mean knee ROM from the baseline 
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Table 8.7: Within-group pairwise comparisons for the knee ROM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.6.5 Subgroup analyses and correlations 
Subgroup analyses were performed using gender as a grouping variable in the main ANOVA 
alongside group allocation to examine if men and women responded differently to the 
interventions in each group. Additionally, correlational analyses (Pearson correlation / 
Spearman’s rho) were performed using a group wise split file command in the SPSS 
software for age, BMI, OA duration and the mean CRMRF dose / SAR (active group only), 
with the percentage changes in the four outcome measures at three stages – from baseline 
to post treatment, from baseline to one-month follow-up and from baseline to three-month 
follow-up. This analysis examined if the outcomes within the groups were influenced by any 
of the above factors. Additionally, correlations were also tested using the same parameters, 
but with group and gender wise split file command to test if the outcomes in men and women 
in each group correlated differently to the parameters given above. The results are explained 
below. 
2 -.475
* .114 .001 0.81
3 -.553
* .130 .001 0.91
4 -.289 .126 .162
1 .475
* .114 .001
3 -.077 .094 1.000
4 .186 .105 .501
1 .553
* .130 .001
2 .077 .094 1.000
4 .263 .100 .069
1 .289 .126 .162
2 -.186 .105 .501
3 -.263 .100 .069
2 -.058 .114 1.000
3 -.242 .130 .420
4 -.215 .126 .577
1 .058 .114 1.000
3 -.185 .094 .341
4 -.157 .105 .849
1 .242 .130 .420
2 .185 .094 .341
4 .027 .100 1.000
1 .215 .126 .577
2 .157 .105 .849
3 -.027 .100 1.000
2 -.021 .114 1.000
3 -.166 .130 1.000
4 -.259 .126 .278
1 .021 .114 1.000
3 -.145 .094 .787
4 -.238 .105 .170
1 .166 .130 1.000
2 .145 .094 .787
4 -.093 .100 1.000
1 .259 .126 .278
2 .238 .105 .170
3 .093 .100 1.000
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Bonferroni.
CTR 1
2
3
4
RFP 1
2
3
4
RFH 1
2
3
4
Mean 
Difference Std. Error Sig.
b
Effect size 
(Hedges's g)Group Time
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8.6.5.1 Subgroup analyses 
For self-reported pain, there was no overall significant effect of gender in the main ANOVA 
for any of the interactions. However, there were significant differences between groups at 
post treatment and one-month follow-up based on gender. While males did not show any 
differences between groups at any time point, females in the active group demonstrated 
highly significant reduction of their pain scores compared to the other two groups at post 
treatment (both p ≤ 0.001) and compared to control group at the one-month follow-up (p = 
0.009). In the pairwise within-group comparisons based on gender, the females in the active 
group demonstrated a more pronounced reduction in pain compared to that of males at post 
treatment (p = 0.014) although both genders achieved significant improvements over time. 
Figure 8.13 shows male and female pain responses separately (plot as obtained from SPSS. 
Figure 8.13: Pain scores – males versus females (Y – axis: estimated marginal means of the 
square root transformed pain data; X – axis: four time points) 
   Males              Females 
 
 
 
 
 
 
 
For the WOMAC global scores, there was no overall significant effect of gender in the main 
ANOVA for any of the interactions. However, there were significant differences between 
groups at post treatment based on gender. While males did not show any differences 
between groups at any time point, females in the active group demonstrated a significant 
reduction in their WOMAC global scores compared to the control group at post treatment (p 
= 0.046). In the pairwise within group comparisons, there were no significant differences 
between the genders at any time point in any group; however, females in the active group 
demonstrated a greater improvement in function over time although both genders achieved 
significant improvements within the groups. Figure 8.14 shows the changes in the male and 
female WOMAC global scores separately. 
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Figure 8.14: WOMAC global scores – males versus females (Y – axis: estimated marginal 
means of the square root transformed WOMAC global data; X – axis: four time points) 
  Male                      Female 
 
 
 
 
 
 
 
For TUG and knee ROM scores there were no noteworthy effects of gender on the outcome, 
except that there was a greater improvement in the knee ROM among the females in the 
active group to post treatment and to one-month follow-up while males showed no 
improvement. 
8.6.5.2 Correlations 
No significant correlations were observed between age, BMI, mean CRMRF dose / SAR of 
the active group or OA duration and the percentage changes of the four outcomes from 
baseline to any of the time points in any of the three groups. This may suggest that age, 
BMI, treatment dose (within the active group) or duration of OA did not significantly influence 
the patients’ response to treatment in this study regardless of the intervention or outcome 
measure. Similarly, there was no significant influence of gender in the above correlational 
analyses in any of the groups. This may suggest that there was no significant difference in 
the way how either gender correlated with age, BMI, mean CRMRF dose / SAR of the active 
group or duration of OA for any of the four outcomes in any of the three groups in this study. 
8.6.6 Post-hoc power and sample size calculation 
All power and sample size calculations were conducted using G*Power (Version 3.1). The 
observed power and the computed sample sizes required for a power of 0.8 for all ANOVA 
main effects and interactions are given below in Table 8.8. The data suggests that with a 
total sample of 45 in the study, the power and sample size requirements have been met. 
 
 
 
216 
Table 8.8: Power and sample size for the main effects and interactions 
 
 
 
 
 
 
 
 
 
 Discussion 
The study investigated the effects of 448 kHz CRMRF on the clinical outcomes of patients 
affected by chronic OA of the knee. To the researcher’s knowledge this is the first such 
study conducted using RF at this operating frequency level and energy type. 
The results revealed significant improvements in OA-related pain and function in participants 
treated with active CRMRF in addition to exercise and advice, when compared to those who 
were treated with exercise and advice only. The fact that the placebo group also improved at 
a greater rate than the control group (although much less pronounced than the active 
treatment) indicated the presence of a placebo effect. This is unsurprising given the fact that 
placebo effect of up to 40% has been shown to exist in various forms of treatments.551-553 
The study participants included 20% more females than males, which reflect the fact that the 
condition affects females more than males.505 Interestingly, the response of female 
participants to the CRMRF intervention was significantly more pronounced than that of male 
participants in this study for the measured outcomes. Whilst the outcome was influenced by 
the gender, other parameters such as age, BMI, the CRMRF dose / SAR within the active 
group or the duration of OA did not influence the outcome significantly. 
Self-reported pain on a 10 cm VAS was used in this study as it is a simple, straight-forward 
and easy to administer measure of the participants’ subjective perception of pain. Although it 
is a valid and reliable measure to be used in clinical research (described in the methods 
section), VAS has been criticised for failing to reflect the elements of multidimensional pain 
construct (e.g. the cognitive and behavioural elements).618 However, VAS is so commonly 
used to evaluate the level of pain in clinical practice that almost all participants were already 
familiar with this scale and had administered it previously while receiving care. It is also 
Outcome measures
Total sample 
required for 0.8 P
18
24
1.00
0.99
VAS pain score
Parameter
TUG test score
Main effect for time
Time*Group interaction
Main effect for time
Time*Group interaction
Time*Group interaction
Main effect for time
Observed 
power
18
42
18
Knee ROM 0.98
0.83
27
45
Non significant
Main effect for time
Time*Group interaction
1.00
0.85
1.00
WOMAC 
osteoarthritis index
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worth noting at this point that the use of WOMAC meant that some other aspects of the pain 
experience of the participants were evaluated. 
The participants were asked to rate ‘the average pain over the last 24 hours’ considering all 
their activities and instances when they did experience more pain or less pain in their knee, 
to reflect on their whole day’s symptoms. Another option was to rate ‘pain now’, which 
however was considered unsuitable since various factors could have influenced a sudden 
spike or reduction in their pain. For example, the hospital building where the study was 
carried out is situated on a hilly terrain. The participants may have come by walking, by car 
or by public transport (such external factors could not be controlled), which would have 
exerted varying levels of stress on the knee and hence could have reflected on their pain 
scores. Taking a 24-hour average of the pain was therefore considered a more robust 
option. The VAS pain measurement could be suitably used for the assessment of the current 
level of pain or for recall of the average pain over a period.619-621 
The literature has suggested that the MCID of VAS vary according to the level of pain622 and 
the type of condition.623 On average, a reduction in pain by a score of around 1.9 – 2.0 out of 
10 (19 – 20%) is generally accepted as MCID.565-567 In this study, the active group reported 
66.11% reduction in pain from baseline to post treatment, 59.50% reduction from baseline to 
one-month follow-up and 44.60% reduction from baseline to three-month follow-up. In 
contrast, the control group reported 7.75% reduction in pain from baseline to post treatment, 
11.31% reduction from baseline to one-month follow-up and 12.20% reduction from baseline 
to three-month follow-up. The changes in the placebo group to the same time points were 
15.84%, 26.36% and 20.92% respectively. It should be noted that the pain results in only the 
active group attained the MCID levels, which was sustained significantly throughout the 
study. 
The pain results clearly demonstrated that the active CRMRF treatment had an immediate 
treatment effect that was over four times more pronounced than that of the placebo while it 
was close to 10 times more pronounced than that of the control intervention. A significant 
proportion of this effect was sustained even after three months from the intervention. This 
study did not employ any follow-up assessments longer than three months. The rate of 
decline could slow with time, which means some of the clinical effects could be retained for 
longer than three months. However, it is difficult to predict when the decline might reach a 
plateau. 
Like the VAS pain, studies have reported different levels of MCID for the WOMAC global 
score. Recently, Hmamouchi et al. (2012)572 suggested that a 16% reduction from the 
WOMAC global baseline score can be considered as MCID, while Angst et al. (2001)624 had 
earlier recommended that a change of 12% would be sufficient. In this study, the active 
group reported 45.16% reduction in the WOMAC global score from baseline to post 
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treatment, 49.85% reduction from baseline to one-month follow-up and 37.54% reduction 
from baseline to three-month follow-up. In contrast, the control group reported 4.24% 
reduction in the WOMAC global score from baseline to post treatment, 21.53% reduction 
from baseline to one-month follow-up and 24.41% reduction from baseline to three-month 
follow-up. The score changes in the placebo group to the time points were 23.44%, 23.73% 
and 29.09% respectively. The changes in WOMAC scores for the active treatment group can 
therefore be considered highly clinically significant. 
The above WOMAC percentage changes suggest that (as stated in the results) while all 
groups demonstrated clinically meaningful changes within, the change in the active group 
was significantly more pronounced when compared to that in the other two groups although 
not these interactions attained statistical significance. Whilst the benefit of exercise and 
advice became evident in the control group only after eight weeks from the start (as shown 
by their reduced WOMAC global scores), the placebo group gained potential additional 
benefits sooner, possibly due to two reasons. Firstly, the higher number of treatment 
sessions they received in the first four weeks and secondly, the presence of placebo effect. 
However, it should be noted that by the one-month follow-up and thereafter the WOMAC 
scores of both placebo and control groups were closely matched. 
The feedback received from the participants who gained a greater reduction in pain and 
hence a greater improvement in physical function suggested that they could enjoy a more 
functionally active life. Nonetheless, interestingly in many instances this increase in function 
led to a return of symptoms in the weeks following the end of treatment. Besides the 
CRMRF treatment effect wearing off, the above reason might be partly responsible as to 
why the symptoms started to increase towards the three-month follow-up phase in many 
participants. Specifically, there were some participants from the active group who 
complained about the symptoms going back to usual pre-intervention levels after they had 
undertaken spells of unaccustomed functional tasks that they normally would not have 
undertaken (potential ‘bounce back’ effect). This feedback was part of informal discussions 
with the participants, which did not form part of the outcome measures. 
The two other outcome measures on walking ability (TUG) and the knee ROM only provided 
limited information regarding the usefulness of CRMRF for OA knee. TUG produced evenly 
matched results in all three groups with no significant difference between them although the 
overall trend was that of significant improvements within all three groups. However, none of 
them reached the proposed MCID levels, and there might be an issue with the level of 
reliability of the TUG results since the participants potentially wore different types of footwear 
during the tests. It was not realistically possible to ensure that the participants wore the 
same pair of footwear for all four assessments. The knee ROM results were highly 
significant within the active group, but not within the other two groups. The overlap between 
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the group variances at the post treatment and the follow-up assessment were possibly too 
high in relation to their mean difference making their interactions insignificant. 
The findings from this study are limited to a ‘high dose’ CRMRF application that generated a 
‘moderate’ thermal response in the participants. The dosage delivery in the active group was 
adjusted based on the verbal feedback from the participants. The overall mean (SD) total 
(CAP + RES) dose of 46.13 (4.26) W delivered over the eight sessions generated moderate 
thermal sensation in the tissues. It is unlikely that the participants would have been able to 
tolerate treatment doses that were any higher since it would have caused thermal 
discomfort. On the other hand, it is likely that the clinical effects demonstrated might have 
been linked to the applied dose (dose-response relationship); however, this can only be 
confirmed with studies that employ contrasting doses of this treatment. Subtle changes in 
the applied dose between participants within the active group did not correlate with a change 
in the clinical outcome. A dose-response relationship for contrasting doses of CRMRF was 
demonstrated in the laboratory study on asymptomatic adults (Chapter 6), hence it remains 
a realistic possibility in clinical populations too. 
The patients who received the active treatment reported experiencing good pain relief for 
close to two days after a treatment session (informal verbal feedback). Many also described 
that after receiving the treatment they felt like ‘having extra cushion’ in the knee. This pain 
relief is unlikely to have been a mere counterirritant effect, although little is known about the 
potential effect of CRMRF on the joint tissues affected by OA. Since lasting pain relief and 
commensurate improvements in function were noted in the actively treated group on a short 
to medium term, it is proposed that the CRMRF energy may potentially have promoted a 
lasting anti-inflammatory effect in the arthritic joint structures and/or the periarticular tissues. 
However, the wearing off the effects (although not completely) within a few weeks after 
treatment suggests that any such benefits might not have been permanent, but rather due to 
reversible changes that were induced in the tissues. 
Future research should investigate whether providing periodic follow-up treatment sessions 
(maintenance dose) would enhance and/or consolidate the obtained benefits. Further 
research should also investigate on the optimum intervention duration, duration of individual 
sessions, spacing between sessions and optimum dosing. To understand the potential 
changes to the articular and periarticular tissues in response to CRMRF treatment, future 
studies should consider employing outcome assessments that can monitor the changes in 
deeper tissues. Additionally, studies in animal models can help to histologically analyse the 
tissue changes resulting from CRMRF exposure. 
The study only experienced less than 7% dropout (3 out of 45) from the beginning to the 
end. While all 15 participants in the active group completed all the intervention and 
assessment sessions, there were two dropouts from the control group. One participant 
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withdrew after the first session citing lack of interest and the second participant withdrew 
prior to his second session citing inability to attend because of an aggravation in symptoms 
(due to an unrelated cause) as the reason. There was one withdrawal from the placebo 
group after completing six treatment sessions. This person did not give a reason, but the 
researcher recollects that he was unsatisfied about a lack of improvement in the symptoms 
to the level he expected. 
Data from all three participants who dropped out were included in the analysis based on an 
intention-to-treat basis, carrying forward their last set of data for the subsequent assessment 
points. The remaining 42 participants progressed through their sessions in an uneventful 
manner completing all segments of the study as expected. There were few instances of 
protocol violations where a scheduled treatment session had to be cancelled and rearranged 
due to extenuating circumstances. No participant missed more than one scheduled session 
in this manner. 
On the final visit, all participants were asked to identify the study group they were allocated 
to, based on their perception about the treatment they received. Four participants (27%) in 
the active group were ‘unsure’ what treatment they received. The remaining 11 participants 
were ‘certain’ they received the active CRMRF intervention. Eight participants (53%) from 
the placebo group could not identify their treatments correctly. The others said they thought 
they had received the placebo mainly due to their lack of improvement in the symptoms. Ten 
participants out of 15 (67%) in the control group were unaware which group they belonged 
to. The above numbers suggest that blinding was achieved to a fair extent, which surpassed 
the expectations of the researcher. It was assumed that the active intervention would be 
easy to identify because of the explicit heating sensation and hence the low blinding rate for 
the group was as expected. In contrast, the fact that most people in the control group could 
not correctly identify their group allocation was surprising. 
As explained in the literature section of this thesis only four previous studies on OA knee 
were identified that employed RF-based intervention below the shortwave frequency 
range.194,249-251 Three of those studies were RCTs.249-251 Only two studies employed RF 
interventions whose frequencies were close to the frequency of CRMRF (448 kHz).249,250 
Taverner and colleagues250 used 480 kHz transcutaneous pulsed radiofrequency (TPRF) 
therapy against a placebo on patients awaiting total knee replacement (TKR). Significant 
reduction in the pain scores at one and four weeks post treatment was reported by the active 
group participants compared to the placebo group. The scope of this study was limited, 
because pain was the only outcome recorded and there were no follow-up assessments 
beyond four weeks. Their four-week follow-up results were consistent with the findings in the 
current study. 
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Comparable results were also obtained by Alcidi and colleagues,249 who tested a similar type 
of 500 kHz RF against TENS in patients with OA knee. The RF therapy yielded a greater 
and longer lasting reduction in pain compared to the TENS. However, the study failed to 
employ appropriate duration of treatment with TENS to make a valid comparison. Moreover, 
TENS is shown to induce more effective pain relief during treatment as opposed to post-
treatment.255 Additionally, the study did not follow-up the participants beyond one month, 
further limiting the scope of the findings. 
Nelson and colleagues251 reported that 15 participants when treated with an active 6.8 MHz 
pulsed electromagnetic field (PEMF) device showed a three-fold improvement in the pain 
scores compared to 19 placebo-treated participants. There were no follow-up assessments, 
and pain was the only outcome measured, which like the above studies, limited the validity 
and relevance of the findings. Similarly, 12 patients presenting with OA knee were treated 
using an 8 MHz RF applicator by Takahashi and colleagues194 in a pilot study. Hyperthermia 
was induced inside the knee joints and significant pain relief was obtained. However, as 
above there were no follow-up assessments of the outcome in this study. 
The current study included adult participants regardless of age or gender and did not 
exclude participants based on OA in their other joints (e.g. hip, ankle) like in many other OA 
knee studies.625-627 On one hand, such broad inclusion criteria may have acted as a 
confounder, but on the other hand it has potentially made the study more reflective of real 
clinical world where patients are often presented with associated problems. The randomised 
study design would have mitigated such confounders to a large extent.628,629 Besides, the 
groups were not significantly different in terms of mean age, BMI, OA duration, or the 
baseline scores of any of the outcome measures. 
One of the potential problems faced in this study was ensuring the proper diagnosis of OA in 
the prospective participants. Patients referred to physiotherapy directly from GP were often 
not diagnosed fully. Instead, the patients were referred by simply stating ‘knee pain’. Also, 
not all patients had previously undergone radiological evaluation at the time of or after 
contacting their GP. Hence, screening such patients using a comprehensive assessment 
system such as the criteria set out by the American College of Rheumatology517,518 was 
crucial to ensure that only those patients who were diagnostically suitable for the study were 
being recruited. The American College of Rheumatology criteria consider the clinical picture 
besides the radiological findings. Under these criteria radiological evaluation is therefore not 
necessary in all cases. The patients referred by the specialist consultants had already 
undergone full diagnostic evaluation including radiographs in almost all cases. The patients 
referred by GPs were not sent for radiological evaluation solely for this study. 
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 Conclusions 
A four-week high dose CRMRF intervention (that produced a moderately thermal response) 
delivered alongside exercises and advice about self-management of OA knee induced a 
statistically significant and clinically meaningful reduction of pain as well as improvement of 
function in patients affected by chronic OA in their knee joints. The effects were significantly 
greater compared to those obtained using the current standard care comprising exercises 
and advice. A placebo CRMRF intervention when delivered in addition to standard care, also 
induced significant clinical benefits when compared to the standard care alone; however, the 
size of the effect was significantly smaller than that obtained with the active CRMRF 
treatment. The study only experienced less than 10% dropout of participants. A post-hoc 
power calculation revealed that the obtained power of the ANOVA main effects of time and 
group-time interactions (where the interactions were significant) in all four outcomes were 
over 80%. 
Although the sample size might not have been big enough to conduct comprehensive 
subgroup analyses, overall the responses obtained from female participants were more 
pronounced than those obtained from male participants. The effects among either gender 
was not influenced by the age or BMI of the participants, or the duration of their OA. Overall, 
the treatment effects obtained with CRMRF appeared to wear off substantially after three 
months from the end of the intervention, which suggests that the treatment might be 
beneficial in the short to medium term. Whether a longer intervention period and/or periodic 
follow-up treatment sessions (maintenance doses) will enhance the outcomes further, is 
unknown but could be usefully investigated with future research. Future clinical studies 
should identify the optimum dosage and intervention parameters and investigate the dose 
response relationship by employing varying doses of CRMRF. 
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9 Chapter 9 – Skin and deep physiological effects of 
CRMRF treatment in patients with OA of the knee joint: 
a single-blind randomised controlled trial 
 Introduction 
Chapter 8 explained how patients affected by OA in their knee joints responded to a four-
week intervention comprising high dose CRMRF and standard care, when compared to a 
standard care only intervention or a placebo CRMRF and standard care intervention. 
Statistically significant (and clinically meaningful) improvements were obtained in pain and 
function with the addition of CRMRF. The second aim of the clinical study was to investigate 
the physiological effects of CRMRF on patients with OA knee and compare them with that of 
asymptomatic adults, which were obtained in the laboratory study (Chapter 6). However, a 
direct comparison between the two was deemed problematic since some of the methods 
that were used in the laboratory study had changed in the clinical segment. These changes 
will be explained in the methodology section of this chapter. 
The laboratory study on asymptomatic adults revealed significant gains in SKT, SBF, deep 
blood flow volume and intensity of flow secondary to application of high dose CRMRF. The 
low dose CRMRF and high dose PSWT groups that were part of the laboratory study did not 
feature in the study on patients with OA knee, since this was a three-group RCT featuring 
only a high dose CRMRF intervention alongside a placebo CRMRF and control condition 
with no CRMRF intervention. The physiological measures were carried out at the first 
session of the clinical trial alongside the clinical outcome measures. Repeat measurement of 
the physiological parameters was unable to be performed during subsequent sessions since 
it would have involved substantially more patient time and was hence deemed unethical. 
From the pilot work, there was no evidence that repeated applications gave rise to different 
results and thus a single recording session for the physiological parameters was adopted. 
 Materials and methods 
9.2.1 Changes to the experimental protocol 
The physiological measurement protocol used for the patients was like that used in the 
laboratory study on asymptomatic adults, with the exceptions below. 
1) The measurements from the skin were obtained from the medial joint line instead of 
lower medial thigh. 
2) The NCV and tissue extensibility, which did not demonstrate any significant change in 
the laboratory study were unavailable in the patient study. 
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3) Instead of the Biopac system and the MyLab70 ultrasound device, equivalent portable 
measurement devices were used in the patient study. The ultrasound probe was not 
changed. 
4) No skin measurements were obtained from the untreated contralateral limb owing to time 
constraints and the lack of effects obtained from the laboratory study. 
9.2.2 Apparatus 
The following devices, which have already been described in detail in chapter 6, were used 
for the experiment. Except Items two and three, all devices are the same as those used in 
the laboratory studies. 
1) Indiba Activ 902 CRMRF device (Indiba S. A., Spain) was used for CRMRF delivery. 
2) The FlexComp Infiniti system (SA7550), a heart rate/blood volume pulse (HR/BVP) 
sensor (P/N: SA9308M), and a skin temperature sensor (P/N: SA9310M) (Thought 
Technology Ltd., Montreal, Canada) were used for SBF and SKT monitoring. 
3) Esaote MyLab25 ultrasound scanning device and an Esaote LA523 ultrasound probe 
(Esaote S.p.A, Genoa, Italy) were used for deep blood flow monitoring. 
4) An infra-red (IR) tympanic thermometer (Braun ThermoScan IRT 4520, Braun GmbH, 
Kronberg, Germany) was used for core temperature measurement. 
5) Blood pressure (BP) and pulse rate (PR) were monitored using a digital upper arm BP 
monitor (Omron M2, Omron Healthcare Europe B.V., Hoofddorp, Netherlands). 
6) A body composition monitor (Omron BF508, Omron Healthcare Europe B.V., Hoofddorp, 
Netherlands) was used to obtain the weight, body fat percentage, visceral fat and the 
body mass index (BMI) measurements of the participants. 
9.2.3 Sample and groups 
The three groups of participants in this experiment have been described in the previous 
chapter. Forty-five patients affected by OA knee were randomly allocated into a CRMRF 
high, CRMRF placebo and control groups, with 15 in each as described. The only difference 
in the method of this experiment compared to the laboratory study was that this experiment 
did not employ a crossover (two-way repeated measures) design. Hence, each participant 
was tested only in one session. 
9.2.4 Experimental procedure 
Like the laboratory study, on the day of the study the participants were asked to attend the 
session by avoiding food, beverages and strenuous exercises within one hour before the 
start. This was to ensure that their physiological condition remained stable during the 
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sessions.80,455,456 A similar experimental procedure to that of the laboratory study was 
employed, with the exceptions stated earlier in this chapter. Signing of the consent form, 
participant screening using an eligibility questionnaire, testing of skin thermal sensitivity and 
the ability to distinguish between warm and cold temperatures and the collection of 
demographic and anthropometric data have been explained in the previous chapter. 
To start the experiment the participants positioned themselves in supine on a treatment 
plinth and were fully supported using pillows. Skin over the medial aspect of the affected 
knee joint and lower medial thigh was prepared and was marked with tape to deliver the 
treatment and obtain the physiological measurements. Skin temperature was recorded from 
the middle of the medial joint line. This was repeated every two minutes until stabilised. The 
stabilised temperature was considered the baseline temperature. The core (tympanic) 
temperature was also monitored at the same time. All data, except those from the FlexComp 
Infiniti and Doppler were entered manually into a participant data collection form (Appendix 
9.1). The experimental timeline and measurements are illustrated in Figure 9.1. 
Figure 9.1: The experimental timeline for the physiological study on patients 
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9.2.5 Data acquisition 
9.2.5.1 Skin physiological measurements 
All skin physiological measurements of SKT and SBF were performed pre-treatment, 
immediately post treatment and 20-minute post treatment for all three groups. The PPG and 
SKT probes from the FlexComp Infiniti data acquisition system were attached to the 
predetermined marked areas on the medial joint line. The probes were positioned within the 
treatment zone and attached using Micropore™ (3M™) tape. All the probes and connecting 
leads were removed from the skin prior to the RF treatment and reattached for post 
treatment measurements. This was done to avoid potential signal interference, probe 
damage and tissue irritation, as explained in chapter 4 (pilot experiments). Reliability of 
probe and electrode placements had been established during the laboratory study by 
extensive pilot works. 
The sampling rate and settings on the FlexComp Infiniti device were pre-set by the 
manufacturer on the appropriate software menu. The FlexComp Infiniti system is battery 
powered and was not required being set up to run well in advance before the start of the 
experiment like Biopac, to ensure proper baselining of the data streams. As determined 
previously, since the SKT took 20 minutes for baselining, the FlexComp system was also set 
up to run for 20 minutes prior to the start. Both SKT and PPG data were collected for 80 
seconds at each of the three measurements (device pre-set). The core (tympanic) 
temperature, BP and PR were also concurrently monitored at the three time points. 
9.2.5.2 Deep physiological measurements 
The deep blood flow measurements were performed pre-and post intervention only, unlike 
the skin measurements. For each participant, blood flow was identified by manoeuvring the 
ultrasound probe over the lower anteromedial aspect of the quadriceps femoris muscle. 
Once the most prominent pulsatile (arterial) flow was identified, skin markings were used to 
establish the accuracy of probe placement and ensure repeatability. Prior to this study, the 
intra-rater reliability for both Doppler and Sonoelastography measurements was established 
in a separate pilot study that involved 12 healthy adult participants (explained in chapter 4, 
pilot experiments). For all participants, the machine settings remained the same for both pre-
treatment and post treatment measurements, and like those used in the laboratory 
experiment. Colour Doppler recordings for velocity of flow were performed first followed by 
power Doppler for volume and intensity of flow. Up to five seconds of blood flow data clips 
were recorded during each measurement, which was then broken down into image frames 
for analysis. 
 
227 
9.2.6 The CRMRF intervention 
The interventions have been explained in detail in the previous chapter. For the active and 
placebo groups, all physiological measurements were performed prior to delivering the 
standard care intervention. For the control group, the intervention was sandwiched between 
the pre-and post measurements. 
9.2.7 Analysis of data 
All data was processed and analysed using Microsoft Office Excel Version 2010 (Microsoft 
Corporation, USA) and IBM SPSS Statistics Version 20 (IBM Corporation, USA). To 
ascertain whether there were any statistically significant differences within the treatment 
groups or between the groups, the group data were compared using a mixed model analysis 
of variance (ANOVA) at three within-group time points (baseline, post treatment and follow-
up) and three between-group conditions (active, placebo and control). Where the data 
exhibited deviation from normality and/or inequality of variances, data transformation was 
performed before performing the analysis using the square root function. To enable a 
comparison between the patient data and the asymptomatic participant data, a similar mixed 
model ANOVA was carried out between the two ‘CRMRF high’ groups. Since the two sets of 
data were not directly comparable due to the reasons stated earlier, data normalization was 
carried out by taking the baseline scores as ‘zero’ and the ‘percentage changes from 
baseline’ as the subsequent points. The two sets of data were compared based on their face 
validity as the equivalence between the two sets of devices (Biopac and FlexComp, and the 
two ultrasound devices) was not able to be tested in this project. The statistical significance 
was set at p ≤ 0.05 (0.8 P, 95% CI). 
 Results 
All 45 participants completed the physiological measurements session. As stated in the 
previous chapter, all types of treatments and measurements were well tolerated and there 
were no reports of any adverse events that might be a consequence of the intervention, 
including any issues due to potential RF overheating. The demographic and the mean (SD) 
anthropometric data from the participants are reported in the previous chapter. There were 
no significant differences between any of the three conditions in either characteristic. The 
details of the CRMRF dosage delivered to the active group participants are also reported in 
the previous chapter. The results of each physiological parameter obtained from the study 
groups are reported below. 
9.3.1 Skin temperature results 
Figures 9.2 & 9.3 shows the mean (SD) SKTs recorded at three time points and the 
percentage changes of mean respectively. The statistical analysis (3*3 mixed methods 
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ANOVA (time, group)) revealed a highly significant main effect for time (within-group 
change) (F (1.377, 57.817) = 155.643, p < 0.001) and a highly significant interaction 
between group and time (F (2.753) = 238.511, p < 0.001). Therefore, the type of intervention 
made a significant difference to the reported SKT values and there was a significant overall 
difference between the pre, post and 20-minute follow-up SKT. There was no significant 
difference between the baseline values of the three groups. 
Results of the pairwise comparisons (adjustment for multiple comparison: Bonferroni), their 
significance values and their effect sizes (where the interaction was relevant and 
meaningful) are reported in Tables 9.1 & 9.2. All significant effects and interactions have 
been highlighted. For the between-group pairwise comparisons it is evident that the active 
group differed significantly from both placebo and control groups at all time points while the 
difference between the placebo and control groups might have been due to the drop in SKT 
in the placebo group due to the cold nature of the coupling medium. Within the active group, 
there was a highly significant increase in the SKT from baseline to post treatment, which 
was sustained significantly over the follow-up phase. The control group also showed a 
significant rise in SKT within-group; however, this was much less pronounced than that of 
the active group. 
Figure 9.2: The mean (SD) SKTs from the three groups 
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Figure 9.3: Percentage change in the mean SKTs from the baseline 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9.1: Within-group pairwise comparisons for SKT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 -.342
* .013 .000 5.99
3 -.307
* .016 .000 5.46
1 .342
* .013 .000
3 .035
* .008 .000 0.58
1 .307
* .016 .000
2 -.035
* .008 .000
2 .204
* .013 .000
3 .035 .016 .088
1 -.204
* .013 .000
3 -.169
* .008 .000
1 -.035 .016 .088
2 .169
* .008 .000
2 -.047
* .013 .003 0.48
3 -.115
* .016 .000 1.06
1 .047
* .013 .003
3 -.067
* .008 .000 0.68
1 .115
* .016 .000
2 .067
* .008 .000
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Bonferroni.
Effect size 
(Hedges's g)Group Time
Mean 
Difference Std. Error Sig.
b
RFH 1
2
3
RFP 1
2
3
CTR 1
2
3
Based on estimated marginal means
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Table 9.2: Between-group pairwise comparisons for SKT 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.3.2 Skin blood flow results 
Figures 9.4 & 9.5 shows the mean (SD) SBFs recorded at three time points and the 
percentage changes of mean respectively. The statistical analysis (3*3 mixed methods 
ANOVA (time, group)) revealed a highly significant main effect for time (within-group 
change) (F (1.554, 65.285) = 21.793, p < 0.001) and a highly significant interaction between 
group and time (F (3.109) = 45.058, p < 0.001). Therefore, the type of intervention made a 
significant difference to the reported SBF and there was a significant overall difference 
between the pre, post and 20-minute follow-up SBF. There was no significant difference 
between the baseline values of the three groups. 
Results of the pairwise comparisons (adjustment for multiple comparison: Bonferroni), their 
significance values and their effect sizes (where the interaction was relevant and 
meaningful) are reported in Tables 9.3 & 9.4. All significant effects and interactions have 
been highlighted. Any change in SBF over time was only noted in the active group, which 
was also significantly higher than that of the other two groups. Between post treatment and 
the 20-minute follow-up there was a drop in the obtained SBF within the active group; 
however, the retained SBF was still significantly higher than that of baseline. There was no 
difference between the placebo and control groups at any time. 
 
RFP -.010 .034 1.000
CTR -.001 .034 1.000
RFH .010 .034 1.000
CTR .009 .034 1.000
RFH .001 .034 1.000
RFP -.009 .034 1.000
RFP .536
* .037 .000 4.91
CTR .294
* .037 .000 3.88
RFH -.536
* .037 .000
CTR -.242
* .037 .000 1.98
RFH -.294
* .037 .000
RFP .242
* .037 .000
RFP .331
* .039 .000 2.87
CTR .191
* .039 .000 2.16
RFH -.331
* .039 .000
CTR -.140
* .039 .003 1.04
RFH -.191
* .039 .000
RFP .140
* .039 .003
Time Group
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Bonferroni.
Effect size 
(Hedges's g)
Mean 
Difference Std. Error Sig.
b
1 RFH
RFP
CTR
2 RFH
RFP
CTR
3 RFH
RFP
CTR
Based on estimated marginal means
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Figure 9.4: The mean (SD) SBFs from the three groups 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.5: Percentage change in the mean SBFs from the baseline 
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Table 9.3: Within-group pairwise comparisons for SBF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9.4: Between-group pairwise comparisons for SBF 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 -.766
* .061 .000 2.81
3 -.540
* .060 .000 2.26
1 .766
* .061 .000
3 .226
* .037 .000
1 .540
* .060 .000
2 -.226
* .037 .000
2 .135 .061 .095
3 .123 .060 .135
1 -.135 .061 .095
3 -.012 .037 1.000
1 -.123 .060 .135
2 .012 .037 1.000
2 .029 .061 1.000
3 .016 .060 1.000
1 -.029 .061 1.000
3 -.012 .037 1.000
1 -.016 .060 1.000
2 .012 .037 1.000
Mean 
Difference Std. Error Sig.
b
RFH 1
2
3
Effect size 
(Hedges's g)Group Time
RFP 1
2
3
CTR 1
2
3
Based on estimated marginal means
b. Adjustment for multiple comparisons: Bonferroni.
*. The mean difference is significant at the .05 level.
RFP .022 .071 1.000
CTR -.027 .071 1.000
RFH -.022 .071 1.000
CTR -.049 .071 1.000
RFH .027 .071 1.000
RFP .049 .071 1.000
RFP .923
* .099 .000 3.00
CTR .767
* .099 .000 2.63
RFH -.923
* .099 .000
CTR -.155 .099 .367
RFH -.767
* .099 .000
RFP .155 .099 .367
RFP .685
* .090 .000 2.50
CTR .529
* .090 .000 1.98
RFH -.685
* .090 .000
CTR -.156 .090 .269
RFH -.529
* .090 .000
RFP .156 .090 .269
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Bonferroni.
Effect size 
(Hedges's g)Time Group
2 RFH
RFP
CTR
3 RFH
RFP
CTR
Mean 
Difference Std. Error Sig.
b
1 RFH
RFP
CTR
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9.3.3 Blood flow volume 
Figures 9.6 & 9.7 shows the mean (SD) deep blood flow volume recorded using power 
Doppler ultrasound pre-and post treatment and the percentage changes of mean 
respectively. The statistical analysis (2*3 mixed methods ANOVA (time, group)) revealed a 
highly significant main effect for time (within-group change) (F (1, 42) = 57.081, p < 0.001) 
and a highly significant interaction between group and time (F (2) = 75.930, p < 0.001). 
Therefore, the type of intervention made a significant difference to the reported blood flow 
volumes and there was a significant overall difference between the pre-and post results. 
There was no significant difference between the baseline values of the three groups. 
Results of the pairwise comparisons (adjustment for multiple comparison: Bonferroni), their 
significance values and their effect sizes (where the interaction was relevant and 
meaningful) are reported in Tables 9.5 & 9.6. All significant effects and interactions have 
been highlighted. Like SBF, any change in blood flow volume over time was only noted 
within the active group, which was also significantly higher than that of the other two groups. 
There was no difference between the placebo and control group results in either within or 
between group pairwise comparisons. 
Figure 9.6: The mean (SD) blood flow volumes from the three groups 
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Figure 9.7: Percentage change in the mean blood flow volumes from the baseline 
 
 
 
 
 
 
 
 
 
 
 
Table 9.5: Within-group pairwise comparisons for blood flow volumes 
 
 
 
 
 
 
Table 9.6: Between-group pairwise comparisons for blood flow volumes 
 
 
 
 
 
 
 
 
 
RFP -.024 .116 1.000
CTR .021 .116 1.000
RFH .024 .116 1.000
CTR .045 .116 1.000
RFH -.021 .116 1.000
RFP -.045 .116 1.000
RFP .690
* .122 .000 1.88
CTR .659
* .122 .000 1.89
RFH -.690
* .122 .000
CTR -.031 .122 1.000
RFH -.659
* .122 .000
RFP .031 .122 1.000
2 RFH
RFP
CTR
Effect size 
(Hedges's g)
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Bonferroni.
Time Group
Mean 
Difference Std. Error Sig.
b
1 RFH
RFP
CTR
1 2 -.647
* .045 .000 1.75
2 1 .647
* .045 .000
1 2 .067 .045 .145
2 1 -.067 .045 .145
1 2 -.009 .045 .848
2 1 .009 .045 .848
CTR
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Bonferroni.
Group Time
Effect size 
(Hedges's g)
Mean 
Difference Std. Error Sig.
b
RFH
RFP
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9.3.4 Blood flow intensity 
Figures 9.8 & 9.9 shows the mean (SD) deep blood flow intensity recorded using power 
Doppler ultrasound pre-and post treatment and the percentage changes of mean 
respectively. The statistical analysis (2*3 mixed methods ANOVA (time, group)) revealed a 
highly significant main effect for time (within-group change) (F (1, 42) = 25.578, p < 0.001) 
and a highly significant interaction between group and time (F (2) = 43.744, p < 0.001). 
Therefore, the type of intervention made a significant difference to the reported blood flow 
intensities and there was a significant overall difference between the pre-and post results. 
There was no significant difference between the baseline values of the three groups. 
Results of the pairwise comparisons (adjustment for multiple comparison: Bonferroni), their 
significance values and their effect sizes (where the interaction was relevant and 
meaningful) are reported in Tables 9.7 & 9.8. All significant effects and interactions have 
been highlighted. Like SBF and blood flow volume, any change in blood flow intensity over 
time was only noted within the active group, which was also significantly higher than that of 
the other two groups. There was no difference between the placebo and control groups. 
Figure 9.8: The mean (SD) blood flow intensities from the three groups 
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Figure 9.9: Percentage change in the mean blood flow intensities from the baseline 
 
 
 
 
 
 
 
 
 
 
Table 9.7: Within-group pairwise comparisons for blood flow intensities 
 
 
 
 
 
 
Table 9.8: Between-group pairwise comparisons for blood flow intensities 
 
 
 
 
 
 
 
 
 
 
RFP -.280 .417 1.000
CTR -.204 .417 1.000
RFH .280 .417 1.000
CTR .077 .417 1.000
RFH .204 .417 1.000
RFP -.077 .417 1.000
RFP 2.462
* .405 .000 2.05
CTR 2.718
* .405 .000 2.34
RFH -2.462
* .405 .000
CTR .257 .405 1.000
RFH -2.718
* .405 .000
RFP -.257 .405 1.000
2 RFH
RFP
CTR
Effect size 
(Hedges's g)Time Group
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Bonferroni.
Mean 
Difference Std. Error Sig.
b
1 RFH
RFP
CTR
1 2 -2.611
* .248 .000 2.17
2 1 2.611
* .248 .000
1 2 .131 .248 .599
2 1 -.131 .248 .599
1 2 .311 .248 .216
2 1 -.311 .248 .216
CTR
Effect size 
(Hedges's g)Group Time
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Bonferroni.
Mean 
Difference Std. Error Sig.
b
RFH
RFP
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9.3.5 Blood flow velocity 
Figures 9.10 & 9.11 shows the mean (SD) blood flow velocity recorded using colour Doppler 
ultrasound pre-and post treatment and the percentage changes of mean respectively. The 
statistical analysis (2*3 mixed methods ANOVA (time, group)) did not reveal any significant 
main effect for time (within-group change); however, there was a small yet significant 
interaction between group and time (F (2) = 3.976, p = 0.026). Therefore, the type of 
intervention made a significant difference to the reported blood flow velocities although there 
was no significant overall difference between the pre-and post results. There was no 
significant difference between the baseline blood flow velocities of the three groups. 
Results of the pairwise comparisons (adjustment for multiple comparison: Bonferroni), their 
significance values and their effect sizes (where the interaction was relevant and 
meaningful) are reported in Tables 9.9 & 9.10. All significant effects and interactions have 
been highlighted. The active group demonstrated a small yet significant increase in the 
blood flow velocity, which was also significantly different from the placebo group. Neither 
placebo nor control group changed significantly within group. 
Figure 9.10: The mean (SD) blood flow velocities from the three groups 
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Figure 9.11: Percentage change in the mean blood flow velocities from the baseline 
 
 
 
 
 
 
 
 
 
 
Table 9.9: Within-group pairwise comparisons for blood flow velocities 
 
 
 
 
 
 
Table 9.10: Between-group pairwise comparisons for blood flow velocities 
 
 
 
 
 
 
 
 
 
 
RFP .044 .384 1.000
CTR -.168 .384 1.000
RFH -.044 .384 1.000
CTR -.211 .384 1.000
RFH .168 .384 1.000
RFP .211 .384 1.000
RFP 1.156
* .418 .025 0.99
CTR .675 .418 .341
RFH -1.156
* .418 .025
CTR -.482 .418 .766
RFH -.675 .418 .341
RFP .482 .418 .766
2 RFH
RFP
CTR
Effect size 
(Hedges's g)Time Group
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Bonferroni.
Mean 
Difference Std. Error Sig.
b
1 RFH
RFP
CTR
1 2 -.591
* .291 .049 0.54
2 1 .591
* .291 .049
1 2 .521 .291 .080
2 1 -.521 .291 .080
1 2 .251 .291 .393
2 1 -.251 .291 .393
CTR
Effect size 
(Hedges's g)Group Time
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Bonferroni.
Mean 
Difference Std. Error Sig.
b
RFH
RFP
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9.3.6 Core temperature, blood pressure and pulse rate 
Like the laboratory study, no significant variations were noted in any of the groups for the 
mean core temperature, mean PR or mean BP. 
9.3.7 Comparison between the normative and patient data 
The statistical analysis (3*2 mixed methods ANOVA (time, group)) revealed a significant 
interaction between the group and time for all physiological outcomes when the 
asymptomatic population data was compared to the patient data. This meant that the 
normative (asymptomatic) population responded differently to the patient population at time 
points two (post treatment) and three (20-minute follow-up) for all outcomes. The responses 
were significantly more pronounced among the patients. Key results are reported in Table 
9.11. 
Table 9.11: Main interactions and pairwise comparisons between the normative and patient 
physiological data 
 
 
 
 
 
 
 
 
 
 
 
 Discussion 
This chapter presented the results of the last part of this research project that overall carried 
out a series of studies relating to the physiological and clinical effects of RF-based treatment 
in asymptomatic adults as well as adult patients affected by chronic OA of the knee joint. In 
this study, the skin and deep physiological measures that increased significantly after 
exposure to a high dose of CRMRF when studied on asymptomatic adults were repeated on 
patients to enable a comparison. The physiological testing was carried out concomitantly 
with the clinical RCT on the same study groups that examined the benefits of CRMRF on 
Physiological measure Parameter F statistic p value
Time*Group interaction 5.167 0.013
Post treatment NS
20-minute follow-up 0.004
Time*Group interaction 5.663 0.012
Post treatment 0.012
20-minute follow-up NS
Time*Group interaction NS
Post treatment NS
Time*Group interaction 7.768 0.009
Post treatment 0.009
Time*Group interaction 12.966 0.001
Post treatment 0.001
Skin temperature
Skin blood flow
Deep blood flow velocity
Deep blood flow volume
Deep blood flow intensity
NS - Not significant
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pain and function in OA knee. All the relevant measurements were carried out during the first 
treatment session of the four-month long clinical trial. However, all experimental groups from 
the laboratory study were not able to be replicated in the patient physiological study owing to 
time constraints and the fact that priority was given to the clinical outcomes study that 
involved three groups only.  
No similar physiological studies conducted on patients employing RF below the shortwave 
frequency range have been reported so far. Hence the author is unable to draw any direct 
comparisons from the literature. To the contrary, considerable numbers of SWT studies have 
been reported in the last several decades, which have been covered in detail in the section II 
of this thesis. In one such study on the physiological effect of PSWT on patients with OA 
knee, Al-Mandeel (2004)192 reported more pronounced skin physiological responses such as 
SKT and SBF among the patients when compared to those obtained from asymptomatic 
adults. Similar MP doses of PSWT were used for both groups of participants. The study also 
suggested that in either group of participants, the key factor that may have determined the 
extent of physiological effect might be the applied dose of RF, with a significantly low MP 
dose of PSWT proving only as good as a placebo.192 
From the results of the current study it is obvious that the physiological responses obtained 
from the patients were significantly more pronounced than those obtained from the 
asymptomatic adults; however, the patients received a significantly higher average treatment 
dose (p = 0.013) in comparison to the earlier laboratory study. In contrast, the SAR in the 
two groups was not significantly different from each other, which effectively negates the 
effects of a difference in the overall dose (SAR was marginally lower for patients). The mean 
(SD) CRMRF doses delivered in the laboratory study and the first session of the clinical 
study were 42.37 (4.64) W and 46.87 (4.08) W respectively, which means the mean dose 
(and hence the total energy) was about 10% higher in the clinical study. While the 
percentage change in SKT after CRMRF intervention was commensurately higher among 
patients, the skin and deep blood flow responses (except blood flow velocity) were more 
than twice as greater among the patients. However, agreeing to the laboratory study, no 
significant changes were noted in the core temperature, BP or PR in any group at any time. 
One of the differences between the laboratory study and the clinical study was that the 
laboratory provided a more controlled environment in terms of room temperature, humidity 
and any potential noise due to interference from other fields. The room temperature was 
always monitored during the laboratory study and maintained within the thermoneutral zone 
for humans. However, it was not possible to alter the room temperature in the hospital, 
although it was periodically monitored. Also, there was no provision to monitor the humidity 
levels in the hospital treatment room. The mean (SD) room temperatures for the CRMRF 
high dose groups in the laboratory and clinical study were 25.12 (1.14) oC and 24.27 (0.93) 
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oC respectively. Ultimately, there was no indication from either study that room temperature 
and/or humidity correlated significantly with the physiological responses from the 
participants. 
The study had its limitations like the laboratory study segments. There was no blinding on 
the part of the therapist who delivered the interventions and performed the assessments 
making this study only single-blind at best. The post treatment skin measurements could 
only be started with a delay of a minimum of two minutes after the end of treatment due to 
skin preparation time. The start of deep blood flow measurements was delayed even further, 
by at least five minutes after the end of treatment. Further, like the laboratory study, 
temperature from the deeper tissues were not measured. No measurements could be 
performed during the intervention phase and the follow-ups of skin measurements could not 
be continued for longer than 20 minutes. 
Together, the above factors have affected the validity of the findings on the physiological 
responses of CRMRF in patients to some extent. Nonetheless, like the laboratory study 
results, there has not been any sharp decline in the responses of the active intervention over 
the follow-up phase. Hence, it is proposed that the effects would have been sustained 
significantly for more than 20 minutes providing a longer therapy window. The reported 
effects from the current clinical study are based on the convention that the participants 
maintained their treatment position throughout the experiment (lying in supine). 
 Conclusions 
The high dose CRMRF delivered to participants affected by OA knee yielded highly 
significant gains in SKT, SBF, deep blood flow volume and intensity of flow, and a marginal 
yet significant increase in the deep blood flow velocity over the placebo and control 
interventions. Core temperature, BP and PR did not change significantly at any time in any 
group. The findings were generally more pronounced than that obtained from the 
asymptomatic adults in the laboratory study; however, the patients had received a higher 
average dose of CRMRF (hence a higher amount of energy) compared to those in the 
laboratory study. The SAR was not significantly different between the two. The results 
confirm that the physiological effects of CRMRF in an asymptomatic population can be 
reproduced in a patient population potentially in a more pronounced manner, and per se the 
effects may indicate the presence of clinical benefits such as those observed in the patients 
affected by OA knee (previous chapter). 
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10 Chapter 10 – General discussion and key messages 
  Introduction 
Radiofrequency-based treatment in therapy-related clinical practice has become less 
common in the contemporary therapy environment in the Western world. This fashionable 
shift in practice became more evident in the recent decades, concomitant with a shift in 
emphasis towards other forms of physical therapy and newer trends in EPAs. However, RF-
based EPAs are still used reasonably widely as revealed by the literature review although 
the clinical application and research are largely limited to the shortwave frequency range. 
The use and research of microwave therapy (microwave diathermy) have also diminished. 
The RF frequencies below the shortwave range (such as the CRMRF employed in this 
research) are not used as commonly as shortwave RF frequencies and little is known about 
their underpinning mechanisms, effects and efficacy due to a scarcity of research in the 
area. Nonetheless, their clinical use and commercial presence have not diminished. It is 
interesting to note that EPAs such as the CRMRF have close resemblance with longwave 
diathermy, an EPA that had been in clinical use decades ago (a complex EPA, the clinical 
use of which diminished owing to practical reasons), although the resemblance is limited to 
the base frequency of RF employed. 
The research described in this thesis was primarily aimed at addressing the shortcomings in 
the knowledge base relating to 448 kHz CRMRF. Three segments of work involving a 
detailed review of therapy-related RF literature, multi-stage laboratory studies on 
asymptomatic adults and hospital-based clinical investigation on patients affected by chronic 
OA of the knee joint were completed. The clinical trial on patients also incorporated the key 
elements of the laboratory-based physiological study. The results of all study segments were 
discussed in detail and the summary findings were laid out in the preceding chapters. As a 
concluding section, this chapter will aim to draw on the main findings and key arguments 
from all segments of this project. 
  Radiofrequency evidence base 
10.2.1 Main findings 
The results of the comprehensive review of literature presented in section II has confirmed 
that the research on RF-based EPAs in therapy practice is largely centred on the shortwave 
frequency range. The quality of the research and its reporting remained poor across the 
whole spectrum of clinical studies, especially the studies published in the earlier decades. 
Often the results proved contradictory, with no clear association between the methodological 
quality score of a study (Downs and Black score) and its reported outcome. The outcomes 
mostly appeared to follow a dose-response relationship. 
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As explained in chapter 2, an all-inclusive approach followed in the literature review and the 
diverse nature of the identified studies precluded a systematic review. If the assumptions of 
a systematic review were to be imposed, only a handful of studies on the effect of SWT on 
OA knee would have met the inclusion criteria. Besides, it should be noted that several 
systematic reviews on the effect of SWT on OA knee have already been published. Among 
the other conditions, sufficient number of qualifying studies were not identified to enable a 
systematic review. In the future, in the event of more studies being published on conditions 
other than OA knee, systematic reviews should be undertaken. These reviews should follow 
stricter inclusion criteria on the methodological aspects such as the RF doses used, the use 
of standardized outcome measures and baseline comparability of the group data. 
Based on the available evidence from the shortwave studies, it is proposed that the only 
clinical conditions where RF-based therapy may be beneficial are chronic OA of the knee, 
chronic LBP, acute postoperative pain and acute postoperative wound healing. Within these 
conditions only OA knee had a reasonable number of studies reported. Except for OA knee 
no recommendations for treatment doses could be made for any of the conditions. It is 
entirely possible that it is the lack of quality studies and hence the lack of quality evidence 
for the other conditions that has lead the researcher to making such a conclusion. It should 
be noted that a ‘lack of evidence’ is not necessarily an ‘evidence of lack’. In this era of 
evidence-based practice, good quality research studies that comply with the required levels 
of methodological robustness and completeness of reporting should continue to be reported 
and reviewed before any claims about efficacy can be proved or disproved. 
The complete lack of studies on the CRMRF frequency range provided the researcher no 
understanding about the effects, efficacy and the theoretical underpinning of this type of RF 
energy. Hence there was little information from the literature review that could be carried 
forward to the next phase in a manner that informed and influenced the later stages of 
CRMRF research in this project. 
10.2.2 Key messages 
In summary, based on the available literature the three key take home messages reached 
from the literature review are given below. 
1) Shortwave therapy delivered at the appropriate dosage parameters can help to alleviate 
pain, reduce inflammation and improve tissue healing in certain conditions. 
2) There is insufficient information available on the effects, efficacy and theoretical 
underpinning of RF-based therapy operating below the shortwave frequency range. 
3) The effects of RF in tissues are largely thermophysiological, although no definitive 
information is available for frequencies lower than shortwaves. 
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  Experiments on physiological effects of RF 
10.3.1 Asymptomatic adults 
The lack of information available on the effects of low frequency RF-based therapies and the 
indication from the literature that per se the predominant biological effect of RF is 
thermophysiological, led the focus on to investigating tissue temperature, tissue extensibility 
and blood flow responses in the laboratory studies. As identified previously, the changes in 
these parameters reflect the body’s response to thermophysiological stimuli. However, due 
to a lack of published studies, it was unclear if the physiological responses to CRMRF would 
have any association to that of SWT. Multiple doses of CRMRF were employed to study the 
level of variation in response and the potential dose response relationship. PSWT is not 
known to cause extremely high thermophysiological responses due to a washout of the heat 
energy from the tissues during its “off cycle”. The inclusion of a high dose PSWT group in 
the study enabled a comparison of its thermophysiological responses with that of CRMRF. 
10.3.1.1 Main findings 
The laboratory study involving asymptomatic adults confirmed that a high dose of CRMRF 
can significantly increase and sustain SKT and skin and deep blood flow changes, 
significantly more than a comparable high dose of PSWT. In fact, the effects induced by 
PSWT were only as big as those induced by a low ‘minimally/sub thermal’ dose of CRMRF. 
More importantly, the skin physiological effects induced by PSWT were not sustained over 
the follow-up assessment phase. By contrast, the low dose CRMRF despite only inducing a 
similar minimal skin thermal perception both significantly enhanced and sustained SKT and 
SBF. It also significantly increased the blood flow volume at depth. These findings are 
interesting from the perspective of a ‘therapy window’ effect where only the CRMRF 
interventions provided a longer lasting effect, to be of clinical use. 
Considering the responses from the two contrasting doses of CRMRF, it is proposed that 
CRMRF is potentially capable of inducing a sustained influence on the physiological 
processes relating to SKT and local blood flow with mechanisms that are either thermal or 
nonthermal or both. While the significantly pronounced effect of high dose CRMRF on blood 
flow may clearly have been due to a significant rise in tissue temperature (effect being 
predominantly thermal), the low dose CRMRF also produced significant rise in blood flow 
(although the ‘effect size’ was smaller) despite a lack of commensurate rise in tissue 
temperature. This might potentially have been a combined thermal and nonthermal effect. 
As discussed, previous research with shortwave has proposed that a tissue temperature rise 
more than 40 oC may be necessary to increase deep blood flow.96 Deep tissue temperature 
was not monitored in the current study, and per se any such correlations cannot be drawn 
for the presented results; however, the tissue temperature is unlikely to have risen to levels 
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above 40 oC in this study. Still, a rise in both the volume and intensity of deep blood flow 
were noted with the high dose CRMRF, while even the low dose CRMRF increased the 
volume of flow. In contrast, a high dose of PSWT that generated a similar small rise in SKT 
as the low dose CRMRF failed to have any impact on the blood flow suggesting its lack of 
notable effect in the absence of significant tissue heating. In other words, unlike CRMRF the 
current study did not reveal any evidence for a potential nonthermal impact of PSWT on 
blood flow. 
Considering the above argument, it is implied that compared to CRMRF a substantially 
higher dose of treatment and hence a substantially higher amount of energy (potentially 
generating a high thermal response) may be needed for PSWT to produce effects like that of 
CRMRF. PSWT was in fact designed to deliver pulsed RF energy to provide physiological 
benefits without an undue rise in tissue temperature like that observed in CSWT. It appears 
from this study that a low dose CRMRF can potentially achieve the same benefits more 
effectively than PSWT without unduly raising the tissue temperature and despite being a 
continuous mode RF therapy. Therefore, it is assumed that the type of applied energy might 
also be a critical factor beside the temperature change, in deciding the level of tissue 
response. 
10.3.1.2 Dose response relationship and SAR 
The high dose CRMRF inducing a more pronounced physiological response than the low 
dose CRMRF indicates a dose-response relationship between groups. The mean dose 
delivered to the high dose group was twice as big as that of the low dose group. In addition, 
there were small variations in dosage within the groups itself since a fixed dose was not 
delivered to everyone in the group (dosing varied based on their thermal perception and 
thermal tolerance). 
Similarly, the physiological responses within the groups varied between participants. 
However, the dose variations within the groups did not concomitantly correlate to this 
variation in the level of physiological responses within the groups. A correlational analysis 
was performed between the applied dose and the percentage change in each physiological 
measure in each group to confirm this. Similarly, no significant correlations were found within 
group between the estimated whole-body SAR and any of the physiological parameters. The 
points given below summarises the above arguments. 
▪ A dose response relationship was observed between the high and low dose CRMRF 
groups. 
▪ There was no dose response relationship within the groups although the participant 
doses and physiological responses were varied. 
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▪ The difference in physiological outcome among the participants in a group was not 
related solely to their differences in the overall dose or SAR. 
It is problematic to calculate the SAR for the local treated area since the exact volume of 
tissues that was exposed to the RF energy cannot be determined. In addition, there are 
issues with potential scattering of the RF waves, which means not all the applied energy 
may reach the target tissues. This means that both parameters that are required to calculate 
an accurate SAR – received energy and the mass of tissue exposed cannot be determined 
accurately. However, the whole-body SAR can be calculated from the total body mass of the 
person and the total applied energy. Hence, if it is assumed that the energy loss due to 
scattering or other causes was zero, the mean (SD) estimated whole body SAR was 0.60 
(0.09) W/kg for the CRMRF high dose group and 0.27 (0.07) W/kg for the low dose group. 
Since the PSWT group had received a higher MP dose of RF energy, the mean (SD) SAR 
was marginally higher at 0.67 (0.10) W/kg. Therefore, it appears that CRMRF can achieve 
more pronounced physiological responses than PSWT when estimated whole body SAR 
levels are considered. 
Since only two doses of CRMRF were studied in this research project based on the 
subjective perception of the participants, the minimum required dose for the optimum 
response in any physiological parameter could not be identified. It has also not been 
possible to identify why some participants were able to receive a higher dose of RF when 
compared to the others. It was thought that the BMI of the individual may positively correlate 
with the level of energy uptake; however, no such correlation or even a trend towards such a 
correlation was observed in the data. As a result, it was noted that the higher the BMI, the 
lower was the SAR. It is therefore proposed that the thermal sensory perception of the 
individual may have been solely responsible for the level of energy uptake. The thermal 
perception is a normally distributed phenomenon in a normative sample. Further studies will 
need to be carried out to further identify the dosage and other intervention parameters. 
Numerous limitations of these studies on the asymptomatic participants have already been 
discussed in chapters 5 & 6. 
10.3.1.3 Key messages 
In summary, based on the responses from the asymptomatic adults the three key take home 
messages from the laboratory study are given below. 
1) Both high and low doses of CRMRF can induce significant skin and deep physiological 
responses and potentially provide a longer ‘therapy window’ when compared to PSWT, 
with the responses being generated at lower estimated SAR levels. 
2) Both thermal and non-thermal mechanisms may underpin the temperature and blood 
flow changes induced by CRMRF in tissues. 
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3) Similar physiological responses generated in patients might lead to commensurate 
clinical benefits. 
10.3.2 Patients with OA knee 
Pathological tissues could respond differently to RF exposure when compared to normal 
tissues,105,192 which means a direct extrapolation of the findings from a normative sample to 
a patient population could be problematic. The literature on the physiological response of 
patients to RF-based EPAs is less extensive when compared to that of asymptomatic 
people. As already identified such evidence for RF below the shortwave frequency band is 
non-existent. Replicating the key elements of the laboratory-based investigation of CRMRF 
on patients with OA knee alongside investigating the clinical benefits using clinical outcomes 
were expected to throw light on an otherwise unexplored area that claims to be beneficial in 
therapy. 
10.3.2.1 Main findings 
The results from the experiments on patients with OA knee demonstrated that a high dose of 
CRMRF can provide even greater physiological benefits in patients with OA knee when 
compared to the effects on a normative sample, while a placebo showed no meaningful 
effects on either group of participants. 
Although the laboratory study on asymptomatic adults involved two additional groups that 
received a low dose CRMRF and a high dose PSWT, they were not carried forward to the 
study on patients. As active treatments, the effects of those two interventions were less 
pronounced when compared to the CRMRF high dose in the laboratory study as explained 
previously. Clinically, based on an anticipated dose response relationship like those 
observed in the lab study (Chapters 5 & 6) and those observed in the past shortwave studies 
on OA knee,192 as well as asymptomatic adults,105 a low dose CRMRF intervention was only 
expected to be clinically less beneficial for a chronic musculoskeletal condition such as OA 
knee when compared to a high dose CRMRF. Low dose CRMRF may have a significant 
clinical value when employed as a treatment option in acute conditions where physiological 
responses without a heating effect are the intended outcome. This would need to be verified 
through further clinical research. Although PSWT had been researched considerably in the 
past, its inclusion was outwith the scope of the clinical trial in this project. 
The whole body estimated SARs were calculated for the patient study as well, like the 
laboratory study. The mean (SD) SAR of the active group that received the high dose 
CRMRF was 0.54 (0.08). Dose-response correlations between groups could not be analysed 
for the patient study as there was only one RF group. Nonetheless, within the active group 
like the laboratory study there were no meaningful or significant correlations between the 
treatment dose or SAR and any of the physiological outcomes. 
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10.3.2.2 Comparison of the patient data with the normative sample data 
As stated, the patient study only examined those physiological parameters that responded to 
a high dose CRMRF in the asymptomatic sample. The changes to the experimental protocol 
when the study was conducted on patients have already been detailed in Chapter 9. Several 
of the comparative details between the two studies have also been discussed in the same 
chapter. This section aims to draw on the key points and issues that were identified. 
In summary, the physiological effects of CRMRF on patients were significantly more 
pronounced in patients than in the asymptomatic sample. The patients received a 10% 
higher overall treatment dose on average when the two were compared. However, their 
SARs did not differ significantly, and the patient SAR was in fact marginally lower as 
reported. There may be several reasons why the patients can receive a higher overall dose 
of CRMRF energy than the asymptomatic participants in the laboratory study. The patients 
who participated in the active group had a significantly higher BMI (and body weight) and 
body fat percentage compared to the asymptomatic participants (data reported in chapters 6 
& 8). The higher body weight also meant that the patients potentially had a higher volume of 
tissues receiving the treatment compared to the healthy participants and were thus able to 
absorb a higher quantity of CRMRF energy yet maintaining a lower rate of absorption (SAR).  
The above argument is vindicated by the fact that there was a strong positive correlation 
between the active group CRMRF dose and the BMI of the group participants. This point is 
further supported by the comparative estimated whole-body SARs in both groups of 
participants. That is, although the patients received a higher average dose, their estimated 
whole-body SAR was lower than that of the asymptomatic participants. Effectively, 
considering the points discussed above the patients could generate a substantially higher 
physiological response despite receiving a lower amount of energy per unit body mass. 
Despite the greater physiological responses among the patients, a direct comparison of the 
results of the two studies may not be valid owing to not only the differences in dosage/SAR, 
but also the other reasons given below. 
The CRMRF being a continuous mode RF is expected to cause heat build-up in tissues; it is 
challenging to deliver a pre-set dose to all participants unless substantially lower doses are 
delivered where there will be no significant heat build -up. Hence, the dosing in both studies 
was regulated according to the recipients’ reported thermal perception that might have been 
different among the two samples. Even if both studies had employed similar average doses 
of CRMRF, comparison of the physiological responses between the two would still have 
been problematic. Firstly, for the skin physiological measures both the devices and the site 
of measurement were changed for the clinical study. No validity studies were undertaken 
prior to the clinical trial to establish the agreement between the Biopac and the FlexComp 
Infiniti units owing to time constraints. All comparisons between the two sets of data are 
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done based on face validity between the two devices. The skin response and rate of change 
of response may both have varied due to either/both reasons. For the deep blood flow, the 
site of measurement and the ultrasound probe remained the same across studies; however, 
the ultrasound scanner device was changed to a portable version for the clinical study. 
Therefore, owing to the above reasons, the statistical comparison (reported in chapter 9) 
was restricted to between the percentage changes in scores from the baseline where the 
baseline was taken as zero in all groups (data normalization). 
The demographic and anthropometric factors differed significantly between the laboratory 
study and the clinical study. This, alongside the presence of pathology may have contributed 
to the patients’ differences in perception of the RF energy. In addition, because of the urge 
to receive treatment, the patients may have shown a more positive attitude towards the RF 
delivery, whereas for the asymptomatic people this could have been a potentially 
unnecessary experience. The patients’ subjective feedback on the ‘pleasantness of 
treatment’ justified this viewpoint since the patients suggested that they liked their knee 
being subjected to heat treatment because they believed it reduced pain and stiffness. No 
measure on tissue extensibility was used in the clinical study. Since the patients might have 
had limited tissue extensibility due to the stiffness associated with their OA knee, it is 
possible that a measure of tissue extensibility might have obtained a different result when 
compared to the asymptomatic people. 
  The clinical outcomes from the OA knee study 
During the set-up period for the RCT, several hinderances and long delays were 
encountered in the administrative procedures between the NHS Trust and the University 
itself. The Trust and the university were not able to expedite matters in a coordinated and 
timely manner despite the study gaining the NHS Ethics approval relatively quickly. The 
researcher understands that a valid existing contract was not in place between the two 
bodies, which otherwise would have helped to speed up the process. The researcher also 
spent considerable time in identifying and establishing a study centre. In hindsight, the 
preparation for the RCT should have been instigated much earlier to allow for all potential 
delays, such as those identified above. 
On the contrary, once the RCT was started the recruitment of 45 patients affected by OA 
knee into the clinical trial was achieved within seven months from the start of recruitment. 
The fact that more than half of all suitable patients who were contacted consented to take 
part helped to speed up recruitment. Although it was anticipated that a greater number of 
participants would be needed to account for potential drop-outs, a smaller actual drop-out 
rate meant that 45 was sufficient to meet the necessary statistical power. With the kind co-
operation of the departmental staff at the study centre, the communication with participants, 
250 
the recruitment process and the running of the trial materialised effectively as anticipated. 
The intervention design, intervention duration and treatment session times were decided 
based on what was realistically able to be achieved in a clinical environment and the current 
best practice. It was well-accepted by all trial participants. On reflection, it appears that the 
above intervention design and the clinical outcome measures used have been effective 
given the positive results from the study. However, whether better results could have been 
obtained with alternate intervention parameters is unknown and warrants further research. 
10.4.1 Main findings 
The randomised controlled trial on patients with OA knee showed that a high dose of 
CRMRF can produce statistically and clinically significant gains in pain and function in the 
short to medium term, which is also significantly more pronounced than the effect produced 
by a placebo or a control treatment condition involving standard care only. The subjective 
feedback from the participants indicated that the intervention substantially improved their 
functional quality of life in the short to medium term. All patients in the active group could 
reduce their pain medication intake and many who were being considered for invasive 
procedures by their consultant, were able to postpone the same (either statistic was not 
documented as an outcome in the study). 
The return of symptoms towards the end of three months after the intervention was in part 
due to the treatment effect wearing off and supposedly also due to the participants’ 
increased physical activity as result of pain relief. The latter observation is based on the 
patient feedback received, where some have said unaccustomed physical activity led to their 
symptoms resurfacing. This is further supported by the observation that several participants 
who continued to restrict their physical activity despite their symptoms reducing after 
CRMRF intervention have continued to sustain their improvement even at the end of the 
three-month follow-up. 
The study demonstrated that a significant increase in the physiological parameters have also 
been associated with a significant improvement in the clinical outcomes of pain and function, 
although they did not necessarily have the same effect sizes. To investigate if these two 
responses were correlated so that whether a rise in the physiological responses can indicate 
potential clinical benefits, a correlational analysis was performed between the percentage 
changes in the physiological parameters of the actively treated group and that in the main 
clinical outcomes of the group. There were no such correlations or even a trend towards 
such a correlation noted. This meant that based on the results of this study a change in the 
physiological responses did not indicate potential clinical benefits. This is also supported by 
the fact that while the placebo CRMRF intervention produced significant clinical benefits 
(although the effect was much smaller than the active treatment), it had not produced any 
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meaningful physiological response. Similarly, the changes in the applied dose of CRMRF or 
the SAR among the participants within the active group did not correlate with the rate of 
change in clinical outcomes. In other words, whether the percentage change in the clinical 
outcomes of one participant was different from that of another participant in the active group 
was not influenced solely by their treatment dose or SAR. 
Since only one group receiving an active RF treatment was employed in the study, a 
comparison with other forms of RF (such as PSWT) or dose-response relations between 
multiple doses of CRMRF was not investigated. Overall, the findings of the clinical trial are 
promising. The literature review suggested that PSWT may be beneficial for the treatment of 
OA knee. As a separate RF-based EPA, CRMRF may also be an effective treatment option 
for the management of OA knee. More studies need to be conducted to examine if the 
results could be replicated in different settings, for more clinical conditions and in other 
patient groups and locations. Dosimetry studies and comparative studies with other similar 
EPAs that claim to be effective for the management of OA knee are also necessary. The 
current findings will provide credible baseline data for such future research, especially since 
the findings achieved sufficient statistical power. 
10.4.2 Key messages 
To conclude, the three key take home messages from the hospital-based investigation are 
given below. 
1) The physiological effects of CRMRF obtained from asymptomatic participants were 
replicated in patients with OA knee and the effects were more pronounced in the patient 
group. 
2) Significant short to medium term gains in pain and function were obtained with a four-
week CRMRF intervention over placebo and the current standard care (control) 
interventions, and the gains were more pronounced in females than in males. 
3) The rise in SKT and local blood flow might be indicative of potential clinical effects, but 
they do not necessarily define the possibility or extent of those clinical benefits. 
  Concluding remarks 
The research project has successfully completed all its segments. The work attempted to 
execute a logical progression and this thesis reports the project in its entirety. In hindsight, 
the work was completed meeting the full expectations of the researcher despite experiencing 
significant delays owing to Ethics approval and other administrative matters, slow participant 
recruitment and various hurdles relating to the setting up and running of a clinical trial within 
the NHS environment. However, apart from the time loss there has not been any adverse 
impact on the overall execution of the project or the potential patient benefits. 
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The focus of the project was pre-determined by the external funder for this work. Whilst they 
were neither directly involved in the design nor implementation of any of the components, 
their focus was determined a priori and was part of the contract between the company and 
the University. There was no reason to seek an adjustment to this contract clause given the 
potential value of CMFRF to a patient population, such as those with OA Knee. However, in 
hindsight, there has not been adequate patient and public involvement in the whole project, 
and especially in the RCT (where it was more relevant) apart from considering the patient 
satisfaction post intervention via a subjective ‘pleasantness of treatment’ feedback. It may be 
argued that the project was carried out with limited resources to a predetermined focus and 
hence it would have been challenging to employ such a comprehensive approach. It is 
proposed that future research in the area should ensure the involvement of patients, 
potential patients and other members of the health care profession in its development, 
design and delivery. 
Significant new findings that contribute to the existing body of evidence, informing clinical 
practice and that could guide future research to new extents were obtained. These findings 
have been reported back to the external stakeholder who remains committed to further 
research in the future. To the author’s knowledge other research projects relating to the 
biological effects of CRMRF are being carried out at other centres, in collaboration with the 
manufacturer. Some of these works have already been published.204,205 The findings from 
the current project are expected to inform on the future research, some of which are in the 
planning stage. For example, the manufacturer is likely to conduct studies investigating deep 
tissue thermal responses to CRMRF application, and how the proposed treatment effects 
might be altering the tissue characteristics in the presence of a pathology. 
Ultimately, the obtained knowledge is expected to benefit the patient community. Some of 
the results from the earlier stages reported in this thesis has already been published in 
international peer-reviewed journals (see list of publications) and more papers are expected 
to be published in the future. The results were also presented at university, national and 
international level conferences. This dissemination is anticipated to aid the academic, clinical 
and patient community and enable a better understanding of this electrophysical agent. 
Above all, this piece of work over the last five years has been a rigorous training exercise for 
the researcher on “how to conduct research”. A range of research skills, both in theory and 
practice, were developed and consolidated. It gave an opportunity to cultivate critical 
thinking, structured planning, and the conduct and evaluation of quantitative research. It is 
hoped that these skills would help the researcher to continue his engagement with clinical 
research throughout the future. 
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12  Appendices 
  Appendix 2.1: Key words and filter terms used in the literature 
searching
Main search terms (‘OR’ key words) 
Electromagnetic field 
Electromagnet* 
EMF 
EME 
Radiofrequency 
Radio frequency 
Radio-frequency 
RF 
Radio wave  
Microwave 
Millimetre wave 
Shortwave 
Short wave 
Short-wave 
Diathermy 
SWD 
SWT 
SW 
Electric field therapy 
EFT 
Tecar 
CRET 
High frequency current 
High frequency therapy 
High frequency energy 
High frequency 
High-frequency 
HFT 
HFC 
HFE 
HF 
Primary filter (‘AND’ key words) 
Biological effects 
Physiological effects 
Clinical effects 
Therapeutic effects 
Thermal effects 
Biolog* 
Physiolog* 
Clinic* 
Therap* 
Therm* 
Effects 
Skin 
Muscle 
Tissue 
Blood 
Elast* 
Exten* 
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Elongation 
Cell* 
Nerv* 
Metabol* 
Biochem* 
Pathol* 
Disease 
Treatment 
Medic* 
Secondary filter (‘NOT’ key words) 
Invasive 
Percutaneous 
Ablation 
Ablat* 
Surgery 
Surgical 
Radiotherapy 
Radiotherap* 
Mobile phone 
Telephon* 
Radar 
MRI 
PET 
Tomograph* 
RFID 
Television 
TV 
Polymer 
Spectroscop* 
Aviation 
Telemetry 
FM 
Robot* 
Plant 
Seed 
Germinat* 
Ocean* 
Fish* 
Communicat* 
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  Appendix 2.2: Cochrane risk of bias assessment tool 
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  Appendix 2.3: Downs and Black checklist for randomised and 
non-randomised studies 
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  Appendix 4.1: Biopac system specifications 
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  Appendix 4.2: MATLAB algorithm for colour Doppler image 
analysis in the laboratory study 
clear; 
  
NbFrame = 12; 
  
counter = zeros(1,NbFrame,'uint32'); 
colourIndex = zeros(1,NbFrame,'uint32'); 
imageROI = zeros(165,226,3,'uint8'); 
ROI_height = 1; 
ROI_width = 1; 
  
%Flag to search the ROI (go=true > search ROI & go=false > stop searching 
%ROI) 
go = true; 
  
%Size of the ROI window 
height = 165; 
width = 226; 
  
for framecounter = 1:NbFrame 
    ROI_height = 1; 
    ROI_width = 1; 
    go = true; 
     
    strframecounter = int2str(framecounter); 
    imagename = strcat('S3N1S2_T_PRE_20140711122826_ 
(',strframecounter,').bmp'); 
  
  
    %Search for the ROI 
    rawImage = imread(imagename); 
    size_raw_img = size(rawImage); 
    heightRaw = size_raw_img(1); 
    widthRaw = size_raw_img(2); 
    for scanHeight = 1:heightRaw 
       for scanWidth = 1:widthRaw 
        if (go == true && (rawImage(scanHeight,scanWidth,1) == 0 && 
rawImage(scanHeight,scanWidth,2) == 236 && rawImage(scanHeight,scanWidth,3) 
== 0)) 
            go = false; 
            for scanROI_H = (scanHeight + 1) : (scanHeight + 165) 
                ROI_width = 1; 
                for scanROI_W = (scanWidth+1) : (scanWidth + 226) 
                    imageROI(ROI_height,ROI_width,:) = 
rawImage(scanROI_H,scanROI_W,:); 
                    ROI_width = ROI_width + 1; 
                end 
                ROI_height = ROI_height + 1; 
            end 
        end 
       end 
    end 
  
  
%     imageScale = imread('scale.bmp'); 
%     size_img_ref = size(imageScale); 
%     heightref = size_img_ref(1); 
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% Calculate the colour doppler index 
        for m = 1:height 
            for n = 1:width 
                %Test whether or not the pixel is grey or not 
                  if ((imageROI(m,n,1) == imageROI(m,n,2)) && 
(imageROI(m,n,2) == imageROI(m,n,3))) 
                       im(m,n) = 0; 
                  else 
                      counter(framecounter) = counter(framecounter) + 1; 
                      im(m,n) = imageROI(m,n,2); 
                      %Add up the green component for the calculation of 
                      %the index 
                      colourIndex(framecounter) = colourIndex(framecounter) 
+ uint32(imageROI(m,n,2)); 
                  end 
            end 
        end 
         
end 
  
% U8 = im2uint8(im); 
% imshow(U8); 
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  Appendix 4.3: MATLAB algorithm for power Doppler image 
analysis in the laboratory study 
clear; 
  
NbFrame = 20; 
  
counter = zeros(1,NbFrame,'uint32'); 
powerIndex = zeros(1,NbFrame,'uint32'); 
imageROI = zeros(165,226,3,'uint8'); 
ROI_height = 1; 
ROI_width = 1; 
  
%Flag to search the ROI (go=true > search ROI & go=false > stop searching 
%ROI) 
go = true; 
  
%Size of the ROI window 
height = 165; 
width = 226; 
  
for framecounter = 1:NbFrame 
    ROI_height = 1; 
    ROI_width = 1; 
    go = true; 
     
    strframecounter = int2str(framecounter); 
    imagename = strcat('S3N1S2_T_PRE_20140711122826_ 
(',strframecounter,').bmp'); 
  
    %Search for the ROI 
    rawImage = imread(imagename); 
    size_raw_img = size(rawImage); 
    heightRaw = size_raw_img(1); 
    widthRaw = size_raw_img(2); 
    for scanHeight = 1:heightRaw 
       for scanWidth = 1:widthRaw 
        if (go == true && (rawImage(scanHeight,scanWidth,1) == 0 && 
rawImage(scanHeight,scanWidth,2) == 236 && rawImage(scanHeight,scanWidth,3) 
== 0)) 
            go = false; 
            for scanROI_H = (scanHeight + 1) : (scanHeight + 165) 
                ROI_width = 1; 
                for scanROI_W = (scanWidth+1) : (scanWidth + 226) 
                    imageROI(ROI_height,ROI_width,:) = 
rawImage(scanROI_H,scanROI_W,:); 
                    ROI_width = ROI_width + 1; 
                end 
                ROI_height = ROI_height + 1; 
            end 
        end 
       end 
    end 
  
  
  
% Calculate the power doppler index 
        for m = 1:height 
            for n = 1:width 
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                %Test whether or not the pixel is grey or not 
                  if ((imageROI(m,n,1) == imageROI(m,n,2)) && 
(imageROI(m,n,2) == imageROI(m,n,3))) 
                       im(m,n) = 0; 
                  else 
                      counter(framecounter) = counter(framecounter) + 1; 
                      im(m,n) = imageROI(m,n,2); 
                      powerIndex(framecounter) = powerIndex(framecounter) + 
uint32(imageROI(m,n,2)); 
                  end 
            end 
        end 
         
end 
  
% U8 = im2uint8(im); 
% imshow(U8); 
  
% figure 
% ax(1) = subplot(211); 
% rgbtest = imread('TestingBestFrame_image001.bmp'); 
% image(rgbtest); title('Original') 
% ax(2) = subplot(212); 
% image(im); title('Processed') 
% colormap(hot(256)) 
% linkaxes(ax,'xy') 
% axis(ax,'image') 
%movie2avi(M, 'D:\Binoy\flow_L1.avi', 'compression', 'None'); 
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  Appendix 4.4: MATLAB algorithm for Elastography image 
analysis in the laboratory study 
%Scan for the ROI from the left 
  
clear; 
%  
NbFrame = 10; 
%  
  
ROI_height_size = 350; 
ROI_width_size = 125; 
  
counter = zeros(1,NbFrame,'uint32'); 
imageROI = zeros(ROI_height_size,ROI_width_size,3,'uint8'); 
  
Index_soft = zeros(1,NbFrame,'uint32'); 
Index_intermediate = zeros(1,NbFrame,'uint32'); 
Index_hard = zeros(1,NbFrame,'uint32'); 
  
go = true; 
  
pointer = 1; 
imageScale = imread('scaleElasticity2.bmp'); 
size_imageScale = size(imageScale); 
heightscale = size_imageScale(1); 
  
scoreTable = csvread('scoringScale.csv'); 
  
%Search for the ROI 
for framecounter = 1:NbFrame 
    ROI_height = 1; 
    ROI_width = 1; 
    goROI = true; 
  
    strframecounter = int2str(framecounter); 
    imagename = strcat('S3N1S1_T_PRE_20140710144418 
(',strframecounter,').bmp'); 
    rawImage = imread(imagename); 
    size_raw_img = size(rawImage); 
    heightRaw = size_raw_img(1); 
    widthRaw = size_raw_img(2); 
  
    %Search for the ROI 
    for scanHeight = 1:heightRaw 
        for scanWidth = 1:widthRaw 
            if (goROI == true && (rawImage(scanHeight,scanWidth,1) == 0 && 
rawImage(scanHeight,scanWidth,2) == 236 && rawImage(scanHeight,scanWidth,3) 
== 0)) 
                goROI = false; 
                for scanROI_H = (scanHeight + 1) : (scanHeight + 
ROI_height_size) 
                    ROI_width = 1; 
                    for scanROI_W = (scanWidth + 2) : (scanWidth + 
ROI_width_size) 
                        imageROI(ROI_height,ROI_width,:) = 
rawImage(scanROI_H,scanROI_W,:); 
                        ROI_width = ROI_width + 1; 
                    end 
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                    ROI_height = ROI_height + 1; 
                end 
            end 
        end 
    end 
     
    goIndex = true; 
    % Calculate the elesticity indexes 
    for m = 1:ROI_height_size 
        for n = 1:ROI_width_size 
            %Find a colour match of the pixel with the scale 
            for p = 1:heightscale 
                if ((goIndex == true) && (imageROI(m,n,1) == 
imageScale(p,1,1)) && (imageROI(m,n,2) == imageScale(p,1,2)) && 
(imageROI(m,n,3) == imageScale(p,1,3))) 
                  goIndex = false; 
                  Index_soft(framecounter) = Index_soft(framecounter) + 
scoreTable(p,2); 
                  Index_intermediate(framecounter) = 
Index_intermediate(framecounter) + scoreTable(p,3); 
                  Index_hard(framecounter) = Index_hard(framecounter) + 
scoreTable(p,1); 
                end 
            end 
            goIndex = true; 
        end 
    end 
end 
     
  
 figure;plot(Index_intermediate,'DisplayName','Index_intermediate');hold 
all;plot(Index_soft,'DisplayName','Index_soft');plot(Index_hard,'DisplayNam
e','Index_hard');hold off; 
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  Appendix 4.5: MATLAB algorithm for colour Doppler image 
analysis in the clinical study 
clear; 
  
NbFrame = 37; 
  
counter = zeros(1,NbFrame,'uint32'); 
colourIndex = zeros(1,NbFrame,'uint32'); 
  
% ROI 
x_origin = 255; 
y_origin = 125; 
ROI_width = 441; 
ROI_height = 461; 
  
im = zeros(ROI_height,ROI_width,3,'uint8'); 
  
for framecounter = 1:NbFrame 
     
    strframecounter = int2str(framecounter); 
    imagename = strcat('P3N48_INITIAL_POST_20160729140439_CD 
(',strframecounter,').bmp'); 
      
    rawImage = imread(imagename); 
    size_raw_img = size(rawImage); 
    heightRaw = size_raw_img(1); 
    widthRaw = size_raw_img(2); 
  
    coordinate_x = 1; 
    coordinate_y = 1; 
     
     
    for scanHeight = y_origin:y_origin + ROI_height 
       for scanWidth = x_origin:x_origin + ROI_width 
              if (rawImage(scanHeight,scanWidth,1) == 
rawImage(scanHeight,scanWidth,2)) && (rawImage(scanHeight,scanWidth,2) == 
rawImage(scanHeight,scanWidth,3)) 
                  im(scanHeight-y_origin+1,scanWidth-x_origin+1,1) = 0; 
                  im(scanHeight-y_origin+1,scanWidth-x_origin+1,2) = 0; 
                  im(scanHeight-y_origin+1,scanWidth-x_origin+1,3) = 0; 
              else 
                  counter(framecounter) = counter(framecounter) + 1; 
                  im(scanHeight-y_origin+1,scanWidth-x_origin+1,1) = 
rawImage(scanHeight,scanWidth ,2); 
                  im(scanHeight-y_origin+1,scanWidth-x_origin+1,2) = 
rawImage(scanHeight,scanWidth ,2); 
                  im(scanHeight-y_origin+1,scanWidth-x_origin+1,3) = 
rawImage(scanHeight,scanWidth ,2); 
                  colourIndex(framecounter) = colourIndex(framecounter) + 
uint32(rawImage(scanHeight,scanWidth,2)); 
              end 
             
       end 
        
    end 
end 
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  Appendix 4.6: MATLAB algorithm for power Doppler image 
analysis in the clinical study 
clear; 
  
NbFrame = 40; 
  
counter = zeros(1,NbFrame,'uint32'); 
powerIndex = zeros(1,NbFrame,'uint32'); 
  
% ROI 
x_origin = 255; 
y_origin = 125; 
ROI_width = 441; 
ROI_height = 461; 
  
im = zeros(ROI_height,ROI_width,3,'uint8'); 
  
for framecounter = 1:NbFrame 
     
    strframecounter = int2str(framecounter); 
    imagename = strcat('P3N48_INITIAL_POST_20160729140439_PD 
(',strframecounter,').bmp'); 
      
    rawImage = imread(imagename); 
    size_raw_img = size(rawImage); 
    heightRaw = size_raw_img(1); 
    widthRaw = size_raw_img(2); 
  
    coordinate_x = 1; 
    coordinate_y = 1; 
     
     
    for scanHeight = y_origin:y_origin + ROI_height 
       for scanWidth = x_origin:x_origin + ROI_width 
        
              if (rawImage(scanHeight,scanWidth,1) == 
rawImage(scanHeight,scanWidth,2)) && (rawImage(scanHeight,scanWidth,2) == 
rawImage(scanHeight,scanWidth,3)) 
                  im(scanHeight-y_origin+1,scanWidth-x_origin+1,1) = 0; 
                  im(scanHeight-y_origin+1,scanWidth-x_origin+1,2) = 0; 
                  im(scanHeight-y_origin+1,scanWidth-x_origin+1,3) = 0; 
              else 
                  counter(framecounter) = counter(framecounter) + 1; 
                  im(scanHeight-y_origin+1,scanWidth-x_origin+1,1) = 
rawImage(scanHeight,scanWidth ,2); 
                  im(scanHeight-y_origin+1,scanWidth-x_origin+1,2) = 
rawImage(scanHeight,scanWidth ,2); 
                  im(scanHeight-y_origin+1,scanWidth-x_origin+1,3) = 
rawImage(scanHeight,scanWidth ,2); 
                  powerIndex(framecounter) = powerIndex(framecounter) + 
uint32(rawImage(scanHeight,scanWidth,2)); 
              end   
       end 
        
    end 
end 
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 Appendix 4.7: Biopac equipment calibration 
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  Appendix 4.8: Ethics approval memo (Protocol number: 
HSK/PG/UH/00015) 
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 Appendix 4.9: Raw data from the thermometer validation study 
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 Appendix 4.10: Informed consent for the intrarater reliability 
study for the ultrasound measurements 
 
 
UNIVERSITY OF HERTFORDSHIRE 
 
ETHICS COMMITTEE FOR STUDIES INVOLVING THE USE OF HUMAN PARTICIPANTS 
(‘ETHICS COMMITTEE’) 
 
FORM EC3 
CONSENT FORM FOR STUDIES INVOLVING HUMAN PARTICIPANTS 
The material contained in this form may be adapted for use in an alternative consent 
form, provided the principles of what is contained in the form are retained 
 
  
I, the undersigned [please give your name here, in BLOCK CAPITALS] 
 
…………………………………………………………………………………………………………… 
of [please give contact details here, sufficient to enable the investigator to get in touch with 
you, such as a postal  or email address] 
 
…..………………………………………………………………………………………………………. 
hereby freely agree to take part in the study entitled [insert name of study here] 
“Physiological effects of radiofrequency (RF)-based therapy – Stage 2”  
1  I confirm that I have been given a Participant Information Sheet (a copy of which is 
attached to this form) giving particulars of the study, including its aim(s), methods and 
design, the names and contact details of key people and, as appropriate, the risks and 
potential benefits, and any plans for follow-up studies that might involve further approaches 
to participants.   I have been given details of my involvement in the study.  I have been told 
that in the event of any significant change to the aim(s) or design of the study I will be 
informed, and asked to renew my consent to participate in it.  
2  I have been assured that I may withdraw from the study at any time without disadvantage 
or having to give a reason. 
3  I have been given information about the risks of my suffering harm or adverse effects.   I 
have been told about the aftercare and support that will be offered to me in the event of this 
happening, and I have been assured that all such aftercare or support would be provided at 
no cost to me.  
 
4  I have been told how information relating to me (data obtained in the course of  the study, 
and data provided by me about myself) will be handled: how it will be kept secure, who will 
have access to it, and how it will or may be used.   
HHSECDA Protocol Number: cHSK/PG/UH/00143 
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5  I have been told what will be done if the study reveals that I have a medical condition 
which may have existed prior to the study, which I may or may not have been aware of, and 
which could affect the present or future health of myself or others. If this happens, I will be 
told about the condition in an appropriate manner and advised on follow-up action I should 
take.   Information about the condition will be passed to my GP, and I may no longer be 
allowed to take part in the study. 
6  I have been told that I may at some time in the future be contacted again in connection 
with this or another study. 
 
Signature of 
participant……………………………………………………………Date…………………………. 
 
 
Signature of (principal) 
investigator…………………………………………………………..Date………………………… 
 
Name of (principal) investigator [in BLOCK CAPITALS please] 
 
…………………………………………………………………………………………………………… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
328 
 Appendix 4.11: Ethics approval for the intrarater reliability 
study for the ultrasound measurements (Protocol number: 
cHSK/PG/UH/00143) 
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 Appendix 4.12: Raw data from the intrarater reliability study 
for the ultrasound measurements 
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 Appendix 5.1: Participant information sheet for the 
laboratory-based study 
 
UNIVERSITY OF HERTFORDSHIRE 
ETHICS COMMITTEE FOR STUDIES INVOLVING THE USE OF HUMAN PARTICIPANTS 
(‘ETHICS COMMITTEE’) 
FORM EC6: PARTICIPANT INFORMATION SHEET 
Title of Research 
"The physiological effects of Radiofrequency (RF)-based therapy" 
 
Introduction 
You are being invited to take part in a research study. Before you decide whether to do so, it 
is important that you understand the research that is being done and what your involvement 
will include. Please take time to read the following information carefully and discuss it with 
others if you wish. Do not hesitate to ask us anything that is not clear or for any further 
information you would like to help you make your decision. Please do take your time to 
decide whether or not you wish to take part. Thank you for reading this. 
What is the purpose of this study? 
The proposed is the first of a series of (up to three) laboratory-based studies planned as part 
of a much wider PhD project, which aims to investigate the physiological response of healthy 
human adults to regional (local body area) application of Radiofrequency Electromagnetic 
Field (RF EMF) energy at a frequency of 448 kHz (448,000 Hertz). The purpose of the 
proposed study (Stage 1) is to investigate the skin thermal responses (how skin surface 
temperature changes over time) to this energy application. The main aims are: 
1. To identify the onset of heating, the point of moderate yet comfortable heating and the 
point of onset of heat discomfort (decided entirely by you, not the researcher) with the 
application of above mentioned RF energy. 
2. To periodically record the baseline (normal) and peak (after treatment) skin temperature 
and map out the skin temperature decline over time (thermal decay process) after 
application of this RF energy. 
Do I have to take part? 
It is completely up to you whether or not you decide to take part in this study. If you do 
decide to take part you will be given this information sheet to keep and be asked to sign a 
consent form. Agreeing to join the study does not mean that you have to complete it. You 
are free to withdraw if you change your mind at any stage without giving a reason. A 
decision to withdraw at any time, or a decision not to take part at all, will not disadvantage 
you in any way. 
What will happen to me if I take part? 
If you decide to take part in this study, you will be asked to attend the physiotherapy 
research lab in the Wright Building, College Lane Campus of the University of Hertfordshire 
for two occasions to receive RF-based treatment to your knee joint area and allow a series 
of skin temperature measurements to be taken from the treated area. Each session will last 
about 90 minutes, which includes screening, treatment, and assessments. Kindly note, all 
these procedures are completely non-invasive. 
On arrival to the laboratory the researcher will receive you and an informed consent will be 
signed by both parties. You will then be changing to appropriate clothing and will sit / lie 
Protocol Number: HSK/PG/UH/00015 
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down comfortably on a treatment couch with knees extended and resting on a pillow. As a 
screening process, prior to RF administration your skin over the treatment area will be tested 
using warm (not warm enough to cause any injury!) and cold water filled test tubes to make 
sure that you (skin of the area treated) can adequately distinguish between warmth and cold 
(skin thermal sensitivity). This screening will eliminate any risk of inadvertent injuries due to 
lack of skin thermal sensation. Hence, if you cannot distinguish between warmth and cold 
you will not be enrolled into the study. After screening and enrolment, yet before starting the 
treatment you will go through an acclimatization period. During this period, the researcher 
will record your 'baseline' (normal) skin temperature of the treatment area using a hand-held 
skin thermometer and will work you through the experimental procedures and give you 
written instructions on 'what to do' during the experiment. 
The RF energy will be delivered using 'HCR 902 Indiba activ Prorecovery' device 
manufactured by Indiba S. A., Barcelona, Spain. The device is proven safe for human use 
(CE marked) and is in use around the world in clinical practice. Round metallic electrodes 
(active electrode) smeared with a special conducting cream will deliver the energy to the 
front of your thigh just above the knee joint. An 'inactive' metal plate electrode will be placed 
under your calf muscles of the same leg to complete the circuit. The intensity of RF energy 
delivered to your knee will be increased incrementally every 30 seconds starting from the 
minimum output level. Throughout, you will be asked to report to the investigator, firstly the 
moment(s) when you begin to feel heat sensation, secondly when the heat builds up 
moderately (good yet comfortable heating), and finally the moment when you may begin to 
feel uncomfortable. The treatment will end at this point. There will be clear and simple 
written instructions on the 'what to do' sheet helping you identify these stages and inform the 
researcher accordingly. Please note, for the final stage the purpose is not to identify the limit 
of your heat tolerance, but the starting point where the heat may begin to make you 
uncomfortable. This point is entirely decided by you and the RF application will be 
terminated outright when you call out 'STOP'. The researcher will not make any attempt to 
prolong the RF application beyond this point. Since the treatment will stop at once this point 
is reached, there should be no risk of any heat injury. The machine itself will only cause a 
gradual build-up of heat commensurate with the intensity of energy delivered. In addition, it 
may be noted that similar patient-led scenarios (intensity of treatment adjusted according to 
patient feedback) already exist and are used safely in clinical practice. Regional (localized) 
application of RF energy (to your knee joint in this case) is not known to cause any effect 
elsewhere in the body. 
The temperature measurements will be repeated immediately after the treatment is stopped 
to record the 'peak' skin temperature reached by RF application and subsequently every 30 
seconds in order to map the process of skin temperature returning to baseline (thermal 
decay process). Thus, these post-treatment measurements will continue till the skin 
temperature returns to the baseline (normal) level. 
What are the possible disadvantages, risks or side effects of taking part? 
There should be no harmful effects or disadvantages caused by participation in this study. 
The researcher will be in close proximity for the duration of the treatment and tests to assist 
if necessary. You can always, at any moment, withdraw from the study. All the assessments 
we carry out are safe and have been used extensively in other research. 
What are the possible benefits of taking part? 
We cannot promise the study will help you, but the information we gather from this study will 
help improve the knowledge base by providing a better understanding of the physiological 
mechanisms underpinning the mode of action of low frequency RF energy and this particular 
treatment modality. The information we get from this study will also help us to plan the 
methodology of the later stages of the research project.  
How will my taking part in this study be kept confidential? 
We will follow ethical and legal practice and all information about you will be handled in 
confidence. If you join the study, some parts of your personal details and the data collected 
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for the study may be looked at by authorized person(s) from the University of Hertfordshire 
(project supervisory team) to check that the study is being carried out correctly. All will have 
a duty of confidentiality to you as a research participant and we will do our best to meet this 
duty. All data and information gathered during the project will be entirely confidential, and 
nothing that might identify you will be made public. Any information about you that leaves the 
university will have your personal identification removed so that you cannot be recognized 
from it. We ask your permission to keep your name, address and phone number at the 
University of Hertfordshire so that we can contact you to make or change appointments 
should this be necessary. This information will only be available to the principal researcher 
involved in the study and will be kept in a locked filing cabinet and/or a password protected 
university computer. If in the future we decide to use your contact details for another study 
assessing yet another aspect of your physiological response to this RF therapy, we will have 
to apply for separate approval from the University of Hertfordshire Research Ethics 
Committee. 
What will happen to the results of the research study? 
The results of the study will form part of the final thesis submitted towards the degree of 
Doctor of Philosophy of the principal investigator. As already mentioned, the methodology of 
the later stages of this project will depend largely on the results from this study. We also 
intend to publish the results of this study as well as future studies of this project in a series of 
relevant international medical conferences and journal publications. However, it can often 
take up to two years after completion of a study for the results to be published. Hence, the 
data will need to be stored securely for a period of five years, before it is destroyed. You will 
not be identified in any report or publication. If you would like a copy of the published results 
you can contact us. 
Who has reviewed this study? 
All research that take place in the University of Hertfordshire is looked at by an independent 
group of people called the Research Ethics Committee (Ethics Committee with Delegated 
Authority, ECDA), to protect your safety, rights, wellbeing and dignity. This study has been 
reviewed and given a favourable opinion by the Health and Human Sciences ECDA. 
Who can I contact if I have any questions? 
If you would like further information or would like to discuss any details personally, please 
get in touch with myself (Binoy Kumaran) the principal investigator of this project or Prof. Tim 
Watson, the principal supervisor of this project, either in writing, by phone, or by email. 
Name: Binoy Kumaran (Principal investigator) 
Phone: 0751 743 0077 
Email: b.r.kumaran@herts.ac.uk 
Address: Binoy Kumaran, PhD Researcher, Department of Allied Health Professions     
and Midwifery, School of Health and Social Work, Room 1H159 Yorkon Building, College 
Lane Campus, University of Hertfordshire. 
Name: Prof. Tim Watson (Director of studies) 
Phone: 01707 284970 
Email: t.watson@herts.ac.uk 
Address: Prof. Tim Watson, Department of Allied Health Professions and Midwifery, School 
of Health and Social Work, College Lane Campus, University of Hertfordshire. 
Although we hope it is not the case, if you have any complaints or concerns about any 
aspect of the way you have been approached or treated during the course of this study, 
please write to the University Secretary and Registrar. 
Thank you very much for reading this information and giving consideration to taking part in 
this study. 
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 Appendix 5.2: Informed consent for the laboratory-based 
study 
 
 FORM EC3 
 (Rev. June 11) 
 
University of Hertfordshire 
 
 CONSENT FORM FOR STUDIES INVOLVING HUMAN PARTICIPANTS 
 
I, the undersigned [please give your name here, in BLOCK CAPITALS] 
 
…………………………………………………………………………………………………………… 
of [please give contact details here, sufficient to enable the investigator to get in touch with 
you, such as a postal or email address] 
 
…..……………………………………………………………………………………………………… 
hereby freely agree to take part in the study entitled: 
"The physiological effects of Radiofrequency (RF)-based therapy" 
1  I confirm that I have been given a Participant Information Sheet (a copy of which is 
attached to this form) giving particulars of the study, including its aim(s), methods and 
design, the names and contact details of key people and, as appropriate, the risks and 
potential benefits, and any plans for follow-up studies that might involve further approaches 
to participants.   I have been given details of my involvement in the study.  I have been told 
that in the event of any significant change to the aim(s) or design of the study I will be 
informed and asked to renew my consent to participate in it.  
2  I have been assured that I may withdraw from the study at any time without disadvantage 
or having to give a reason. 
3  I have been given information about the risks of my suffering harm or adverse effects.   I 
have been told about the aftercare and support that will be offered to me in the event of this 
happening, and I have been assured that all such aftercare or support would be provided at 
no cost to me.  
4  I have been told how information relating to me (data obtained in the course of  the study, 
and data provided by me about myself) will be handled: how it will be kept secure, who will 
have access to it, and how it will or may be used.   
5  I have been told what will be done if the study reveals that I have a medical condition 
which may have existed prior to the study, which I may or may not have been aware of, and 
which could affect the present or future health of myself or others. If this happens, I will be 
told about the condition in an appropriate manner and advised on follow-up action I should 
take.   Information about the condition will be passed to my GP, and I may no longer be 
allowed to take part in the study. 
6  I have been told that I may at some time in the future be contacted again in connection 
with this or another study. 
Protocol Number: HSK/PG/UH/00015 
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Signature of 
participant……………………………………………………………Date…………………………. 
 
 
 
Signature of (principal) 
investigator…………………………………………………………...Date………………………… 
 
Name of (principal) investigator [in BLOCK CAPITALS please] 
………………………………………………………………………………………………………… 
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 Appendix 5.3: Ethics approval for the laboratory-based study 
(Protocol number: HSK/PG/UH/00015) 
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 Appendix 5.4: Randomisation chart for the order of 
attendance to the laboratory sessions 
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 Appendix 5.5: Eligibility questionnaire and subjective 
information form for the participants 
PARTICIPANT SUBJECTIVE INFORMATION FORM 
 
Name:          
Date of birth:        Height (m): 
Gender:        Weight (kg): 
Occupation:        Body fat (%): 
Contact details:       Visceral fat: 
Date and time of assessment:     Body Mass Index: 
MEDICAL QUESTIONNAIRE: PLEASE TICK THE APPROPRIATE BOXES BELOW 
           Yes     No 
Did you eat in the last one hour?   
Did you drink coffee or alcoholic beverages in the last one hour?   
Did you do any strenuous exercise in the last one hour?   
Do you smoke?   
Are you pregnant?   
Have you suffered from any infections or high fever in the last week?   
Do you use a hearing aid?   
Do you suffer from hypersensitivity to heat?   
Do you suffer from any skin conditions around your right knee joint?   
Do you suffer from any cardiac or blood pressure related disorders?   
Do you suffer from Diabetes?   
Do you wear a cardiac pacemaker or any other electronic implants?   
Do you have a metal implant in your right lower limb?   
Have you sustained any injury to your right knee joint in the last three 
months? 
  
Have you ever suffered from arterial or venous diseases in your legs?   
Have you ever suffered from Tuberculosis?   
Have you ever suffered from Cancer or malignancy?   
Are you allergic to Micropore tape?   
Study number: 
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 Appendix 5.6: Image representative of the three heating 
points to be reported by the participants 
 
THREE TIME POINTS 
 
 
 
 
 
 
 
 
 
 
 
1. Say "HEATING" when you begin to 
feel any warmth over the treatment 
area. 
 
 
2. Say "DEFINITE HEATING" when 
you feel moderate yet comfortable 
warmth in the treatment area. 
 
 
3. Say "STOP" straight away when the 
heating starts to become 
uncomfortable. 
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 Appendix 5.7: Participant data collection form 
 
 
EXPERIMENTAL DATA COLLECTION FORM 
 
Treatment mode one: CAP / RES 
 
Date and time of assessment: 
 
Starting room temperature (o C): 
 
Starting room humidity (%): 
 
Side treated: Right / Left 
 
Treatment sequence: 
 
Device start time: 30 minutes 
 
Pre-treatment measurements Treated side (o C)   Control (o C) 
Baseline skin temperature   
Baseline core temperature  
     Time (M: S), Intensity   Mean power (W) 
Thermal onset   
Definite thermal   
Thermal discomfort   
 
Post-treatment measurements Treated side (o C)   Control (o C) 
Peak skin temperature   
Peak core temperature  
 
 
 
Study number: 
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Thermal decay process to baseline (o C) every 30 seconds 
           
           
           
           
           
           
           
           
           
Follow-up measurements  Treated side (o C)   Control (o C) 
Final skin temperature   
Final core temperature  
 
Ending room temperature (o C): 
 
Ending room humidity (%): 
 
Treatment mode two: CAP / RES 
 
Date and time of assessment: 
 
Starting room temperature (o C): 
 
Starting room humidity (%): 
 
Side treated: Right / Left 
 
Treatment sequence: 
 
Device start time: 30 minutes 
 
Pre-treatment measurements Treated side (o C)   Control (o C) 
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Baseline skin temperature   
Baseline core temperature  
     Time (M: S), Intensity   Mean power (W) 
Thermal onset   
Definite thermal   
Thermal discomfort   
 
Post-treatment measurements Treated side (o C)   Control (o C) 
Peak skin temperature   
Peak core temperature  
 
Thermal decay process to baseline (o C) every 30 seconds 
           
           
           
           
           
           
           
           
           
Follow-up measurements  Treated side (o C)   Control (o C) 
Final skin temperature   
Final core temperature  
 
Ending room temperature (o C): 
 
Ending room humidity (%): 
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 Appendix 6.1: Participant information sheet for the 
laboratory-based study 
 
UNIVERSITY OF HERTFORDSHIRE 
 
ETHICS COMMITTEE FOR STUDIES INVOLVING THE USE OF HUMAN 
PARTICIPANTS (‘ETHICS COMMITTEE’) 
FORM EC6: PARTICIPANT INFORMATION SHEET 
 
Title of Research 
"The physiological effects of radiofrequency (RF)-based therapy – Stage 2" 
(“Stage 2” is a logical progression of the “Stage 1” we have completed recently. In Stage 1 
study we investigated some of the more basic aspects of RF-based therapy, the findings of 
which have informed the design of Stage 2 study) 
Introduction 
You are being invited to take part in a research study.  Before you decide whether to do so, 
it is important that you understand the research that is being done and what your 
involvement will include.  Please take the time to read the following information carefully and 
discuss it with others if you wish.  Do not hesitate to ask us anything that is not clear or for 
any further information you would like to help you make your decision.  Please do take your 
time to decide whether or not you wish to take part.  Thank you for reading this. 
What is the purpose of this study? 
The proposed is the second of a series of laboratory-based studies planned as part of the 
PhD project, which aims to investigate the physiological responses of healthy human adults 
to regional (local body area) application of Radiofrequency Electromagnetic Field (RF EMF) 
energy at a frequency of 448 kHz (Kilo Hertz). The aims of the proposed study (Stage 2) are 
– firstly, investigate the following physiological responses to the 448 kHz RF energy 
application, secondly, compare those physiological effects to the effects generated by the 
application of Pulsed Shortwave Therapy (PSWT, operates at a base RF of 27.12 MHz), and 
thirdly to investigate whether the addition of manual therapy (massage) to the RF treatment 
regime changes the physiological responses. 
1. Local skin temperature 
2. Local skin blood flow 
3. Local deep blood flow 
4. Local nerve conduction velocity 
5. Local pressure pain threshold 
6. Core temperature (tympanic) 
7. Pulse rate 
Do I have to take part? 
It is completely up to you whether or not you decide to take part in this study.  If you do 
decide to take part you will be given this information sheet to keep and be asked to sign a 
consent form.  Agreeing to join the study does not mean that you have to complete it.  You 
are free to withdraw at any stage without giving a reason.  A decision to withdraw at any 
time, or a decision not to take part at all, will not affect your education or your relationship 
with the university (should this be relevant). 
 
HHSECDA Protocol Number: cHSK/PG/UH/00143 
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How long will my part in the study take? 
If you decide to take part in this study, you will be involved in it for the next few weeks 
attending a minimum of three sessions (or more if you agree), each lasting for about 75 - 90 
minutes. 
What will happen to me if I take part? 
If you decide to take part in this study, you will be asked to attend the physiotherapy 
research laboratory (LF311) in the Wright Building, College Lane Campus of the University 
of Hertfordshire to receive RF-based treatment to your knee joint area and allow a series of 
physiological measurements to be taken from the treated area before and after treatment. 
Each session will last about 75 - 90 minutes, which includes some paperwork, screening, 
treatment, and assessments. Kindly note, all these procedures are harmless and completely 
non-invasive, and in line with procedures routinely employed in current clinical practice. 
On arrival to the laboratory the principal investigator will receive you and the first thing to 
happen is to sign an informed consent by both parties. Some paperwork will follow, where 
you will be asked screening questions such as “Have you eaten in the last one hour?” or 
“Did you injure your knee recently?” You will then change to appropriate clothing (shorts) 
and undergo height, weight and body composition (body mass index, body fat percentage) 
measurements. Subsequently you will lie down comfortably on a treatment couch with knees 
extended and resting on a pillow. As a second screening prior to RF administration, your 
skin over the treatment area will be tested using warm (not warm enough to cause any 
injury!) and cold water filled test tubes to make sure that you (skin on the area treated) can 
distinguish adequately between warmth and cold (called ‘skin thermal sensitivity’). This 
screening will eliminate any risk of inadvertent injuries due to lack of skin thermal sensation. 
If you cannot distinguish between warmth and cold you will not be enrolled into the study. 
After screening and enrolment, you will undergo ‘pre-treatment measurements where the 
researcher will record your 'baseline' (normal) physiological measures (listed in the above 
section) from the treatment area using a series of non-invasive measurement systems and 
then talk you through the experimental procedures, what to expect during treatment and 
what to do if you have a problem. The physiological measurements will be repeated and 
recorded immediately after the treatment to compare between pre and post treatment 
values. 
The RF energy will be delivered for 15 minutes at a set dosage using either 'HCR 902 Indiba 
activ Prorecovery' device, or one of the PSWT devices currently used in the Department of 
Allied Health Professions and Midwifery. Both devices are proven safe for human use (CE 
marked) and are in use around the world in clinical practice. For the Indiba device round 
metallic electrodes (active electrode) smeared with a special conducting cream will deliver 
the energy to the front of your thigh just above the knee joint. An 'inactive' metal plate 
electrode will be placed under your calf muscles of the same leg to complete the machine 
circuit. For the PSWT device shortwave energy will be delivered using a large monode drum 
electrode positioned in air about one centimeter vertically above the treated area (will not 
touch the skin). The intensity of RF energy delivered to your knee will remain constant for 
the duration of the treatment in both cases. You may receive either a low intensity (little or 
no warmth felt) or a moderate intensity (appreciable warmth felt) treatment depending on the 
number of sessions you choose to attend and the experimental groups you represent. 
Regional (localized) application of RF energy (around your knee joint in this case) is not 
known to cause any effect elsewhere in the body. In addition to the RF, you may also 
receive manual therapy (massage) to the local area performed at the same time. If you feel 
any discomfort any time during the session, you may ask the investigator to ‘STOP’ the 
procedures. 
What are the possible disadvantages, risks or side effects of taking part? 
There should be no harmful effects or disadvantages caused by participation in this study. 
The researcher will be in close proximity for the duration of the treatment and the tests to 
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assist if necessary. You can always, at any moment, withdraw from the study. All the 
assessments we carry out are safe and have been used extensively in other research. 
What are the possible benefits of taking part? 
We cannot promise the study will help you, but the information we gather from this study will 
help improve the knowledge base by providing a better understanding of the physiological 
mechanisms underpinning the mode of action of low frequency RF energy and this particular 
treatment modality. The information we get from this study will also help us to plan the 
methodology of the later stages of the research project. 
How will my taking part in this study be kept confidential? 
We will follow ethical and legal practice and all information about you will be handled in 
confidence. If you join the study, some parts of your personal details and the data collected 
for the study may be looked at by authorized person(s) from the University of Hertfordshire 
(project supervisory team) to check that the study is being carried out correctly. All will have 
a duty of confidentiality to you as a research participant and we will do our best to meet this 
duty. All data and information gathered during the project will be entirely confidential, and 
nothing that might identify you will be made public. Any information about you that leaves the 
university will have your personal identification removed so that you cannot be recognized 
from it. We ask your permission to keep your name, address and phone number at the 
University of Hertfordshire so that we can contact you to make or change appointments 
should this be necessary. This information will only be available to the principal researcher 
involved in the study and will be kept in a locked filing cabinet and/or a password protected 
university computer. If in the future we decide to use your contact details for another study 
assessing yet another aspect of your physiological response to this RF therapy, we will have 
to apply for separate approval from the University of Hertfordshire Research Ethics 
Committee. 
What will happen to the results of the research study? 
The results of the study will form part of the final thesis submitted towards the degree of 
Doctor of Philosophy of the principal investigator. As already mentioned, the methodology of 
the later stages of this project will depend largely on the results from this study. We also 
intend to publish the results of this study as well as future studies of this project in a series of 
relevant international medical conferences and journal publications. However, it can often 
take up to two years after completion of a study for the results to be published. Hence, the 
data will need to be stored securely for a period of five years, before it is destroyed. You will 
not be identified in any report or publication. If you would like a copy of the published results 
you can contact us. 
Who has reviewed this study? 
All research that take place in the University of Hertfordshire is looked at by an independent 
group of people called the Research Ethics Committee (Ethics Committee with Delegated 
Authority, ECDA), to protect your safety, rights, wellbeing and dignity. This study has been 
reviewed and given approval (protocol number given on the first page) by the Health and 
Human Sciences ECDA. 
Who can I contact if I have any questions? 
If you would like further information or would like to discuss any details personally, please 
get in touch with myself (Binoy Kumaran) the principal investigator of this project or 
Professor Tim Watson, the principal supervisor of this project, either in writing, by phone, or 
by email. 
Name: Binoy Kumaran (Principal investigator) 
Phone: 0751 743 0077 
Email: b.r.kumaran@herts.ac.uk 
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Address: Binoy Kumaran, PhD Researcher, Department of Allied Health Professions     
and Midwifery, School of Health and Social Work, Room 1H159 Yorkon Building, College 
Lane Campus, University of Hertfordshire. 
Name: Professor Tim Watson (Director of studies) 
Phone: 01707 284970 
Email: t.watson@herts.ac.uk 
Address: Prof. Tim Watson, Department of Allied Health Professions and Midwifery, School 
of Health and Social Work, College Lane Campus, University of Hertfordshire. 
Although we hope it is not the case, if you have any complaints or concerns about 
any aspect of the way you have been approached or treated during the course of this 
study, please write to the University Secretary and Registrar. 
Thank you very much for reading this information and giving consideration to taking 
part in this study. 
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 Appendix 6.2: Ethics approval for the laboratory-based study 
(Protocol number: cHSK/PG/UH/00143) 
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 Appendix 6.3: Informed consent for the laboratory-based 
study 
 
UNIVERSITY OF HERTFORDSHIRE 
ETHICS COMMITTEE FOR STUDIES INVOLVING THE USE OF HUMAN 
PARTICIPANTS (‘ETHICS COMMITTEE’) 
 
FORM EC3 
CONSENT FORM FOR STUDIES INVOLVING HUMAN PARTICIPANTS 
The material contained in this form may be adapted for use in an alternative consent 
form, provided the principles of what is contained in the form are retained 
  
I, the undersigned [please give your name here, in BLOCK CAPITALS] 
 
…………………………………………………………………………………………………………… 
of [please give contact details here, sufficient to enable the investigator to get in touch with 
you, such as a postal or email address] 
 
…..……………………………………………………………………………………………………… 
hereby freely agree to take part in the study entitled [insert name of study here] 
“Physiological effects of radiofrequency (RF)-based therapy – Stage 2”  
1  I confirm that I have been given a Participant Information Sheet (a copy of which is 
attached to this form) giving particulars of the study, including its aim(s), methods and 
design, the names and contact details of key people and, as appropriate, the risks and 
potential benefits, and any plans for follow-up studies that might involve further approaches 
to participants. I have been given details of my involvement in the study.  I have been told 
that in the event of any significant change to the aim(s) or design of the study I will be 
informed and asked to renew my consent to participate in it.  
2  I have been assured that I may withdraw from the study at any time without disadvantage 
or having to give a reason. 
3  I have been given information about the risks of my suffering harm or adverse effects.   I 
have been told about the aftercare and support that will be offered to me in the event of this 
happening, and I have been assured that all such aftercare or support would be provided at 
no cost to me.  
4  I have been told how information relating to me (data obtained in the course of  the study, 
and data provided by me about myself) will be handled: how it will be kept secure, who will 
have access to it, and how it will or may be used.   
5  I have been told what will be done if the study reveals that I have a medical condition 
which may have existed prior to the study, which I may or may not have been aware of, and 
which could affect the present or future health of myself or others. If this happens, I will be 
told about the condition in an appropriate manner and advised on follow-up action I should 
take.   Information about the condition will be passed to my GP, and I may no longer be 
allowed to take part in the study. 
HHSECDA Protocol Number: cHSK/PG/UH/00143 
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6  I have been told that I may at some time in the future be contacted again in connection 
with this or another study. 
 
Signature of 
participant………………………………………………………………Date……………………….. 
 
 
Signature of (principal) investigator………………………………….Date………………………… 
 
Name of (principal) investigator [in BLOCK CAPITALS please] 
 
…………………………………………………………………………………………………………... 
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 Appendix 6.4: Randomisation chart for the order of 
attendance to the laboratory study sessions 
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 Appendix 6.5: Eligibility questionnaire and subjective 
information form for the participants 
PARTICIPANT SUBJECTIVE INFORMATION FORM 
 
Name:          
Date of birth:        Height (m): 
Gender:        Weight (kg): 
Occupation:        Body fat (%): 
Contact details:       Visceral fat: 
Date and time of assessment:     Body Mass Index: 
MEDICAL QUESTIONNAIRE: PLEASE TICK THE APPROPRIATE BOXES BELOW 
           Yes     No 
Did you eat in the last one hour?   
Did you drink coffee or alcoholic beverages in the last one hour?   
Did you do any strenuous exercise in the last one hour?   
Do you smoke?   
Are you pregnant?   
Have you suffered from any infections or high fever in the last week?   
Do you use a hearing aid?   
Do you suffer from hypersensitivity to heat?   
Do you suffer from any skin conditions around your right knee joint?   
Do you suffer from any cardiac or blood pressure related disorders?   
Do you suffer from Diabetes?   
Do you wear a cardiac pacemaker or any other electronic implants?   
Do you have a metal implant in your right lower limb?   
Have you sustained any injury to your right knee joint in the last three 
months? 
  
Have you ever suffered from arterial or venous diseases in your legs?   
Have you ever suffered from Tuberculosis?   
Have you ever suffered from Cancer or malignancy?   
Are you allergic to Micropore tape?   
Study number: 
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 Appendix 6.6: Participant data collection form 
 
 
EXPERIMENTAL DATA COLLECTION FORM 
 
Treatment Session 1:  
 
Date and time of assessment: 
 
Starting room temperature (o C): 
 
Starting room humidity (%): 
 
Side treated: Right / Left 
 
Pre-treatment measurements and Doses 
Baseline skin temperature (treated)  
Baseline core temperature  
Thigh length (cm)  
Leg length (cm)  
Baseline blood pressure  
Baseline pulse rate  
 
Post-treatment measurements 
Peak & Follow-up core temperature  
Peak & Follow-up blood pressure  
Peak & Follow-up pulse rate  
 
Ending room temperature (o C): 
 
Ending room humidity (%): 
 
Study number: 
352 
Treatment Session 2: 
 
Date and time of assessment: 
 
Starting room temperature (o C): 
 
Starting room humidity (%): 
 
Side treated: Right / Left 
 
Pre-treatment measurements 
Baseline core temperature  
Baseline blood pressure  
Baseline pulse rate  
 
Post-treatment measurements 
Peak & Follow-up core temperature  
Peak & Follow-up blood pressure  
Peak & Follow-up pulse rate  
 
Ending room temperature (o C): 
 
Ending room humidity (%): 
 
Treatment Session 3: 
 
 
Date and time of assessment: 
 
Starting room temperature (o C): 
 
Starting room humidity (%): 
 
Side treated: Right / Left 
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Pre-treatment measurements 
Baseline core temperature  
Baseline blood pressure  
Baseline pulse rate  
 
Post-treatment measurements 
Peak & Follow-up core temperature  
Peak & Follow-up blood pressure  
Peak & Follow-up pulse rate  
 
Ending room temperature (o C): 
 
Ending room humidity (%): 
 
Treatment Session 4: 
 
Date and time of assessment: 
 
Starting room temperature (o C): 
 
Starting room humidity (%): 
 
Side treated: Right / Left 
 
Pre-treatment measurements 
Baseline core temperature  
Baseline blood pressure  
Baseline pulse rate  
 
Post-treatment measurements 
Peak & Follow-up core temperature  
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Peak & Follow-up blood pressure  
Peak & Follow-up pulse rate  
 
Concealment checker 
Session 1 Session 2 Session 3 Session 4 
 
 
   
 
Ending room temperature (o C): 
 
Ending room humidity (%): 
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 Appendix 6.7: Randomisation chart for the order of 
attendance to the laboratory sessions in the pilot study 
determining CRMRF intervention 
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 Appendix 8.1: Visual analogue scale (VAS) for self-reported 
pain 
 
‘VAS’ Pain Intensity Scale 
 
 
 
1. Mark the line at the point which best corresponds to the intensity of 
pain you have experienced in the last 24 hours caused by the 
arthritis in your knee joint. 
 
 
 
 
Least           Worst 
possible          possible 
pain           pain 
 
 
 
 
 
 
2. Mark the line at the point which best corresponds to the intensity of 
pain you are experiencing now caused by the arthritis in your 
knee joint. 
 
 
 
 
 
Least           Worst 
possible          possible 
pain           pain 
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 Appendix 8.2: Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) 
 
‘WOMAC’ OSTEOARTHRITIS INDEX 
 
INSTRUCTIONS TO THE PARTICIPANTS 
 
In Sections A, B, and C questions are asked in the following format. Please mark your 
answers by putting an “ X ”  in one of the boxes. 
 
EXAMPLES: 
1. If you put your “ X ”  in the box on the far left as shown below: 
 
None Mild Moderate Severe Extreme 
     
Then you are indicating that you feel no pain. 
 
2. If you put your “ X ”  in the box on the far right as shown below, 
 
None Mild Moderate Severe Extreme 
     
Then you are indicating that you feel extreme pain. 
3. Please note: 
a) The further to the right you place your “ X ” , the more pain you feel. 
b) The further to the left you place your “ X ” , the less pain you feel. 
c) Please do not place your “ X ”  outside any of the boxes. 
 
You will be asked to indicate on this type of scale the amount of pain, stiffness or disability 
you have felt during the last 48 hours. 
 
Think about your affected knee when answering the questions. Indicate the severity of your 
pain and stiffness, and the difficulty you have in doing daily activities that (you feel) are 
caused by the arthritis in your knee. 
 
 
X 
X 
358 
Section A: PAIN 
 
Think about the pain you felt in your knee due to your arthritis during the last 48 hours. 
 
QUESTION: How much pain have you had.. 
1. Walking on a flat surface? 
None Mild Moderate Severe Extreme 
     
 
2. When going up or down stairs? 
None Mild Moderate Severe Extreme 
     
 
3. At night while in bed? (that is – pain that disturbs your sleep) 
None Mild Moderate Severe Extreme 
     
 
4. While sitting or lying down? 
None Mild Moderate Severe Extreme 
     
 
5. While standing? 
None Mild Moderate Severe Extreme 
     
 
Section B: STIFFNESS 
Think about the stiffness (not pain) you felt in your knee due to your arthritis during the last 
48 hours. 
 
Stiffness is a sensation of decreased ease in moving your joint. 
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6. How severe has your stiffness been after you first woke up in the morning? 
None Mild Moderate Severe Extreme 
     
 
7. How severe has your stiffness been after sitting or lying down or while resting later in 
the day? 
None Mild Moderate Severe Extreme 
     
 
Section C: DIFFICULTY PERFORMING DAILY ACTIVITIES 
Think about the difficulty you had in doing the following daily physical activities caused by 
the arthritis in your knee during the last 48 hours. 
 
 
By this we mean your ability to move around and look after yourself. 
 
QUESTION: How much difficulty have you had.. 
 
8. When going down the stairs? 
None Mild Moderate Severe Extreme 
     
 
9. When going up the stairs? 
None Mild Moderate Severe Extreme 
     
 
10. When getting up from a sitting position? 
None Mild Moderate Severe Extreme 
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11. While standing? 
None Mild Moderate Severe Extreme 
     
 
12. When bending to the floor? 
None Mild Moderate Severe Extreme 
     
 
13. When walking on a flat surface? 
None Mild Moderate Severe Extreme 
     
 
14. When getting in or out of a car, or getting on or off a bus? 
None Mild Moderate Severe Extreme 
     
 
15. While going shopping? 
None Mild Moderate Severe Extreme 
     
 
16. When putting on your socks or panty hose or stockings? 
None Mild Moderate Severe Extreme 
     
 
17. When getting out of bed? 
None Mild Moderate Severe Extreme 
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18. When taking off your socks or panty hose or stockings? 
None Mild Moderate Severe Extreme 
     
 
19. While lying in bed? 
None Mild Moderate Severe Extreme 
     
 
20. When getting in or out of the bathtub? 
None Mild Moderate Severe Extreme 
     
 
21. While sitting? 
None Mild Moderate Severe Extreme 
     
 
22. When getting on or off the toilet? 
None Mild Moderate Severe Extreme 
     
 
23. While doing heavy household duties? 
None Mild Moderate Severe Extreme 
     
 
24. While doing light household duties? 
None Mild Moderate Severe Extreme 
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 Appendix 8.3: NHS Health Research Authority (HRA) approval 
letter (REC reference: 15/NW/0529) 
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 Appendix 8.4: Patient invitation letter to the potential 
participants in the OA knee trial 
 
 
Binoy Kumaran 
PhD Researcher (Physiotherapy) 
School of Health and Social Work 
University of Hertfordshire 
College Lane 
Hatfield, Hertfordshire 
AL10 9AB 
 
Date:          
 
 
Dear  
We are currently undertaking a research study to investigate the effects of radiofrequency-
based physiotherapy treatment on pain and quality of life of patients who are suffering from 
osteoarthritis in one or both of their knee joints. 
We would like to invite you to take part in the study. Before you decide it is important to 
understand why the research is being done and what it involves. We have tried to explain 
the study in the information sheet included with this letter. Please take time to read them 
carefully. If you would like more information about this project, please don’t hesitate to 
contact me using the phone number or address given at the end of the information sheet. 
You may also discuss the study with your GP if you wish. In addition, if you would prefer to 
discuss any aspects of this study with a third person who is an independent advisor to the 
study, ……………………………………………… is willing to answer any questions you might 
have. He/she can be contacted on ……………………………. 
Please take time to decide whether or not you wish to take part. If you would like to help us 
and join the study, please could you complete the form included with this letter and return it 
to us in the pre-paid envelope provided. We will then contact you shortly to discuss the 
project with you and to arrange a suitable day and time for you to come to the outpatient 
physiotherapy wing of the ‘Hemel Hempstead General Hospital’ for your first appointment. 
Thank you 
Yours sincerely 
 
 
Mr Binoy Kumaran (PhD Researcher) 
 
Professor Tim Watson (Principal / Chief Investigator) 
 
NHS REC Reference Number: 15/NW/0529 
University HHSECDA Protocol Number: HSK/PG/NHS/00312 
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 Appendix 8.5: Participant information sheet in the OA knee 
trial 
 
 
 
PARTICIPANT INFORMATION SHEET 
 
You are being invited to take part in a research study. Before you decide whether to do so, it 
is important that you understand the research that is being done and what your involvement 
will include. Please take time to read the following information carefully and discuss it with 
others if you wish. Do not hesitate to ask us anything that is not clear or for any further 
information you would like to help you make your decision. Part I tells you the purpose of this 
study and what will happen to you if you take part. Part II gives you more detailed 
information about the conduct of the study. Please do take time to decide whether or not you 
wish to take part. Thank you for reading. 
 
PART I 
 
Title of Research 
“Clinical effects of 448 kHz Capacitive Resistive Monopolar Radiofrequency (CRMRF) 
based therapy on patients suffering from chronic osteoarthritis of the knee joint.” 
 
Why am I being invited? 
We understand that you have been diagnosed with osteoarthritis (OA) in one or both of your 
knee joints, and that you have been referred for physiotherapy treatment. We are planning to 
undertake a research study in order to test the efficacy of a particular type of physiotherapy 
treatment, in which you might be eligible to take part. The proposed clinical trial aims to 
investigate the clinical benefits (if any) of Radiofrequency (RF) Electromagnetic Field based 
treatment on adult patients like you, who are suffering from OA of the knee joint. The specific 
name of the treatment used in this study is ‘Capacitive Resistive Monopolar Radiofrequency 
(CRMRF)’ and will be delivered using the device ‘Indiba Activ 902’, manufactured by Indiba 
S. A., Barcelona, Spain. 
What is radiofrequency-based therapy? 
Radiofrequency is a part of the electromagnetic fields. They have various applications in the 
field of medicine. Low energy RF (up to 30 MHz (Megahertz) in frequency) is often used in 
physiotherapy treatments to relieve pain and inflammation through applying heat at various 
intensities. Most commonly used RF-based therapy in physiotherapy is called ‘shortwave 
therapy’, which operates at a wave frequency of 27.12 MHz. However, the CRMRF therapy 
used in this study operates at 448 kHz (kilohertz). As of now, CRMRF therapy is not 
commonly used in the UK although it has been available for clinical use since many years. 
How will the aim of the study be achieved? 
At the moment we don’t know whether the symptoms of OA can be improved with this type 
of treatment. If it can be improved, is the effect any better than a mere ‘placebo effect’ or is it 
genuine? Is it better than the current treatments given to patients with OA? Placebo effect is 
the phenomenon of someone's symptoms improving when they've only been given a dummy 
NHS REC Reference Number: 15/NW/0529 
University HHSECDA Protocol Number: HSK/PG/NHS/00312 
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treatment. To find out, we need to compare the treatments in a so-called ‘randomised 
controlled trial’ (RCT). This means that we put people randomly into different treatment 
groups (three in this study) and compare them at the beginning and end of the study using 
various outcome measurements. Which treatment you will receive is completely decided by 
chance. Your allocation to any group will be ‘blinded’ in order to avoid any potential 
‘participant bias’ due to your knowledge of the group you are in. That means we will not be 
able to tell you the group you are in until the end of the study. 
In this study, the three treatment groups are as follows: 
Group I – Will receive CRMRF treatment and current standard NHS treatment. 
Group II – Will receive placebo CRMRF treatment and current standard NHS treatment. 
Group III – Will receive current standard NHS treatment only. 
The current standard NHS treatment for OA knee involves a combination of exercises, 
advice and supportive therapies (such as hot/cold application, manual therapy and electrical 
stimulation) as deemed appropriate by your clinician. ‘Placebo CRMRF’ is a dummy 
treatment delivered using the same active CRMRF device, but with its output turned off, to 
investigate the presence of a potential ‘placebo effect’. 
If you decide against taking part, you will automatically receive the current standard 
treatment (as in Group III) when your turn comes on the waiting list. 
What are the measurements that will be taken? 
Two types of measurements will be taken – clinical and physiological. 
The clinical measurements taken at various stages during the study are as follows: 
1. Pain measurement – A self-reported numerical scale, rating the level of your knee 
pain from 0 – 10 (‘0’ means no pain and ‘10’ means maximum pain). You will be 
asked to mark a point on a 10 cm long line to denote your level of pain. 
2. WOMAC – A self-reported easy to score ‘quality of life’ questionnaire based on your 
knee joint function. WOMAC stands for Western Ontario and McMaster Universities 
Osteoarthritis Index. 
3. Knee Range of Movement – This will be manually tested by the researcher using a 
device called ‘goniometer’ or an ‘inclinometer’. It measures how far can you bend or 
straighten your knee joint. 
4. Timed up and go (TUG) test – This is a simple functional test where the time taken 
by you to complete a functional task is measured. The task is to get up from a chair, 
walk forward six meters, turn around and walk back to sit on the chair. This will be 
performed at your ‘normal’ comfortable pace, which means if you are in pain it may 
take longer for you to complete the task. 
The physiological measurements taken at various stages during the study are as follows: 
1. Skin temperature – The local skin temperature on your knee joint will be measured 
using a non-invasive surface temperature measurement device. 
2. Skin blood flow – The amount of blood flow on the skin in your knee joint area will be 
measured using a non-invasive method called ‘photoplethysmography’, which 
involves attaching a small device to your skin surface for the duration of the test. 
3. Deep blood flow – Blood flow to the deeper tissues such as the muscles will be 
measured using Doppler Ultrasound. 
 
Do I have to take part? 
It is completely up to you whether or not you take part in this study. If you do decide to take 
part, you will be asked to sign a consent form. Agreeing to join the study does not mean that 
you have to complete it. You are free to withdraw at any stage without giving a reason. A 
decision to withdraw at any time, or a decision not to take part at all, will not affect your care 
in any way. 
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How long will I need to be involved? 
If you decide to take part in this study, you will be involved in it for the next four months, 
attending eight treatment sessions during the first four weeks and two follow-up sessions (for 
measurements only) one month and three months after the treatment is finished. In total you 
will need to attend 10 sessions in four months. 
What will I have to do now? 
After reading this document if you consider taking part in this research, please fill in the 
attached return form and send it to the researcher in the pre-paid envelope. We will contact 
you to explain any more questions you may have about the study and arrange suitable times 
for you to come to the outpatient physiotherapy wing of the ‘Hemel Hempstead General 
Hospital’ and take part in the study. 
What will happen to me if I take part? 
If you decide to take part in this study, you will be asked to attend the above stated location 
to receive CRMRF treatment to your affected knee joint and allow the measurements (as 
discussed) to be taken. The duration of the sessions you attend will vary. The first and the 
eighth sessions will be the longest, lasting just over 90 minutes each, which includes some 
paperwork, screening, treatment, and assessments. Sessions 2–7 and the last two sessions 
will be substantially shorter. Kindly note that all procedures involved are harmless, 
completely non-invasive and in line with procedures routinely employed in clinical practice. 
On arrival to the clinic the investigator will receive you and will explain the study. You will 
then be asked to sign a consent form. Subsequently you will be asked to change to 
appropriate clothing (shorts) to lie down comfortably on a treatment couch with knees 
extended and resting on a pillow. As a primary screening, your skin over the treatment area 
will be tested using warm (not warm enough to cause any injury!) and cold water filled test 
tubes to make sure that you can adequately distinguish between warmth and cold (called 
‘skin thermal sensitivity’). This screening will eliminate any risk of inadvertent injuries due to 
lack of skin thermal sensation. If you cannot distinguish between warmth and cold you 
will not be enrolled into the study. After this you will be asked some questions such as 
“Have you eaten in the last one hour?” or “Did you injure your knee recently?” Your height, 
weight and body fat levels will also be recorded. 
After screening and enrolment, you will undergo the clinical and physiological measurements 
listed previously. You will then be talked through the experimental procedures, what to 
expect during the treatment and what to do if you have a problem. The CRMRF energy will 
be delivered for 15 minutes using the ‘Indiba Activ 902' device, which is proven safe for 
human use (CE marked) and is in use around the world in clinical practice. The schemes of 
treatment and assessments that will take place at each visit are listed in the section below. 
What will happen during the sessions? 
Following is what will be done from sessions 1 – 10. 
Session 1: Physiological measurements, clinical measurements, CRMRF treatment. 
Sessions 2–7: CRMRF treatment, clinical measurements (pain only). 
Session 8: Physiological measurements, clinical measurements, CRMRF treatment. 
Session 9: First follow-up clinical measurements. 
Session 10: Second follow-up clinical measurements. 
What are the possible disadvantages, risks or side effects of taking part? 
There should be no harmful effects caused by your participation, additional to physically 
participating in the study and any disadvantages associated with OA itself that may be 
already explained to you by your consultant/GP. During the assessments you will be asked 
to perform normal activities of daily life such as walking and bending the knee joint, which 
may cause some knee discomfort. However, you will be asked to perform those activities in 
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the same way as you would normally do, minimizing the pain as much as possible. The 
researcher will also be in close proximity for the duration of the tests to assist if necessary. 
All the assessments we carry out are safe and have been used extensively in other 
research. 
What if something goes wrong? 
Any potential complaint about the way you have been dealt with during the study or any 
potential harm you might suffer will be addressed. The detailed information on this is given in 
‘Part II’ of this document.  
Will my taking part be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part II.  
This completes Part I. If the information in Part I has interested you and you are considering 
participation, please now read the additional information in Part II. 
 
PART II 
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available 
about the condition. If this happens, we will tell you about it and discuss with you whether 
you want to continue in the study. If you decide to withdraw, nothing will change in your 
normal care. Also, on receiving new information we might consider it to be in your best 
interest to withdraw you from the study. We will explain the reasons for this. 
What will happen if I don’t want to carry on with the study?  
You will be able to withdraw from the study at any time and without having to give a reason. 
This will not affect your normal care in any way. If you withdraw we will not use the data 
collected up to your withdrawal.  
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions. If you remain unhappy and wish 
to make a formal complaint, you can do so through the NHS Complaints Procedure. Details 
can be obtained from the hospital.  
If you are harmed due to someone’s negligence, then compensation may be provided. If you 
are harmed by taking part in this research project by an unforeseen accident (non-negligent 
harm), then there are no special compensation arrangements in place. However, this is 
thought to be highly unlikely. Regardless, if you wish to complain, or have any concerns 
about any aspect of the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms will be available to you. 
How will my taking part in this study be kept confidential? 
We will follow ethical and legal practice and all information about you will be handled in 
confidence. If you join the study, parts of the data collected from you (except personal data) 
may be looked at by authorized person(s) from the University of Hertfordshire (sponsors of 
this study) to check that the study is being carried out correctly. All will have a duty of 
confidentiality to you as a research participant and we will do our best to meet this duty. All 
data and information gathered during the project will be entirely confidential, and nothing that 
might identify you will be made public. Any information about you that leaves the university 
will have your personal identification removed so that you cannot be recognized from it. We 
ask your permission to keep your name, address and phone number at the University of 
Hertfordshire for the duration of your involvement in the study so that we can contact you to 
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make or change appointments should this be necessary. This information will only be 
available to the two researchers (named below) involved in the study and will be kept in a 
locked filing cabinet and/or a password protected university computer. 
Will my GP be informed of my involvement in the study? 
Your GP will be informed in writing that you are participating in this study, but only if you 
consent to us to do so. 
What will happen to the results of the research study? 
The results of the study will form part of the final thesis submitted towards the degree of 
Doctor of Philosophy of Binoy Kumaran (PhD Researcher). We also intend to disseminate 
the results of this study in relevant international conferences and journal publications. 
However, it can often take up to a year or more after the completion of a study for the results 
to be published. Hence, the data will need to be stored securely for a period of at least one 
year, before it is destroyed. You will not be identified in any report or publication. You will be 
given a copy of the final results, but if you would like a copy of the published articles as well, 
you can contact us. 
Who is organising and funding the research? 
This research study is organized by the ‘University of Hertfordshire’ (the sponsor) in 
collaboration with the ‘Hertfordshire Community NHS Trust’. It is funded by the device 
manufacturer Indiba, S. A., Barcelona, Spain.  
Who has reviewed this study? 
All research in the NHS is reviewed by an independent group of people called Research 
Ethics Committee (REC) to protect your safety, rights, wellbeing and dignity. This study has 
been reviewed and approved by the NRES Committee Northwest - GM South. In addition, all 
research that take place in the University of Hertfordshire is reviewed by an independent 
group of people called the Ethics Committee with Delegated Authority (ECDA) to protect 
your safety, rights, wellbeing and dignity. This study has been reviewed and given approval 
by the Health and Human Sciences ECDA (HHSECDA) of the University of Hertfordshire. 
Both protocol numbers are given on top of the first page. 
Who can I contact if I have any questions? 
If you would like further information or would like to discuss any details personally, please 
get in touch with myself (Binoy Kumaran, PhD Researcher) or Professor Tim Watson, the 
Chief / Principal Investigator of this project, either in writing, by phone, or by email. 
Name: Binoy Kumaran (PhD Researcher) 
Phone: (44) (0) 751 743 0077 
Email: b.r.kumaran@herts.ac.uk 
Address: Binoy Kumaran, PhD Researcher, Physiotherapy, Department of Allied Health 
Professions and Midwifery, School of Health and Social Work, 1H159 Yorkon Building, 
University of Hertfordshire, College Lane, Hatfield, Hertfordshire, AL10 9AB. 
Name: Professor Tim Watson (Chief / Principal Investigator) 
Phone: (44) (0) 1707 284970 
Email: t.watson@herts.ac.uk 
Address: Professor Tim Watson, Physiotherapy, Department of Allied Health Professions 
and Midwifery, School of Health and Social Work, University of Hertfordshire, College Lane, 
Hatfield, Hertfordshire, AL10 9AB. 
Thank you. 
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 Appendix 8.6: Participant ‘form to return’ in the OA knee trial 
 
 
 
Please fill in the form and return to: 
 
Binoy Kumaran 
PhD Researcher (Physiotherapy) 
School of Health and Social Work 
University of Hertfordshire 
College Lane 
Hatfield, Hertfordshire 
AL10 9AB 
 
 
From 
 
Your ‘title’ and ‘full name’: 
Gender: 
Date of Birth: 
Contact phone number(s): 
Your ‘home’ and ‘email’ (if available) addresses: 
 
 
Please tick appropriately: 
 
I would like to take part in the study titled    Yes 
“Clinical effects of 448 kHz Capacitive 
Resistive Monopolar Radiofrequency (CRMRF) 
based therapy on patients suffering from    No 
chronic osteoarthritis of the knee joint.” 
 
 
 
 
NHS REC Reference Number: 15/NW/0529 
University HHSECDA Protocol Number: HSK/PG/NHS/00312 
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 Appendix 8.7: Patient randomisation chart for the OA knee 
clinical trial 
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 Appendix 8.8: Informed consent for the participants in the OA 
knee trial 
 
 
 
 
CONSENT FORM 
 
Study ID: ………………   Site: ……………………………………………... 
 
Participant ID: …………   Initials: ………….. DOB: …………………… 
 
Principal Investigator: Professor Tim Watson PhD Researcher: Mr Binoy Kumaran 
 
Study Title: Clinical effects of 448 kHz Capacitive Resistive Monopolar 
Radiofrequency (CRMRF) based therapy on patients suffering from chronic 
osteoarthritis of the knee joint. 
Participant to  
Initial each box 
 
1. I confirm that I have read and understand the Participant Information Sheet, 
Dated ……………………. Version ……… giving particulars of the above 
study. I have had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary, and that I can withdraw from 
the study at any time without having to give a reason, and without my 
medical care or legal rights being affected. 
 
3. I understand that my medical records may be looked at by responsible 
members of the research team. I have been assured that strict 
confidentiality will be maintained. I give permission to these individuals to 
access my medical records. 
 
4. I agree to my GP being informed on my participation in the study. 
 
5. I agree to take to take part in the above study. 
 
 
________________________ ________________ ____________________ 
Name of participant Date Signature 
 
_________________________ ________________ ____________________ 
Name of person taking consent Date Signature 
NHS REC Reference Number: 15/NW/0529 
University HHSECDA Protocol Number: HSK/PG/NHS/00312 
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Professor Tim Watson 
Binoy Kumaran 
School of Health and Social Work 
University of Hertfordshire 
Phone (Binoy Kumaran): (44) (0) 751 743 0077 
Email: b.r.kumaran@herts.ac.uk 
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 Appendix 9.1: Participant data collection form in the OA knee 
trial 
 
 
EXPERIMENTAL DATA COLLECTION FORM 
 
Pre-intervention Assessment (Session 1) 
 
Date and time of assessment: 
 
Starting room temperature (o C): 
 
Starting room humidity (%): 
 
Side treated: Right / Left 
 
Pre-treatment measurements and Doses 
Baseline skin temperature (treated)  
Baseline core temperature  
Thigh length (cm)  
Leg length (cm)  
Baseline blood pressure  
Baseline pulse rate  
Baseline knee flexion ROM  
Baseline knee extension ROM  
Baseline ‘Timed up and go’ test  
 
Post-treatment measurements 
Peak & Follow-up core temperature  
Peak & Follow-up blood pressure  
Peak & Follow-up pulse rate  
 
Study number: 
NHS REC Reference Number: 15/NW/0529 
University HHSECDA Protocol Number: HSK/PG/NHS/00312 
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Ending room temperature (o C): 
 
Ending room humidity (%): 
 
 
Post Intervention Assessment (Session 8) 
 
Date and time of assessment: 
 
Starting room temperature (o C): 
 
Starting room humidity (%): 
 
Pre-treatment measurements 
Baseline core temperature  
Baseline blood pressure  
Baseline pulse rate  
Post knee flexion ROM  
Post knee extension ROM  
Post ‘Timed up and go’ test  
 
Post-treatment measurements 
Peak & Follow-up core temperature  
Peak & Follow-up blood pressure  
Peak & Follow-up pulse rate  
 
Ending room temperature (o C): 
 
Ending room humidity (%): 
 
 
 
 
 
 
378 
Follow-up Assessment One (Session 9) 
 
Date and time of assessment: 
 
First follow-up knee flexion ROM  
First follow-up knee extension ROM  
First follow-up ‘Timed up and go’ test  
 
 
Follow-up Assessment Two (Session 10) 
 
Date and time of assessment: 
 
Second follow-up knee flexion ROM  
Second follow-up knee extension ROM  
Second follow-up ‘Timed up and go’ test  
 
Concealment checker 
 
RF group RFP group Control group 
 
 
  
 
